

Evidence Extractions

Question: What are the core elements of initial clinical history and examination, in the evaluation of children and young people under 19 years old who have nocturnal enuresis?

1

Grading: 2+	<i>Well-conducted case-control or cohort studies with a low risk of confounding, bias or chance and a</i>
--------------------	--

Reference number 774	Study Type	Cohort	RID:
Butler R;Holland P;Devitt H;Hiley E;Roberts G;Redfern E;			547
The effectiveness of desmopressin in the treatment of childhood nocturnal enuresis: predicting response using pretreatment variables			
1998 81		pgs 29	36
Suppl			
3			

Number of subjects	66 children
Inclusion/Exclusion Criteria:	Inclusion: Aged 8 to 16 years, wet at least 4 times over 4 weeks, no associated daytime wetting, primary NE – never been dry for more than 6 months, normal clinical examination with no neurological or urological cause for the enuresis, not statedemted for learning difficulties, not undergoing enuresis-related treatment, parental and child consent.
Characteristics of subjects or environment/prognostic factor	54 boys, 12 girls, mean age 10.4 (SD 1.7) years, age range 8.1 to 14.5 years
Recruitment:	Referred as outpatients for monosymptomatic NE
Setting:	Leeds, UK
Interventions/Test /Factor being investigated	Child and parental factors
Comparitors	No comparison
Length of Study/ Follow-up	No follow up
Outcome measures studies	Factors affecting treatment outcomes
Results	<p>Child measures: impact on lifestyle, beliefs about bedwetting, perceived intolerance, self image, self esteem and self-perception profile</p> <p>Parental measures: concerns, beliefs about bedwetting, revised maternal intolerance scale, attitudes to bedwetting, efforts to treat NE, maternal self esteem and perceived stress scale.</p> <p>The measures were collected at a pre-clinic home visit or first clinic visit. There were no statistically significant differences in patients between any of the measures. Children had 20 micrograms intranasal or 0.2 mg oral desmopressin for 2 weeks, parents were then instructed to double the dose. A follow up appointment was at 4 weeks.</p> <p>The study showed the following were significant in predicting outcome: severity of wetting before treatment, child's birth weight, child's perception of maternal intolerance, the perceived impact on the child's life (situational), parental belief that the enuresis is a physical problem, that it will go on for years and that the child wets the bed to retaliate against the parent.</p> <p>The following were not significant in predicting outcome: age, sex, demographic or situational variables.</p>
Funding	Ferring Pharmaceuticals

Does the study answer the question?	The study showed the following were significant in predicting outcome: severity of wetting before treatment, child's birth weight, child's perception of maternal intolerance, the perceived impact on the child's life (situational), parental belief that the enuresis is a physical problem, that it will go on for years and that the child wets the bed to retaliate against the parent.
Effect due to factor in study?	The study identified significant predictors of treatment outcome
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Children had primary NE and a mean age of 10.4 years

Internal Validity

Reference number	1500	Study Type	Cohort	RID:
Butler RJ;Brewin CR;Forsythe W;				392
Relapse in children treated for nocturnal enuresis: prediction of response using pre-treatment variables				
1990	18	BEHAV PSYCHOTHER	pgs 65	72

Number of subjects 37 patients (n=24 who had been treated with modified dry bed training and n=13 had been treated with an alarm).

Inclusion/Exclusion Criteria: Inclusion: successfully treated (achieved 14 consecutive dry nights) within 16 weeks of treatment with an alarm or modified dry bed training.

Characteristics of subjects or environment/prognostic factor 28 boys, 9 girls; the mean age was 9.6 years (age range 6.1 to 12.4 years) at the time of treatment; 83.8% had primary NE, 16.2% had secondary NE; 24 had been treated with modified dry bed training, 13 had been treated with an alarm

Recruitment: Patients successfully treated with alarm or modified dry bed training, and followed up.

Setting: Leeds, UK.

Interventions/Test /Factor being investigated Pre-treatment assessment variables predicting relapse.

Comparitors Between children who relapsed and children who did not relapse.

Length of Study/ Follow-up No follow up.

Outcome measures studies Predicting relapse.

Results The study conducted a parent-child interview – age, wetting history, presence of urgency, frequency and action previously adopted to control bedwetting; maternal questionnaire on bed wetting – maternal beliefs of cause, attribution, feelings, concerns over bed wetting; tolerance scale (Morgan and Young, 1975); child interview – beliefs and reactions to bedwetting.
The treatment outcomes were speed of acquisition to dryness, and persistence of dryness.
The study conducted 2 sets of follow-up appointments, 6 at 4 week intervals to find out the number of wet nights, the other a long term follow-up by questionnaire.

The study combined children who relapsed after modified dry bed training and children who relapsed after alarm therapy, In total 13 children relapsed (10 were

originally treated with modified dry bed training and 3 were originally treated with alarm therapy)

The study showed children who relapsed were more likely to have had more wet nights over the 16 weeks of treatment ($p < 0.05$); more likely to attribute their bed wetting to drinking too much prior to going to bed ($p < 0.05$); less likely to attribute it to being too cold to arise from the bed during the night ($p < 0.05$); more likely to have a history of secondary NE ($p < 0.001$); and more likely not to worry over the bedwetting ($p < 0.01$).

The study states only more likely to have a history of secondary NE and more likely not to worry over the bedwetting can be regarded with any degree of confidence as the alpha level should be set no higher than $p < 0.01$ with 78 comparisons.

Funding Not reported

Does the study answer the question? The study reports children who relapsed were more likely to have a history of secondary NE and more likely not to worry over the bedwetting. There was a small correlation that children who relapsed were more likely to have had more wet nights over the 16 weeks of treatment, more likely to attribute their bed wetting to drinking too much prior to going to bed and less likely to attribute it to being too cold to arise from the bed during the night.

Effect due to factor in study? The study identified predictors for relapse.

Consistency of results with other studies? No other similar studies.

How directly applicable to population of the guideline? Children had been successfully treated with alarms of DBT and had a mean age of 9.6 years.

Internal Validity

Reference number	527	Study Type	Cohort	RID:
Butler RJ;Holland P;Robinson J;				515
Examination of the structured withdrawal program to prevent relapse of nocturnal enuresis				
2001	166		pgs 2463	2466

Number of subjects 51 patients

Inclusion/Exclusion Criteria: Inclusion: at least 90% dry nights while on medication (desmopressin or imipramine), on medication for at least 4 months, no neurological or urological cause of NE, vulnerable to relapse due to at least 2 unsuccessful attempts at medication withdrawal by gradual dose tapering

Characteristics of subjects or environment/prognostic factor 37 boys and 14 girls, mean age was 11.8 (sd 2.06) years, age range 7.7 to 15.9 years, 37 children were treated with desmopressin and 14 with imipramine, the mean length of treatment was 10.6 (sd 5.04) months (range 4 to 24 months). The doses of desmopressin were 8 children on 10 micrograms, 17 on 20 micrograms or 0.2 mg, 9 on 40 micrograms or 0.4 mg, 2 on 60 micrograms or 0.6 mg and 1 on 80 micrograms. The doses of imipramine were 10 on 25 mg, 2 on 50 mg and 2 on 75 mg.

Recruitment: Not reported

Setting: Leeds, UK

Interventions/Test /Factor being investigated Factors predicting response to structured withdrawal program

Comparitors	No comparison
Length of Study/ Follow-up	6 month follow up
Outcome measures studies	Factors predicting response to structured withdrawal program
Results	<p>The withdrawal program was during week on taking medication on day 1, 3, 4 and 6; in week 2 on days 1, 2, 4 and 7; in week 3 on days 2 5 and 7; in week 4 on days 1, 3 and 6; in weeks 5 on days 2 and 5; in week 6 on days 2 and 6; in week 7 on days 3 and 7 and in week 8 on day 4. Alarm treatment was offered on medication free nights. 38 children stayed dry during weeks 9 and 10, 72.2% of these remained dry at 6 months.</p> <p>The study showed there was no association between the types of medication and outcome at weeks 9 and 10 (p=0.303) or at 6 months (p=0.667).</p> <p>At weeks 9 and 10 success was associated with a higher number of dry medication nights (p=0.011) and no medication nights (p=0.002).</p> <p>At weeks 9 and 10 there was no association between success and age (p=0.057), gender (p=0.259), use of the alarm (p=0.976), dose level of desmopressin (p=0.7) or imipramine (p=0.65), duration of treatment before withdrawal (p=0.760).</p> <p>At 6 months success was associated with a higher number of dry medication nights (p=0.005) and no medication nights (p=0.008).</p>
Funding	Leeds Metropolitan University
Does the study answer the question?	At weeks 9 and 10 and at 6 months success was associated with a higher number of dry medication nights and no medication nights.
Effect due to factor in study?	Study showed a structured withdrawal program could increase continued dryness
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Children had a mean age of 11.8 years

Internal Validity

Reference number	1215	Study Type	Cohort	RID:
Butler RJ;Redfern EJ;Forsythe WI;				598
The child's construing of nocturnal enuresis: a method of inquiry and prediction of outcome				
1990	31		pgs 447	454

Number of subjects	45 patients with nocturnal enuresis
Inclusion/Exclusion Criteria:	Inclusion: aged over 6 years, wet at least 4 times a month, normal examination, normal urine microscopy, normal intelligence, not undergoing any enuresis related treatment, living with natural parent(s).
Characteristics of subjects or environment/prognos tic factor	42 boys and 13 girls. The mean age was 10.2 (sd 2.04) years, age range 6.9 to 14.7 years, and 4 children had associated diurnal enuresis.
Recruitment:	Referred as outpatients because of NE.

Setting:	Out-patients, UK.
Interventions/Test /Factor being investigated	Tolerance scale and child interview.
Comparitors	Treatment success with an alarm.
Length of Study/ Follow-up	No follow up.
Outcome measures studies	Factors relating to treatment success with an alarm.
Results	<p>The study examined – tolerance scale, child interview – anticipation of change, resistance to change, perceived family reactions, secrecy. Children were treated with an alarm and were encouraged to waken quickly, remove and dry sensitive plate, switch off the alarm and use the toilet to complete urination; the child was required to remove wet clothes and sheets and replace them with dry ones and reset the alarm. Treatment was for 16 weeks.</p> <p>4 children dropped out and excluded from results, and 2 children had missing outcome measures.</p> <p>There was no statistically significant difference in ages or between males and females, but maternal intolerance was significantly higher in males than females. 65.3% were successfully treated. The study showed age was a significant predictor of response, but maternal intolerance, sex or presence of diurnal enuresis was not related to response.</p> <p>The presence of resistance constructs and the absence of perceived family support were significant predictors of treatment failure (p<0.05). The following were not predictors of treatment failure: perceived family intolerance, teased by siblings and secrecy.</p> <p>The study showed the probability of successful treatment increases with age but decreases with the presence of resistance constructs.</p>
Funding	Not reported.
Does the study answer the question?	The study showed that the probability of successful treatment increased with age but decreased with the presence of resistance constructs.
Effect due to factor in study?	Study identified significant predictors of treatment response.
Consistency of results with other studies?	No other similar studies.
How directly applicable to population of the guideline?	Children had a mean age of 10.2 years.

Internal Validity

Reference number	331	Study Type	Cohort	RID:
				491
	Butler RJ;Robinson JC;Holland P;Doherty-Williams D;			
	Investigating the three systems approach to complex childhood nocturnal enuresis--medical treatment interventions			
2004	38	pgs	117	121

Number of subjects	66 patients
Inclusion/Exclusion Criteria:	Inclusion: aged 5 to 16 years old, wetting at least 4 times a week, no major daytime wetting, attending mainstream school, no neurological or urological problems, parents and child consent
Characteristics of subjects or environment/prognostic factor	44 males and 22 females, mean age 10.41 years (sd 2.38) 47 had primary NE, 16 had secondary NE, 63.6% had no dry nights during 14 night baseline, 18.2% had 1 to 2 dry nights, 9.1% had 3 to 6 dry nights, 24 had multiple wetting, 11 did not have multiple wetting, 29 had a family history of NE, 12 did not have a family history of NE, 57.4% had tried alarms, 51.8% had tried desmopressin 9.5% had tried imipramine, 11.9% had tried oxybutynin 16.7% had tried other treatments.
Recruitment:	Referred as outpatients for NE
Setting:	Leeds, UK
Interventions/Test /Factor being investigated	3 systems approach
Comparitors	No comparison
Length of Study/ Follow-up	No follow up
Outcome measures studies	Dryness banding
Results	<p>The three system approach was used to obtain information on 6 clinical signs – urgency, frequency, passes small voids, wakes after wetting, small or variable wet patches, wets soon after sleep; parents answered often or rarely to each sign. The study also recorded demographics, school attended, family history, birth weight, mothers age at birth, early feeding practice, child's weight and height, presence of other predictive factors, previous and current treatments.</p> <p>If children scored on 2 or more items representing bladder overactivity they were described as non-monosymptomatic and prescribed 5 to 10 mg oxybutynin or ditropan for 4 weeks; if the child did not have 2 or more signs they were described as monosymptomatic and prescribed 0.4 mg desmopressin for 4 weeks; treatment was continued for a further 4 weeks if success criterion (of >50 reduction in number of wet nights) was met, if children did not meet the success criterion they were the prescribed desmopressin and anticholinergics</p> <p>13 children dropped out</p> <p>In the desmopressin group of 42 children (7 were missing) 7 children achieved no dry nights, 4 children achieved 1 to 24% dry nights, 7 children achieved 25 to 49% dry nights, 10 children achieved 50 to 89% dry nights and 7 children achieved 90 to 100% dry nights</p> <p>In the anticholinergic group of 24 children (6 were missing) 3 children achieved no dry nights, 6 children achieved 1 to 24% dry nights, 3 children achieved 25 to 49% dry nights, 5 children achieved 50 to 89% dry nights and 1 child achieved 90 to 100% dry nights</p> <p>In the desmopressin and anticholinergic group of 30 children (2 were missing) 5 children achieved no dry nights, 5 children achieved 1 to 24% dry nights, 3 children achieved 25 to 49% dry nights, 10 children achieved 50 to 89% dry nights and 5 children achieved 90 to 100% dry nights</p> <p>The study showed there were no predictive factors for desmopressin, although 50% of children wet soon after sleep</p> <p>For anticholinergics medication the predictive factors were age (p = 0.03), frequency (p = 0.01), passing small voids (p = 0.03), small or variable wet patches (p = 0.029) and wakes soon after voiding (p = 0.062).</p> <p>There were no predictive variables for the combination group.</p>

Funding Ferring Pharmaceuticals, UK

Does the study answer the question? The study showed there were no predictive factors for desmopressin, although 50% of children wet soon after sleep
For anticholinergics medication the predictive factors were age, frequency, passing small voids, small or variable wet patches and wakes soon after voiding.
There were no predictive variables for the combination group.

Effect due to factor in study? Study identified predictive factors for treatment outcome with anticholinergics

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Children had a mean age of 10.41 years

Internal Validity

Reference number	3910	Study Type	Cohort	RID:
Cayan S;Doruk E;Bozlu M;Duce MN;Ulusoy E;Akbay E;				748
The assessment of constipation in monosymptomatic primary nocturnal enuresis				
2001	33		pgs 513	516

Number of subjects 5350 patients surveyed. 679 found to have primary NE. 125 of the 679 with primary enuresis attended for interview and ultrasound scan. There were 4671 controls (no enuresis).

Inclusion/Exclusion Criteria: Inclusion: primary monosymptomatic NE, wetting 2 or more times a week.
Exclusion: secondary NE, neurological abnormalities, history of colon surgery, bowel disease, developmental delay, or metabolic disease.

Characteristics of subjects or environment/prognostic factor Primary NE group: the mean age was 9.23 years (sd 2.36) and 59.6% were male.
Control group the mean age was 9.14 years (sd 2.89) and 59.6% were male.

Recruitment: Day care centres and primary and secondary schools between October 1998 and August 1999.

Setting: Both rural and urban areas of Turkey.

Interventions/Test /Factor being investigated Diagnosis of constipation.

Comparitors Comparison between proportion of children with enuresis who were constipated and proportion of controls with constipation.

Length of Study/ Follow-up No follow up.

Outcome measures studies Diagnosis of constipation.

Results Children were sent a questionnaire about micturition and defecation habits (82.3% response rate). Children with NE were invited to attend a hospital to undergo a neurological examination (physical examination, electroencephalogram if needed, serum creatinine levels) and abdominal sonogram (plain abdominal film), which 125 out of 679 attended. All children had normal serum creatinine levels and renal sonograms.
Constipation was described as less than 3 bowel movements a week for at least 6

months

There was a statistically significant difference in the number of children with constipation between the children with NE (7.06%) and control children (1.45%) p = 0.000.

Funding Not reported.

Does the study answer the question? There was a statistically significant difference in the number of children with constipation between the children with NE and control children.

Effect due to factor in study? The study identified differences in constipation rates between children with NE and children without NE.

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Children had primary NE and a mean age of 9.23 years.

Internal Validity

Reference number	1624	Study Type	Cohort	RID:
	Cutler C;Middleton AWJ;Nixon GW;			639
	Radiographic findings in children surveyed for enuresis			
1978	11		pgs 480	482

Number of subjects 216 patients

Inclusion/Exclusion Criteria: Inclusion: Referred of NE for intravenous pyelogram and voiding cystourethrogram between July 1974 and June 1975 for NE

Characteristics of subjects or environment/prognostic factor 59.3% were male. The male mean age was 7.54 years, the female mean age was 5.36 years. The mean age of males with normal studies was 7.35 years, the mean age of males with abnormal studies was 8.17 years. The mean age of females with normal studies was 7.54 years, the mean age of females with abnormal studies was 4.68 years. 47% had NE alone, 51% had NE and diurnal enuresis, 2% had diurnal enuresis alone.

Recruitment: Referred of NE for investigations between July 1974 and June 1975

Setting: Primary Medical Centre, Utah, USA

Interventions/Test /Factor being investigated Intravenous pyelogram and voiding cystourethrogram

Comparitors No comparison

Length of Study/ Follow-up No follow up

Outcome measures studies radiographic abnormalities, surgery

Results

89 radiographic abnormalities were found, 59 of which were clinically significant. 31.5% of males had radiographic abnormalities and 28.4% of females had radiographic abnormalities.

There were 53 cases of upper urinary tract abnormalities, 43 of which were clinically significant. The most common was vesicoureteral reflux in 32 children, 5 of which had bilateral reflux and 27 had unilateral reflux. 4 children had ureteropelvic junction obstruction, 2 had hydrocalycosis, 2 had ureterovesical junction obstruction, 1 had pyelonephritis. Other non clinically significant abnormalities identified were duplicated collecting structure (5 children), renal ectopia (2 children), malrotation (2 children) and pyelocalyceal diverticulum (1 child)

135 children had clinical data available, of these 31% had a history of UTI prior to roentgenography.
 5.2% of children with NE alone had UTI, 25.2% of children with diurnal enuresis with or without Ne had UTI.
 54.8% of children with UTI had abnormal radiographic findings.

Surgery from radiographic findings:
 Children with UTI – 7 had meatotomy, internal urethrotomy or urethral dilatation for stenosis (minor surgery), 6 had bilateral or unilateral ureteroneocystostomy and 1 had posterior urethral valve destruction (major surgery).
 Children without UTI – 8 had meatotomy, internal urethrotomy or urethral dilatation for stenosis (minor surgery), 4 had bilateral or unilateral ureteroneocystostomy and 0 had posterior urethral valve destruction (major surgery).

Statistical evaluation of children needing surgery
 Minor surgery – 0 males with UTI, 5 males without UTI, 9 females with UTI, 1 female without UTI, 5 with NE, 8 with diurnal enuresis with or without NE. the mean age was 5.6 years.

Major surgery – 3 males with UTI, 2 males without UTI, 4 females with UTI, 1 female without UTI, 1 with NE, 7 with diurnal enuresis with or without NE. the mean age was 5.5 years.

Funding Not reported

Does the study answer the question? 89 radiographic abnormalities were found, 59 of which were clinically significant. 31.5% of males had radiographic abnormalities and 28.4% of females had radiographic abnormalities.

Effect due to factor in study? Study identified radiographic findings in children with NE

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Male children had a mean age of 7.54 years and females had a mean age of 5.36 years

Internal Validity

Reference number 1183 **Study Type** **Cohort** RID:
 Devlin JB;O’Cathain C; 595
 Predicting treatment outcome in nocturnal enuresis
 1990 65 pgs 1158 1161

Number of subjects 127 patients

Inclusion/Exclusion Criteria:	<p>Inclusion: aged 6 to 18 years, wet at least 2 nights a week</p> <p>Exclusion: overt psychiatric disturbance requiring urgent referral to the child guidance service, moderate or greater mental handicap, urological or neurological causes of incontinence</p>
Characteristics of subjects or environment/prognostic factor	<p>The mean age was 8.8 years, age range 6 to 17 years; male:female ratio was 2:1; 11% were in socioeconomic group I, 14% in group II, 11% in group III, 32% in group IV, 25% in group V and 7% in group VI; the unemployment rate was 30% among fathers, 70% among mothers</p> <p>83% had primary NE, 17% had secondary NE; 83% had night time only wetting, 17% had night and day time wetting; 2 children had UTI, 4 had urological abnormality. 20% had a stressful event in early childhood consisting of a hospital admission (17% due to physical illness, 2% due to physical handicap, 1 % due to sexual abuse)</p> <p>A prior attendance at the child guidance clinic was recorded: 21% for a reactive disorder, 6% for a learning disorder, 3% for a mental handicap, 2% for developmental delay, 2% for a personality disorder and 1% for a psychosomatic disorder</p> <p>52 children admitted to stress in the family – 13 due to financial difficulties, 11 due to marital discord, 7 due to unemployment, 6 due to death in family, 6 due to other family disharmony, 2 due to serious illness in the family and 7 due a combination of the above</p> <p>9% had a family history of psychiatric illness, 18% had adverse housing</p> <p>2% of parents had no concern about the bedwetting, 12% were a little concerned, 44% had moderate concern and 42% had a great deal of concern. 8% of children had no concern about the bedwetting, 26% were a little concerned, 34% had moderate concern and 32% had a great deal of concern</p>
Recruitment:	Consecutive referrals to community based enuresis clinic from GP, paediatricians, clinical method officers and a small number from the child guidance service
Setting:	Community based clinic, Dublin, Ireland
Interventions/Test /Factor being investigated	Factors which affect continuing success
Comparitors	No comparisons
Length of Study/ Follow-up	12 month follow up
Outcome measures studies	Factors which affect continuing success at 6 and 12 months
Results	<p>22 children became dry at the baseline and were not treated with an alarm, 1 of these relapsed by 12 months, 8 children were lost to follow up after the initial visit and 1 was referred for surgical management. Therefore 96 children were treated with an alarm, 81 of these children became dry for 42 nights.</p> <p>The study showed no stressful event for the child ($p<0.05$), no psychiatric disorder ($p<0.01$), no stress in the family ($p<0.02$), moderate to great parental concern ($p<0.05$) and moderate to great child distress ($p<0.01$) increased the chance of continuing success at 6 months. The study showed at 6 months that children with no adverse events increased failure rate by 5%, family stress increased the risk by 20%, lack of child's distress doubled the risk and family stress and lack of child's distress quadrupled the risk.</p> <p>The study showed no daytime wetting ($p<0.02$), no urological disorder ($p<0.01$), no psychiatric disorder ($p<0.01$), no developmental disorder ($p<0.01$), parental concern ($p<0.01$) and the child's distress ($p<0.01$) increased the chance of continuing success at 12 months. The study showed at 12 months that children with no adverse events the risk of failure was 1 in 10, lack of child distress stress increased the risk by 1 quarter, developmental delay increased the risk by 1 third, psychiatric disorder increased the risk by 1 third, having lack of child's distress and developmental delay quadrupled the risk, having lack of child's distress and psychiatric disorder quadrupled the risk, developmental delay and psychiatric disorder increased the risk fivefold, having all there increased the risk 20-fold.</p>

Funding	Not reported
Does the study answer the question?	The study showed no stressful event for the child, no psychiatric disorder, no stress in the family, moderate to great parental concern and moderate to great child distress increased the chance of continuing success at 6 months. The study showed no daytime wetting, no urological disorder, no psychiatric disorder, no developmental disorder, parental concern and the child's distress increased the chance of continuing success at 12 months
Effect due to factor in study?	The study identified characteristics which predict continuing success with treatment
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Children had a mean age of 8.8 years

Internal Validity

Reference number 1472 **Study Type** **Cohort** RID: 622
 Dische S;Yule W;Corbett J;Hand D;
 Childhood nocturnal enuresis: factors associated with outcome of treatment with an enuresis alarm
 1983 25 pgs 67 80

Number of subjects	245 patients
Inclusion/Exclusion Criteria:	Inclusion: wet at least 3 times every week
Characteristics of subjects or environment/prognostic factor	Mean age was 7.9 years, age range 4.2 to 14.3 years, ratio of boys:girls was 1.6:1
Recruitment:	Referred to clinician over 5 year period from April 1972 to March 1977 to 4 Community Health special investigation clinics in south-east London UK
Setting:	Southeast London UK
Interventions/Test /Factor being investigated	Factors affecting treatment outcome
Comparitors	No comparison
Length of Study/ Follow-up	No follow up
Outcome measures studies	Factors predicting treatment outcome
Results	Initial interview and examination and the exclusion or urinary infection or other abnormalities by laboratory assessment. Children kept a diary of dry nights for 9 weeks during when parents and children were seen every 2 to 3 weeks and given encouragement and help for family difficulties. The study collected data on demographic data – age, sex, birth order, family size, social class based on the registrar general's classification of the occupation of the male head of household, unemployed and single-parent families were coded in separate categories; parents rating of child's behaviour; teachers rating of child's

behaviour; previous treatment for NE; primary or secondary NE; presence of UTI; occurrence of marked daytime wetting; occurrence of soiling; family difficulties; unsatisfactory housing; serious financial hardship; mother working full or part time; history of enuresis in parents or siblings.
Children were treated with an alarm.

The study showed unsatisfactory housing ($p < 0.01$) and family difficulties ($p < 0.05$) adversely affect initial success. The failure rate of either of these alone was 12% if both were present the failure rate increased to 47%.

The study showed children with deviant scores on the teacher's rating scale ($p < 0.05$) and the presence of family difficulties ($P < 0.01$) were related to relapse.

The study showed deviant scores on the teacher's rating scale ($p < 0.05$) and the presence of family difficulties ($P < 0.01$) adversely affect long-term success.

Funding

Not reported

Does the study answer the question?

The study showed unsatisfactory housing and family difficulties adversely affect initial success. The study showed children with deviant scores on the teacher's rating scale and the presence of family difficulties were related to relapse. The study showed deviant scores on the teacher's rating scale and the presence of family difficulties adversely affects long-term success.

Effect due to factor in study?

The study identified factors affecting treatment success

Consistency of results with other studies?

No other similar studies

How directly applicable to population of the guideline?

Children had a mean age of 7.9 years

Internal Validity

Reference number	4098	Study Type	Cohort	RID:
Eller DA;Austin PF;Tanguay S;Homsy YL;				856
Daytime functional bladder capacity as a predictor of response to desmopressin in monosymptomatic nocturnal enuresis				
1998	33	Eur Urol	pgs 25	29
	Suppl			
	3			

Number of subjects

51 patients

Inclusion/Exclusion Criteria:

Inclusion: monosymptomatic NE, wet at least 3 times a week

Characteristics of subjects or environment/prognostic factor

37 boys and 14 girls, mean age 11 years, age range 5 to 11 years

Recruitment:

Presented at the institutions

Setting:

2 centre in Canada and 1 centre in USA

Interventions/Test /Factor being investigated

Factors predicting response to desmopressin

Comparitors	No comparison
Length of Study/ Follow-up	No follow up
Outcome measures studies	Factors predicting response to desmopressin
Results	<p>8 patients were excluded due to insufficient data. 8 patients were excluded due to lack of bladder capacity values. Therefore 35 patients were included in the evaluation.</p> <p>A voiding history was conducted on the number of wet nights per week, nocturia, frequency, urgency dysuria and the presence of daytime wetting; if patients displayed symptoms other than NE they were excluded from the study. The study conducted voiding diaries, daytime functional bladder capacity and urine osmolality. Desmopressin was given over 2 weeks starting at 10 micrograms rising by 10micrograms every 3 days until a response was achieved or 40 micrograms was reached.</p> <p>The study showed daytime functional bladder capacity (p=0.009), maximal functional bladder capacity expressed as a percentage of normal (p=0.006) and age (p=0.008) were significant predictors of response to desmopressin</p> <p>The study showed children who had 70% or more bladder capacity had an 83% chance of success with desmopressin.</p>
Funding	Not reported
Does the study answer the question?	The study showed daytime functional bladder capacity, maximal functional bladder capacity expressed as a percentage of normal and age were significant predictors of response to desmopressin
Effect due to factor in study?	The study identified significant predictors of response to desmopressin
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Children had monosymptomatic NE and a mean age of 11 years

Internal Validity

Reference number	1134	Study Type	Cohort	RID:
Evans JH;Meadow SR;				589
Desmopressin for bed wetting: length of treatment, vasopressin secretion, and response.[see comment]				
1992	67		pgs 184	188

Number of subjects	55 children, 28 in the 1 month group, 27 in the 3 month group
Inclusion/Exclusion Criteria:	<p>Inclusion: aged 5 to 16 years, wet at least 2 nights a week, referred by GP, community medical officer, urologist or paediatrician</p> <p>Exclusion: taking medication that might cause diuresis (e.g. salbutamol), UTI in previous 2 weeks</p>
Characteristics of subjects or environment/prognos tic factor	<p>In the 1 month group: the median age was 10 years, age range 6 to 16 years, 17 out of 28 were male, 19 had previously tried treatment for NE, 15 were wet less than or equal to 2 nights a week, 10 had adverse family or social factors, 9 had a Rutter A2 score of greater than 18, 9 were aged less than 8 years, 9 had adverse housing, 8 had diurnal symptoms, 1 had allergic rhinitis.</p> <p>In the 3 month group: the median age was 10.8 years, age range 6 to 16 years, 17</p>

out of 27 were male, 19 had previously tried treatment for NE, 17 were wet less than or equal to 2 nights a week, 11 had adverse family or social factors, 8 had a Rutter A2 score of greater than 18, 7 were aged less than 8 years, 6 had adverse housing, 7 had diurnal symptoms, 1 had allergic rhinitis.

Recruitment:	Referred by GP, community medical officer, urologist or paediatrician to enuresis clinic
Setting:	hospital outpatient department, Leeds
Interventions/Test /Factor being investigated	Comparison of characteristics between responses to desmopressin for children treated with 1 month desmopressin and 3 month desmopressin.
Comparitors	Between treatment lengths and response
Length of Study/ Follow-up	No follow up
Outcome measures studies	Differences in characteristics of children who responded to desmopressin and children who did not respond to desmopressin
Results	<p>Children were given 20 micrograms desmopressin rising to 40 micrograms desmopressin if child had any wet nights in first 3 nights of treatment</p> <p>The study measured response to desmopressin based on treatment length and nocturnal urine volume, nocturnal urine osmolality and nocturnal urine AVP concentration.</p> <p>There were no significant difference between children treated for 1 month and children treated for 3 months in: the proportion of responders during and after treatment and the difference in the number of children who became completely dry</p> <p>The study showed there were no significant differences between children who responded and children who did not to desmopressin in nocturnal urine volume, nocturnal urine osmolality and nocturnal urine AVP concentration.</p>
Funding	Ferring Pharmaceuticals
Does the study answer the question?	<p>The study showed there were no significant differences between children who responded and children who did not to desmopressin in nocturnal urine volume, nocturnal urine osmolality and nocturnal urine AVP concentration.</p> <p>The study showed the length of treatment did no significantly change the response rate.</p>
Effect due to factor in study?	The study showed there were no significant differences between children who responded and children who did not to desmopressin
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Children had an age range 6 to 16 years

Internal Validity

Reference number	3920	Study Type	Cohort	RID:
Kruse S;Hellstrom AL;Hanson E;Hjalmas K;Sillen U;Swedish ESG;				757
Treatment of primary monosymptomatic nocturnal enuresis with desmopressin: predictive factors				
2001	88		pgs 572	576

Number of subjects 392 patients with primary nocturnal monosymptomatic enuresis.

Inclusion/Exclusion Criteria:	Inclusion: aged 6 to 12 years, primary NE, and at least 10 wet nights in 28 nights.
Characteristics of subjects or environment/prognostic factor	75% were male, and the age range was 6 to 12 years.
Recruitment:	Not reported.
Setting:	Multicentre study, Sweden.
Interventions/Test /Factor being investigated	Patient characteristics and predictive factors for the outcome of treatment with 20 to 40 micrograms desmopressin.
Comparitors	Between those who responded to treatment with desmopressin and those who didn't.
Length of Study/ Follow-up	No follow up.
Outcome measures studies	Response to desmopressin in relation to characteristics.
Results	<p>The following characteristics were recorded: gender, age, heredity, sleep pattern, previous treatments, number of wet episodes during the night, timing of wet episodes, diary of 4 week baseline period including number of wet nights, dose of treatment, number of wet nights in last 4 weeks of treatment.</p> <p>Patients had 6 weeks of 20 to 40 micrograms desmopressin. The response to desmopressin was split into 4 categories: no response, partial response (less than 50% reduction), responders (50 to 90% reduction) and full responders (greater than 90% reduction).</p> <p>The study showed there was a significant difference in the response rate to desmopressin by age (responders and full responders were older), the timing of wet episodes (responders wet after midnight, where as non responders wet before and after midnight). Fewer wet nights during observation period had a better response rate to desmopressin, and the frequency of wetting was also significantly different with more frequent being less likely to respond.</p> <p>The study showed there was no difference in the response rate to desmopressin for gender, hereditary and previous treatment.</p>
Funding	Ferring Pharmaceuticals, Malmo, Sweden
Does the study answer the question?	The study showed there was a significant difference in the response rate to desmopressin by age (responders and full responders were older), the timing of wet episodes (responders wet after midnight, where as non responders wet before and after midnight). Children with fewer wet nights during observation period had a better response to desmopressin, and the frequency of wetting was also significantly different with more frequently wet children being less likely to respond.
Effect due to factor in study?	The study showed significant predictors for treatment success with desmopressin.
Consistency of results with other studies?	No other similar studies.
How directly applicable to population of the guideline?	Children had an age range of 6 to 12 years and monosymptomatic primary NE.

Internal Validity

Reference number 674 **Study Type** **Cohort** RID:
 Kruse S;Hellstrom AL;Hjalmas K; 534
 Daytime bladder dysfunction in therapy-resistant nocturnal enuresis. A pilot study in urotherapy
 1999 33 pgs 49 52

Number of subjects 22 children, 11 in the treatment group and 11 controls

Inclusion/Exclusion Criteria: Inclusion: aged over 10 years, tried several treatments for NE and with hold pattern daytime
 Exclusion: no neurological disorder or other disease

Characteristics of subjects or environment/prognostic factor For children who were in the treatment group: 8 boys and 3 girls, mean age was 12.8 years, median ages was 12, age range was 10 to 16 years, 6 children had been treated for daytime urge incontinence but for 1 to 5 years had no micturition problems during the day. The mean baseline wetting was 10.5 nights over 2 weeks. Most children had received latest treatment in previous 12 months
 For children who were in the control group: 6 boys and 5 girls, mean age was 12 years, median ages was 11, age range was 10 to 16 years, 5 children had been treated for daytime urge incontinence. The mean baseline wetting was 8.7 nights over 2 weeks.

Recruitment: Referred to the department for severe therapy-resistant primary NE

Setting: Sweden

Interventions/Test /Factor being investigated Micturition treatment

Comparitors Between children treated for micturition problems and those not treated

Length of Study/ Follow-up No follow up

Outcome measures studies Response rates

Results For the treatment group: volumes and time of micturitions and fluid intakes were recorded over 1 or 2 days, voided volumes at night were also recorded, if the child was dry the amount voided in the morning was recorded.
 The child was the given information on how the bladder works and was told to void every 2 to 3 hours and drink regularly during the day
 After 1 month all children in the treatment group had significantly improved, 1 child was taken to the bathroom at night a 5 had started desmopressin, 1 of which became completely dry. After 5 months 4 children had started desmopressin, 1 had dropped out and started acupuncture.
 In the group without pre-treatment measurements 5 children used the alarm, after 5 months 2 children were still using the alarm and after 12 months no one was using the alarm.

Funding Not reported

Does the study answer the question? After 1 month all children treated for micturition were significantly drier.

Effect due to factor in study? Study suggest micturition increases dryness

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Children were treatment resistant

Internal Validity

Reference number 3921 **Study Type** **Cohort** RID: 758
Kwak KW;Park KH; 758
Clinical inconsistency of lower urinary tract symptoms between questionnaire and bladder diary in children with nocturnal enuresis
2008 180 pgs 1085 1089

Number of subjects 108 patients with enuresis.

Inclusion/Exclusion Criteria: Inclusion: wet at least 2 times a week.

Characteristics of subjects or environment/prognostic factor 80 males and 28 females, mean age 7.2 years, age range 5 to 15 years, and 60% had previous treatment for NE.

Recruitment: Visiting enuresis clinic between Jan 2003 and March 2006.

Setting: Hospital, Korea.

Interventions/Test /Factor being investigated Bladder diaries.

Comparitors Non validated LUTS questionnaire.

Length of Study/ Follow-up No follow up.

Outcome measures studies Difference in two methods: 3-day bladder diary and questionnaire.

Results Non validated LUTS questionnaire completed 1 month before clinic visit, Bladder diary kept for 3 days 1 to 2 weeks after first visit, comparison on classification of NE (monosymptomatic (MNE) or non monosymptomatic (NMNE)), urinary frequency, daytime incontinence and voiding postponement. The study also considered the differences in MVV, AVV, % MVV/EBC, max flow rate and residual urine between monosymptomatic children and non monosymptomatic children as classified by the questionnaire and then by the bladder diaries

The study used the Kappa test to compare results of the two methods. The results discrepancies between the classification of NE (kappa test 0.292), and showed there was no significant consistency for urinary frequency (kappa test = 0.912). The study showed no consistency on daytime incontinence (kappa test 0.356) and voiding postponement (Kappa test 0.505).

For classification of MNE and NMNE by the bladder diaries the study showed the MVV ($p = 0.006$), AVV ($p = 0.001$) and % MVV/EBC ($p = 0.041$) to be statistically different between children with MNE and NMNE, There was no statistical difference in the max flow rate ($p = 0.225$) and residual urine ($p = 0.854$) between MNE and NMNE.

For classification of MNE and NMNE by the non validated LUTS questionnaire the study showed no statistically significant difference between MNE and NMNE on the MVV ($p = 0.559$), AVV ($p = 0.597$) and % MVV/EBC ($p = 0.947$), the max flow rate ($p = 0.122$) and residual urine ($p = 0.187$).

Funding Not reported.

Does the study answer the question? The study showed there were differences in the results of the non validated LUTS questionnaire and the bladder diaries.

Effect due to factor in study? The study identified differences in information collected from a bladder diary and from a questionnaire.

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Children were treatment resistant and had a mean age of 7.2 years

Internal Validity

Reference number 667 **Study Type** **Cohort** RID: 109
 McGrath KH;Caldwell PHY;Jones MP;
 The frequency of constipation in children with nocturnal enuresis: A comparison with parental reporting
 2008 44 pgs 19 27

Number of subjects 277 patients

Inclusion/Exclusion Criteria: Inclusion: referred to clinic by GP or paediatrician between 26 June 2003 and 7 November 2005 for assessment and management of bedwetting.

Characteristics of subjects or environment/prognostic factor The mean age was 9.25 years, age range 4.8 to 17.5 years and 65.7% were male.

Recruitment: Referred to clinic by GP or paediatrician between 26 June 2003 and 7 November 2005 for assessment and management of bedwetting, NE clinic, The Children's Hospital, Westmead, Sydney, Australia (tertiary paediatric teaching institution).

Setting: Australia

Interventions/Test /Factor being investigated Constipation is assessed by parental questionnaire and clinician assessment.

Comparitors Between two assessments.

Length of Study/ Follow-up No follow up.

Outcome measures studies Differences in two assessments and differences between constipated and non constipated children.

Results The parental questionnaire was completed at initial presentation prior to seeing the clinician. It contained questions on child's pattern of NE, history of UTIs, fluid intake, bowel habits and parental identification of constipation.
 The clinician's assessment was by an experienced paediatrician using the parental questionnaire as a prompt to obtain further information and clarification from parent and child, a history of urinary function, bowel habits, fluid and dietary intake and previous treatment for NE. The child was examined including abdominal palpitation. Constipation was defined on the Rome II definition: having more than one of the following – frequency of defecation 3 times a week or less, consistency of stool described as hard (Bristol types 1-3), the presence of straining during defecation

Differences in constipated and non constipated children:
 There was a statistical difference between children who were constipated and

children who were not constipated on previous treatment with an alarm (more children who were constipated had tried an alarm). There was a statistical difference between children who were constipated and children who were not constipated on gender, severity of NE – frequency and amount of urine leakage, previous treatment with desmopressin and tricyclics.

Comparison of parental questionnaire and clinicians assessment:
Of the children parents reported as constipated, 22 out of 39 were found to be constipated by the clinicians and 17 out of 39 were found not to be constipated by the clinician. Of the children parents reported as not constipated 73 out of 231 were found to be constipated by the clinicians and 158 out of 231 were found not to be constipated by the clinician.

Differences in individual parameters of two assessments:
There was a statistical difference in the reported of soiling in the last 6 months and frequency of defecation between parental questionnaires and clinicians assessment. There was no statistical difference between straining and consistency of stools between parental questionnaires and clinicians assessment.

Funding	Not reported
Does the study answer the question?	The study showed children who were constipated were more likely to have tried an alarm. The study showed there was a statistical difference in the reporting of soiling in the last 6 months and frequency of defecation between parental questionnaires and clinicians assessment. There were some differences in the parental diagnosis of constipation and the clinicians.
Effect due to factor in study?	Study considered the difference in reporting of constipation and soiling.
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Set in tertiary care and had a mean age of 9.25 years.

Internal Validity

Reference number	1077	Study Type	Cohort	RID:
				580
Persson-Junemann C;Seemann O;Kohrmann KU;Junemann KP;Alken P;				
Comparison of urodynamic findings and response to oxybutynin in nocturnal enuresis				
1993	24	Eur Urol	pgs 92	96

Number of subjects	63 patients
Inclusion/Exclusion Criteria:	Inclusion: pre-treated persistent NE, wet at least 4 nights a week Exclusion: anatomic-urologic defects, overt neurologic disease, prior infection
Characteristics of subjects or environment/prognostic factor	37 were male, 26 were female. The age range was 6 to 14 years, median was 8.5 years. 59% had diurnal symptoms (frequency, urge) and 14% had occasional daytime wetting
Recruitment:	Not reported, at Department of Urology, Mannheim Hospital, University of Heidelberg, FRG
Setting:	University of Heidelberg, FRG
Interventions/Test /Factor being investigated	Standard urodynamic evaluation, treatment with oxybutynin

Comparitors	No comparison
Length of Study/ Follow-up	No follow up
Outcome measures studies	Differences in urodynamic findings, response to treatment with oxybutynin
Results	<p>In 10 (16%) children the urodynamic findings were normal without any detectable urinary storage or micturition disorder,</p> <p>In the remaining 53 patients (84%) had findings attributed to an inadequate bladder storage function.</p> <p>51 children (81%) had reduced maximal bladder capacity, values of less than 50% the predicted normal was found in 20 children (32%), 2 children (3%) had reduced bladder capacity was concomitant with a decreased bladder compliance</p> <p>43 children had uninhibited detrusor contractions – 18 children had Grade 1 involuntary contraction (16-50 cm H₂O); 11 children had Grade 2 involuntary contraction (50-100 cm H₂O); 14 children had Grade 3 involuntary contraction (greater than 100 cm H₂O). In all but 1 child the uninhibited contractions and reduced capacity were coherent</p> <p>Most children also presented with a low-compliant bladder (mean 77%) the grade-related frequency was reciprocal depending on tendency</p> <p>All children were treated with oxybutynin. 70% of the original 63 children were either successful or had an improved rate.</p> <p>In the children with normal urodynamic findings 30% of children were either successful or had an improved rate.</p> <p>In children with uninhibited bladder contractions 77% were either successful or had an improved rate</p> <p>In children with detrusor instability: 78% of children with Grade 1 were either successful or had an improved rate; 9% of children with Grade 2 were either successful or had an improved rate; 64% of children with Grade 3 were either successful or had an improved rate</p> <p>76% of children all children with reduced bladder capacity were either successful or had an improved rate</p> <p>There was significant benefit in 84% of children with limited reduction and in 65% of children with more than 50% reduction of the age-corresponding estimate</p> <p>41% of children with normal bladder capacity responded to treatment.</p> <p>There was no significant age or gender response to treatment with oxybutynin.</p>
Funding	Not reported
Does the study answer the question?	Children with uninhibited bladder contractions, graduation of destrutor instability, reduced bladder capacity and the extent of volume decrease were all more successful in the treatment with oxybutynin
Effect due to factor in study?	Study identified predictors of response to oxybutynin
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	treatment resistant population with a median age of 8.5 years

Internal Validity

Reference number	1585	Study Type	Cohort	RID:
	Redman JF;Seibert JJ;			635
The urodiographic evaluation of the enuretic child				

Number of subjects	138 patients
Inclusion/Exclusion Criteria:	Inclusion: aged 3 to 8 years old, with at least 1 of the following symptoms, gained from initial examination: hesitancy or straining to void, diminished urinary stream size noticed on multiple occasions, frequent dysuria, diurnal enuresis, history of recent onset NE after long period of dryness, UTI or history of UTI
Characteristics of subjects or environment/prognostic factor	Exclusion: patients referred for UTI who also had NE (NE had to be main reason for referral to be included in study) Not reported
Recruitment:	Referred for NE between July 1972 and July 1977, University of Arkansas college of medicine and Arkansas Children's Hospital
Setting:	Arkansas, USA
Interventions/Test /Factor being investigated	IVP or cystography
Comparitors	No comparison
Length of Study/ Follow-up	No follow up
Outcome measures studies	Radiographic findings
Results	<p>Children had an initial evaluation including a history specific for urologic complaints, physical examination and urinalysis</p> <p>21 children had a significant abnormality noted wither on IVP or cystography. 2 children produced any yield of significant abnormal findings; UTI documented by history or confirmed by urinalysis and / or culture and symptoms and signs of lower urinary tract obstruction</p> <p>The authors reported a history of diurnal enuresis did not indicate significant findings unless the patients also had an infection or obstruction</p> <p>Of patients with a history of UTI: On abnormal IVP, 6 children had loss of renal cortex and / or caliectasis. On abnormal cyctogram, 10 children had reflux, 0 children had urethral valves, and 7 children had trabeculated bladder with diverticula.</p> <p>Of patients with infected urine: On abnormal IVP, 2 children had loss of renal cortex and / or caliectasis. On abnormal cyctogram, 4 children had reflux, 0 children had urethral valves, and 3 children had trabeculated bladder with diverticula.</p> <p>Of patients with symptoms of obstruction: On abnormal IVP, 0 children had loss of renal cortex and / or caliectasis. On abnormal cyctogram, 1 child had reflux, 1 child had urethral valves, and 2 children had trabeculated bladder with diverticula.</p>
Funding	Not reported
Does the study answer the question?	<p>21 children had a significant abnormality noted wither on IVP or cystography. 2 children produced any yield of significant abnormal findings; UTI documented by history or confirmed by urinalysis and / or culture and symptoms and signs of lower urinary tract obstruction</p> <p>The authors reported a history of diurnal enuresis did not indicate significant findings unless the patients also had an infection or obstruction</p>
Effect due to factor in study?	Study identified characterisitcs in a NE population

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Children had an age range of 3 to 8 years

Internal Validity

Reference number	776	Study Type	Cohort	RID:
Riccabona M;Oswald J;Glauninger P;				548
Long-term use and tapered dose reduction of intranasal desmopressin in the treatment of enuretic children				
1998	81		pgs 24	25
	Suppl			
	3			

Number of subjects 155 patients

Inclusion/Exclusion Criteria: Inclusion: aged over 5 years, wet at least 3 nights a week, no urological abnormalities on ultrasound, no post-residual urine, negative urine culture, nocturnal urine volume exceeding their present bladder capacity as recorded on a 3-day/night/frequency/volume chart

Characteristics of subjects or environment/prognostic factor 68% were male, 32% were female, mean age was 8 years, age range was 5 to 19 years. 15% had additional daytime urge symptoms and received oxybutynin before desmopressin therapy. 85% had monosymptomatic NE

Recruitment: Patients had primary NE

Setting: Austria

Interventions/Test /Factor being investigated Desmopressin withdrawal program

Comparitors No comparison

Length of Study/ Follow-up Median 18 months follow up

Outcome measures studies Response to structured withdrawal program from desmopressin

Results Children had 20 micrograms intranasal desmopressin titrated to 40 micrograms or 50 micrograms after 2 days if the child did not become dry within 48 hours. This was maintained for 4 to 6 weeks.

After 4 weeks of complete dryness the dose was reduced by 10 micrograms and after each additional 4 weeks dry a further 10 micrograms reduction was done. The medication was stopped after 4 weeks dry on 10 micrograms dose. Medication was restarted at the previous dose if a relapse occurred in the reduction phase (relapse was 2 or more wet nights over 2 weeks. Children were also advised to minimize or avoid drinking 2 to 3 hours before bedtime.

113 patients responded to desmopressin. 110 patients achieved complete dryness with no relapses and remained dry without treatment. 11 patients achieved dryness after relapses during or after therapy, 5 had relapses during the reduction phase, 6 after therapy.

11 children improved and had no more than 2 wet nights per week. 22 children did not respond to therapy or improved slightly and had more than 2 wet nights per week.

	The mean duration of treatment was 28 weeks with a range of 3 months to over 2 years. The mean dosage of desmopressin was 30 micrograms and median follow up was 18 months
Funding	Not reported
Does the study answer the question?	71% of children achieved complete dryness with no relapses and remained dry without treatment with the withdrawal program
Effect due to factor in study?	Study suggested withdrawal program increased continuing success
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Children had a mean age of 8 years
Internal Validity	No comparison group
Reference number	4077
Study Type	Cohort
Schaumburg HL;Rittig S;Djurhuus JC;	
No relationship between family history of enuresis and response to desmopressin	
2001 166	
	RID: 775
	pgs 2435 2437
Number of subjects	381 patients: 328 with NE and n= 53 controls (no enuresis).
Inclusion/Exclusion Criteria:	Inclusion: monosymptomatic NE and had received some type of treatment previously.
Characteristics of subjects or environment/prognostic factor	NE group: 220 boys and 108 girls. The mean age of the boys was 10 years (age range 5 to 17 years), and the mean age of the girls was 10.5 years (age range 5 to 17 years). Controls: 31 boys and 22 girls. The mean age was 10 years (age range 7 to 13 years). There was no statistically significant difference in the gender differences between the two groups.
Recruitment:	Referred by GP to enuresis clinic.
Setting:	Enuresis clinic Denmark.
Interventions/Test /Factor being investigated	Questionnaire of NE, 20 micrograms intranasal desmopressin for 1 week, 40 micrograms intranasal desmopressin for second week.
Comparitors	Between children with NE and controls (no enuresis).
Length of Study/ Follow-up	No follow up.
Outcome measures studies	Differences in family history of enuresis and response to desmopressin.
Results	Questionnaire - type of NE (primary or secondary – secondary was wetting after a period of at least 6 months dry), family history of NE (1st order relatives were siblings and parents) if a family history was present the duration of NE was specified, and presence of daytime symptoms. Children were described as severe NE if they had at least 3 wet nights a week.

There was a statistically significant difference for family history of NE between children with NE and children without NE. 245 out of 328 (75% of children with NE) had a positive family history, compared to 20 out of 53 (38%) of children in the control group ($p < 0.001$). The prevalence of first order relatives with a history of NE was higher in patients with NE than the controls.

Although patients were referred for monosymptomatic NE 27% indicated additional daytime symptoms. 90% of patients had severe NE, 10% had non severe NE. There was a high prevalence of family history in both these groups. There was no statistically significant difference within or between subgroups regarding gender, monosymptomatic NE and the presence of additional daytime symptoms, primary/secondary EN or a positive family history of NE (first order or other relative).

All patients with NE had treatment with desmopressin. There was no statistical differences in the rates of response between children with severe NE and children with non-severe NE or in the prevalence of a positive family history.

Funding

Not reported.

Does the study answer the question?

There was a statistically significant difference for family history of NE between children with NE and children without NE.

There was no statistical differences in the rates of response to desmopressin between children with severe NE and children with non-severe NE or in the prevalence of a positive family history.

Effect due to factor in study?

Study identified differences in characteristics of patients with NE and without NE.

Consistency of results with other studies?

No other similar studies.

How directly applicable to population of the guideline?

Children had an age range of 5 to 17 years.

Internal Validity

Reference number	1689	Study Type	Cohort	RID:
Siegel S;Rawitt L;Sokoloff B;Siegel B;				645
Relationship of allergy, enuresis, and urinary infection in children 4 to 7 years of age				
1976	57		pgs 526	528

Number of subjects

234 patients

Inclusion/Exclusion Criteria:

Inclusion: 4 to 7 years, middle to upper middle class, Caucasian
 Exclusion: children with occasional NE and occasional day wetting

Characteristics of subjects or environment/prognostic factor

75% were aged 4 to 5 years, 25 % were aged 6 to 7 years

Recruitment:

Not reported

Setting:

USA

Interventions/Test /Factor being investigated

Rate of NE in children treated for UTI and children with allergy

Comparitors	No comparison
Length of Study/ Follow-up	No follow up
Outcome measures studies	Number of children with persistent NE (wetting every week)
Results	<p>Group 1 was 50 children previous treated for UTI and 55 healthy controls matched for age and sex. Group 2 was 69 children with allergies, with nasal bronchial hypersensitivity to respiratory allergens severe enough to warrant avoidance, medication and desensitization and 60 controls without allergies matched for age and sex</p> <p>There was no statistical difference between the number of children with persistent NE (night wetting every week) between children previously treated for UTI and controls (20% in each group). There was no statistical difference between the number of children with persistent NE (night wetting every week) between children with allergies and controls (13% in allergy group and 23% in control group).</p>
Funding	Not reported
Does the study answer the question?	There was no statistical difference between the number of children with persistent NE (night wetting every week) between children previously treated for UTI and controls (20% in each group). There was no statistical difference between the number of children with persistent NE (night wetting every week) between children with allergies and controls (13% in allergy group and 23% in control group).
Effect due to factor in study?	Study did not identify any differences
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Children had an age range of 4 to 7 years

Internal Validity

Reference number	1152	Study Type	Cohort	RID:
Sujka SK;Piedmonte MR;Greenfield SP;				591
Enuresis and the voiding cystourethrogram: a re-evaluation.[see comment]				
1991	38		pgs 139	142

Number of subjects	86 patients in results 132 originally
Inclusion/Exclusion Criteria:	Inclusion: NE, patients give full historical details (see result section) Exclusion: UTI
Characteristics of subjects or environment/prognos tic factor	<p>46 out of 86 were male.</p> <p>13 patients had reflux and 70 did not have reflux</p> <p>In the reflux group: the mean age was 6.6 years, 23% were male, 62% had daytime wetting, 46% had urgency, 31% had frequency, 82% had secondary NE</p> <p>In the non-reflux group: the mean age was 7.45 years, 61% were male, 54% had daytime wetting, 24% had urgency, 24% had frequency, 23% had secondary NE</p>
Recruitment:	Patients seen between July 1984 and July 1986

Setting:	Department of Urology, Buffalo, USA
Interventions/Test /Factor being investigated	Historical details, urine cultures, a contract voiding cystourethrogram (VCUG), upper urinary tract studies (intravenous pyelogram (IVP) or renal ultrasound)
Comparitors	No comparisons
Length of Study/ Follow-up	No follow up
Outcome measures studies	Presence of symptoms indicating a greater likelihood of VUR
Results	<p>Historical details: age of presentation, daytime wetting, urgency, frequency, UTI, primary or secondary NE Urine cultures, a contract voiding cystourethrogram (VCUG), upper urinary tract studies (intravenous pyelogram (IVP) or renal ultrasound) The study conducted a linear logistic regression model to investigate if the presence of symptoms indicating a greater likelihood of VUR</p> <p>Historical details: In the reflux group: the mean age was 6.6 years, 23% were male, 62% had daytime wetting, 46% had urgency, 31% had frequency, 82% had secondary NE In the non-reflux group: the mean age was 7.45 years, 61% were male, 54% had daytime wetting, 24% had urgency, 24% had frequency, 23% had secondary NE</p> <p>Results of logistic regression analysis: daytime wetting had a regression coefficient of 0.2255 and p value of 0.7298; urgency had a regression coefficient of 1.1794 and p value of 0.1708; frequency had a regression coefficient of -0.5778 and p value of 0.5306; secondary NE had a regression coefficient of 0.6379 and p value of 0.3221</p> <p>Results of 17 refluxing ureters in 13 patients with reflux and no history of UTI: grade I reflux there were 7 refluxing ureters, 1 with scarring and 0 had undergone surgery; grade II reflux there were 5 refluxing ureters, 0 with scarring and 0 had undergone surgery; grade III reflux there were 3 refluxing ureters, 0 with scarring and 0 had undergone surgery; grade IV reflux there were 4 refluxing ureters, 2 with scarring and 2 had undergone surgery; grade V reflux there were 0 refluxing ureters, 0 with scarring and 0 had undergone surgery.</p>
Funding	Grant from the National Cancer Institute
Does the study answer the question?	The study showed no historical details could predict if children had VUR. The study showed out of 13 patients with reflux there were 7 grade I refluxing ureters and 12 greater than or equal to grade II refluxing ureters
Effect due to factor in study?	Study did not identify any differences
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	the mean age of children with reflux was 6.6 years and the mean age of children without reflux 7.45 years

Internal Validity

Reference number 443 **Study Type** **Cohort**
Tanaka Y;Kawauchi A;Yoneda K;Naitoh Y;Yamao Y;Iwasaki H;Mizutani Y;Miki T;
Vesicoureteral reflux detected among patients with nocturnal enuresis

RID:
501

Number of subjects	1088 patients
Inclusion/Exclusion Criteria:	Not reported
Characteristics of subjects or environment/prognostic factor	<p>Mean age 9.9 years, 738 were male, 350 were female. 627 had monosymptomatic NE, 461 had day time symptoms. 70 children had reflux, 36 of which had monosymptomatic NE and 34 had day time symptoms</p> <p>Characteristics of children with reflux: the mean age of children when reflux was found was 8.8 (sd 3.1) years, 71% were male, 7% had pyuria, 1% had a renal (kidney) scar, 75% had over active bladder.</p>
Recruitment:	Visited clinic with NE and underwent voiding cystourethrography (VCUG), Department of urology, Kyoto Prefectural University of Medicine
Setting:	Japan
Interventions/Test /Factor being investigated	Clinical history of NE, family history, check for existing diseases, urinary analysis, urological disease, voiding cystourethrography (VCUG), cystometry, intravenous pyelography or renal ultrasonography, radiography of lumbar vertebrae to assess occult spina bifida
Comparitors	No comparison
Length of Study/ Follow-up	No follow up
Outcome measures studies	Clinical difference in children with and without reflux
Results	<p>Clinical history of NE, family history, check for existing diseases, urinary analysis, urological disease, voiding cystourethrography (VCUG), cystometry, intravenous pyelography or renal ultrasonography, radiography of lumbar vertebrae to assess occult spina bifida. Children were treated with anticholinergics drugs (oxybutynin chloride and propiverine hydrochloride)</p> <p>70 children had reflux, 36 of which had monosymptomatic NE and 34 had day time symptoms</p> <p>Clinical characteristics of children with reflux: the mean age of children when reflux was found was 8.8 (sd 3.1) years, 71% were male, 7% had pyuria, 1% had a renal (kidney) scar, 75% had over active bladder.</p> <p>A total of 86 ureters had reflux: 25 (29%) were grade I, 50 (58%) were grade II, 11 (13%) were grade III, 0 (0%) were grade IV and 0 (0%) were grade V.</p> <p>Resolution of reflux in patients follow-up for 2 years or more 4 out of 6 (66%) with grade I reflux had resolved; 11 out of 20 (55%) with grade II reflux had resolved; 3 out of 6 (50%) with grade III reflux had resolved.</p> <p>There was no statistically significant difference in the number of children with improved NE 2 years after the first visit between children with resolution of reflux and children without resolution of reflux. 61% of children with resolution of reflux had improved NE compared to 36% of patients without resolution of reflux.</p> <p>The study compared characteristics of patients with reflux to patients without reflux. Having a positive history of NE in siblings and frequency were both statistically more common in children with reflux. The following showed no statistical difference: sex, age, secondary NE, frequency of NE per week, positive history of NE in parents, daytime incontinence, UTI and occult spina bifida.</p>
Funding	Not reported

Does the study answer the question? The study showed having a positive history of NE in siblings and frequency were both statistically more common in children with reflux

Effect due to factor in study? Study identified differences between the two groups

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Children had a mean age of 9.9 years

Internal Validity

Reference number 1120 **Study Type** **Cohort** RID:
van dM; 586
Urodynamics in enuretic children
1992 17 Clin Nucl Med pgs 200 205

Number of subjects 124 patients

Inclusion/Exclusion Criteria: Not reported

Characteristics of subjects or environment/prognostic factor 50 children were aged 5 to 7 years, 37 patients were aged 8 to 10 years, 22 patients were aged 11 to 13 years and 15 patients were aged 14 to 18 years. Treatment resistant patients

Recruitment: Not reported

Setting: Netherlands

Interventions/Test /Factor being investigated Renography

Comparitors No comparison

Length of Study/ Follow-up No follow up

Outcome measures studies Urodynamic findings

Results Children were examined under physiologic conditions

61% of children had micturition
55% had decreased bladder capacity
22% had abnormal urine flow pattern
7% had anatomical obstruction
14% had functional disturbance
4% had changeable urine flow patterns
23% had renography
9.6% had had vesico-renal reflux
1.5% had significant dilated renal pelvis
7% had slight non-obstructive dilated pelvis
1.7% had parenchymal kidney damage (3 out of 5 of these children also had vesico-renal reflux)

0.8% had had afunctional kidney
 2.4% had other clinical factors which were not important.

Funding Not reported

Does the study answer the question? The study aim was to identify abnormalities probably related to NE

Effect due to factor in study? The study identified characteristics of an NE population

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Treatment resistant populatiuon with an age range of 5 to 18 years

Internal Validity

Reference number 4091 **Study Type** **Cohort** RID:
 Yeung CK;Sreedhar B;Leung VT;Metreweli C; 789
 Ultrasound bladder measurements in patients with primary nocturnal enuresis: a urodynamic and treatment outcome correlation
 2004 171 PGS 2589 2594

Number of subjects 514 patients

Inclusion/Exclusion Criteria: Inclusion: aged 5 to 18 years, monosymptomatic primary NE

Characteristics of subjects or environment/prognostic factor Mean age 11.2 years

Recruitment: Enuresis clinic from 1998 to 2002

Setting: Hong Kong

Interventions/Test /Factor being investigated Bladder wall thickness and bladder volume for response to desmopressin

Comparitors No comparison

Length of Study/ Follow-up No follow up

Outcome measures studies Relationship between bladder wall thickness and bladder volume in response to desmopressin

Results 339 normal age matched children without urinary symptoms referred for other minor surgery.
 Children under went scans with patient supine using ATL 500 and ESAOTE Technos ultra sound unit with 5 MHz frequency probe 20 minutes after drinking as much as possible. Renal volumes were also calculated

The study showed children with a thicker bladder wall were less likely to respond to desmopressin. The study showed children with a larger bladder volume were more likely to respond to desmopressin

Children who became completely dry on desmopressin had a mean bladder wall thickness of 0.3633 (sd 0.098), children who had a good response had 0.3763 (sd 0.10), partial response 0.4153 (sd 0.14), no response 0.4143 (sd 0.15). The overall mean BT was 0.3953 (sd 0.13)

Children who became completely dry on desmopressin had a mean bladder volume of 636 (sd 232.6), children who had a good response had 564 (sd 264), partial response 527.96 (sd 273.5), no response 454 (sd 275.57). The overall mean BVI was 535 (sd 261.27)

Funding	Not reported
Does the study answer the question?	The study showed children with a thicker bladder wall were less likely to respond to desmopressin. The study showed children with a larger bladder volume were more likely to respond to desmopressin
Effect due to factor in study?	Study showed children with a thicker bladder wall were less likely to respond to desmopressin. The study showed children with a larger bladder volume were more likely to respond to desmopressin
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Children had monosymptomatic NE and had a mean age of 11.2 years

Internal Validity

Reference number	665	Study Type	Cohort	RID:
Zink S;Freitag CM;von G;				108
Behavioral Comorbidity Differs in Subtypes of Enuresis and Urinary Incontinence				
2008	179		pgs 295	298

Number of subjects	97 patients
Inclusion/Exclusion Criteria:	Inclusion: Referred to specialist outpatient clinic for elimination of disorders between January 2004 and July 2006 Exclusion: organic forms of urinary incontinence.
Characteristics of subjects or environment/prognostic factor	45 children had monosymptomatic NE (MNE) and 52 children had non monosymptomatic NE (NMNE).
Recruitment:	Referred for elimination disorders to Department of Child and Adolescent Psychiatry.
Setting:	Saarland University Hospital, Germany
Interventions/Test /Factor being investigated	Psychological and radiological examination.
Comparitors	Between monosymptomatic (MNE) and non monosymptomatic (NMNE) children.
Length of Study/ Follow-up	Not reported
Outcome measures studies	Differences in CBCL score, ICD-10 score, uroflow, ultrasound residual urine, and bladder wall thickness.

Results The study conducted: a detailed history, pediatric examination (height, weight, head circumference, examination of chest organs, ears, nose, throat, blood pressure, abdomen, neurological investigation and genital examination), 24 to 48 hour voiding protocols, sonography (kidneys, urinary tract, bladder wall thickness, residual urine, rectal diameter), uroflowmetry. The ICD-10 score was based on a standardised mental status examination (Clinical Assessment Scale of Child and Adolescent Psychopathology-D6) and mutual consensus conferences. CBCL questionnaire which consisted of 113 problem items, 3 aspects – internalizing problem score (withdrawal, somatic complaints, anxiety, depression) externalizing problem score (delinquent and aggressive behaviour) and total problem score (sum of all behaviour problems). A problem score of greater than 63 was the 90th percentile and used for diagnosis.

Statistically significant difference for having more than 5 ml residual urine (more common in NMNE), mean number of mm bladder wall thickness (thicker in NMNE).

The following results showed no statistically significant difference between children with MNE and children with NMNE; on the CBCL questionnaire the number of patients internalizing T value greater than 63, the number of patients externalizing T value greater than 63, the number of patients with total T value greater than 63; on the ICD-10 score the number of patients externalising disorder, the number of patients with internalising disorder, the number of patients with other disorder, the number of patients with at least 1 psychiatric diagnosis excluding encopresis, the number of patients with encopresis; on the uroflow test the number of patients with pathological, the mean ml volume, the mean ml/sec flow; on ultrasound the mean ml volume of residual urine and on the bladder wall thickening the number of children with greater than 2.5mm

Funding Not reported

Does the study answer the question? The study showed children with NMNE were more likely to have more than 5 ml residual urine and a higher mean number of mm bladder wall thickness.

Effect due to factor in study? The study showed children with NMNE were more likely to have more than 5 ml residual urine and a higher mean number of mm bladder wall thickness.

Consistency of results with other studies? No other similar studies.

How directly applicable to population of the guideline? No age range given.

Internal Validity

Grading: 2-	Case-control or cohort studies with a high risk of confounding bias, or chance and a significant risk
--------------------	--

Reference number 3287	Study Type	Cohort	RID:
Fielding D;			701
Factors associated with drop-out, relapse and failure in the conditioning treatment of nocturnal enuresis			
1985 13		pgs 174	185

Number of subjects 97 patients, 46 with night and day time wetting, 51 with night time only wetting

Inclusion/Exclusion Criteria: Inclusion: aged 5 to 15 years, no UTI, showed no evidence of organic pathology and had not been treated with the previous 12 months
Nocturnally enuretic only – child must have displayed no day time wetting after the age of 4 years

Characteristics of subjects or environment/prognostic factor Diurnal enuresis was defined as persistent daytime wetting in the absence of organic lesion after the age of 5 years with a wetting frequency of at least once a week. The extent of wetting ranged from damp underclothes to more obvious voiding causing the wetting of top clothes.
Not reported

Recruitment: Referred to the two specialist clinics set up for the trial Liverpool UK

Setting: Liverpool UK

Interventions/Test /Factor being investigated 30 variables to predict treatment outcome

Comparitors No comparison

Length of Study/ Follow-up 12 month follow up

Outcome measures studies 30 variables to predict treatment outcome

Results Children with daytime wetting were not included in the investigation

Extensive interview – history and current status of enuresis, family history of enuresis, social background, occurrence of other behavioural problems. Parents were asked to keep a 4 week record of wet and dry days before treatment began. At the second appointment a water load test was conducted to assess maximum functional bladder capacity. Patients were randomly assigned to retention control training with an alarm or to alarm only therapy. 30 variables were derived from 3 pre-treatment assessment measures – interview, baseline record of wetting-frequency, clinic measure of bladder capacity.

Factors to predict treatment outcome: 52 children had treatment, 17 children did not become dry after 14 weeks treatment with the alarm. Three variables were associated with treatment failure: frequency of micturition ($p < 0.01$), urgency of micturition ($p < 0.05$) and previous experience of alarm treatment ($p < 0.02$). Neither small pre-treatment functional bladder capacity, behavioural deviance score or severity of night time wetting were related to treatment failure.

Factors to predict relapse: 18 out of 34 children had relapsed by 12 months after treatment with the alarm, many however had subsequently become dry following re-treatment. None of the 30 variables were associated with relapse

Funding Not reported

Does the study answer the question? Three variables were associated with treatment failure: frequency of micturition, urgency of micturition and previous experience of alarm treatment. None of the 30 variables were associated with relapse

Effect due to factor in study? Study identified variables associated with treatment failures

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Children had an age range of 5 to 15 years

Internal Validity

Reference number 1411 **Study Type** **Cohort** RID:
Houts AC;Peterson JK;Liebert RM; 617
The effect of prior imipramine treatment on the results of conditioning therapy in children with enuresis
1984 9 J Pediatr Psychol pgs 505 509

Number of subjects 57 patients

Inclusion/Exclusion Criteria: Inclusion: lifelong history of NE

Characteristics of subjects or environment/prognostic factor 45 males, 12 females, the mean age for males was 7.97 (SD 2.16) years, the mean age for females was 8.13 (sd 2.04) years, the majority wet the bed every night
All had consulted a family physician about NE, 16% had undergone at least 1 major urological examination, 39% had been treated with clinical trial of imipramine in the previous year and had failed to correct the problem.

Recruitment: Not reported

Setting: USA

Interventions/Test /Factor being investigated Factors associated with relapse after alarm treatment: age, gender family history, length of treatment, previous treatment with imipramine

Comparitors No comparison

Length of Study/ Follow-up 1 year follow up

Outcome measures studies Factors associated with relapse

Results Treatment success was defined as 14 consecutive dry nights at the end of 8 to 12 weeks of treatment and still dry at follow up interviews (at 6 and 12 months).
Relapse was described as 1 wet nights per 2 weeks
The study reported the majority of relapses happened by 6 months.

The study showed the following factors were significantly associated with relapse: prior treatment with imipramine

The study showed the following factors were not significantly associated with relapse: age, gender family history, length of treatment

The study went on to examine the relationship between prior treatment with

imipramine and with relapse. The study suggested severity of NE could be a factor, however there was no significant difference in the mean number of wet nights, the longest reported period of dryness and initial severity of bed wetting between children who relapsed and those who remained dry.

Funding Not reported

Does the study answer the question? The study showed the following prior treatment with imipramine was significantly associated with relapse.

Effect due to factor in study? Study identified factors associated with relapse

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? males had a mean age of 7.97 years and females had a mean age of 8.13 years

Internal Validity

Reference number	3918	Study Type	Cohort	RID:
Jensen IN;Kristensen G;				756
Alarm treatment: analyses of response and relapse				
1999 202			pgs 73	75

Number of subjects 237 patients

Inclusion/Exclusion Criteria: Inclusion: aged 5 to 19 years, no daytime urination problems, no other disease of the urinary tract, at least 3 wet nights per week, personal and parental motivation to solve the problem together

Characteristics of subjects or environment/prognostic factor Aged 5 to 19 years

Recruitment: Not reported

Setting: Denmark

Interventions/Test /Factor being investigated 4 variables to predict response to alarm treatment

Comparitors No comparison

Length of Study/ Follow-up No follow up

Outcome measures studies Response to alarm treatment

Results The study considered: how often the child was wet before treatment, how often the child was wet after treatment, did the child become completely dry during treatment, was the child dry 1 year after treatment

The study stated the patients with the highest number of wet nights were more successful than those with fewer wet nights. The study showed age and gender impact on treatment response. The study stated girls had a higher number of wet

nights and therefore have a higher probability of being cured by an alarm. The study reported the number of wet nights rises until the child is 10 years old, while the number of children with NE declines between 6 and 10 years old. However the frequency of wet nights for the remaining age group increases, the authors state this could be because spontaneous remission is more frequent for children with a lower number of wet nights or secondary NE may also lead to an increased frequency of wet nights.

Funding	Not reported
Does the study answer the question?	The study stated the patients with the highest number of wet nights were more successful than those with fewer wet nights. The study showed age and gender impact on treatment response.
Effect due to factor in study?	Study identified factors predicting treatment response
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	children had an age range of 5 to 19 years

Internal Validity

Reference number	448	Study Type	Cohort	RID:
Nappo S;Del G;Chiozza ML;Biraghi M;Ferrara P;Caione P;				504
Nocturnal enuresis in the adolescent: a neglected problem				
2002	90	pgs	912	917

Number of subjects	107 patients
Inclusion/Exclusion Criteria:	Inclusion: wet at least 1 night a month in previous 6 months, pubertal stage >2 using tanner classification, aged over 13 years, no neurological disease or known renal or urinary tract disease
Characteristics of subjects or environment/prognostic factor	63 males, 44 females, mean age 15.3 years. 74% had primary NE, 71% had monosymptomatic NE, 37% were first born, 75% were only child
Recruitment:	From 7 centres in Northern and Southern Italy
Setting:	Centres in Northern and Southern Italy
Interventions/Test /Factor being investigated	Questionnaire to inform treatment
Comparitors	No comparisons
Length of Study/ Follow-up	Not reported
Outcome measures studies	Patient characteristics, response to desmopressin
Results	A questionnaire based on history, results of physical and diagnostic examinations and therapy History – family and personal with attention to pregnancy, delivery and birth weight;

neonatal period, age of requirement and attainment of urinary and faecal control, coexistent pathologies, occurrence of allergies, surgery and stressful events
 Characteristics of NE – primary or secondary, monosymptomatic or symptomatic, severity of bedwetting, presence of obstipation or encopresis, UTIs, sleep characteristics, previous examinations and therapies, day time symptoms (occurrence of frequency – more than 7 voids/day, urgency, urge incontinence, and / or holding manoeuvres
 Physical examination – weight, height, arterial BP, assessment of pubertal stage, inspection of abdomen, external genitalia, lower legs and lumbosacral regions, tests for glucose, bacteria, protein and blood cells in urine, urine culture, serum glucose, creatinine and electrolytes, renal and bladder ultrasonography and uroflowmetry. Further examination (cystography and urodynamics) were under taken in selected patients with daytime symptoms

The study showed
 Statistical differences for:
 Monosymptomatic NE was significantly more frequent in males than females. NMNE was more frequent in females regardless of age
 Females were more likely to have UTI

Non statistical differences in:
 74% had primary NE, 26% had secondary NE. 80% of males had primary NE and 64% of females had primary NE there was no statistically significant difference. 71% had monosymptomatic NE, 29% had symptomatic NE
 There was no difference in family history of NE according to age, gender, types of NE. 37% of patients were first born, 28% second born, 75% were an only child, 2.8% were adopted
 The mean neonatal weight was 3.45kg, range 2.1 to 4.7 kg, two patients were born at less than 2.5kg, 9 patients were born at less than 38 weeks all had primary NE 17 patients reported major stressful event, this was not related to the type of NE 29.9% had undergone minor surgery, 5.6% had eating disorders
 12.1% had UTIs, 20% in MNE and 42% in NMNE (not statistically different)
 Ostipation was found in 34% of females and 17% of males (54% with NMNE and 20% with MNE)
 NE was severe (greater than 3 wet nights a week) in 80% of patients 45% were wet every night (no relation to age, gender or type of NE)
 Previous treatment: 20% had never sought medical help (no difference in age, gender or severity) 39% had seen paediatricians, 24% had seen psychiatrists, 17% had seen GPs and 15% seen urologists, 3% had seen gynaecologists, also sees were andrology, ephrology or alternative medicine specialists
 40% had never received previous treatment, 52.3% had tried oral desmopressin – 79% had responded with 1 patient having a headache. The patients with symptomatic NE were treated with anticholinergics (8 patients) or anticholinergics and oxybutynin (5 patients) or bladder training and biofeedback (4 patients). 8 patients who had not responded to desmopressin were treated with an alarm which was not tolerated by 2. 3% of patients refused all treatment or were not compliant with treatment.

Response to desmopressin:
 There was no statistically significant difference in the following variables between those who responded to desmopressin and those who did not: gender, age, family history, frequency of NE (number of wet nights per week)

Funding	Not reported
Does the study answer the question?	The study considered the characteristics as shown in the results section. There was no statistically significant difference in the following variables between those who responded to desmopressin and those who did not: gender, age, family history, frequency of NE (number of wet nights per week)
Effect due to factor in study?	The study did not identify any differences in patient characteristics
Consistency of results with other studies?	No other similar studies

How directly applicable to population of the guideline? Children had a mean age of 15.3 years

Internal Validity

Reference number 3940 **Study Type** **Cohort** RID:
O'Regan S;Yazbeck S;Hamberger B;Schick E; 763
Constipation a commonly unrecognized cause of enuresis
1986 140 Am J Dis Child pgs 260 261

Number of subjects 29 patients

Inclusion/Exclusion Criteria: Patients were referred for assessment or to eliminate renal pathologic conditions. Constipation was described as – more than 72 hours between bowel movements, presence of overflow incontinence (encopresis), passage of small, hard, scibalous stools with intermittent passage of large stools, poor emptying and dilation of rectal ampulla after defecations determined by rectal examination and grossly decreased level of perception and increased tolerance to balloon insufflation during rectal manometry combined with any element of the four alone.

Characteristics of subjects or environment/prognostic factor Not reported.

Recruitment: Referred for assessment or to eliminate renal pathologic conditions.

Setting: University of Montreal, Canada.

Interventions/Test /Factor being investigated Assessment and treatment of constipation.

Comparitors No comparison.

Length of Study/ Follow-up 9.2 months follow up.

Outcome measures studies Becoming dry.

Results 25 out of 29 patients had been referred for assessment and treatment of enuresis, 4 had severe functional constipation in the absences of urinary symptoms.

22 out of 25 with enuresis children had a history of constipation. The children underwent urodynamic studies to assess for bladder instability. The children were treated with phosphate enemas.

All patients had bladder instability identified by either the presence of uninhibited contractions of the detrusor during the filling phase of the bladder with an amplitude equal or greater than 15 cm H₂O or the occurrence of destrusor contraction at the end of or after urinary flow.

The mean response time to treatment of NE was 16 (sd 10) days with a range of 3 days to 6 weeks prior to resolution.

At follow up 5 out of 7 males had no NE, 2 out of 7 had partial response or wet once a week (from a baseline of 7 nights a week). 9 out of 10 girls had no NE, and 1 out of 10 had partial response or wet once a week (from a baseline of 7 nights a week). 5 children failed to undergo therapy, 1 was treated with imipramine and had a complete response, and 4 children continued to have NE.

Funding Not reported.

Does the study answer the question? All children who were treated for constipation initially became dry, there were some relapses at follow up. The authors said the study “strongly implicated unrecognized rectal distention as an etiologic factor of enuresis.

Effect due to factor in study? Study showed treating constipation can increase dryness.

Consistency of results with other studies? No other similar studies.

How directly applicable to population of the guideline? Very specialist referral group, unclear patient characteristics.

Internal Validity

Reference number	817	Study Type	Cohort	RID:
Robson W;Leung AKC;Van H;				141
Primary and secondary nocturnal enuresis: Similarities in presentation				
2005	115		pgs 956	959

Number of subjects 170 patients with either primary nocturnal enuresis (PNE) or secondary nocturnal enuresis (SNE).

Inclusion/Exclusion Criteria: Inclusion: aged of 3.5 years, wet at least 1 night a month, primary NE (PNE) was children who had never achieved a period of night time dryness of over 6 consecutive months; or secondary NE (SNE) was described as the child having had a period of night time dryness of over 6 consecutive months

Characteristics of subjects or environment/prognostic factor Exclusion: parent or guardian did not know if the child had experience a period of dryness of at least 6 months, structural abnormality of bladder or urethra, major neurologic problem, or morbid obesity.
103 were male, 67 were female, the mean age for children with PNE was 8.05 (sd 2.96), for SNE was 8.12 (sd 3.78)

Recruitment: Attended pediatric urology voiding dysfunction clinic, Health Sciences Centre

Setting: University of Oklahoma, USA

Interventions/Test /Factor being investigated Comparison of patient characteristics for PNE and SNE

Comparitors No comparison

Length of Study/ Follow-up No follow up

Outcome measures studies Differences in patient characteristics of children with PNE or SNE

Results Questionnaire considering: age and gender, frequency of voiding, nocturia, urgency, squatting behaviour for girls, daytime wetting, UTI, constipation, ADHD, VUR, uroflow and post void residual

There was a statistically significant difference between PNE and SNE for constipation:
In PNE 74.59% had constipation compared to 57.54% in SNE (p = 0.394; OR 2.17, 95% CI 1.07, 4.41)

There was no statistically significant difference between PNE and SNE for:

Male gender: In PNE 59.35% compared to 63.93% in SNE (p = 0.7259)
 Age when voiding on own: In PNE 2.35 (sd 0.71) years compared to 2.13 (sd 0.61) years in SNE (p = 0.0.538)
 Age when assessed: In PNE 8.05 (sd 2.96) years compared to 8.12 (sd 3.78) years in SNE (p = 0.0.9024)
 Infrequent voiding: In PNE 14% compared to 17% in SNE (p = 0.6275)
 Normal frequency: In PNE 45% compared to 48% in SNE (p = 0.7318)
 Frequent voiding: In PNE 41% compared to 35% in SNE (p = 0.4825)
 Nocturia: In PNE 25% compared to 22% in SNE (p = 0.6906)
 Urgency: In PNE 85% compared to 77% in SNE (p = 0.1791)
 Squatting behaviour for girls: In PNE 36% compared to 38% in SNE (p = 0.8231)
 Daytime wetting: In PNE 86% compared to 79% in SNE (p = 0.2468)
 UTI: In PNE 57.72% compared to 65.96% in SNE (p = 0.3832)
 ADHD: In PNE 18.03% compared to 15.22% in SNE (p = 0.8199)
 VUR: In PNE 36.73% compared to 17.65% in SNE (p = 0.2273)
 Normal uroflow: In PNE 63.72% compared to 60.98% in SNE (p = 0.8506)
 Tower: In PNE 0.88% compared to 4.88% in SNE (p = 0.1731)
 Interrupter: In PNE 19.47% compared to 17.07% in SNE (p = 0.8193)
 Obstructive: In PNE 8.13% compared to 8.51% in SNE (p = 1.000)
 Postvoid residual: In PNE 39.47% compared to 38.30% in SNE (p = 1.0)

Funding Not reported

Does the study answer the question? The authors reported the only significant difference between children with PNE and SNE was constipation with more children with SNE having constipation

Effect due to factor in study? Study identified a significant difference between patients with primary and secondary NE

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Mean age 8.05 and 8.12 years

Internal Validity

Reference number	86	Study Type	Cohort	RID:
	Van Hoecke E;Baeyens D;Vanden B;Hoebeke P;Vande W;			473
	Early detection of psychological problems in a population of children with enuresis: construction and validation of the Short Screening Instrument for Psychological Problems in Enuresis			
2007	178		pgs	2611 2615

Number of subjects Phase I (construction of the SSIPPE): Sample 1, n=261. n=141 patients from previous psychological/emotional problems prevalence studies and 120 from ADHD prevalence studies. Sample 1A (emotional problems): n=63 children. Sample 1B (ADHD): n=48. Phase II (validation of SSIPPE): Sample 2 (newly admitted): n=109.

Inclusion/Exclusion Criteria: Phase II: exclusion: children with anatomical or neurological abnormalities, mental retardation or chronic diseases.

Characteristics of subjects or environment/prognostic factor Aged 6 to 12 years old. Participants had monosymptomatic and non-monosymptomatic nocturnal enuresis diagnosed in a tertiary care setting. The participants had taken part in prevalence studies on psychological/emotional problems (141 patients) and ADHD (120 patients) in enuresis. Sample 1A (63 patients) had enuresis with a clinical/subclinical score on the internalising scale of the CBCL. Sample 1B (48 patients) with diagnosis of ADHD on the DBDRS and the Diagnostic interview schedule for children, parent version.

	Phase II (validation of SSIPPE): 109 children (76 boys and 33 girls) with a mean age of 8.5 years (s.d. 2.4).
Recruitment:	Validation participants were newly admitted to hospital.
Setting:	Pediatric Uro/Nephrologic centre (Ghent Uni hosp).
Interventions/Test /Factor being investigated	Psychological assessments.
Comparitors	No comparisons.
Length of Study/ Follow-up	No follow-up.
Outcome measures studies	Phase I: emotional problems -31 items of internalising scale of the CBCL. ADHD based on the DBDRS -18 items of the inattention and hyperactivity/impulsivity scales used to find highest loading items for inclusion in SSIPPE.Phase II:sensitivity/specificity
Results	<p>Phase I: Highest loading items of internalising scale of CBCL and ADHD scales of DBDRS on prinicpal factor analysis:</p> <p>Feels others reacting negatively: 0.74 (anxious/depressed) - CBCL Feels worthless: 0.65 (anxious/depressed) - CBCL Unhappy: 0.65 (anxious/depressed) - CBCL Lacks energy: 0.69 (withdrawn) - CBCL Nausea: 0.78 (physical complaints) - CBCL Headaches: 0.73 (physical complaints) - CBCL Stomach problems: 0.72 (physical complaints) - CBCL Insufficient attention: 0.82 (inattention) - DBDRS Difficulty organising tasks: 0.82 (inattention) - DBDRS Forgetful in daily tasks: 0.81 (inattention) - DBDRS Talks continuously: 0.79 (hyperactivity/impulsivity) - DBDRS Busy: 0.79 (hyperactivity/impulsivity) - DBDRS Running or climbing: 0.75 (hyperactivity/impusivity) - DBDRS</p> <p>Phase II: Prediction of CBCL internalising symptoms - sensitivity: 0.75, specificity: 0.91. DBDRS - inattention sensitivity: 0.29, specificity: 0.99; hyperactivity/impulsivity sensitivity: 0.36, specificity: 0.99.</p>
Funding	Not reported.
Does the study answer the question?	<p>ROC curve analysis showed classification accuracty of 88% (considered good). Showed that the 3 SSIPPE subsclsss had an excellent specificity, leading to few false-negative results and low sensitivity of inattention and hyperactivity/impulsivity leading to higher number of false-positive results.</p> <p>The authors concluded that the SSIPPE was a time efficient and cost-effective first screening of psychological problems and gives an indication of whether a full psychiatric /psychological screening is necessary.</p>
Effect due to factor in study?	
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Aged 6 to 12 years

Internal Validity

Reference number 4083 **Study Type** **Cohort** RID: 781
 Van Hoecke E;Hoebeke P;Braet C;Walle JV;
 An assessment of internalizing problems in children with enuresis
 2004 171 pgs 2580 2583

Number of subjects 84 patients with enuresis and 36 patients without enuresis

Inclusion/Exclusion Criteria: Inclusion: night time and or day time wetting.
 Exclusion: anatomical neurological abnormalities,or mentally retarded children.

Characteristics of subjects or environment/prognostic factor Enuresis group: 75% were male, the mean age was 10 years, 77% had night time wetting, and 23% had night and day time wetting.
 Control group: 51.4% were male, and the mean age was 10.2 years.
 There was a statistically significant difference in distribution of gender types of the two groups.

Recruitment: Second visit to Paediatric Uro/Nephrologic Centre.

Setting: The Ghent University Hospital, Belgium.

Interventions/Test /Factor being investigated The Social Anxiety Scale for Children (SAS-C), the state-trait anxiety inventory for children (STAI-C), The shortened depression questionnaire for children (SDQ-C), The Self-Perception Profile for Children by Harter (SPP-C),and Child Behaviour Checklist (CBCL).

Comparitors Between children with enuresis and without enuresis.

Length of Study/ Follow-up No follow up.

Outcome measures studies Scores on the measurement scales.

Results The Social Anxiety Scale for Children (SAS-C) – measures cognitive and affective anxious reactions in different situation in 9 to 12 years old children.
 The state-trait anxiety inventory for children (STAI-C) – self reported inventory measure instrument to identify situation anxiety in 8 to 15 years old children, contains 20 sentences which refer to the feelings of the child at a certain moment.
 The shortened depression questionnaire for children (SDQ-C) – 9-item scale is a shortened version of the depression questionnaire for children and was developed for early identification of depressive or declining depressive children.
 The Self-Perception Profile for Children by Harter (SPP-C) – measures self-concept in 8 to 12 year of children and consists of 6 subscales.
 Child Behaviour Checklist (CBCL) – 3 broadband scales of internalising, externalising and total problems, study only used withdrawal, somatic complaints, anxious/depressive and social problem, a T-score of 63 or higher was considered clinical.
 Results of CBCL score: Comparing children with enuresis and children without enuresis the following were statistically significantly different: the raw score for withdrawal and the raw score for anxious/depressive; the t scores for internalising problems and total problems. The following were not statistically significantly different: the raw score for physical complaints and social problems.
 The study showed for children within the clinical range of the CBCL score for internalizing problems in the enuresis group 19.7% compared to 11.6% in the control group; for internalizing problems in the enuresis group 20.4% compared to 6.1% in the control group.
 Results of the SAS-C, STAI-C, SDQ-C and SPP-C scores: Comparing children with enuresis and children without enuresis the following were statistically significantly different: on the SAS-C score was social desirability. The following were not statistically significantly different: on the SAS-C score – social situations, intellectual situations, athletic situations, physical appearance, cognitive reactions, emotional

reactions, total anxiety; the STAI-C score, the SDS-C score, on the SPP-C score – scholastic competence, social acceptance, athletic competence, physical appearance, behavioural conduct, global self worth.

The study compared correlations between CBCL and SPP-C, STAI-C and SDQ-C for the entire sample: there was a statistically significant difference for SPP-C score compared to CBCL score for social acceptance, behavioural conduct and global self worth. There was no statistically significant difference between the STAI-C and SDQ-C scores and CBCL scores.

The study compared correlations between CBCL and SPP-C, STAI-C and SDQ-C for the children with enuresis: there was no statistically significant difference for SPP-C, the STAI-C and SDQ-C scores compared to CBCL score.

Funding Not reported.

Does the study answer the question? There was a statistically significant difference between children with NE and children without NE on the CBCL score for the raw score for withdrawal and the raw score for anxious/depressive, and the t scores for internalising problems and total problems; and on the SAS-C score for social desirability.

Effect due to factor in study? There was a statistically significant difference between children with NE and children without NE.

Consistency of results with other studies? No other similar studies.

How directly applicable to population of the guideline? Children had a mean age of 10 years in the NE group and 10.2 years in the control group.

Internal Validity

Reference number	650	Study Type	Cohort	RID:
Yeung CK;Chiu HN;Sit FK;				531
Bladder dysfunction in children with refractory monosymptomatic primary nocturnal enuresis				
1999	162		pgs	1049 1054

Number of subjects N=46

Inclusion/Exclusion Criteria: Inclusion: monosymptomatic primary nocturnal enuresis; Treatment failure defined as non-response - failure to achieve an average decrease of 50% or greater in bedwetting frequency weekly during therapy) or significant relapse of enuretic symptoms to 3 or more wet nights weekly after stopping treatment. Exclusions: any identifiable urinary symptoms other than nocturnal enuresis.

Characteristics of subjects or environment/prognostic factor 37 chinese boys and 9 girls. Aged 7 to 15 years old (mean age 10.2). The participants had monosymptomatic primary nocturnal enuresis (3 or more nights weekly) and had treatment failure. Previously the participants had been part of an interhospital prospective treatment study of primary nocturnal enuresis and had 12-weeks of oral desmopressin with or without an enuretic alarm.

Recruitment: Not reported.

Setting: Evaluation done in hospital. Assume in China?

Interventions/Test /Factor being investigated Bladder dysfunction through urodynamic study(day) and EEG and cystometry monitoring (night).

Comparitors Not reported.

**Length of Study/
Follow-up**

None reported.

**Outcome measures
studies**

Daytime and nighttime urinary output; functional bladder capacity; decrease of 50% or greater in no. of wet nights during treatment.

Results

Evaluations were done by natural and conventional filling urodynamic study in the daytime and simultaneous EEG and cystometry monitoring during sleep at night.

The study wrote that: pattern 1 - normal daytime urodynamics with significant bladder instability at night with normal volume voiding precipitated by unstable detrusor contractions in 14 boys(34%). Pattern 2- normal daytime urodynamics with frequent small volume voiding at night, probably representing latent bladder instability, in 4 boys (10%). Pattern 3 involved abnormal daytime urodynamics with small bladder capacity, a disordinated daytime voiding pattern and marked nighttime bladder instability associated with poor sleep in 6 boys (15%). Pattern 4 was abnormal daytime urodynamics with an obstructive pattern, and marked daytime and nighttime detrusor hypercontractility (mean maximum detrusor pressure 178 cm water) in 8 boys (20%). Pattern 5 was abnormal daytime urodynamics with a dysfunctional daytime voiding pattern and frequent small volume nighttime voiding in 8 girls and 1 boy (22%).

The home recordings of urinary output showed the majority of patients had a daytime to nighttime urinary output ratio of greater than 1 (mean 2.43, range 0.89 to 6.32). Almost none had nocturnal polyuria (table 1).

Table 1: daytime and nighttime urine output:

Mean urine output +/- s.d (ml):

pattern	daytime	nighttime	mean daytime/nighttime output +/- s.d
1	810 +/- 291	360 +/-222	2.92 +/-1.77
2	1182 +/- 348	596 +/-364	2.31 +/-0.89
3	797 +/- 72	423 +/-224	2.44 +/-1.27
4	818 +/- 196	433 +/-67	1.98 +/-0.75
5	868 +/- 78	436 +/-129	2.15 +/-0.69
overall:	867 +/-244	429 +/-209	2.43 +/-1.24

Functional bladder capacity ranged from 60 to 380ml (mean 192) which was closely correlated with bladder capacity on cystometry during natural filling urodynamics (table 2).

Table 2: functional bladder capacity

pattern	Mean Bladder capacity +/- s.d (ml)			%
	cystometric	functional	expected for age	
	functional/expected capacity			
1	252 +/-103	247 +/-95	343 +/-67	72 +/-23
2	233 +/-30	210 +/-26	353 +/-75	62 +/-19
3	129 +/-123	167 +/-88	355 +/-79	49 +/-27
4	92 +/-58	118 +/-51	390 +/-57	30 +/-9
5	174 +/-77	197 +/-71	385 +/-69	53 +/-22
overall	178 +/-106	192 +/-85	364 +/-67	54 +/-25

A 4-week course of 400microgrammes desmopressin orally at bedtime still produced a significant response - greater than 50% decrease in the number of wet nights during treatment in 47% of the patients, although symptoms relapsed on stopping therapy in all.

Response to desmopressin therapy

Mean no. wet nights/week +/- s.d

Pattern	before therapy	during therapy	% patients significantly improved
1	5.9 +/- 1.5	3.7 +/- 3.0	50
2	5.5 +/- 1.0	1.3 +/- 1.8	75
3	5.2 +/- 1.1	2.3 +/- 2.8	60
4	5.0 +/- 1.1	2.3 +/- 1.7	50

	5	4.6 +/- 1.7	3.4 +/- 1.8	14
	overall	5.3 +/- 1.4	2.9 +/- 2.4	47
Funding	Not reported.			
Does the study answer the question?	<p>All patients had a small functional bladder capacity compared with that expected of their age and they voided small volumes frequently. This finding was associated with various patterns of bladder dysfunction.</p> <p>They concluded that monosymptomatic nocturnal enuresis is a heterogeneous condition consisting of a spectrum of disorders and various types of bladder dysfunction that probably contribute significantly to its pathogenesis, especially in patients with treatment failure and refractory symptoms. Nocturnal enuresis may be the only symptom even in children with gross underlying bladder dysfunction.</p>			
Effect due to factor in study?				
Consistency of results with other studies?	No other similar studies			
How directly applicable to population of the guideline?	Aged 7 to 15 years old, mean age 10.4 years and had primary monosymptomatic NE			
Internal Validity				

Question: What is clinical and cost effectiveness of additional investigation and treatment in children who have not responded to an adequate trial of both desmopressin and or alarms?

9

Funding	Study states desmopressin was Ferring AB, Sweden but does not report funding
Does the study answer the question?	The study showed that more children became dry with desmopressin and children on desmopressin had fewer wet nights at the end of treatment but there was little difference in the number of wet nights between the number of wet nights at follow up.
Effect due to factor in study?	Yes
Consistency of results with other studies?	
How directly applicable to population of the guideline?	Age range 7-15 years
Internal Validity	Unclear allocation concealment, number of drop outs not reported, inclusion criteria not reported Double blind trial
Reference number	3902
Study Type	Randomised Controlled Trial
RID:	741
Austin PF;Ferguson G;Yan Y;Campigotto MJ;Royer ME;Coplen DE;	
Combination therapy with desmopressin and an anticholinergic medication for nonresponders to desmopressin for monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial	
	pgs
2008 122	1027 1032
Number of subjects	34 patients, 16 in desmopressin and placebo, 18 in desmopressin and tolterodine
Inclusion/Exclusion Criteria:	Inclusion: aged 6 to 17 years, monosymptomatic primary NE, failed treatment of tablet 0.6mg desmopressin as monotherapy (both partial and non response), 4 wet nights a week Exclusion: PUT symptoms, bowel elimination problems (eg encopresis or constipation), day time wetting, increased or decrease voiding frequency, receiving anticholinergic treatment, know allergy to anticholingergics used for bladder relaxation, any history of gastric retention, uncontrolled narrow-angle glaucoma.
Characteristics of subjects or environment/prognostic factor	In the desmopressin and placebo group the mean age was 10.5 (sd 2.25) years, 12 out of 16 were male, the mean number of wet nights was 6.56 (sd 0.81) per week at baseline. In the desmopressin and tolterodine group the mean age was 10.56 (sd 2.28) years, 12 out of 18 were male, the mean number of wet nights was 6.22 (sd 1.16) per week at baseline
Recruitment:	Patients referred to paediatric clinic for treatment of NE
Setting:	Paediatric clinic, USA
Interventions/Test /Factor being investigated	Group A: 0.6 mg Desmopressin and placebo Group B: 0.6 mg desmopressin and 4 mg tolterodine
Comparitors	Between groups A and B
Length of Study/ Follow-up	1 months
Outcome measures studies	Number of children who achieved 14 consecutive dry nights, Number of children who achieved >50% improvements in the number of dry nights
Results	1 month of treatment Number of children who achieved 14 consecutive dry nights:

Outcome measures studies	full and partial response, mean number of wet nights in last 2 weeks of trial, adverse events, drop out	
Results	<p>5 weeks of each treatment</p> <p>Children underwent a 2 week observation period and then 2 weeks of 0.4 mg desmopressin at bedtime to ensure only therapy resistant children were included</p> <p>Full response 5 out of 25 responded to imipramine, 0 out of 25 responded to tolterodine or placebo.</p> <p>>50% improvement 2 out of 25 had a partial response to imipramine only and 1 out of 25 children had a partial response to tolterodine. 0 out of 25 had a partial response to placebo.</p> <p>Mean number of wet nights in last 2 weeks of treatment: In the tolterodine group the mean number of wet nights in the last 2 weeks of treatment was 10.4 (SD 3.9), in the imipramine group the mean was 7.8 (SD 5.1) and in the placebo group the mean was 11 (SD 3.9). Imipramine was significantly better than the placebo (p=0.001) and significantly better than tolterodine (p=0.006)</p> <p>Number of drop outs: In the imipramine group 1 child dropped out due to nausea and in the placebo group 1 child dropped out due to becoming spontaneously dry</p> <p>Adverse events: In the group treated with imipramine, 3 children had slight mood changes, 2 had insomnia, 1 had palpitations, 2 had slight nausea (1 of which dropped out). In the group treated with tolterodine 1 child had slight mood change. There were no adverse events in the placebo group.</p>	
Funding	Not reported	
Does the study answer the question?	The study showed that imipramine was more effective in giving a full response, it also showed that imipramine was significantly better than both tolterodine and placebo treatment.	
Effect due to factor in study?	Yes	
Consistency of results with other studies?	No other studies to compare to	
How directly applicable to population of the guideline?	Age range 6-13 years	
Internal Validity	Cross over trial	
Reference number 1711 Stenberg A;Lackgren G; 1994 94	Study Type Randomised Controlled Trial	RID: 1506 pgs 841 846
Number of subjects	10 patients were allocated either to placebo or desmopressin tablets.	

Inclusion/Exclusion Criteria:	Inclusion criteria: adolescents (12 years or older) suffering from severe Primary NE, defined as a minimum of 3 wet nights per week during an observation period of 2 weeks. Exclusion criteria: daytime wetting, urinary tract infection, or urinary tract abnormalities. Patients could have not been treated with any conditioning device or any other antienuretic regimen 2 weeks before entry into the study.
Characteristics of subjects or environment/prognostic factor	20 males and 5 females with a mean age of 13.5 years (range 11 to 21 years) median 13.0. Baseline wetting 4.7 (SD 1.1) wet nights per week. All patients but three had previously used the bell and pad conditioning system with no improvement. 15 patients had been treated with antidepressant drugs. Other drugs, which had failed were: ephedrine (4 patients) and terodiline, propantheline, and emepromium bromide (1 patient each). 9 patients had a family history of enuresis.
Recruitment:	Not reported.
Setting:	Children's hospital. Sweden
Interventions/Test /Factor being investigated	<p>First 2 week single blind titration period was started and 200 and 400micrograms of DDAVP were administered. All patients were given diary cards and the registration of dry and wet nights was done by the parents. For the long-term treatment period, each patient was given the lowest dosage of demopressin that reduced the number of wet nights by 50% or more. The patients who did not have a reduction in wet nights continued on the 400microgram dose.</p> <p>Double-blind period- during the first 2 weeks the first 10 patients were allocated to placebo or desmopressin tablets. After 2 weeks treatment, each patient was crossed over to the alternate therapy. This was a separate part of the study and all patients who were included in the double blind part continued with the long-term studies.</p> <p>Long term treatment period- open period with two 12 week spans with demopressin treatment each followed by a 2 week observation period without use of medication. Patients were then divided into 1) full responders, with just 1 wet night; 2)intermediate responders with two to 3 wet nights, and 3)nonresponders with more than 3 wet nights per week. No significant crossover period occurred between full responders and nonresponders.</p>
Comparitors	Desmopressin versus placebo
Length of Study/ Follow-up	Follow up for 2 weeks after treatment.
Outcome measures studies	Mean number of wet nights, adverse events
Results	<p>First 2 week single blind titration period- during this period the mean number of wet nights per week was 4.9 ± 1.2 and during the dose titration for the first week when the patients received 200 micrograms, the mean number of wet nights was 2.8 ± 2.2. In the second week of dose titration the patients received a daily dose of 400micrograms. The mean number of wet nights 2.4 ± 2.3. Throughout the dose titration period, there was a decrease of about 50% in bed wetting compared to the observation period.</p> <p>Double-blind period- The mean baseline value of wet nights per week was 4.7 ± 1.1. During the 2 weeks on desmopressin, the mean number of wet nights was reduced to 1.8 ± 1.4. The corresponding value for the placebo period was 4.1 ± 1.5. the difference between placebo and desmopressin in mean number of wet nights was 2.35 units with a 95% confidence interval for the population difference from 1.5 to 3.1</p> <p>Long term treatment period I- 23 patients entered the first long term treatment period. The number of wet nights for the whole group was 2.0 ± 2.1. Eleven patients were full responders, 5 intermediate and 7 did not respond to the drug.</p> <p>Midtreatment observation period- mean number of wet nights per week increased to 3.0 ± 2.3. 1 patient did not turn up for follow up.</p> <p>Long term treatment period II- 17 patients entered the second long term period, 3 on 200micrograms tablets and 14 on 400 micrograms daily. The mean number of wet</p>

Results	3 weeks of treatment Mean number of wet nights Group A (desmopressin) had a mean number of wet nights of 30.9 (sd 28.7) while Group B (placebo) had a mean number of wet nights of 57.5 (sd 26.1).
Funding	Not reported
Does the study answer the question?	The study shows children treated with desmopressin had fewer wet nights compared to children treated with placebo.
Effect due to factor in study?	Yes
Consistency of results with other studies?	No other studies.
How directly applicable to population of the guideline?	Children had an age range of 7 to 16 years.
Internal Validity	Cross over trial. No wash out.

Reference number 495 **Study Type** **Randomised Controlled Trial** RID:
Tuvemo T; 1513
DDAVP in childhood nocturnal enuresis
1978 67 pgs 753 755

Number of subjects	18 children in total. 8 patients received intervention in the first 28 day period and 10 received it in the second 28 day period.
Inclusion/Exclusion Criteria:	Inclusion: Age at least 6 years.
Characteristics of subjects or environment/prognostic factor	Age: ranged 6-12 years. Previous treatment: children had not responded satisfactorily to previous treatment with imipramine or amitriptyline. Baseline wetting: mean (SEM) number of dry nights out of 28: 7.5 (2.98).
Recruitment:	Not reported.
Setting:	University Hospital, Sweden.
Interventions/Test /Factor being investigated	A: Intervention group received 20 micro-grams intranasal DDAVP (minerin) just before bedtime after emptying bladder. B: Identical placebo as above (crossover trial). 28 days in each condition.
Comparitors	Placebo then intervention (crossover trial).

Length of Study/ Follow-up	No follow-up
Outcome measures studies	Mean number of dry nights out of 28. Side effects. Number of children whose results were said to be excellent. Follow-up after 6 months.
Results	Mean (SE no. of dry nights out of 28: A= 21.7 (1.72), B= 12.1 (2.07), p<0.001. Prior to the trial the children were dry 8 (mean 7.5, SEM=2.98) out of 2 nights. No of children whose results were said to be excellent: 8; relatively good: 8; unsatisfactory: 2. Side effects: none reported (no physical or subjective side effects observed).
Funding	Not reported.
Does the study answer the question?	The main conclusion of the study was that DDAVP (20 micrograms) administered intranasally at bedtime statistically significantly prevented bed-wetting compared to a placebo.
Effect due to factor in study?	Not sure. No power calculation given and only 18 participants with no clear allocation concealment.
Consistency of results with other studies?	
How directly applicable to population of the guideline?	Intervention and population was of interest to the guideline, few of the outcomes reported were those relevant to the guideline.
Internal Validity	Active and placebo results combined so cannot see any order or carryover effects. Study reports that it was randomised and a code was given but no details of randomisation were given.

Reference number 32 **Study Type** **Randomised Controlled Trial** RID:
Tuygun C;Eroglu M;Bakirtas H;Gucuk A;Zengin K;Imamoglu A; 399
Is second-line enuretic alarm therapy after unsuccessful pharmacotherapy superior to first-line therapy in the treatment of monosymptomatic nocturnal enuresis?
2007 78 pgs 260 263

Number of subjects	84 patients in total, 35 in group A, 49 in group B and 19 in group C
Inclusion/Exclusion Criteria:	Inclusion: monosymptomatic nocturnal enuresis, wet at least 3 times a week during the last 3 months Exclusion: Diurnal enuresis, polyuric disorders, genitourinary system abnormalities, neurological disorders, recurrent UTIs
Characteristics of subjects or environment/prognos tic factor	The median age was 8 years (range 6-13 years). The ratio of male/ female was 3/2. There was no significant difference between the three group's age or sex. 71.73% had at least one parent with a history of enuresis. At baseline 54.34% were wet 25-30 nights a month, 20.65% were wet 20-25 nights a month and 25% were wet 15-20 nights a month.
Recruitment:	Not reported
Setting:	Turkey, treatment at home

Interventions/Test /Factor being investigated	Group A: alarm Group B: desmopressin Group C: those who were in group B but did not become dry were changed to have alarm treatment
Comparitors	Between groups A, B and C
Length of Study/ Follow-up	6 months
Outcome measures studies	>90% decrease in number of wet nights, 50-90% decrease in number of wet nights, relapse at 6 months, change in number of wet nights
Results	<p>Treatment was for 3 months</p> <p>>90% decrease in number of wet nights: After 3 months of treatment in group A (alarm) 20 out of 35 children (57.14%) had achieved a >90% in number of wet nights compared to 25 out of 49 (51.02%) in group B (desmopressin) and 13 out of 19 (68.42%) in group C (desmopressin then alarm). These differences were not significant.</p> <p>50-90% decrease in number of wet nights: After 3 months of treatment in group A (alarm) 9 out of 35 children (27.71%) had achieved a 50-90% in number of wet nights compared to 15 out of 49 (30.61%) in group B (desmopressin) and 3 out of 19 (15.78%) in group C (desmopressin then alarm). These differences were not significant.</p> <p>Relapse at 6 months: At 6 months 10 out of 35 children (28.57%) had relapsed compared to 27 out of 49 (55.10%) in group B (desmopressin) and 6 out of 9 (31.57) in group C (desmopressin then alarm). The difference between groups A and B was significant $p=0.008$ but the difference between groups A and C was not significant.</p> <p>Change in mean number of wet nights: In group A (alarm) at baseline the mean number of wet nights per month was 23.2 (SD 6.23) at the end of treatment it was 3.41 (SD7.68), this difference was significant $p<0.001$. In group B (desmopressin) at baseline the mean number of wet nights per month was 23.44 (SD 6.3) at the end of treatment it was 10.7 (SD 10.94), this difference was significant $p<0.001$. In group C (desmopressin then alarm) at baseline the mean number of wet nights was 28 (SD 1.37) at the end of treatment it was 5.5 (SD 10.65), this difference was significant $p<0.001$. The difference between groups A, B and C was also significant $p=0.008$.</p>
Funding	Not reported
Does the study answer the question?	The study showed that treating children with an alarm was more effective than desmopressin in reducing the number of wet nights, it also showed that if patients did not respond to desmopressin treating them with an alarm did lead to a reduction in the number of wet nights. The study showed that few children who were treated with an alarm, both as initial treatment and as secondary treatment were significantly less likely to relapses than those treated with desmopressin. All groups had a significant reduction in the mean number of wet nights per month.
Effect due to factor in study?	Yes
Consistency of results with other studies?	
How directly applicable to population of the guideline?	Children were aged between 6-13 years

Internal Validity

Grading: 1-	Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*
--------------------	---

Reference number 27 Study Type Randomised Controlled Trial RID:
 Butler RJ;Brewin CR;Forsythe WI; 1502

A comparison of two approaches to the treatment of nocturnal enuresis and the prediction of effectiveness using pre-treatment variables
 1988 I 29 J Child Psychol Psychiatry pgs 501 509

Number of subjects 74 in total

Inclusion/Exclusion Criteria: Inclusion: Aged over 6 years, wetting at least 5 times a week for a month, normal clinical examination, normal urine on microscopy, normal intelligence, not having any form of enuresis-related drug or psychotherapeutic treatment

Characteristics of subjects or environment/prognostic factor 76% were boys, The mean age was 9.7 years (range 6.1-14.4 years)
 48.6% has previously been treated with an alarm, in the DBT group 66% had been previously been treated with an alarm compared to 25% in the alarm group

Recruitment: Patients were referred as out patients for treatment of NE

Setting: Leeds, UK. At home

Interventions/Test /Factor being investigated Group A: alarm
 Group B: MDBT with alarm but without reprimands

Comparitors Between groups A and B

Length of Study/ Follow-up 0 months

Outcome measures studies Dry for 14 consecutive nights, change in number of wet nights, dropouts

Results Modified dry bed training removed the punitive elements

16 weeks treatment

The drop out rates were 8 in the alarm group and 2 in the DBT-M group. Four more were terminated by agreement early in the DBT-M group.

14 consecutive dry nights were achieved by 20 out of 28 children in the alarm group and 15 out of 35 in the DBT group.

The baseline number of dry nights (during 4 week baseline period) was 1.02 for the DBT-M group and 1.07 for the Enuresis Alarm, $t < 1$, $p > 0.10$. The number of dry nights in the last 4 weeks of treatment was 23.79 for the DBT-M group and 20.76 for the enuresis alarm group. The differences between all outcome measures were not statistically significant.

The mean number of wet nights per week at end of treatment for the alarm was 1.81 compared to 1.05 for the dry bed training.

Funding Not reported

Does the study answer the question? A modified version of the Dry Bed Training was compared to the standard enuresis alarm treatment. The DBT-M had was an alarm plus training in comparison to just an alarm. Both had success rates of 70%. The author concludes that the the additional procedures involved in DBT-M do not seem to increase effectiveness substantially maybe ue to the amount of training given (one night).

Effect due to factor in study? Yes (NB there is a 15% spontaneous cure rate)

Consistency of results with other studies?

How directly applicable to population of the guideline? Children were aged over 6 years

Internal Validity

Reference number 362 **Study Type** **Randomised Controlled Trial** RID:
Butler RJ;Forsythe WI;Robertson J; 453
The body-worn alarm in the treatment of childhood enuresis
1990 44 pgs 237 241

Number of subjects In study 2: 48 in total, 24 in each group

Inclusion/Exclusion Criteria: Inclusion: wet at least 4 nights a week for a month, normal physical examination, normal urine microscopy, normal intelligence, not previously treated for NE with any conditioning method (except alarms), previously unsuccessful with pad and bell alarm, no associated diurnal enuresis

Characteristics of subjects or environment/prognostic factor The mean age was 10.6 years (range 7.4-14.7 years), 81% were boys
In group A the mean age was 10.2 years, the baseline number of dry nights was 1.2, and the male to female ratio was 19:5. In group B the mean age was 11.1 years, the baseline number of dry nights was 1.3, and the male to female ratio was 20:4
All patients had previously been unsuccessfully treated with pad and bell alarm

Recruitment: Referred as out-patients for treatment of Ne (in both studies)

Setting: Leeds, UK, at home

Interventions/Test /Factor being investigated Group A: MDBT with alarm (pad and bell)
Group B: alarm (body worn)

Comparitors Between group A and B

Length of Study/ Follow-up 6 months

Outcome measures studies Dry for 14 consecutive nights, number of wet nights, relapses

Results Modified dry bed training removed the punitive elements

16 weeks treatment

14 consecutive dry nights:
In group A (DBT) 14 out of 24 children achieved 14 consecutive dry nights compared to 20 out of 24 in group B (alarm). The difference was not statistically significant.

The mean number of wet nights before achieving 14 consecutive dry nights was 53.7 in group A (DBT) and 40.7 in group B (alarm).

There was an immediate response with both interventions, and from week 3 the body-worn alarm group consistently achieved more dry nights. The difference was significant at week 3 ($t=2.28$, $df=43$, $p<0.05$); and week 4 ($t=2.26$, $df=42$, $p<0.05$). At week 7 the children in the MDBT group achieved the same number of dry nights as the body-worn alarm group did in week 3.

Mean number of wet nights in 16 weeks
 In group A (DBT) the mean number of wet nights was 28.7 compared to 25 in group B (alarm). The difference was not statistically significant.

The mean number of wet nights per week at end of treatment for the alarm was 1.6 compared to 1.8 for the MDBT.

Number of children who relapsed:
 7 out of 14 of the DBT group relapsed within 6 months, 9 out of 20 relapsed in the alarm group.

Number of drop outs:
 1 out of 24 children dropped out of the alarm group compared to 2 out of 24 in the DBT group.

Funding Not reported

Does the study answer the question? It compares two types of alarms, the body-worn alarm and the pad and bell (modified dry-bed training). Both were equally effective in the first study (70%) and the second study initial arrest was 58% for the MDBT group and 83% for the body-worn alarm group, however the difference was not significant. The body-worn alarm achieved a greater number of dry nights earlier than the other group. The relapse rate was higher in the second study than the first study, the difference between groups was not significant.

Effect due to factor in study? Yes (NB there is a 15% spontaneous cure rate)

Consistency of results with other studies?

How directly applicable to population of the guideline? Children were aged between 6.1 years and 15.6 years

Inadequate concealment method

Internal Validity

Reference number	436	Study Type	Randomised Controlled Trial	RID:
Dimson SB;				1511
DDAVP and urine osmolality in refractory enuresis				
1986 61			pgs 1104	1107

Number of subjects 17 in total, cross over trial

Inclusion/Exclusion Criteria:
 Inclusion: failed to respond to drugs or alarm, aged 6-13 years
 Exclusion: organic cause of Ne, UTI, more dry nights than wet in baseline period of 2 years, had been dry between 2 and 3 1/2 - 4years

Characteristics of subjects or environment/prognostic factor
 14 were boys, the age range was 6-13 years, baseline wetting was greater than 50% wet nights during a 2 week observation period
 3 children had encopresis
 All children had failed to respond to alarms and drug treatment (study reports drug treatment to be mainly imipramine and amitriptyline)

Recruitment: patients who attended enuretic clinic Woolwich, east London, UK

Setting: London, UK

Interventions/Test /Factor being investigated
 Group A: intranasal desmopressin (20 micro grams)
 Group B: matching placebo

Comparitors	Between groups A and B
Length of Study/ Follow-up	No follow up
Outcome measures studies	achieving 14 consecutive dry nights, mean number of wet nights after 2 weeks of treatment, relapse
Results	2 weeks of treatment Number of children who achieved 14 consecutive dry nights: in group A (desmopressin) 2 out of 17 children achieved 14 consecutive dry nights compared to 0 in group B (placebo) Relapse All children relapsed after trial ended (17 out of 17) Mean number of wet nights per week: In group A (desmopressin) the mean number of wer nights was 3.4 compared to 5.0 in group B (placebo)
Funding	There were no side effects Ferring Pharmaceuticals
Does the study answer the question?	The study showed that children were more likely to become dry when treted with desmopressin and have fewer wet ngihts than when treated with placebo
Effect due to factor in study?	Yes
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Aged 6-13 years

Internal Validity This is a cross over trial

Reference number	429	Study Type	Randomised Controlled Trial	RID:
Fjellestad-Paulsen A;Wille S;Harris AS;				1514
Comparison of intranasal and oral desmopressin for nocturnal enuresis				
1987	62		pgs 674	677

Number of subjects	30 in total
Inclusion/Exclusion Criteria:	Inclusion: Exclusion: organic causes of NE, day time wetting, UTI, diurnal wetting, faecal soiling, neurological or urological abnormalities, more than 3 wet nights a week during baseline
Characteristics of subjects or environment/prognos tic factor	There were 20 boys, the mean age was 9.8 (SD 2.5) years, range 6-15 years, the mean number of dry nights at baseline was 2.2 (SD 0.2) 60% had failed to respond to alarms, 23% to desmopressin, 26% to tricyclics and 20% to anticholinergics
Recruitment:	Not reported
Setting:	Sweden

Interventions/Test /Factor being investigated	Group A: oral desmopressin 200 micro grams Group B: intranasal desmopressin 20 micro grams Group C: placebo
Comparitors	Between treatment groups
Length of Study/ Follow-up	1 week
Outcome measures studies	Mean number of dry nights, becoming totally dry
Results	<p>Patients had 2 weeks of placebo then 2 weeks of each treatment</p> <p>During treatments the mean number of dry nights was 4 in group A (oral desmopressin), 4.1 in group B (intranasal desmopressin) and 2.5 in group C (placebo)</p> <p>In group A (oral desmopressin) 2 patients became totally dry, compared to 1 in group B (intranasal desmopressin)</p> <p>At follow up 9 children were totally dry</p> <p>Side effects: 2 patients had nasal discomfort and 3 complained of epistaxis (there was no difference between placebo and treatment arms)</p>
Funding	Ferring AB Malmo Sweden
Does the study answer the question?	The study showed that desmopressin is more effective than placebo
Effect due to factor in study?	
Consistency of results with other studies?	
How directly applicable to population of the guideline?	Age 6-15 years
Internal Validity	This was a cross over trial, wash out of one week between treatments Not intention to treat

Reference number 233 **Study Type** **Randomised Controlled Trial** RID:
 Gibb S;Nolan T;South M;Noad L;Bates G;Vidmar S; 1504
 Evidence against a synergistic effect of desmopressin with conditioning in the treatment of nocturnal enuresis
 2004 144 pgs 351 357

Number of subjects 207 patients, 101 in group A and 106 in group B

Inclusion/Exclusion Criteria: Inclusion: non-responders to desmopressin intranasal spray after 4 weeks of treatment, aged 6-16 years old and who wet the bed at least 2 a week
 Exclusion: neuropathic bladder, urinary tract abnormality, cystic fibrosis, allergic rhinitis, UTI in the previous 2 weeks, taking imipramine or diuretics

Characteristics of subjects or environment/prognostic factor In group A (desmopressin and alarm) 63% were male, the mean age was 8.5 (1.78 SD), the mean number of wet nights in the preceeding 28 nights to treatment starting was 23.9 (5.05 SD), 45% had a positive family history, 14% had secondary enuresis, 11% had day time wetting. 37% had previous tried alarms and 31% had previously

	<p>tried medication for treatment of NE</p> <p>In group B (placebo and alarm) 73% were male, the mean age was 8.3 (1.93 SD), the mean number of wet nights in the preceding 28 nights to treatment starting was 23.7 (5.83 SD), 42% had a positive family history, 8.5% had secondary enuresis, 7.5% had day time wetting. 31% had previously tried alarms and 26% had previously tried medication for treatment of NE</p>
Recruitment:	Children were recruited from the general paediatric out-patient clinic at the Royal Children's hospital Melbourne
Setting:	At home
Interventions/Test /Factor being investigated	<p>Group A: 20 - 40 micro grams desmopressin (nasal spray) and alarm (pad and bell)</p> <p>Group B: placebo (nasal spray) and alarm (pad and bell)</p>
Comparitors	Between group A and B
Length of Study/ Follow-up	2 months
Outcome measures studies	28 dry nights, wet nights during treatment, drop out, adverse events
Results	<p>The study ran a 4-week "run in" of 358 patients treated with intranasal desmopressin. After 4 weeks non responders were randomised to two groups: group A had desmopressin intranasal spray and alarm (pad and bell) and group B had a placebo nasal spray and alarm (pad and bell)</p> <p>28 dry nights: In group A (alarm and placebo) 51 out of 106 children achieved 28 dry nights compared to 52 out of 101 children in group B (alarm and desmopressin)</p> <p>Drop out: In group A (alarm and placebo) 17 out of 106 children dropped out compared to 9 out of 101 children in group B (alarm and desmopressin)</p> <p>Mean number of wet nights: In group A (alarm and placebo) the mean number of wet nights per week was 2.4 (sd1.53) compared to 1.8 (sd 1.13) in group B (alarm and desmopressin)</p> <p>Adverse events: 1 child who received desmopressin with alarm reported headaches 1 child who received placebo with alarm reported nose bleeds</p> <p>The authors noted that day wetters were more likely to be non-responders to desmopressin 71% (20 out of 28)</p>
Funding	Research grant from Ferring Pharmaceuticals to the Murdoch Children's Research Institute
Does the study answer the question?	The study showed a non-significant difference in the number of patients achieving 28 dry nights between patients who received alarm with desmopressin and patients who received alarm with placebo. There was also a non-significant difference between the groups for the number of patients who relapsed and the change in number of wet nights.
Effect due to factor in study?	Yes (NB there is a 15% spontaneous cure rate)
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Yes - age range was 6-16 years

Internal Validity

Reference number	390	Study Type	Randomised Controlled Trial	RID:
Terho P;				1507
Desmopressin in nocturnal enuresis				
1991	145		pgs 818	820
Number of subjects	52 children.			
Inclusion/Exclusion Criteria:	Inclusion: lifelong nocturnal enuresis; no diurnal wetting; no soiling; no urological or renal pathological conditions.			
Characteristics of subjects or environment/prognostic factor	Previous treatment: 52 had night awakening; 52 had fluid restriction; 29 had used tricyclic antidepressants; 25 had used enuresis alarms. Age range: 5-13 years; 35 boys and 17 girls. Baseline wetting: mean (SD) number of dry nights per week: 0.6 (0.2). Almost all patients had a family history of wetting.			
Recruitment:	Finnish School children. Does not say how recruited.			
Setting:	Turku, Finland.			
Interventions/Test /Factor being investigated	A: intranasal desmopressin (20 micrograms) at bedtime rising to 40 micrograms if no response. B: placebo. Duration of treatment: 2 periods of 3 weeks in each condition. This part of the study was followed by a 3-week observation period.			
Comparators	Between treatment and placebo. Crossover trial?			
Length of Study/ Follow-up	3 weeks observation period after the study.			
Outcome measures studies	Mean number of dry nights per week; amount becoming totally dry during and after treatment; relapse after treatment; side effects.			
Results	Mean (SD) number of dry nights per week: The mean number of wet nights per week in the desmopressin group was 2.6 compared to 4.9 in the placebo group All comparisons among the 3 treatment options differed significantly ($p < 0.01$). 15 (29%) children became totally dry during desmopressin treatment. 5 children remained dry after treatment. 47 patients relapsed after treatment. Side effects: non reported.			
Funding	Does not say how funded. The author is from the Department of Health, Central School Clinic, Turku, Finland. Desmopressin was provided by Mr Per Wilhelmson, Ferring pharmaceuticals.			
Does the study answer the question?	The authors conclude that 'in a selected and severely enuretic population an increase from a mean of 0.6 to a mean of 4.5 dry nights per week with a dose of 20 micrograms desmopressin is regarded as a good response, although a further increase of dry nights would be welcomed.'			
Effect due to factor in study?	Can not be sure. The methodology is lacking.			

Consistency of results with other studies?

How directly applicable to population of the guideline? The intervention and population are the interest of this guideline.

Internal Validity Cross over trial, No washout reported.
Short follow up.
Called it a randomised double-blind, placebo-controlled cross-over study but did not specify how randomised, blinded or concealed.

Reference number 4119 **Study Type** **Randomised Controlled Trial** RID:
Vogt M;Lehnert T;Till H;Rolle U; 1518
Evaluation of different modes of combined therapy in children with monosymptomatic nocturnal enuresis
2009 BJU Int pgs
Sep 17

Number of subjects N=43 children (Group A N=24, Group B N=19)

Inclusion/Exclusion Criteria: Inclusion criteria: patients aged >5 and <=15 years with monosymptomatic nocturnal enuresis.
Exclusion criteria: treatment of enuresis within the last 12 months, daytime symptoms, or renal disease.

Characteristics of subjects or environment/prognostic factor 13/43 children achieved dryness after initial monotherapy or discontinued treatment.
Group A (N=16): female/male: 5/11, mean age: 6.7 (5-13), number of wet nights: 9.81 (sd 2.93)
Group B (N=14): female/male: 7/7, mean age: 6.4 (5-13), number of wet nights: 10.5 (sd 3.59)

Recruitment: Patients attending the outpatient clinic were invited to take part in the study.

Setting: Outpatient clinic

Interventions/Test /Factor being investigated Desmopressin followed by alarm treatment is compared to alarm treatment followed by desmopressin. Desmopressin was administered orally with an initial dose of 0.2mg (one tablet) for the first two weeks, followed by 0.4mg (two tablets) at night time for another 10 weeks.

Comparitors Comparisons are made between Group A (initially treated with desmopressin) Group B (initially treated with alarm).

Length of Study/ Follow-up Treatment for 12 weeks (desmopressin or alarm). For symptomatic only children, 12 weeks further treatment of desmopressin/alarm for Group A and alarm/desmopressin for Group B. Final evaluation after 1 year.

Outcome measures studies Complete dryness (maximum of 2 wet nights/ month, equals a 90% reduction of wet nights =response) in accordance to the standardization of the International Children's Continence Society.

Results After 12 weeks of treatment, 4/24 in Group A and 5/19 in Group B become dry and excluded from the treatment study. Another 4 children discontinued the treatment.

The remaining 30 were included in the analysis (16 in Group A and 14 in Group B). After the 3 months of single therapy and 3 months of combined therapy, 11/16 children in Group A and 11/14 in Group B were dry (P>0.2).

In total, 22/30 (73%) of children were dry, which consisted of 12/18 boys and 10/12 girls (P>0.2).
Of the children with a normal maximum voided volume, 79% (19/24) achieved dryness, whereas only 3/6 children with small voided volumes become dry (P=0.3).
13/19 of children with nocturnal polyuria and 9/11 with no nocturnal polyuria became

	dry after 6 months (P=0.672).
Funding	Not stated.
Does the study answer the question?	Yes. This study showed that combined therapy (desmopressin/alarm) can help children with MNE to achieve dryness in 73%. No significant difference was found between Group A and Group B, that is, the order of treatment.
Effect due to factor in study?	There was an unclear risk of selection and performance bias. No prior consideration of sample study was conducted. Uncertain that the overall effect is due to study intervention.
Consistency of results with other studies?	
How directly applicable to population of the guideline?	Direct.
Internal Validity	Unclear about the risk of selection and performance bias as no allocation concealment and blindness are described in the study. Low attrition bias and detection bias.

Grading: 2+	<i>Well-conducted case-control or cohort studies with a low risk of confounding, bias or chance and a</i>
--------------------	--

Reference number 663	Study Type	Cohort	RID:
Kosar A;Arikan N;Dincel C;			532
Effectiveness of oxybutynin hydrochloride in the treatment of enuresis nocturna--a clinical and urodynamic study			
1999 33		pgs 115	118

Number of subjects	36 children
Inclusion/Exclusion Criteria:	Inclusion: failed to respond to 25 mg imipramine for children aged 6 to 8 years and 50 mg imipramine from children aged over 8 years, wet at least 4 nights a week, stop taking medication 2 months before the trial, no history of any other urological problem, appeared healthy
Characteristics of subjects or environment/prognostic factor	Children had an age range of 6 to 18 years, the mean baseline number of wet nights per week was 6.1 (sd 1.4). 3 children had spina bifida, 33.3% had a family history of bedwetting and 19.4% day time wet
Recruitment:	Attending clinic
Setting:	Turkey
Interventions/Test /Factor being investigated	Oxybutynin
Comparitors	No comparison
Length of Study/ Follow-up	None reported
Outcome measures studies	Mean number of wet nights per week
Results	The study showed in children treated with 15 mg daily oxybutynin had a mean number of wet nights per week of 2.7 (sd 1.3) compared to a baseline wetting of 6.1 (sd 1.4) wet nights per week. The study did not present results for 10 mg daily oxybutynin or 20 mg daily oxybutynin.
Funding	Not reported
Does the study answer the question?	The study showed oxybutynin reduced the mean number of wet nights per week in children who had failed to respond to imipramine
Effect due to factor in study?	Yes
Consistency of results with other studies?	No other studies
How directly applicable to population of the guideline?	Children were aged 6 to 18 years

Internal Validity

Reference number 785 **Study Type** **Cohort** RID:
 Radvanska E;Kovacs L;Rittig S; 135
 The Role of Bladder Capacity in Antidiuretic and Anticholinergic Treatment for Nocturnal Enuresis
 2006 176 pgs 764 769

Number of subjects 19 in total

Inclusion/Exclusion Criteria: The trial was the second part to a study
 Inclusion: non responders (less than 50% improvement) to 2 weeks of 20 micrograms intranasal desmopressin. Primary monosymptomatic NE, wet at least 3 nights per week, aged 5 to 18 years, no history of urological abnormalities, no day time incontinence, and no constipation.

Characteristics of subjects or environment/prognostic factor The mean age was 10.1 (sd 2.1) years, the mean number of wet nights per week before desmopressin treatment was 5.2 (sd 1.6) after desmopressin treatment the baseline mean number of wet nights per week was 4 (sd 1.2).

Recruitment: Attending enuresis outpatients clinic.

Setting: University Children's Hospital, Bratislava

Interventions/Test /Factor being investigated Desmopressin 20 micrograms intranasal and 5 mg oxybutynin twice daily.

Comparitors None.

Length of Study/ Follow-up Not reported.

Outcome measures studies Mean number of wet nights.

Results 2 weeks of treatment

 The mean number of wet nights after 2 weeks of treatment was 1.7 (sd 1.4) per week. Before treatment but after 2 weeks of desmopressin alone the mean number of wet nights per week was 4 (sd 1.2), $p < 0.001$.

Funding Slovak Academic Grant Agency

Does the study answer the question? The study showed children resistant to desmopressin can respond to combined desmopressin and oxybutynin to see a reduction in the mean number of wet nights.

Effect due to factor in study? Yes

Consistency of results with other studies? No other studies

How directly applicable to population of the guideline? Mean age of children 10.1 years

Internal Validity

Reference number	576	Study Type	Cohort	RID:
Serel TA;Perk H;Koyuncuoglu HR;Kosar A;Celik K;Deniz N;				520
Acupuncture therapy in the management of persistent primary nocturnal enuresis--preliminary results.[see comment]				
2001	35		pgs 40	43
Number of subjects	50 patients			
Inclusion/Exclusion Criteria:	Inclusion: wet at least 3 nights a week failed treatment with desmopressin, imipramine or oxybutinin Exclusion: history of UTI, bladder dysfunction, other medical problems			
Characteristics of subjects or environment/prognostic factor	33 were male, the mean age was 10.3 years (range 9 to 18 years)			
Recruitment:	Seen between January 1997 and April 1999			
Setting:	Turkey			
Interventions/Test /Factor being investigated	Acupuncture			
Comparitors	No comparison			
Length of Study/ Follow-up	13 months follow up			
Outcome measures studies	complete dryness			
Results	Children were a 30 minute acupuncture treatment with disposable acupuncture needles on 10 consecutive days in a month. The study showed within 6 months of starting treatment 43 out of 50 (86%) were completely dry, 2 out of 50 (4%) were 80% dry, 5 (10%) had relapsed and their therapy was intensified to produce a satisfactory response. After 13 months 40 patients were available for follow up, 35 of these were dry, 7 continued to have acupuncture of 2 days each month and were at least 80% dry. 3 patients had showed success and had started other treatments. There were no side effects			
Funding	Not reported			
Does the study answer the question?	The study treatment with acupuncture could lead to complete dryness in children who had failed treatment with desmopressin, imipramine or oxybutinin			
Effect due to factor in study?	Yes			

Consistency of results with other studies? No other studies

How directly applicable to population of the guideline? Children had an age range of 9 to 18 years

Internal Validity

Reference number	872	Study Type	Cohort	RID:
Wikstrom S;Tapper J;				558
Are repeated desmopressin treatment attempts successful?				
1997	183		pgs 33	34

Number of subjects 96 patients

Inclusion/Exclusion Criteria: Inclusion: aged 5 to 8 years when first attempted treatment; no urological history, UTI, structural abnormality; no daytime incontinence; no urological, gastrointestinal, renal or cardiovascular disease; have tried 3 previous treatments with the most recent being desmopressin

Characteristics of subjects or environment/prognostic factor 44 were male, the mean age was 6 years when children first tried treatment, the study age range was 7 to 18 years. 79% had a positive family history, 96% were wet 6 to 7 nights a week
28% had only tried desmopressin, 71% had tried alarms and 58% had tried alarms with desmopressin

Recruitment: Patients treated for primary NE between 1983 and 1994

Setting: Childrens Hospital, University of Helsinki Finland

Interventions/Test /Factor being investigated Intranasal desmopressin 20-40 micrograms at bedtime

Comparitors No comparisons

Length of Study/ Follow-up 3 to 6 months

Outcome measures studies Number of children who became dry

Results Children were given 20 to 40 micro grams intranasal desmopressin at bedtime for 4 to 6 weeks. If patients responded the treatment was continued for 3 months using the dose the child responded at. If the child still dry after 3 months the treatment was continued for 3 to 6 months, but gradually reduced in dosage to 10 micro grams until the child was dry for 3 to 6 months.

If the child did not respond to desmopressin after 4 to 6 weeks, children who had partially responded were given an alarm as well for 12 weeks, those who had not responded were taken off desmopressin and given an alarm instead for 12 weeks. In some children who failed treatment was stopped for 6 to 9 months and then started again.

The study showed in children treated with desmopressin alone 14 out of 28 (50%) were cured, 10 out of 28 (36%) were dry when on desmopressin and 4 (14%) were still wet. In children treated with desmopressin and alarm 36 out of 68 (53%) were cured, 15 out of 68 (22%) were dry on treatment and 17 out of 68 (25%) were still wet.

The study noted children over the age of 14 years thought desmopressin alone was the only acceptable form of treatment.

The study did a sub group analysis on age to show children aged 7 to 8 years, 7 out of 10 (70%) were cured, 1 out of 10 (10%) were dry with desmopressin and 2 out of 10 (20%) were still wet. For children aged 9 to 13 years 35 out of 67 (52%) were cured, 15 out of 67 (22%) were dry with desmopressin and 17 out of 67 (25%) were still wet. For children aged 14 to 18 years, 8 out of 19 (42%) were cured, 9 out of 19 (47%) were dry with desmopressin and 2 out of 19 (11%) were still wet.

Funding

Not reported

Does the study answer the question?

Study shows children who have not responded to desmopressin during the first 3 attempts of treatment for nocturnal enuresis may respond to another attempt of desmopressin but most children require the addition of an alarm as they did not respond to desmopressin. The study noted children over the age of 14 years thought desmopressin alone was the only acceptable form of treatment.

Effect due to factor in study?

Yes

Consistency of results with other studies?

No other studies consider this treatment

How directly applicable to population of the guideline?

Children had a mean age of 6 years

Internal Validity

Question: In children and young people with nocturnal enuresis, how does patient or parent/carer choice over treatment intervention influence treatment outcomes?

10

Grading: 1++	High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias
---------------------	---

Reference number 35 Study Type **Randomised Controlled Trial** RID: 858
 Lottmann H; Froeling F; Alloussi S; El-Radhi AS; Rittig S; Riis A; Persson BE;
 A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis
 2007 61 pgs 1454 1460

Number of subjects	221 in total
Inclusion/Exclusion Criteria:	Inclusion: aged 5-15 years, primary NE Exclusion: daytime urgency, frequency (>7 micturitions during day time), voiding postpoement, infrequency (< 3 voiding during daytime), the use of non-pharmacological treatment for NE in previous 60 days, organic urological disease, day time wetting, diabetes insipidus, UTI, clinically significant renal, hepatic, gastrointestinal, pulmonary, cardiovascular, endocrine, or neurological disease
Characteristics of subjects or environment/prognostic factor	The mean age was 9.6 (SD 2.4) years, 71.6% were male; 34.4% were aged 5-8 years, 40.8% were aged 9-11 years 24.8% were aged 12-15 years
Recruitment:	Not reported
Setting:	26 centres in Europe
Interventions/Test /Factor being investigated	120 or 240 micrograms desmopresin melt
Comparitors	0.2 or 2X0.2 mg desmopresin tablet
Length of Study/ Follow-up	3 weeks
Outcome measures studies	Patient preference
Results	26 centres in France, Germany, the Netherlands, UK, Sweden, Denmark, Norway, Finland and Iceland 3 weeks of each treatment. The study did ITT analysis The study showed: 55.7% preferred the MELT formulation (95% CI: 48.7-62.7), compared with 44.3% who preferred the tablet formulation (95% CI: 37.5-51.3%; p=0.112). Treatment preference was strongly correlated with age (p=0.006), but not with treatment sequence (p=0.54) or dose (p=0.08). For patients aged <12 years (n=160), a statistically significant preference for the MELT formulation (60.6%; 95% CI: 52.6-68.2% and p=0.009) was reported. In the 5-8 years age group (n=72) and the 9-11 years (n=89), preference for MELT approached significance.
Funding	Ferring pharmaceutical
Does the study answer the question?	The study showed: 55.7% preferred the MELT formulation, compared with 44.3% who preferred the tablet formulation. Treatment preference was strongly correlated with age, but not with treatment sequence or dose.
Effect due to factor in study?	Yes

**Consistency of results
with other studies?**

**How directly applicable
to population of the
guideline?** Age range 5-15 years

Internal Validity Cross over trial

Grading: 2+	<i>Well-conducted case-control or cohort studies with a low risk of confounding, bias or chance and a</i>
--------------------	--

Reference number 686	Study Type	Cohort	RID:
Diaz SD;Chaviano AH;Maizels M;Yerkes EB;Cheng EY;Losavio J;Porten SP;Sullivan C;Zebold KF;Hagerty J;Kaplan WE;			116
Office Management of Pediatric Primary Nocturnal Enuresis: A Comparison of Physician Advised and Parent Chosen Alternative Treatment Outcomes			
2007 178			pgs 1758 1762

Number of subjects	119 patients: n=76 in the physician treatment plan group and n=43 in the parent treatment plan group.
Inclusion/Exclusion Criteria:	Inclusion: Primary NE, wetting at night during sleep during any 6 month interval without any known causative problem, more than 2 wet nights per week. Exclusion: coexisting anatomical urological problems (vesicourethral reflux or posterior urethral valves), dysfunctional elimination syndrome or urinary tract infection within a year before evaluation, and day-time wetting.
Characteristics of subjects or environment/prognostic factor	85 males and 34 females. The mean age (sd) was 10 ± 3.
Recruitment:	Not reported
Setting:	Children's Memorial Hospital, Chicago Illinois USA
Interventions/Test /Factor being investigated	Physician treatment plan (n=76) Parent treatment plan (n=43) The physician treatment plans (76 patients) included an alarm, age appropriate incentives to reward dryness, an elimination diet to address possible underlying food sensitivities, oxybutinin to address small functional bladder capacity using a 3 times daily dose when functional bladder capacity is decreased according to the home diary, oxybutinin at a nightly dose (based on empirical clinical experience), desmopressin prescribed at a dose of 0.1mg at bedtime for children 8 to 13 years, and finally a bowel program if there was constipation. The parent chosen plans (43 children) included the personalised choice of single or combined use of a moisture alarm with age appropriate inducements, oxybutinin/desmopressin according to the presented dose scheme, an elimination diet and/or a bowel program.
Comparitors	Between physician and parent chosen plans.
Length of Study/ Follow-up	12 weeks.
Outcome measures studies	Differences in physician advised treatment and parent chosen treatment
Results	Time to Primary Nocturnal Enuresis (PNE) remission using physician advised treatment was significantly sooner than with parent chosen therapy (25th percentile 2 vs. 10 weeks). At the end of 12 weeks the probability of remission for the physician advised treatment group was significantly higher than for the parent chosen alternative treatment group (88% vs. 29%, p<0.00001).
Funding	Not reported.
Does the study answer the question?	The study showed physician advised treatment was more effective than parent chosen treatment.
Effect due to factor in study?	Yes

**Consistency of results
with other studies?**

**How directly applicable
to population of the
guideline?** Children had a mean age of 10 (sd 3) years

Internal Validity This is a non-randomized study.

Question: What is the clinical and cost effectiveness of dry bed training for children and young people under 19 years old who have nocturnal enuresis?

11

Grading: 1+	<i>Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias</i>
--------------------	---

Reference number 360 Study Type **Randomised Controlled Trial** RID:
 Bennett GA;Walkden VJ;Curtis RH;Burns LE;Rees.J.;Gosling JA; 445
 Pad-and-buzzer training, dry-bed training, and stop-start training in the treatment of primary nocturnal enuresis
 1985 13 pgs 309 19

Number of subjects 40 in total, 18 in group A, 23 in group B and 20 in group C and 12 in group D

Inclusion/Exclusion Criteria: Inclusion: primary NE, not dry for more than 4 weeks, at least 6 wet night during 14 night baseline, negligilbe day time wetting
 Exclusion: encopresis, previous behavioural intervention, gross psychopathology

Characteristics of subjects or environment/prognostic factor 63% were boys, the mean age was 8.5 (3.2 SD) years, the age range was 5-12 years

Recruitment: Referred from GP

Setting: At home, Rochdale UK

Interventions/Test /Factor being investigated Group A: alarm (pad and buzzer)
 Group B: stop-start training (sphincter muscle exercises)
 Group C: DBT with alarm
 Group D: Control group - waiting list were given star chart after first dry night

Comparitors Between treatment groups

Length of Study/ Follow-up 0 months

Outcome measures studies 14 consecutive dry nights, mean wet nights at end of treatment, drop out

Results Dry bed training included: waking schedule, retention control training, positive practice and cleanliness training

Stop start training was sphincter muscle exercises

12 weeks treatment

Results:
 Dry for 14 consecutive nights:
 In group A (alarm) 4 out of 9 children, became dry for 14 nights compared to 2 out of 12 in group B (stop start training), 5 out of 10 children, in group C (DBT with alarm) and 0 out of 9 children, in group D (control).

Drop out:
 32 children in total dropped out. In group A (alarm) 9 children, dropped out compared to 11 children in group B (stop start training) 10 children in group C (DBT with alarm) and 3 children in group D (control). All drop outs were after the first assessment before treatment was started

Mean number of wet nights:
 The mean number of wet nights per week at end of treatment for the alarm group was 1 (SD 1.95) compared to 3.25 (SD 3.55) in the stop start training group, 1.4 (SD 4.65) for the dry bed training group and 5.15 (SD 1.5) for the no treatment alarm group.

Funding None reported

Does the study answer the question? Both alarm alone and DBT with alarm gave good results for achieving 14 dry nights (44% and 50%) and were moer effective than the stop start training and no treatment. There was no significant difference in the number of drop outs in each group

Effect due to factor in study? Yes (NB there is a 15% spontaneous cure rate)

Consistency of results with other studies? Similar results with other studies

How directly applicable to population of the guideline? Yes the age range was 5-12 years old

Internal Validity There is a high drop out rate, unclear allocation concealment

Reference number 1754 **Study Type** **Randomised Controlled Trial** RID: 391
 Bollard J;Nettelbeck T;Roxbee L;
 Dry-bed training for childhood bedwetting: a comparison of group with individually administered parent instruction
 1982 20 Behav Res Ther pgs 209 217

Number of subjects 30 in total: 10 in each group (Group A: DBT with alarm, Group B: DBT without alarm, and Group C: Waiting list)

Inclusion/Exclusion Criteria: Inclusion: wet at least 1 night a week, no underlying pathology, and no current treatment.
 Exclusion: organic causes of NE.

Characteristics of subjects or environment/prognostic factor 18 were male. In group A (DBT and alarm) the mean age was 8 years and 5 months, the mean baseline wetting was 4.9 nights per week. In group B (DBT without alarm) the mean age was 9 years and 4 months, the mean baseline wetting was 5.0 nights per week. In group C (waiting list) the mean age was 9 years and 5 months, the mean baseline wetting was 5.3 nights per week.

Recruitment: Selected from outpatients list, Adelaide Children's Hospital, Australia.

Setting: Outpatients, Adelaide Children's Hospital.

Interventions/Test /Factor being investigated Group A: DBT with alarm
 Group B: DBT without alarm
 Group C: Waiting list

Comparitors Between treatment groups.

Length of Study/ Follow-up 3 months of follow up.

Outcome measures studies Number of children achieving 14 consecutive dry nights, mean number of wet nights per week in the last week of treatment, and number of children relapsing or failed.

Results Results from Cochrane review, presented in graphs in paper.
 Dry bed training included: waking schedule, retention control training, positive practice and cleanliness training and weekly meetings for parents and children.
 Treatment was until 14 consecutive dry nights were achieved or 8 weeks.
 14 consecutive dry nights:
 In Group A (DBT with alarm) 9 out of 10 children achieved 14 consecutive dry nights compared to 2 out of 10 in Group B (DBT without alarm) and 0 out of 10 in Group C (waiting list).

Mean number of wet nights per week in the last week of treatment:
 In Group A (DBT with alarm) the mean number of wet nights was 0.2 compared to 3.25 in Group B (DBT without alarm) and 5.3 in Group C (waiting list).

Number of children relapsing or failed:
 In Group A (DBT with alarm) 3 out of 10 children relapsed compared to 4 out of 10 in Group B (DBT without alarm) and there were no results for Group C (waiting list).

Funding

Does the study answer the question? The study shows children treated with DTB and alarm were more likely to achieve 14 consecutive dry nights and have fewer wet nights compared to children treated with DBT without alarm or no treatment.

Effect due to factor in study? Yes.

Consistency of results with other studies? Similar results with other studies comparing DBT without an alarm to a control group.

How directly applicable to population of the guideline? Children had mean ages of 8 years and 5 months to 9 years and 5 months.

Internal Validity Results presented from Cochrane as presented in graph in paper. Unclear allocation concealment.

Reference number 54 **Study Type** **Randomised Controlled Trial** RID:
 Nawaz S;Griffiths P;Tappin D; 450
 Parent-administered modified dry-bed training for childhood nocturnal enuresis: Evidence for superiority over urine-alarm conditioning when delivery factors are controlled
 2002 17 Behavioral Interventions pgs 247 260

Number of subjects 36 in total, 12 in each group

Inclusion/Exclusion Criteria: Inclusion: functional NE defined in DSM-IV (aged over 5 years, wet at least 2 times a week for 3 months, NE not due to primary medical or physiological pathology), aged between 7-12 years, attending a mainstream school, wetting 4 or more nights a week, no foreseen domestic disruption during treatment time, readiness to be involved in trial

Characteristics of subjects or environment/prognostic factor Exclusion: diurnal enuresis or encopresis, bedwetting secondary to organic or psychiatric disorder and those unwilling to cooperate
 In group A (DBT with alarm) the mean age was 9.93 years (1.81 SD), 50% were male, the mean baseline number of wet nights per week was 5.58 (1.31 SD), The mean deprivation category (0-7) was 4.67 (2.15 SD)

In group B (alarm) the mean age was 9.93 years (1.99 SD), 50% were male, the mean baseline number of wet nights per week was 5.50 (1.45 SD), The mean deprivation category (0-7) was 4.75 (1.91 SD)

In group C (control) the mean age was 9.84 years (1.84 SD), 50% were male, the mean baseline number of wet nights per week was 5.92 (1.08 SD), The mean deprivation category (0-7) was 5.75 (1.71 SD)

Recruitment: From nine health centres (GPs, GP nurses, health visitors, community paediatricians)

Setting: Scotland, UK, treatment at home

Interventions/Test /Factor being investigated Group A: DBT with alarm
 Group B: alarm
 Group C: control group - no treatment

Comparitors	Between groups A, B and C
Length of Study/ Follow-up	6 months
Outcome measures studies	dry for 14 consecutive nights, mean number of wet nights, relapse
Results	<p>Dry bed training included: waking schedule, retention control training, positive practice and cleanliness training</p> <p>Patients were treated for 16 weeks or until dry Dry for 14 consecutive nights: In group A (DBT with alarm) 8 out of 12 children (67%) became dry for 14 nights compared to 3 out of 12 children (25%) in group B (alarm) and 1 out of 12 children (8%) in group C (control). This difference was significant ($p < 0.01$)</p> <p>Mean number of wet nights: The mean number of wet nights per week at the end of treatment was 0.83 (sd 1.4) for children who had DBT with an alarm; for children who had an alarm the mean number of wet nights was 3.25 (sd 2.67) and for children in the control group (waiting list) the mean number of wet nights was 5 (sd 2.26)</p> <p>Relapse: At 3 month follow up, no children had relapsed. At 6 month follow up 1 out of 4 children in group A (DBT with alarm) and 1 out of 9 children in group B (alarm) had relapsed), both children were wetting 3 nights a week.</p>
Funding	None reported
Does the study answer the question?	The study showed that DBT with alarm was significantly more effective at achieving 14 dry nights compared to alarm alone and no treatment. The study also showed that DBT with alarm had a greater reduction in the mean number of wet nights compared to alarm alone and no treatment.
Effect due to factor in study?	Yes (NB there is a 15% spontaneous cure rate associated with NE)
Consistency of results with other studies?	Similar results to other studies comparing DBT with alarm alarm to alarms and control group
How directly applicable to population of the guideline?	The age range was 7-12 years
Internal Validity	Unclear allocation concealment

Grading: 1-	Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*
--------------------	---

Reference number 371	Study Type	Randomised Controlled Trial	RID:
Bollard J;Nettelbeck T;			446
A comparison of dry-bed training and standard urine-alarm conditioning treatment of childhood bedwetting			
1981 19	Behav Res Ther	pgs 215	226

Number of subjects	120 children, 82 males and 38 females. 20 in each group
Inclusion/Exclusion Criteria:	Inclusion: through medical examination, wet at least 1 night a week, no other treatment during study Exclusion: organic causes of NE
Characteristics of subjects or environment/prognostic factor	In group A (DBT with therapist in home) had a mean age of 9.3 years and 14 were male, the baseline mean number of wet nights was 5.8. In group B (DBT with therapist in hospital) had a mean age of 8.11 years and 13 were male, the baseline mean number of wet nights was 5.2. In group C (DBT with parents as therapist in home) had a mean age of 9.7 years and 16 were male, the baseline mean number of wet nights was 6.0. In group D (DBT with parents as therapist in home without alarm) had a mean age of 8.6 years and 14 were male, the baseline mean number of wet nights was 5.7. In group E (alarm) had a mean age of 8.8 years and 14 were male, the baseline mean number of wet nights was 6.0. In group F (waiting list) had a mean age of 8.1 years and 1 were male, the baseline mean number of wet nights was 4.7.
Recruitment:	Children who were outpatients of the Adelaide Children's Hospital.
Setting:	Outpatient service of Adelaide Children's Hospital
Interventions/Test /Factor being investigated	Group A: DBT with therapist in home Group B: DBT with therapist in hospital Group C: DBT with parents as therapist in home Group D: DBT with parents as therapist in home without alarm Group E: Alarm Group F: Waiting list
Comparitors	Between treatment groups
Length of Study/ Follow-up	Followup at 3, 6 and 12 months
Outcome measures studies	14 consecutive dry nights, mean number of wet nights per week at the end of week 20, relapses
Results	Dry bed training included: waking schedule, retention control training, positive practice and cleanliness training Treatment was until patient achieved 14 consecutive dry nights or for 20 weeks 14 consecutive dry nights: In group A (DBT with therapist in home) 20 out of 20 achieved 14 consecutive dry nights compared to 20 out of 20 in group B (DBT with therapist in hospital), 20 out of 20 in group C (DBT with parents as therapist in home), 5 out of 20 in group D (DBT with parents as therapist in home without alarm), 16 out of 20 in group E (alarm) and 2 out of 20 in group F (waiting list). Mean number of wet nights per week at the end of week 20: In group A (DBT with therapist in home) the mean number of wet nights was 0 compared to 0 in group B (DBT with therapist in hospital), 0 in group C (DBT with parents as therapist in home), 3.8 in group D (DBT with parents as therapist in home without alarm), 0.6 in group E (alarm) and 4.4 in group F (waiting list).

Number of children who relapsed:
 In group A (DBT with therapist in home) 5 out of 20 relapsed compared to 6 out of 20 in group B (DBT with therapist in hospital), 4 out of 20 in group C (DBT with parents as therapist in home), 2 out of 5 in group D (DBT with parents as therapist in home without alarm), 6 out of 16 in group E (alarm) and 2 out of 2 in group F (waiting list).

Funding research undertaken as part requirement for the degree of doctor of philosophy.

Does the study answer the question? Study showed children treated with DBT and an alarm were more likely to achieve 14 consecutive dry nights and have fewer wet nights compared to children treated with DBT and no alarm, alarm or no treatment.

Effect due to factor in study? Yes

Consistency of results with other studies? Similar results with other studies comparing DBT with an alarm to an alarm and control groups

How directly applicable to population of the guideline? Children had mean ages from 8.1 to 9.7

No Blinding, unclear allocation concealment

Internal Validity

Reference number 467 **Study Type** **Randomised Controlled Trial** RID:
 Keating JCJ;Butz RA;Burke E;Heimberg RG; 451

Dry bed training without a urine alarm: lack of effect of setting and therapist contact with child

1983 14 pgs 109 115

Number of subjects 30 in total, 7 in group A (DBT with hospital training for parents and child), 9 in group B (DBT with home training for parent and child), 7 in group C (DBT with hospital training for parents), 7 in group D (waiting list)

Inclusion/Exclusion Criteria: Include: diurnally continent, child must be able to follow instructions, wet at least 50% of nights
 Exclude: organic causes of Ne, day time wetting

Characteristics of subjects or environment/prognostic factor The mean age is 8.1 years, the age range was 4 to 14 years. Children were wet at least 50% of nights

Recruitment: Newspaper adverts, referred from friends, paediatric urologist, psychologist

Setting: Hospital or home, Albany, USA

Interventions/Test /Factor being investigated Group A: DBT (no alarm) with hospital training for parents and child; 7 children
 Group B: DBT (no alarm) with home training for parent and child; 9 children
 Group C: DBT (no alarm) with hospital training for parents; 7 children
 Group D: waiting list; 7 children

Comparitors Between treatment groups

Length of Study/ Follow-up 5 months follow up

Outcome measures studies number of children who achieved 14 consecutive dry nights, mean number of wet nights in the final week of treatment, number of children who relapsed.

Results	<p>Dry bed training included: waking schedule, retention control training, positive practice and cleanliness training</p> <p>Data taken from Cochrane as presented in graphical form in paper</p> <p>5 weeks of treatment</p> <p>14 consecutive dry nights: In group A (DBT (no alarm) with hospital training for parents and child) 7 out of 7 children achieved 14 consecutive dry nights compared to 5 out of 9 in group B (DBT (no alarm) with home training for parent and child) and 6 out of 7 in group C (DBT (no alarm) with hospital training for parents). No results for group D (waiting list).</p> <p>Mean number of wet nights in final week of treatment: In group A (DBT (no alarm) with hospital training for parents and child) children had a mean number of wet nights of 2.7 compared to 2.5 in group B (DBT (no alarm) with home training for parent and child), 1.9 in group C (DBT (no alarm) with hospital training for parents) and 2 in group D (waiting list).</p> <p>Relapse: In group A (DBT (no alarm) with hospital training for parents and child) 2 out of 7 children relapsed compared to 2 out of 5 in group B (DBT (no alarm) with home training for parent and child) and 2 out of 6 in group C (DBT (no alarm) with hospital training for parents). No results for group D (waiting list).</p>
Funding	
Does the study answer the question?	Study shows children treated with dry bed training where training is given in a hospital were more likely to achieve 14 consecutive dry nights compared to no treatment or training at home. Children who had DBT where only parents had training in a hospital had fewer wet nights per week at the end of treatment compared to other dry bed training or no treatment.
Effect due to factor in study?	Yes
Consistency of results with other studies?	Study shows similar results to other studies comparing DBT with an alarm and DBT without an alarm and waiting list group
How directly applicable to population of the guideline?	Children had an age range of 4 to 14 years
Internal Validity	No blinding, unclear allocation concealment

Question: What is the clinical and cost effectiveness of bladder training / retention control training for children and young people under 19 years old who have nocturnal enuresis?

12

Grading: 1+	Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
--------------------	--

Reference number 1413 Study Type **Randomised Controlled Trial** RID: 276
 Hamano S;Yamanishi T;Igarashi T;Ito H;Murakami S;
 Functional bladder capacity as predictor of response to desmopressin and retention control training in monosymptomatic nocturnal enuresis
 2000 37 Eur Urol pgs 718 722

Number of subjects 114 in total 54 in group A (desmopressin), 60 in group B (retention control training)

Inclusion/Exclusion Criteria: Inclusion: primary monosymptomatic NE, aged 5 to 15 years, and wet at least 4 times a week
 Exclusion: organic causes of NE or UTI.

Characteristics of subjects or environment/prognostic factor 88 out of 114 were male.
 In group A (desmopressin) the mean age was 9.2 (sd 2.2) years. The mean baseline wetting was 6.8 (sd 0.7) nights a week, 88.9% were wet every night and 67% (sd 24) had normal bladder capacity.
 In group B (retention control training) the mean age was 9.4 (sd 2.3) years. The mean baseline wetting was 6.7 (sd 0.9) nights a week, 85% were wet every night and 59% (sd 22) had normal bladder capacity.

Recruitment: Presented to clinic between April 1993 and October 1998.

Setting: Chiba, Japan

Interventions/Test /Factor being investigated Group A: desmopressin 5 micrograms intranasally increasing in 5 microgram increments up to 20 micrograms if no response
 Group B: retention control training where children were asked once a day to avoid voiding for a long as possible to expand bladder capacity. The amount voided was recorded.
 Both groups also had fluid restriction at bedtime.

Comparitors Between groups A and B

Length of Study/ Follow-up 2 weeks of follow up

Outcome measures studies Number of children who achieved 14 consecutive dry nights. Adverse events.

Results Treatment was for 12 weeks
 Number of children who achieved 14 consecutive dry nights:
 In group A (desmopressin) 21 out of 54 children achieved 14 consecutive dry nights compared to 14 out of 60 in group B (retention control training)
 Adverse events:
 In group A (desmopressin) 2 out of 54 children had nasal discomfort, no patients in group B (retention control training) had nasal discomfort.
 Relapse rates:
 In group A (desmopressin) 17 out of 21 children relapsed compared to 5 out of 14 patients in group B (retention control training).

Funding Not reported

Does the study answer the question? The study showed that more children treated with desmopressin achieved 14 consecutive dry nights compared to children treated with retention control training.

Effect due to factor in study? Yes

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Children were aged 5 to 15 years.

Internal Validity

Grading: 1-	Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*
--------------------	---

Reference number	360	Study Type	Randomised Controlled Trial	RID:
				429
Bennett GA;Walkden VJ;Curtis RH;Burns LE;Rees.J.;Gosling JA;				
Pad-and-buzzer training, dry-bed training, and stop-start training in the treatment of primary nocturnal enuresis				
1985	13		pgs 309	19

Number of subjects	40 in total, 9 in group A, 10 in group B and 9 in group C
Inclusion/Exclusion Criteria:	Inclusion: primary NE, not dry for more than 4 weeks, at least 6 wet night during 14 night baseline, negligible day time wetting Exclusion: encopresis, previous behavioural intervention, gross psychopathology
Characteristics of subjects or environment/prognostic factor	63% were boys, th mean age was 8.5 (3.2 SD) years, the age range was 5-12 years
Recruitment:	Referred from GP
Setting:	At home, Rochdale UK
Interventions/Test /Factor being investigated	Group A: alarm (pad and buzzer) Group B: stop-start training (sphincter muscle exercises) Group C: DBT with alarm Group D: Control group - waiting list were given star chart after first dry night
Comparitors	Between treatment groups
Length of Study/ Follow-up	0 months
Outcome measures studies	14 consecutive dry nights, mean dry nights at follow up, drop out
Results	12 weeks treatment Results: Dry for 14 consecutive nights: In group A (alarm) 4 out of 9 children, became dry for 14 nights compared to 2 out of 12 in group B (stop start training), 5 out of 10 children, in group C (DBT with alarm) and 0 out of 9 children, in group D (control). Drop out: 32 children in total dropped out. In group A (alarm) 9 out of 18 children, dropped out compared to 11 out of 21 children in group B (stop start training) 10 children in group C (DBT with alarm) and 3 children in group D (control).
Funding	None reported
Does the study answer the question?	Both alarm alone and DBT with alarm gave good results for achieving 14 dry nights (44% and 50%) and were more effective than the stop start training and no treatment. There was no significant difference in the number of drop outs in each group
Effect due to factor in study?	Yes (NB there is a 15% spontaneous cure rate)
Consistency of results with other studies?	No other similar studies

How directly applicable to population of the guideline? Yes the age range was 5-12 years old

Internal Validity There is a high drop out rate

Reference number 499 **Study Type** **Randomised Controlled Trial** RID:
Harris LS;Purohit AP; 386
Bladder training and enuresis: a controlled trial

1977 15 pgs 485 490

Number of subjects 18 in total, 9 in Group A (retention control training), 9 in Group B (waiting list).

Inclusion/Exclusion Criteria: Inclusion: recruited from newspaper adverts, wet at least 1 night a week, aged 5 to 13 years.
Exclusion: organic causes of NE, day time wetting, mental deficiency, urinary infection, diabetes, anatomical defects, or current treatment for NE.

Characteristics of subjects or environment/prognostic factor In Group A (retention control training) 5 out of 9 were male, the mean age was 9.2 years, the baseline wetting was 3.2 nights a week.
In Group B (waiting list) 7 out of 9 were male, the mean age was 8.8 years, the baseline wetting was 5 nights a week.

Recruitment: Newspaper advert.

Setting: Queen's University, Kingston, Ontario, Canada

Interventions/Test /Factor being investigated Group A: retention control training. 5 nights in a camp, then 30 days with parents. Retention control training - on the first day the child was asked to drink fluid and the time to void was recorded as was the volume voided. After this children were encouraged to hold for longer, and were given 1 point for each extra 2 minutes held. The child was then taught that the longer they held the more urine they passed. Once the child understood this they were given points based on the amount of urine passed. Points were exchanged for toys and games etc.
Group B: waiting list

Comparitors Between treatment groups.

Length of Study/ Follow-up 9 weeks of follow up.

Outcome measures studies Mean number of wet nights at the end of treatment.

Results Mean number of wet nights per week at the end of treatment:
In Group A (retention control training) the mean number of wet nights per week was 2.6 compared to 5 nights in Group B (waiting list).

Funding Not reported.

Does the study answer the question? The study showed that children treated with retention control training had fewer wet nights per week after treatment compared to those in the waiting list group.

Effect due to factor in study? Yes

Consistency of results with other studies? No other similar studies.

How directly applicable to population of the guideline? Children were aged 5-13 years.

Internal Validity There was no blinding. The baseline characteristics appear to be different.

Reference number 384 **Study Type** **Randomised Controlled Trial** RID:
lester A;Marchesi A;Cohen A;lester M;Bagnasco F;Bonelli R; 318
Functional enuresis: pharmacological versus behavioral treatment
1991 7 pgs 106 108

Number of subjects 168 in total, 36 in group A (imipramine), 36 in group B (3 step program) and 96 in group C (counselling, 3 step program and education)

Inclusion/Exclusion Criteria: Inclusion: functional enuresis.
Exclusion: organic causes of NE or emotional disturbance.

Characteristics of subjects or environment/prognostic factor The age range was 6 to 11

Recruitment: Patients seen between 1979 and 1988.

Setting: Genoa University, Genova, Italy

Interventions/Test /Factor being investigated Group A: imipramine for 6 weeks 0.9-1.5mg/kg (maximum dosage 50 mg).
Group B: 3 step program of reassurance to parents, bladder control training and waking with an alarm clock before micturition, and parental involvement.
Group C: motivational therapy and 3 step program.

Comparitors Between treatment groups

Length of Study/ Follow-up 12 month follow up.

Outcome measures studies Number of children who achieved 14 consecutive dry nights. Relapse after 12 months.

Results Children in the bladder training group took part in a three step program which was 1) reassurance to the parents and tried to encourage the child; 2) bladder retention training (drink more during the morning and afternoon, reduce the number of times voided during the day, trying to hold for at least 8 hours and interrupt voiding – stop start training) and behaviour training (drink as little as possible after 7 pm, urinate before going to bed and wake up once or twice using an alarm clock); 3) parents were involved in the treatment to help the child practice and avoid family conflicts. Children in the motivation therapy group had the 3 step program as described and motivational therapy where child, in a group, discussed their problems with a psychiatrist.

Treatment was for 6 months.

Number of children who achieved 14 consecutive dry nights:
In group A (imipramine) 14 out of 36 achieved 14 consecutive dry nights compared to 24 out of 36 in group B (3 step program) and 81 out of 96 in group C (counselling, 3 step program and education).

	Relapse after 12 months In group A (imipramine) 2 out of 14 relapsed compared to 2 out of 24 in group B (3 step program) and 3 out of 81 in group C (counselling, 3 step program and education).
Funding	Not reported
Does the study answer the question?	The study showed that more children treated with counselling, 3 step program and education achieved 14 consecutive dry nights compared to imipramine or the 3 step program.
Effect due to factor in study?	Yes
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Children were aged 6 to 11 years.

Internal Validity

Reference number	251	Study Type	Randomised Controlled Trial	RID:	
	Kahan E;Morel D;Amir J;Zelcer C;				406
	A controlled trial of desmopressin and behavioral therapy for nocturnal enuresis				
1998	77		pgs 384		388

Number of subjects	228 in total, 70 in group A (desmopressin and behaviour), 75 in group B (placebo and behaviour) and 76 in group C (desmopressin)
Inclusion/Exclusion Criteria:	Inclusion: primary NE, wet at least 2 times a week, aged 8-14 years Exclusion: previous treatment, other physical disorders, previous traumatic life events, psychiatric disorders, abnormal laboratory findings
Characteristics of subjects or environment/prognostic factor	In group A (desmopressin and behaviour) the mean baseline wetting was 5.1 (sd 2.1) nights a week, in group B (placebo and behaviour) the mean wetting was 5.5 (sd 1.8) and in group C (desmopressin) it was 5.8 (sd 1.6).
Recruitment:	Seen at primary care clinic
Setting:	Golda Medical Center, General Sick Fund, Israel
Interventions/Test /Factor being investigated	Group A: desmopressin (20 micrograms intranasally) and behaviour therapy of ensuring the child knows Ne is not due to "powerful external forces" but a psychologic mechanism Group B: placebo and behaviour therapy Group C: desmopressin
Comparitors	between treatment groups
Length of Study/ Follow-up	2 months follow up
Outcome measures studies	Mean number of wet nights per week at the end of treatment and at follow up, the number of children who achieved 14 consecutive dry nights, relapse, adverse events
Results	The child was made aware that "the problem is not a consequence of powerful external forces, but a psychologic mechanism which requires conscious self-control and that can be solved by wiliness and taking responsibility". The child was then taught sphincter muscle exercises. The child was also asked to go to bed earlier and

drink less than usual, the child was also taught general physical exercises

Treatment was for 8 weeks

Number of children who achieved 14 consecutive dry nights

In group A (desmopressin and behaviour) 22 out of 70 achieved 14 consecutive dry nights compared to 12 out of 75 in group B (placebo and behaviour) and 31 out of 76 in group C (desmopressin)

Mean number of wet nights per week at the end of treatment

In group A (desmopressin and behaviour 70 children) the mean number of wet nights per week was 3.0 (sd 2.0) compared to 3.3 (sd 2.2) in group B (placebo and behaviour 75 children) and 4.5 (sd 1.8) in group C (desmopressin 76 children)

Mean number of wet nights per week at follow up

In group A (desmopressin and behaviour 70 children) the mean number of wet nights per week was 2.6 (sd 1.7) compared to 3.0 (sd 2.0) in group B (placebo and behaviour 74 children) and 4.7 (sd 1.8) in group C (desmopressin 76 children)

Adverse events:

In group A (desmopressin and behaviour) 5 out of 70 had nasal itch compared to 1 out of 75 in group B (placebo and behaviour) and 4 out of 76 in group C (desmopressin)

Drop outs:

In group A (desmopressin and behaviour) 6 out of 70 dropped out compared to 1 out of 75 in group B (placebo and behaviour) and 0 out of 76 in group C (desmopressin)

Number of children who relapsed:

In group A 18 out of 22 children relapsed compared to 6 out of 12 in group B and 28 out of 31 in group C

Funding

Lapidot laboratories

Does the study answer the question?

The study shows more children treated with desmopressin and behaviour or desmopressin alone had successful treatment compared to children treated with placebo and behaviour

Effect due to factor in study?

Yes

Consistency of results with other studies?

How directly applicable to population of the guideline?

Children were aged 8-14 years

Internal Validity

Question: What is the clinical and cost effectiveness of lifting and/or waking for children and young people under 19 years old who have nocturnal enuresis?

13

Grading: 1+	Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
--------------------	--

Reference number 1738 Study Type Randomised Controlled Trial RID:
 Bhatia MS;Dhar NK;Rai S;Malik SC; 352

Enuresis: an analysis of 82 cases

1990 44 Indian J Med Sci pgs 337 342

Number of subjects 60 in total: 20 in group A (placebo and restriction of fluid with avoiding punishment), 20 in group B (imipramine) and 20 in group C (imipramine and restriction of fluid with avoiding punishment). The groups were matched for age and sex. There were originally 82 children. 22 dropped out due to not being seen at follow up and were not included in the results.

Inclusion/Exclusion Criteria: Inclusion: aged 4 to 12 years, NE or diurnal enuresis or daytime wetting.
 Exclusion: organic causes of NE.

Characteristics of subjects or environment/prognostic factor 39 out of 60 were male. 15 children were aged 4-5 years, 30 children were aged 6-8 years and 15 children were aged 9-12 years. 63.4% had NE only, 29.3% had both NE and diurnal enuresis 7.3% had diurnal enuresis only. 21.9% had a family history of enuresis, 50% wet daily, 31.6% wet 1-3 times a week, 12.3% wet once a month and 6.1% wet occasionally.

Recruitment: Not reported.

Setting: Delhi, India.

Interventions/Test /Factor being investigated Group A: placebo and restriction of fluid with avoiding punishment and waking.
 Group B: Imipramine 10 mg for children aged 3-6 years, 25 mg for children aged over 6 years. The dose was doubled after 2 weeks if there was no improvement.
 Group C: imipramine and restriction of fluid with avoiding punishment and waking

Comparators Between treatment groups.

Length of Study/ Follow-up 6 months follow up.

Outcome measures studies Number of children who achieved 14 consecutive dry nights.

Results Fluid restriction was described as "restricting fluids in the evening" as well as avoiding punitive attitude of the parents and waking the child one hour after sleep.

Treatment was for 6 weeks

Number of children who achieved 14 consecutive dry nights:
 In group A (behaviour and placebo) 4 out of 20 children achieved 14 consecutive dry nights compared to 12 out of 20 in group B (imipramine) and 18 out of 20 in group C (imipramine and behaviour).

Drop outs
 22 in total due to being unavailable for follow up.

Funding Not reported.

Does the study answer the question? The study showed that children treated with imipramine and the behaviour intervention or imipramine alone were more likely to achieve 14 consecutive dry nights compared to children treated with a placebo and behaviour intervention.

Effect due to factor in study? Yes.

Consistency of results with other studies? No other studies compared fluid restriction.

How directly applicable to population of the guideline? Children were aged 4 to 12 years.

Internal Validity Drop outs were not included in the results.

Reference number 1146 **Study Type** **Randomised Controlled Trial** RID:
EI Anany FG;Maghraby HA;EI-Din S;bdel-Moneim AM; 389
Primary nocturnal enuresis: A new approach to conditioning treatment
1999 53 pgs 405 409

Number of subjects 125 in total, 70 in Group A, 55 in Group B

Inclusion/Exclusion Criteria: Inclusion: wet at least 3 nights a week, and aged over 7 years.
Exclusion: organic causes of NE, secondary NE, polysymptomatic, Urinary, structural or clinical neurological abnormalities.

Characteristics of subjects or environment/prognostic factor In Group A 46 out of 70 were boys, the mean age was 13.23 (sd 3.75) years, and the age range was 7-21 years. The baseline wetting was 5.24 (sd 1.22) wet nights per week.
In Group B 32 out of 55 were boys, the mean age was 12.49 (sd 3.62) years, and the age range was 7-19 years. The baseline wetting was 5.13 (sd 1.17) nights a week.

Recruitment: Not reported.

Setting: Egypt

Interventions/Test /Factor being investigated Group A: clock alarm set while still expected to be dry i.e. before child usually wets
Group B: clock alarm set 2-3 hours after child goes to bed
Both groups also had fluid restriction for 2 hours before going to bed

Comparitors Between treatment groups.

Length of Study/ Follow-up 6 months

Outcome measures studies Dry for 14 consecutive nights (success) in first month, after 3 months, and at 6 months follow up.

Results Treatment was for 4 months
In Group A (alarm set before child wets) 54 out of 70 children became dry compared to 34 out of 55 in Group B (alarm set 2-3 hours after bed) in the first month of treatment.

In Group A (alarm set before child wets) 8 out of 54 children relapsed at 3 months compared to 3 out of 34 in Group B (alarm set 2-3 hours after bed).

In Group A (alarm set before child wets) 13 out of 54 children were relapsed at 6 months compared to 5 out of 34 in Group B (alarm set 2-3 hours after bed).

Funding There was a high drop out rate of 64 children after the first month.
Not reported.

Does the study answer the question? The study evaluates two benefits of waking children at different times.

Effect due to factor in study? Yes.

Consistency of results with other studies? No other similar studies.

How directly applicable to population of the guideline? The study evaluates children aged 7 to 21 years. However the mean ages are 12 and 13 years.

Internal Validity

Reference number 346 **Study Type** **Randomised Controlled Trial** RID:
 Fournier JP;Garfinkel BD;Bond A;Beauchesne H;Shapiro SK; 431
 Pharmacological and behavioral management of enuresis
 1987 26 J Am Acad Child Adolesc Psychiatry pgs 849 853

Number of subjects 64 in total, 8 in each group

Inclusion/Exclusion Criteria: Inclusion: aged between 5 and 14 years, no history of UTI or disease, no physical or neurological disorder, at least 2 wet nights a week for previous 6 months, no treatment in previous 3 months, no significant cognitive impairment or mental retardation, informed consent to random allocation of treatment

Characteristics of subjects or environment/prognostic factor 73% were boys, the mean age was 8.5 years, 70% of children lived with their biological parent, 14% lived with a single parent, 83% were either the oldest or second eldest child in their family, 77% had had a first degree relative with enuresis and 61% had another relative with enuresis

Recruitment: Newspaper adverts and referred from paediatricians

Setting: at home, Montreal Canada

Interventions/Test /Factor being investigated Group A: Imipramine
 Group B: Alarm
 Group C: Placebo
 Group D: Random waking
 Group E: Alarm with imipramine

 The paper also considered alarm with a placebo, random waking with a placebo and imipramine with random waking however there were no results presented for these groups.

Comparitors Between treatment groups

Length of Study/ Follow-up 3 months

Outcome measures studies Change in number of wet nights, drop out

Results Random waking was the parent waking the child any time before midnight.

 6 weeks treatment
 There were 8 patients in each group

 In group A (imipramine) the mean number of wet nights was 1.9 compared to 2.5 in group B (alarm), 5 in group C (placebo), 3.3 in group D (random waking) and 1 in group E (alarm with imipramine)

 Drop out:

	In total 4 boys dropped out due to side-effects or non-compliance and 1 girl dropped out due to having a UTI
Funding	Not reported
Does the study answer the question?	The study showed that imipramine had a faster effect than the other treatments, however at 4 weeks the most effective treatments were alarm, alarm with imipramine and imipramine alone. At the 3 month follow up the most successful treatments were alarm and imipramine.
Effect due to factor in study?	Yes (NB there is a 15% spontaneous cure rate)
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	children were aged 5 - 14 years old
Internal Validity	This is a double blind trial The study had 3 more groups (alarm with placebo, random waking with placebo and imipramine and random waking) however there were no results for these 3 groups
Reference number	384
Study Type	Randomised Controlled Trial
RID:	847
lester A;Marchesi A;Cohen A;lester M;Bagnasco F;Bonelli R; Functional enuresis: pharmacological versus behavioral treatment	
1991	7
	pgs 106 108
Number of subjects	168 in total, 36 in group A (imipramine), 36 in group B (3 step program) and 96 in group C (counselling, 3 step program and education)
Inclusion/Exclusion Criteria:	Inclusion: functional enuresis Exclusion: organic causes of NE, emotional disturbance
Characteristics of subjects or environment/prognostic factor	The age range was 6 to 11
Recruitment:	Patients seen between 1979 and 1988
Setting:	Genoa University, Genova, Italy
Interventions/Test /Factor being investigated	Group A: imipramine for 6 weeks 0.9-1.5mg/kg maximum dosage 50 mg Group B: 3 step program of reassurance to parents, bladder control training and waking with an alarm clock before micturition, parental involvement Group C: motivational therapy and 3 step program
Comparators	Between treatment groups
Length of Study/ Follow-up	12 month follow up
Outcome measures studies	Number of children who achieved 14 consecutive dry nights, relapse after 12 months
Results	Children in the bladder training group took part in a three step program which was 1) reassurance to the parents and tried to encourage the child; 2) bladder retention training (drink more during the morning and afternoon, reduce the number of times voided during the day, trying to hold for at least 8 hours and interrupt voiding – stop start training) and behaviour training (drink as little as possible after 7 pm, urinate before going to bed and wake up once or twice using an alarm clock); 3) parents

were involved in the treatment to help the child practice and avoid family conflicts. Children in the motivation therapy group had the 3 step program as described and motivational therapy where child, in a group, discussed their problems with a psychiatrist.

Treatment was for 6 months

Number of children who achieved 14 consecutive dry nights
In group A (imipramine) 14 out of 36 achieved 14 consecutive dry nights compared to 24 out of 36 in group B (3 step program) and 81 out of 96 in group C (counselling, 3 step program and education)

Relapse after 12 months
In group A (imipramine) 2 out of 14 relapsed compared to 2 out of 24 in group B (3 step program) and 3 out of 81 in group C (counselling, 3 step program and education)

Funding Not reported

Does the study answer the question? The study showed that more children treated with counselling, 3 step program and education achieved 14 consecutive dry nights compared to imipramine or the 3 step program.

Effect due to factor in study? Yes

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Children were aged 6 to 11 years

Internal Validity

Reference number 164 **Study Type** **Randomised Controlled Trial** RID:
Turner RK;Young GC;Rachman S; 18

Treatment of nocturnal enuresis by conditioning techniques

1970 8 pgs 367 391

Number of subjects 115 in total: 15 in group A, 15 in group B, 12 in group C, 15 in group D and 17 in group E

Inclusion/Exclusion Criteria: Inclusion: aged between 4-15 years, and wet at least 3 times a week.
Exclusion: organic pathology, adverse home conditions with contra-indicated treatment by this method, having tried conditioning treatment in the previous year

Characteristics of subjects or environment/prognostic factor The mean age was 7.5 (2.6 SD) years (10 children were aged over 10 years), 69.6% were boys, 90% had primary NE, 65.2% were wet every night, 7% were wet 6 times a week, 5.1% were wet 5 times a week, 15.7% were wet 4 times a week and 7% were wet 3 times a week. 68.7% had a family history of NE.

Recruitment: Referred from school medical officer or brought for treatment by parents to 2 clinics in east London, UK.

Setting: London, UK, and treatment administered at home.

Interventions/Test /Factor being investigated Group A: alarm with continuous signal
Group B: alarm with twin signal
Group C: alarm with intermittent twin signal (after first 2 weeks alarm was sometimes disconnected)
Group D: random waking
Group E: placebo tablet

Comparitors	Between groups A, B, C, D and E
Length of Study/ Follow-up	3 years
Outcome measures studies	Number of children achieving 14 consecutive dry nights.
Results	<p>Random waking consisted of the parents being given a chart with random times on it when the child should be woken.</p> <p>14 consecutive dry nights: 3 out of 15 in group A (alarm with continuous signal) achieved 14 nights dry compared to 2 out of 15 in group B (alarm with twin signal), 1 out of 15 in group D (random waking) and 4 out of 17 in group E (placebo). The study states these differences are not significant.</p> <p>Drop-out: From groups A, B and C: 39 patients dropped out From groups D and E: 1 patient dropped out These drop outs are due to non-compliance with treatment procedure.</p> <p>The study did not report the results for group C</p>
Funding	The Bethlem-Maudsley Research Fund
Does the study answer the question?	The study reported low rates of success of achieving 14 consecutive dry nights, with placebo patients having the highest results of 24%, the alarm with continuous signal (20%), alarm with twin signal (13%) and random waking (6%). The differences were not significant.
Effect due to factor in study?	Yes.
Consistency of results with other studies?	No other similar studies.
How directly applicable to population of the guideline?	Age range was 4-15 years.
Internal Validity	39 patients dropped out in total from groups A, B and C and 1 from groups D and E, it is unclear which individual groups patients dropped out from. There are no results reported for group C.

Grading: 1-	<i>Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*</i>
--------------------	--

Reference number 340	Study Type	Randomised Controlled Trial	RID:
Baker BL;			432

Symptom treatment and symptom substitution in enuresis

1969	74	J Abnorm Psychol	pgs 42	49
------	----	------------------	--------	----

Number of subjects 30 patients in total

Inclusion/Exclusion Criteria: Patients were excluded if there was an organic cause of wetting

Characteristics of subjects or environment/prognostic factor 67% were boys. The median age was 8 years with a range of 6-12 years. 4 patients had secondary enuresis. More than half the patients wet every night

Recruitment: From newspaper adverts

Setting: At home, USA

Interventions/Test /Factor being investigated
 Group A: alarm
 Group B: waking using an alarm clock and star chart
 Group C: waiting list group

Comparitors Between treatment groups

Length of Study/ Follow-up no follow up

Outcome measures studies Change in number of wet nights
 Self image questionnaire

Results Star charts were used to keep a record of the child's progress and the child was woken at a set time every night (chosen at start of trial to be before when the child usually wets), once the child was dry for several nights they were not woken for a week, if dry during the week the parents were told if the child wets wake them for the two following nights

10 weeks treatment
 10 patients in each group

Mean number of wet nights per week in the last 3 weeks of treatment:
 In group A (alarm) the mean number of wet nights was 1.8, in group B (waking and star chart) the mean number of wet nights was 3.1 and in group C (waiting list) the mean number of wet nights was 5.9.

number of children who achieved 14 consecutive dry nights:
 in the alarm group 11 out of 14 children had 14 consecutive dry nights compared to 2 out of 14 in the waking group and 0 out of 14 in the control group.

Relapsed:
 In total, 4 patients relapsed

Funding None reported

Does the study answer the question? Significantly more children became dry for 14 nights when treated with alarm therapy compared to no treatment (79% compared to 0%).

Effect due to factor in study? Yes (NB there is a 15% spontaneous cure rate)

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? The age range was 6-12 years

Internal Validity Allocation method to treatment group isn't reported

Question: What is the clinical and cost effectiveness of fluid and dietary advice for children and young people under 19 years old who have nocturnal enuresis?

14

Grading: 1+	Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
--------------------	--

Reference number 1738 Study Type Randomised Controlled Trial RID:
 Bhatia MS;Dhar NK;Rai S;Malik SC; 846

Enuresis: an analysis of 82 cases

1990 44 Indian J Med Sci pgs 337 342

Number of subjects	60 in total: 20 in group A (placebo and restriction of fluid with avoiding punishment), 20 in group B (imipramine) and 20 in group C (imipramine and restriction of fluid with avoiding punishment). The groups were matched for age and sex. There were originally 82 children, 22 dropped out due to not being seen at follow up and were not included in the results.
Inclusion/Exclusion Criteria:	Inclusion: aged 4 to 12 years, NE or diurnal enuresis or daytime wetting. Exclusion: organic causes of NE.
Characteristics of subjects or environment/prognostic factor	39 out of 60 were male. 15 children were aged 4-5 years, 30 children were aged 6-8 years and 15 children were aged 9-12 years. 63.4% had NE only, 29.3% had both NE and diurnal enuresis 7.3% had diurnal enuresis only. 21.9% had a family history of enuresis, 50% were wet daily, 31.6% wet 1-3 times a week, 12.3% wet once a month and 6.1% wet occasionally.
Recruitment:	Not reported.
Setting:	Delhi, India.
Interventions/Test /Factor being investigated	Group A: placebo and restriction of fluid with avoiding punishment and waking Group B: Imipramine 10 mg for children aged 3-6 years, 25 mg for children aged over 6 years. The dose was doubled after 2 weeks if there was no improvement Group C: imipramine and restriction of fluid with avoiding punishment and waking.
Comparators	Between treatment groups.
Length of Study/ Follow-up	6 months follow up
Outcome measures studies	Number of children who achieved 14 consecutive dry nights.
Results	Fluid restriction was described as "restricting fluids in the evening" as well as avoiding punitive attitude of the parents and waking the child one hour after sleep. Treatment was for 6 weeks Number of children who achieved 14 consecutive dry nights: In group A (behaviour and placebo) 4 out of 20 children achieved 14 consecutive dry nights compared to 12 out of 20 in group B (imipramine) and 18 out of 20 in group C (imipramine and behaviour)
Funding	Drop outs 22 in total due to being unavailable for follow up. Not reported
Does the study answer the question?	The study showed that children treated with imipramine and the behaviour intervention or imipramine alone were more likely to achieve 14 consecutive dry nights compared to children treated with a placebo and behaviour intervention.
Effect due to factor in study?	Yes.

Consistency of results with other studies? No other studies compared fluid restriction.

How directly applicable to population of the guideline? Children were aged 4 to 12 years.

Internal Validity Drop outs were not included in the results

Reference number 350 **Study Type** **Randomised Controlled Trial** RID:
McKendry JB;Stewart DA;Khanna F;Netley C; 409

Primary enuresis: relative success of three methods of treatment

1975 113 Can Med Assoc J pgs 953 955

Number of subjects 222 in total 73 in group A (diet restriction) and 74 in group B (imipramine)

Inclusion/Exclusion Criteria: Inclusion: aged over 5 years
Exclusion: organic causes of NE

Characteristics of subjects or environment/prognostic factor The mean age was 9 years age range was 5 to 17 years. Some children ("a few") had diurnal wetting.
In group A (diet restriction) the mean baseline wetting was 83.4%, in group B (imipramine) the mean baseline wetting was 82.3%.

Recruitment: Not reported

Setting: The Hospital for Sick Children, Toronto, Canada

Interventions/Test /Factor being investigated Group A: diet restriction (the diet contained no milk, butter, cheese, eggs, citrus fruit juices, tomato, coca or chocolate. Instead apple juice, ginger ale and water were used as fluid substitutes
Group B: 10mg Imipramine increasing to 40mg for children aged under 10 years and 60mg for children older than 10 years if needed
The study also considered an alarm which gave the child an electric shock, this is not normal clinical practice and therefore the treatment group was not included in the review

Comparitors Between group A and group B

Length of Study/ Follow-up Group A (diet restriction) had 3 months follow up and group B (imipramine) had 19 month follow up

Outcome measures studies Number of children who achieved 14 consecutive dry nights after treatment and at follow up, greater than 50% improvement in the number of dry nights after treatment and at follow up, drop out, adverse events

Results Number of children who achieved 14 consecutive dry nights:
In group A 1 out of 64 achieved 14 consecutive dry nights compared to 13 out of 62 in group B (imipramine)

Greater than 50% improvement in the number of dry nights:
In group A 34 out of 64 achieved a greater than 50% improvement in the number of dry nights compared to 28 out of 62 in group B (imipramine)

Number of children who achieved 14 consecutive dry nights at follow up:
In group A 1 out of 1 achieved 14 consecutive dry nights compared to 19 out of 34 in group B (imipramine)

Greater than 50% improvement in the number of dry nights at follow up:
In group A 0 out of 1 achieved a greater than 50% improvement in the number of dry nights compared to 8 out of 34 in group B (imipramine)

Drop outs:

In group A (diet restriction) 9 out of 73 dropped out compared to 12 out of 74 in group B (imipramine)

Adverse events:

In group A (diet restriction) 2 out of 12 children became aggressive

In group B (imipramine) 3 out of 16 children had headaches, abdominal pain or fatigue

Funding

Not reported

Does the study answer the question?

The study showed that children treated with imipramine were more likely to become dry or have an 50-80% improvement in the number of dry nights compared to children treated with dietary restriction. Children from Group A had a shorter followup as after 3 months parents switched treatment due to the diet being unsuccessful

Effect due to factor in study?

Yes

Consistency of results with other studies?

No other studies comparing diet restriction to imipramine

How directly applicable to population of the guideline?

Children were aged 5 to 17 years

Internal Validity

Question: What is the clinical and cost effectiveness of star charts and other reward systems for children and young people under 19 years old who have nocturnal enuresis?

15

Grading: 1+	<i>Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias</i>
--------------------	---

Reference number 360 Study Type Randomised Controlled Trial RID: 845
 Bennett GA;Walkden VJ;Curtis RH;Burns LE;Rees.J.;Gosling JA;

Pad-and-buzzer training, dry-bed training, and stop-start training in the treatment of primary nocturnal enuresis

1985 13 pgs 309 19

Number of subjects 40 in total, 9 in group A, 10 in group B and 9 in group C

Inclusion/Exclusion Criteria: Inclusion: primary NE, not dry for more than 4 weeks, at least 6 wet night during 14 night baseline, negligible day time wetting
 Exclusion: encopresis, previous behavioural intervention, gross psychopathology

Characteristics of subjects or environment/prognostic factor 63% were boys, th mean age was 8.5 (3.2 SD) years, the age range was 5-12 years

Recruitment: Referred from GP

Setting: At home, Rochdale UK

Interventions/Test /Factor being investigated Group A: alarm (pad and buzzer)
 Group B: stop-start training (sphincter muscle exercises)
 Group C: DBT with alarm
 Group D: Control group - waiting list were given star chart after first dry night

Comparitors Between treatment groups

Length of Study/ Follow-up 0 months

Outcome measures studies 14 consecutive dry nights, mean dry nights at follow up, drop out

Results 12 weeks treatment

Results:
 Dry for 14 consecutive nights:
 In group A (alarm) 4 out of 9 children, became dry for 14 nights compared to 2 out of 12 in group B (stop start training), 5 out of 10 children, in group C (DBT with alarm) and 0 out of 9 children, in group D (star chart).

Drop out:
 32 children in total dropped out. In group A (alarm) 9 children, dropped out compared to 11 children in group B stop start training) 10 children in group C (DBT with alarm) and 3 children in group D (star chart).

Change in mean number of wet nights:
 The mean number of wet nights per week at end of treatment for the alarm group was 1 (SD 1.95) compared to 3.25 (SD 2.60) in stop start training group, 1.4 (SD 1.8) for the dry bed training group and 5.15 (SD 1.5) for the star chart alarm group.

Funding None reported

Does the study answer the question? Both alarm alone and DBT with alarm gave good results for achieving 14 dry nights (44% and 50%) and were more effective than the stop start training and no treatment. There was no significant difference in the number of drop outs in each group

Effect due to factor in study? Yes (NB there is a 15% spontaneous cure rate)

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Yes the age range was 5-12 years old

Internal Validity There is a high drop out rate

Reference number 370 **Study Type** **Randomised Controlled Trial** RID:
Ronen T;Wozner Y;Rahav G; 412
Cognitive intervention in enuresis
1992 14 pgs 1 14

Number of subjects 77 in total: 20 in group A (counselling), 19 in group B (alarm), 20 in group C (star chart), and 18 in group D (waiting list).

Inclusion/Exclusion Criteria: Inclusion: aged over 5 years, children attending a community mental health clinic with primary NE.
Exclusion: organic causes of NE, or mental or developmental problems.

Characteristics of subjects or environment/prognostic factor The mean age was 10.05 (sd 2.28) years, the mean baseline wetting over 3 weeks in group A (counselling) was 19.8 (sd 1.73) days, in group B (alarm) was 19.8 (sd 2.14), group C (star chart) was 18.9 (sd 2.21) and in group D (waiting list) was 18 (sd 8.72) days.

Recruitment: Children attending a community mental health clinic with primary NE.

Setting: Israel.

Interventions/Test /Factor being investigated Group A: Cognitive and behavioural self-control education therapy
Group B: Pad and bell alarm
Group C: star chart - stars were given for a dry night
Group D: waiting list

Comparitors Between treatment groups.

Length of Study/ Follow-up 6 months follow up.

Outcome measures studies Number of children dry for 3 consecutive weeks, mean number of wet nights in 3 weeks at the end of treatment, failed or relapse after 6 months, and drop out rates.

Results Stars were given as a reward for a dry night; cognitive behaviour therapy consisted of parents and children being taught 5 components of "modification of misconceptions and irrational beliefs; rational analysis of bedwetting; sensitization to pressure in bladder; self-control training in different situations; exercises in self-observation, charting, and Self assessment and self-reinforcement".

Treatment was for 18 weeks

Number of children who were dry for 3 consecutive weeks
In group A (counselling) 15 out of 20 children were dry for 3 consecutive weeks compared to 12 out of 19 in group B (alarm), 6 out of 20 in group C (star chart) and 0 out of 18 in group D (waiting list).

Mean number of wet nights in 3 weeks at the end of treatment:
The mean number of wet nights over 3 weeks at the end of treatment in group A (counselling, 18 children) was 1.03 (sd 2.15). In group B (alarm 15 children) mean was 1.23 (sd 5.28), group C (star chart 14 children) was 3.33 (sd 5.8) and in group D (waiting list 16 children) the mean number of wet nights was 17.22 (sd 9).

Number of children who failed or relapsed after 6 months
 In group A (counselling) 3 out of 18 children failed or relapsed compared to 9 out of 15 in group B (alarm) and 8 out of 14 in group C (star chart).

Drop out:
 In group A (counselling) 2 out of 20 children dropped out compared to 4 out of 19 in group B (alarm), 6 out of 20 in group C (star chart) and 11 out of 18 in group D (waiting list).

Funding Not reported.

Does the study answer the question? The study shows children treated with counselling or alarms were more successful than the other treatment groups.

Effect due to factor in study? Yes

Consistency of results with other studies? No other similar studies.

How directly applicable to population of the guideline? Children were aged over 5 years.

Internal Validity

Reference number 338 **Study Type** **Randomised Controlled Trial** RID:
 van Londen A;van Londen-Barentsen MW;van Son MJ;Mulder GA; 435
 Arousal training for children suffering from nocturnal enuresis: a 2 1/2 year follow-up
 1993 31 pgs 613 615

Number of subjects 127 in total, 38 in group A, 39 in group B and 36 in group C

Inclusion/Exclusion Criteria: Inclusion: aged between 6-12 years

Characteristics of subjects or environment/prognostic factor The mean age was 8.6 years, 70% were boys, 87% had primary NE

Recruitment: Not reported

Setting: Netherlands, treatment at home

Interventions/Test /Factor being investigated Group A: alarm with reward stickers for correct behaviour and punishment sticker for incorrect behaviour
 Group B: alarm with reward stickers for dry nights and punishment sticker for wet nights
 Group C: alarm

Comparitors Between groups A, B and C

Length of Study/ Follow-up 2.5 years

Outcome measures studies dry for 14 consecutive nights, relapse

Results	<p>20 weeks treatment</p> <p>Dry at 14 nights: In group A (alarm with reward stickers for correct behaviour) 37 out of 38 children achieved 14 dry nights compared to 33 out of 39 in group B (alarm with reward sticker for dry nights and punishment sticker for wet nights) and 26 out of 36 in group C (alarm alone). These differences were significant when comparing group A to group B (binomial test $P < 0.001$) and group (binomial test $P < 0.000$).</p> <p>Relapse at 2.5 years follow up: In group A (alarm with reward stickers for correct behaviour) 10 out of 37 had relapsed at the end of 2.5 year follow up compared to 15 out of 33 in group B (alarm with reward sticker for dry nights and punishment sticker for wet nights) and 13 out of 26 in group C (alarm alone).</p> <p>The two star charts were (1) two reward stickers were given immediately for correct behaviour of waking to the alarm within 3 minutes, going to the toilet after, returning to bed and resetting the alarm, and one sticker was asked for as a charge for incorrect behaviour and (2) two reward stickers were given in the morning for a dry bed or one sticker was asked for as a charge for a wet bed.</p>
Funding	Not reported
Does the study answer the question?	The study showed that giving a child an alarm with reward stickers for correct behaviour was significantly more successful in achieving 14 dry nights compared to giving a child an alarm with reward stickers for dry nights and punishment sticker for wet nights or an alarm alone
Effect due to factor in study?	Yes (NB there is a 15T spontaneous cure rate associated with NE)
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Age range is 6-12 years
Internal Validity	Inadequate concealment method

Grading: 1-	<i>Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*</i>
--------------------	--

Reference number 340 Study Type Randomised Controlled Trial RID:
 Baker BL; 433

Symptom treatment and symptom substitution in enuresis

1969 74 J Abnorm Psychol pgs 42 49

Number of subjects 30 patients in total

Inclusion/Exclusion Criteria: Patients were excluded if there was an organic cause of wetting

Characteristics of subjects or environment/prognostic factor 67% were boys. The median age was 8 years with a range of 6-12 years. 4 patients had secondary enuresis. More than half the patients wet every night

Recruitment: From newspaper adverts

Setting: At home, USA

Interventions/Test /Factor being investigated Group A: alarm
 Group B: star chart and waking
 Group C: waiting list

Comparitors Between treatment groups

Length of Study/ Follow-up 0 months

Outcome measures studies Change in number of wet nights
 Self image questionnaire

Results Star charts were used to keep a record of the child's progress and the child was woken at a set time every night (chosen at start of trial to be before when the child usually wets), once the child was dry for several nights they were not woken for a week, if dry during the week the parents were told if the child wets wake them for the two following nights

10 weeks treatment
 10 patients in each group

Mean number of wet nights per week in the last 3 weeks of treatment:
 In group A (alarm) the mean number of wet nights was 1.8, in group B (waking and star chart) the mean number of wet nights was 3.1 and in group C (waiting list) the mean number of wet nights was 5.9.

Number of children who achieved 14 consecutive dry nights:
 In group A (alarm) 11 out of 14 children achieved 14 consecutive dry nights compared to 2 out of 14 in group B (waking and star chart) and 0 out of 14 in group C (waiting list).

Relapsed:
 In total, 4 patients relapsed

Funding None reported

Does the study answer the question? Significantly more children became dry for 14 nights when treated with alarm therapy compared to no treatment (79% compared to 0%).

Effect due to factor in study? Yes (NB there is a 15% spontaneous cure rate)

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? The age range was 6-12 years

Internal Validity Allocation method to treatment group isn't reported

Reference number 1751 **Study Type** **Randomised Controlled Trial** RID:
Fava GA;Cracco L;Facco L; 390
Positive reinforcement and enuresis
1981 8 pgs 149 152

Number of subjects 20 in total, 10 in Group A (star chart), 10 in Group B (play therapy).

Inclusion/Exclusion Criteria: Inclusion: primary NE. Wet every night.
Exclusion: secondary NE

Characteristics of subjects or environment/prognostic factor In Group A (star chart) 6 out of 10 were male, the mean age was 8 (sd 1.66) years
There were no baseline characteristics for Group B.

Recruitment: Consecutive children at a child guidance centre.

Setting: Mexico

Interventions/Test /Factor being investigated Group A: behaviour modification – Children were given a star on a chart where the whole family could see and a reward (such as pocket money) for a dry night. If no improvement after 15 nights children were lifted at night to void
Group B: unstructured play therapy.

Comparators Between treatment groups.

Length of Study/ Follow-up 1 year follow up.

Outcome measures studies Number of children who achieved 14 consecutive dry nights and number of children who relapsed or failed after 1 year.

Results The star chart treatment group had a star given by parents on the family calendar, so the whole family could see. For a dry night, a reward for example pocket money was given after each star. Play therapy was described as “unstructured play therapy; behavioural suggestions were carefully excluded”.

Treatment was for 3 months

Number of children who achieved 14 consecutive dry nights:
In Group A (star charts) 8 out of 10 children became dry for 14 consecutive nights (2 of which had to be lifted) compared to 1 out of 10 children in Group B (play therapy).

Number of children who relapsed or failed after 1 year
In Group A (star charts) 2 out of 10 failed or relapsed compared to 9 out of 10 children in Group B (play therapy).

Funding Not reported

Does the study answer the question? The study showed that children treated with star charts were more likely to achieve 14 consecutive dry nights compared to children treated with play therapy.

Effect due to factor in study? Yes

Consistency of results with other studies? No other studies compared star charts to play therapy.

How directly applicable to population of the guideline? Children in treatment group had a mean age of 8 years.

Internal Validity No baseline characteristics were given for the play therapy group

Reference number 540 **Study Type** **Randomised Controlled Trial** RID:
Maxwell C;Seldrup J; 326
Factors relating to the optimum effect of imipramine in the treatment of enuresis
1971 21 pgs 1352 1356

Number of subjects 135 in total: cross over trial with 125 in each group due to 10 drop outs.

Inclusion/Exclusion Criteria: Inclusion: aged 5-12 years, normal except for NE, wet at least 3 times a week, stable home environment for 8 weeks.
Exclusion: organic causes of NE, MAO inhibitors within previous 2 weeks.

Characteristics of subjects or environment/prognostic factor 84 out of 125 were male. The age range was 5 to 12 years. The mean baseline number of dry nights in 28 nights was 7 (sd 7).

Recruitment: Not reported.

Setting: UK

Interventions/Test /Factor being investigated Group A: imipramine 25 mg for children aged 5-7 years, 50 mg children aged 8-12 years and star chart.
Group B: placebo and star chart.

Comparitors Between groups A and B

Length of Study/ Follow-up For 4 weeks consisting of the treatment period.

Outcome measures studies Mean number of wet nights per month at the end of treatment, adverse events.

Results Stars (coloured blue) were given for a dry night. After 3 dry nights in a row an extra gold star was given.

Treatment was for 4 weeks

Mean number of wet nights per month at the end of treatment:
In group A (imipramine and star chart) the mean number of wet nights per month was 11.4 (sd 8.7) compared to 14.8 (sd 8.5) nights in group B (placebo and star chart).

Adverse events:
In group A (imipramine and star chart) 2 out of 125 suffered anorexia, 1 out of 125 suffered diarrhoea, 1 out of 125 suffered constipation, 1 out of 125 suffered

	depression, 1 had nose bleed, 1 had irritability, 1 had faecal staining, 1 had drowsiness and 1 had oral infection. There were no side effects in group B (placebo and star chart).
Funding	Not reported
Does the study answer the question?	The study showed that children treated with imipramine and star chart had fewer wet nights per month compared to those treated with placebo and star chart.
Effect due to factor in study?	Yes
Consistency of results with other studies?	No other studies compared star charts to imipramine.
How directly applicable to population of the guideline?	Children were aged 5 to 12 years.
Internal Validity	There was no washout between treatments. Cochrane report states it is difficult to determine the impact of the star chart.

Question: What is the clinical and cost effectiveness of alarms for children and young people under 19 years old who have nocturnal enuresis?

16

Grading: 1+	Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
--------------------	--

Reference number 372 Study Type Randomised Controlled Trial RID: 55
 Bradbury MG;Meadow SR;

Combined treatment with enuresis alarm and desmopressin for nocturnal enuresis

1995 84 Acta Paediatr pgs 1014 1018

Number of subjects 71 in total: 36 in group A and 35 in group B.

Inclusion/Exclusion Criteria: Inclusion: aged 6-15 years old, and wet at least 1 night per week.
 Exclusion: if the patient had neuropathetic bladder, urinary tract abnormalities, cystic fibrosis, allergic rhinitis, deafness or learning difficulties, UTI or taking medication which might cause diuresis.

Characteristics of subjects or environment/prognostic factor In group A (alarm with desmopressin): 69% were male, the mean age was 10 years old, mean number of dry nights in observation week was 2.3, 39% had family problems, 22% had a Rutter A2 score > 17, 0 had housing problems, 44% had tried enuresis alarms before, 5% also day time wet, and 17% had secondary enuresis.
 In group B (alarm): 66% were male, the mean age was 9.7 years old, mean number of dry nights in observation week was 2.3, 31% had family problems, 17% had a Rutter A2 score > 17, 0 had housing problems, 37% had tried enuresis alarms before, 6% were also day time wet, and 15% had secondary enuresis.

Recruitment: Referred by GPs, community medical officers, urologists or paediatricians.

Setting: Treatment administered at home, Leeds UK.

Interventions/Test /Factor being investigated Group A: desmopressin with alarm
 Group B: alarm

Comparators Between groups A and B

Length of Study/ Follow-up 6 months.

Outcome measures studies Change in number of wet nights, numbers of children dry for 4 weeks, and numbers relapsing.

Results For all children (71)
 Dry for 4 weeks:
 In group A (alarm and desmopressin) 27 out of 33 children achieved 4 weeks dry compared to 16 out of 27 in group B (alarm). This difference is significant (p<0.005).

 Relapse:
 In group A (alarm and desmopressin) 4 children relapsed compared to 3 in group B (alarm). This difference was not significant.

 Change in mean number of dry nights per week:
 During the observation period both group A (alarm and desmopressin) and group B (alarm) had a mean number of dry nights of 2.3.
 At the end of treatment group A (alarm and desmopressin) had a mean number of dry nights of 6.1 compared to 4.8 in group B (alarm). This difference was significant (P<0.01)

 Drop outs
 In group A (alarm and desmopressin) 0 children dropped out compared to 2 in group B (alarm), this difference was not significant.

 For children with severe wetting (40)
 Dry for 4 weeks:
 In group A (alarm and desmopressin) 14 children achieved 4 weeks dry compared to

6 in group B (alarm), this difference is significant ($p < 0.01$).

Relapse:

In group A (alarm and desmopressin) 2 children relapsed and in group B (alarm) 2 children relapsed.

Change in mean number of dry nights per week:

During the observation period both group A (alarm and desmopressin) had a mean number of dry nights of 0.8 and group B (alarm) had a mean number of dry nights of 1.1.

At the end of treatment group A (alarm and desmopressin) had a mean number of dry nights of 5.7 compared to 3.7 in group B (alarm). This difference was significant ($P < 0.01$)

For children with family and behavioural problems (30)

Dry for 4 weeks:

In group A (alarm and desmopressin) 13 children achieved 4 weeks dry compared to 4 in group B (alarm). This difference is significant ($p < 0.05$).

Relapse:

In group A (alarm and desmopressin) 2 children relapsed and in group B (alarm) 2 children relapsed.

Change in mean number of dry nights per week:

During the observation period both group A (alarm and desmopressin) had a mean number of dry nights of 2.6 and group B (alarm) had a mean number of dry nights of 2.5.

At the end of treatment group A (alarm and desmopressin) had a mean number of dry nights of 6.3 compared to 4.8 in group B (alarm). This difference was significant ($P < 0.01$)

Funding

None reported

Does the study answer the question?

In all patients significantly more children became dry for 4 weeks in alarm and desmopressin than the alarm alone group. Children who had alarm with desmopressin had significantly more dry nights than those who had alarm therapy alone. There was no significant difference between the relapse rate and drop out rate.

In children with behavioural and family problems significantly more children became dry for 4 weeks in alarm and desmopressin than the alarm alone group. Children who had alarm with desmopressin had significantly more dry nights than those who had alarm therapy alone. There was no difference between the relapse rate.

No difference in relapse

In severe wetting group significantly more children became dry for 4 weeks in alarm and desmopressin than the alarm alone group. Children who had alarm with desmopressin had significantly more dry nights than those who had alarm therapy alone. There was no difference between the relapse rate.

Effect due to factor in study?

Yes.

Consistency of results with other studies?

No other studies considered this subgroup.

How directly applicable to population of the guideline?

Children were aged 6 - 15 years old.

Internal Validity

Reference number 362

Study Type

Randomised Controlled Trial

RID:

Butler RJ;Forsythe WI;Robertson J;

46

The body-worn alarm in the treatment of childhood enuresis

Number of subjects	In study 1: 40 in total, 20 in each group In study 2: 48 in total, 24 in each group
Inclusion/Exclusion Criteria:	Study 1 Inclusion: wet at least 4 nights a week for a month, normal physical examination, normal urine microscopy, normal intelligence, not previously treated for NE with any conditioning method.
Characteristics of subjects or environment/prognostic factor	Study 1 The mean age was 8.11 years (range 6.1-15.6 years). 63% were boys. In group A the mean age was 8.2 years, the baseline number of dry nights was 1.2 and the male to female ratio was 14:6. In group B the mean age was 9.1 years, the baseline number of dry nights was 0.7 and the male to female ratio was 11:9.
Recruitment:	Referred as out-patients for treatment of NE.
Setting:	Leeds, UK, treatment administered at home.
Interventions/Test /Factor being investigated	Study 1 Group A: pad and bell alarm Group B: body worn alarm
Comparitors	Between group A and B in each study
Length of Study/ Follow-up	6 months
Outcome measures studies	Number of children dry for 14 consecutive nights, change in number of wet nights, and relapses.
Results	16 weeks treatment. Success was reaching 14 consecutive dry nights. Study 1: Both alarms were 70% effective: 14 out of 20 children became dry for 14 consecutive nights. The drop out rate was 15%: 3 out of 20 children for the pad and bell alarm and 10% 2 out of 20 children for the body-worn alarm. There were no statistical differences between groups. The relapse rates at 6 months were 4 out of 14 children for the pad and bell alarm and 3 out of 14 children for the body-worn alarm. There was no statistical difference between groups. The mean number of wet nights per week at end of treatment for the pad and bell alarm was 1.2 compared to 1 for the body worn alarm.
Funding	Not reported
Does the study answer the question?	It compares two types of alarms, the body-worn alarm and the pad and bell (modified dry-bed training). Both were equally effective in the first study (70%) and the second study initial arrest was 58% for the MDBT group and 83% for the body-worn alarm group, however the difference was not significant. The body-worn alarm achieved a greater number of dry nights earlier than the other group. The relapse rate was higher in the second study than the first study, the difference between groups was not significant.
Effect due to factor in study?	Yes.
Consistency of results with other studies?	No other similar studies.

How directly applicable to population of the guideline? Children were aged between 6.1 years and 15.6 years.

Internal Validity Inadequate concealment method.

Reference number 258 **Study Type** **Randomised Controlled Trial** RID:
Leebeek-Groenewegen A;Blom J;Sukhai R;Van D; 21
Efficacy of desmopressin combined with alarm therapy for monosymptomatic nocturnal enuresis
2001 166 pgs 2456 2458

Number of subjects 93 in total: 47 in group A and 46 in group B.

Inclusion/Exclusion Criteria: Inclusion: uncomplicated NE, and wet for at least 3 nights per week.
Exclusion: treatment in previous 2 weeks for NE, day time wetting, pollakisuria, use of medication which interacts with desmopressin, underlying cardiovascular, hepatic, urological, or psychiatric disease, or insufficient motivation for use of alarm.

Characteristics of subjects or environment/prognostic factor The age range was 6-14 years old. No other characteristics given.

Recruitment: Patients seen in 2 specialist enuresis clinics as part of a Dutch general paediatric outpatient department.

Setting: Treatment administered at home.

Interventions/Test /Factor being investigated Group A: alarm with desmopressin for 3 weeks, then desmopressin for 3 weeks and then alarm for 3 weeks.
Group B: alarm and placebo for 6 weeks then alarm for 3 weeks.

Comparitors Between group A and B.

Length of Study/ Follow-up 6 months.

Outcome measures studies The number of children who had a greater than 90% reduction in mean number of wet nights, mean number of wet nights, and the number of children who had a greater than 90% reduction in mean number of wet nights at 6 months.

Results The number of children who had a greater than 90% reduction in mean number of wet nights:
In the alarm and desmopressin group 15 out of 43 children achieved a 90% reduction compared to 18 out of 38 in the alarm and placebo group.

Mean number of wet nights:
The mean number of wet nights in the alarm and desmopressin group was 2.77 compared to 2.21 in the alarm and placebo group.

The number of children who had a greater than 90% reduction in mean number of wet nights at 6 months:
In the alarm and desmopressin group 17 out of 41 children achieved a 90% reduction at 6 months compared to 17 out of 37 in the alarm and placebo group.

Funding Ferring B. V., Hoofddorp, the Netherlands

Does the study answer the question? The authors stated that alarm with desmopressin resulted in significantly fewer wet nights during first 3 weeks compared to alarm alone but there was no significant difference at 6 months. There was no difference in the number of children cured at 2 weeks after treatment or at the 6 month follow up.

Effect due to factor in study? Yes.

(desmopressin).

Behavioural changes:

The behavioural changes were not related to the type of treatment or success of treatment. However there were significant positive changes in intellectual, physical appearance, anxiety, popularity (analysed through the Piers-Harris Subscales). There were also significant positive results on the Achenbach CBCL, Internalizing and Externalizing Behaviour Scores and Social, Thought and Attention Problems Subscales.

Funding National Health Research and Development Program and Fering Inc

Does the study answer the question? There was no significant difference in the number of children achieving 14 consecutive dry nights between those receiving alarm and those receiving desmopressin. The study also reported a positive change in the children's behaviour; however this was not related to treatment type or outcome success.

Effect due to factor in study? Yes.

Consistency of results with other studies? Similar with other studies comparing alarms to desmopressin.

How directly applicable to population of the guideline? Children were aged over 7 years.

Internal Validity There were no significant differences between the 3 treatment groups' baseline characteristics.

Reference number 137 **Study Type** **Randomised Controlled Trial** RID:
Lynch NT;Grunert BK;Vasudevan SV;Severson RA; 11
Enuresis: comparison of two treatments
1984 65 pgs 98 100

Number of subjects 60 boys, 20 in each group

Inclusion/Exclusion Criteria: Inclusion: wet at least 2 times a week.
Exclusion: day time wetting.

Characteristics of subjects or environment/prognostic factor The age range was 5-12 years.

Recruitment: Selected from a pool of children in the first 3 grades at the local school and from paediatric referrals.

Setting: At home.

Interventions/Test /Factor being investigated Group A: star chart for 2 weeks and then an alarm
Group B: control - no treatment, waiting list group

Comparitors Between groups A and B.

Length of Study/ Follow-up 10 weeks.

Outcome measures studies Number of children dry for 14 consecutive dry nights, change in number of wet nights, and drop out rates.

Results 10 weeks treatment

14 consecutive nights dry:
In group A (star chart then alarm) 7 out of 18 children (39%) became dry for 14 nights compared to 0 out of 18 (0%) in group B (control)

Change in number of wet nights:
At baseline group A (star chart then alarm) had a mean number of wet nights of 11.11 (SD 2.90), and group B (control) had a mean number of 11.55.
During the last week of treatment group A (star chart then alarm) had a mean number of wet nights of 1.69 (SD 2.28) and group B (control) 5.15 (SD 1.5).

Drop outs
1 child dropped out from the alarm group compared to none in the waiting list group.

The study reported that the alarms did malfunction during the treatment which may have affected the results.

Funding Not reported.

Does the study answer the question? The study showed that giving the child an alarm was more effective than no treatment.

Effect due to factor in study? Yes.

Consistency of results with other studies? Similar to other studies comparing alarms to no treatment.

How directly applicable to population of the guideline? Children's age range was 5-12 years.

Internal Validity All patients were boys
No details of blinding

Reference number 54 **Study Type** **Randomised Controlled Trial** RID:
Nawaz S;Griffiths P;Tappin D; 2

Parent-administered modified dry-bed training for childhood nocturnal enuresis: Evidence for superiority over urine-alarm conditioning when delivery factors are controlled

2002 17 Behavioral Interventions pgs 247 260

Number of subjects 36 in total, 12 in each of the three study groups.

Inclusion/Exclusion Criteria: Inclusion: functional NE defined in DSM-IV (aged over 5 years, wet at least 2 times a week for 3 months, NE not due to primary medical or physiological pathology), aged between 7-12 years, attending a mainstream school, wetting 4 or more nights a week, no foreseen domestic disruption during treatment time, readiness to be involved in trial, bedwetting secondary to organic or psychiatric disorder and those unwilling to cooperate.
Exclusion: diurnal enuresis or encopresis.

Characteristics of subjects or environment/prognostic factor

In group A, Dry-bed training (DBT) with alarm, the mean age was 9.93 years (1.81 SD), 50% were male, the mean baseline number of wet nights per week was 5.58 (1.31 SD), The mean deprivation category (0-7) was 4.67 (2.15 SD)

In group B (alarm) the mean age was 9.93 years (1.99 SD), 50% were male, the mean baseline number of wet nights per week was 5.50 (1.45 SD), The mean deprivation category (0-7) was 4.75 (1.91 SD)

In group C (control-no treatment) the mean age was 9.84 years (1.84 SD), 50% were male, the mean baseline number of wet nights per week was 5.92 (1.08 SD), The mean deprivation category (0-7) was 5.75 (1.71 SD)

Recruitment:	From nine health centres (GPs, GP nurses, health visitors, community paediatricians)
Setting:	Scotland, UK, treatment at home.
Interventions/Test /Factor being investigated	Group A: DBT with alarm Group B: alarm Group C: control group - no treatment
Comparitors	Between groups A, B and C
Length of Study/ Follow-up	6 months
Outcome measures studies	Dry for 14 consecutive nights, change in number of wet nights, and relapse.
Results	<p>Patients were treated for 16 weeks or until dry</p> <p>Dry for 14 consecutive nights: In group A (DBT with alarm) 8 out of 12 children (67%) became dry for 14 nights compared to 3 out of 12 children (25%) in group B (alarm) and 1 out of 12 children (8%) in group C (control). This difference was significant ($p < 0.01$)</p> <p>Change in number of wet nights: The mean number of wet nights for group A (DBT and alarm) was 0.83 (sd 1.4) compared to 3.25 (sd 2.67) for group B (alarm) and 5 (sd 2.26) for group C (control)</p> <p>Relapse: At 3 month follow up, no children had relapsed. At 6 month follow up 1 child in group A (DBT with alarm) and 1 child in group B (alarm) had relapsed). Both children were wetting 3 nights a week.</p>
Funding	None reported
Does the study answer the question?	The study showed that DBT with alarm was significantly more effective at achieving 14 dry nights compared to alarm alone and no treatment. The study also showed that DBT with alarm had a greater reduction in the mean number of wet nights compared to alarm alone and no treatment.
Effect due to factor in study?	Yes.
Consistency of results with other studies?	No other studies for this sub group.
How directly applicable to population of the guideline?	The age range was 7-12 years.

Internal Validity

Reference number	369	Study Type	Randomised Controlled Trial	RID:	
	Ng CFN;Wong SN;Hong Kong Childhood Enuresis Study Group.;				52
	Comparing alarms, desmopressin, and combined treatment in Chinese enuretic children				
2005	20	Pediatr Nephrol	pgs	163	169

Number of subjects 105 in total: 35 in group A, 38 in group B, 32 in group C.

Inclusion/Exclusion Criteria:	Inclusion: Primary NE, age range 7-15 years, wetting at least 3 times a week in baseline 2 weeks. Exclusion: UTI in previous 3 months, day time wetting, polyuric disorders, abnormal urinalysis, renal disease, previous diuretics, unwilling to be randomised previous treatment of alarms, desmopressin or tricyclics
Characteristics of subjects or environment/prognostic factor	The mean age was 9.5 (1.8 SD) years, and the age range 7-12 years. In group A (alarm) the mean age was 9.5 (1.8 SD) years, 57% children were in the age range 7-9 years, 40% in 10-12 years and 3% in 13-15 years. 63% were boys, and the mean baseline number of wet nights a week was 5.1 (1.5 SD). In group B (desmopressin) the mean age was 9.2 (1.8 SD) years, 69% children were in the age range 7-9 years, 26% in 10-12 years and 5% in 13-15 years. 68% were boys, and the mean baseline number of wet nights a week was 5.3 (1.4 SD). In group C (alarm with desmopressin) the mean age was 9.8 (1.2 SD) years, 50% children were in the age range 7-9 years, 47% in 10-12 years and 3% in 13-15 years. 66% were boys, and the mean baseline number of wet nights a week was 4.9 (1.2 SD).
Recruitment:	Patients presented to 9 public hospitals in Hong Kong with primary NE.
Setting:	Hong Kong, and treatment administered at home.
Interventions/Test /Factor being investigated	Group A: alarm Group B: oral desmopressin Group C: alarm with oral desmopressin
Comparators	Between groups A, B and C.
Length of Study/ Follow-up	12 weeks.
Outcome measures studies	Number of children who were dry for 14 consecutive nights, change in number of wet nights, drop out, and relapse.
Results	12 weeks treatment Dry for 14 consecutive nights: In group A (alarm) 8 out of 35 children achieved 14 dry nights, compared to 16 out of 38 children, in group B (desmopressin) and 20 out of 32 children in group C (alarm and desmopressin). This difference was significant $p = 0.014$. The mean number of wet nights per week at end of treatment for the alarm group was 2.8 (SD 2.2) compared to 2.7 (SD 2.4) for the desmopressin group and 1.3 (SD 1.9) for the desmopressin and alarm group. Drop out: 12 children dropped out in total, 7 out of 35 (20%) from group A (alarm), 2 out of 38 (5%) from group B (desmopressin) and 3 out of 32 (9%) from group C (alarm and desmopressin). Relapse: In the alarm group 0 out of 8 children relapsed at 3 months, compared to 9 out of 16 in the desmopressin group and 7 out of 20 in the alarm with desmopressin group.
Funding	Hong Kong Paediatric Nephrology Society with a research grant from Ferring Pharmaceuticals Limited
Does the study answer the question?	The study showed that significantly more patients achieved 14 consecutive dry nights if they were treated with alarm or desmopressin alone (71% compared to 42.9% and 52.6%). The study also showed that there was a significant difference between groups in the % reduction of wet nights during the last 4 weeks of treatment and during the first 4 weeks of follow up, with patients being treated with alarm and desmopressin being significantly more successful than alarm or desmopressin alone.
Effect due to factor in study?	Yes.

Consistency of results with other studies? Similar to other studies with same comparison.

How directly applicable to population of the guideline? Age range was 7-15 years.

Internal Validity Chinese population.

Reference number 353 **Study Type** **Randomised Controlled Trial** RID:
Sukhai RN;Mol J;Harris AS; 38
Combined therapy of enuresis alarm and desmopressin in the treatment of nocturnal enuresis
1989 148 Eur J Pediatr pgs 465 467

Number of subjects 28 in total: 28 in each group. Patients switched groups after 2 weeks.

Inclusion/Exclusion Criteria: Inclusion: normal urine concentration capacity of 800 mosmol/kg or higher, wet 3 or more nights a week, no neurological or renal disorder, no history of daytime wetting, no chronic urinary tract infection, and no neurological or cardiovascular disease.

Characteristics of subjects or environment/prognostic factor The mean age was 11 (2.4 SD) years, 75% were boys, 71% attended normal primary school and 29% attended classes or schools for those with learning difficulties. 31% had a positive family history of bed wetting and 65% had previously tried treatment for NE. The mean number of dry nights per week before starting treatment was 1.4 (0.3 SD).

Recruitment: Not reported.

Setting: Holland, treatment administered at home.

Interventions/Test /Factor being investigated Group A: alarm with desmopressin.
Group B: alarm with placebo.

Comparitors Between groups A and B.

Length of Study/ Follow-up 6 months follow up.

Outcome measures studies The mean number of dry nights per week.

Results 2 weeks of each treatment with 2 week washout.

The mean number of dry nights per week:
In the alarm and desmopressin the mean number of dry nights per week was 5.1 (sd 0.4) compared to 4.1 (sd 0.4) in the alarm and placebo group.

Funding Ferring B.V, Holland provided Minrin Nasal pipettes

Does the study answer the question? Alarm and desmopressin had a greater number of dry nights after treatment compared to alarm and placebo.

Effect due to factor in study? Yes

Consistency of results with other studies? No other similar studies.

How directly applicable to population of the guideline? Age range was 7-16 years.

Internal Validity Patients switched treatment groups after 2 weeks.
Recruitment is not reported.

Grading: 1-	<i>Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*</i>
--------------------	--

Reference number 340 Study Type **Randomised Controlled Trial** RID:
 Baker BL; 26

Symptom treatment and symptom substitution in enuresis

1969 74 J Abnorm Psychol pgs 42 49

Number of subjects 30 patients in total: 14 in each of the two groups.

Inclusion/Exclusion Criteria: Patients were excluded if there was an organic cause of wetting.

Characteristics of subjects or environment/prognostic factor 67% were boys. The median age was 8 years with a range of 6-12 years. 4 patients had secondary enuresis. More than half the patients wet every night.

Recruitment: From newspaper adverts.

Setting: At home, USA

Interventions/Test /Factor being investigated Group A: alarm
 Group B: control group - not treatment (waiting list)
 The study also considered regular waking which was not included as it is not a relevant comparator

Comparitors Between groups A and B

Length of Study/ Follow-up 10 weeks.

Outcome measures studies Mean number of wet nights, numbers of children who were dry for 14 consecutive nights, and relapse.

Results 10 weeks treatment

 Dry for 14 consecutive nights:
 In group A (alarm) 11 out of 14 children became dry for 14 nights compared to 0 out of 14 children in group B (control).

 Mean number of wet nights:
 In group A (alarm) the mean number of wet nights per 3 weeks was 1.8 compared to 5.9 in group B (control).

 Relapsed:
 In total, 4 patients relapsed

Funding None reported

Does the study answer the question? Significantly more children became dry for 14 nights when treated with alarm therapy compared to no treatment (79% compared to 0%).

Effect due to factor in study? Yes.

Consistency of results with other studies? Similar to other studies with same comparison.

How directly applicable to population of the guideline? The age range was 6-12 years.

Internal Validity Allocation method to treatment group isn't reported.

Reference number 360 **Study Type** **Randomised Controlled Trial** RID:
Bennett GA;Walkden VJ;Curtis RH;Burns LE;Rees.J.;Gosling JA; 44
Pad-and-buzzer training, dry-bed training, and stop-start training in the treatment of primary nocturnal enuresis
1985 13 pgs 309 19

Number of subjects 40 in total: 9 in group A, 10 in group B and 9 in group C.

Inclusion/Exclusion Criteria: Inclusion: primary NE, not dry for more than 4 weeks, at least 6 wet nights during 14 night baseline, negligible daytime wetting.
Exclusion: encopresis, previous behavioural intervention, or gross psychopathology.

Characteristics of subjects or environment/prognostic factor 63% were boys. The mean age was 8.5 (3.2 SD) years and the age range was 5-12 years.

Recruitment: Referred from GP.

Setting: Treatment administered at home, Rochdale UK.

Interventions/Test /Factor being investigated Group A: alarm (pad and buzzer)
Group B: dry bed training (DBT) with alarm
The study also considered star charts, bladder training and sphincter muscle exercises which was not included as it is not a relevant comparator.

Comparitors Between treatment groups.

Length of Study/ Follow-up 12 weeks

Outcome measures studies Number of children achieving 14 consecutive dry nights, mean number of dry nights at follow up,and drop outs.

Results 12 weeks treatment

Results:
Dry for 14 consecutive nights:
In group A (alarm) 4 out of 9 children, became dry for 14 nights compared to 5 out of 10 children, in group B (DBT with alarm).

Drop out:
32 children in total dropped out
In group A (alarm) 9 children, dropped out compared to 10 children in group B (DBT with alarm)

Mean number of wet nights:
The mean number of wet nights per week at end of treatment for the alarm group was 1 (SD 1.95) compared to 1.4 (SD 1.8) for the dry bed training group and 5.15 (SD 1.5) for the no treatment alarm group.

Funding None reported

Does the study answer the question? Both alarm alone and DBT with alarm gave good results for achieving 14 dry nights (44% and 50%). All patients in the treatment groups saw an increase in the number of dry nights over the 12 week follow up, with alarms having the highest number of wet nights then DBT with alarm. There was no significant difference in the number of drop outs in each group.

Effect due to factor in study? Yes.

Consistency of results with other studies? Similar to other studies with same comparison.

How directly applicable to population of the guideline? Yes the age range was 5-12 years old.

Internal Validity There is a high drop out rate.

Reference number 342 **Study Type** **Randomised Controlled Trial** RID:
Bollard J;Nettelbeck T; 886
A component analysis of dry-bed training for treatment for bedwetting
1982 20 Behav Res Ther pgs 383 390

Number of subjects Experiment 2
Number of children: 100
Number of boys: A:14; B:13; C:16; D:14; E:14; F:11

Inclusion/Exclusion Criteria: Organic causes of nocturnal enuresis excluded
Daytime wetting exclusion not mentioned.

Characteristics of subjects or environment/prognostic factor Children with thorough medical examination; regularly wetting at least one night per week; no other treatment during trial. Previous treatment: no details.

Mean age
A: 9.3
B: 8.11
C: 9.7
D: 8.6

Recruitment: Not reported

Setting: Australia, treatment at home

Interventions/Test /Factor being investigated Experiment 2
Group A (20): DBT (A+W+CT+PP) with therapist at home
Group B (20): DBT (A+W+CT+PP) with therapist at hospital
Group C (20): DBT (A+W+CT+PP) with parents as therapists at home
Group D (20): DBT (W+CT+PP) with parents as therapists at home without enuresis alarm
Group E: alarm
Group F: waiting list control

Comparators Between treatment groups

Length of Study/ Follow-up Duration of treatment: until 14 consecutive dry nights or 20 weeks.
Follow-up at 3, 6 and 12 months

Outcome measures studies 14 consecutive dry nights, mean number of wet nights

Results DBT compared to alarm only. DBT significantly more effective in terms of number of wet nights and days to dryness.

Mean number of wet nights per week at end of week 20.
(including drop-outs) A:0; B:0; C:0; D: (n=20) 3.8; E: 0.6; F:4.4
(excluding drop-outs) A:0; B:0; C:0; D: (n=8) 1.3; E:0.6; F:4.4

Number achieving 14 consecutive dry nights: A:20; B:20; C:20; D:5; E:16; F:2.
p<0.05.

Funding Not reported

Does the study answer the question? DBT compared to alarm only. DBT significantly more effective in terms of number of wet nights and days to dryness.

Effect due to factor in study? Yes

Consistency of results with other studies? Similar to results in Bolard 1981

How directly applicable to population of the guideline? Mean age range of 8.6 to 9.7 years

Internal Validity

Reference number	371	Study Type	Randomised Controlled Trial	RID:
Bollard J;Nettelbeck T;				885
A comparison of dry-bed training and standard urine-alarm conditioning treatment of childhood bedwetting				
1981	19	Behav Res Ther	pgs 215	226

Number of subjects 120 children: 20 in each of the 6 groups.

Inclusion/Exclusion Criteria: Inclusion: through medical examination, wet at least 1 night a week, and no other treatment during study.
Exclusion: organic causes of NE.

Characteristics of subjects or environment/prognostic factor In group A (DBT with therapist in home) children had a mean age of 9.3 years and 14 were male. The baseline mean number of wet nights was 5.8.
In group B (DBT with therapist in hospital) children had a mean age of 8.11 years and 13 were male. The baseline mean number of wet nights was 5.2.
In group C (DBT with parents as therapist in home) children had a mean age of 9.7 years and 16 were male. The baseline mean number of wet nights was 6.0.
In group D (DBT with parents as therapist in home without alarm) children had a mean age of 8.6 years and 14 were male. The baseline mean number of wet nights was 5.7.
In group E (alarm) children had a mean age of 8.8 years and 14 were male. The baseline mean number of wet nights was 6.0.
In group F (waiting list) children had a mean age of 8.1 years and 1 were male. The baseline mean number of wet nights was 4.7.

Recruitment: Children who were outpatients of the Adelaide Children's Hospital.

Setting: Outpatient service of Adelaide Children's Hospital

Interventions/Test /Factor being investigated Group A: DBT with therapist in home
Group B: DBT with therapist in hospital
Group C: DBT with parents as therapist in home
Group D: DBT with parents as therapist in home without alarm
Group E: Alarm

Inclusion/Exclusion Criteria:	Inclusion: boys with enuresis Exclusion: those who were undergoing traditional treatment
Characteristics of subjects or environment/prognostic factor	The mean age was 10.4 years, the mean IQ is 85.4 (20.12 SD)
Recruitment:	From a fishing village in Ghana
Setting:	Ghanian fishing community, at home
Interventions/Test /Factor being investigated	Group A: amitriptyline Group B: alarm The study also looked at shaming which is not a relevant comparison so results are not reported
Comparators	Between treatment groups.
Length of Study/ Follow-up	3 months
Outcome measures studies	Change in number of wet nights
Results	7 weeks treatment The mean number of wet nights per week at the end of treatment was 3.2 for the alarm group and 4 for the amitriptyline group. The median number of days for initial arrest were 15.5 for alarm therapy and 20 for amitriptyline Follow-up was conducted after 3 months after treatment. Alarm therapy was the only treatment that was continuously successful. The post-treatment ranking was 3.20 and following treatment was 1.49, $t=3.98$, $p<0.001$.
Funding	None reported
Does the study answer the question?	The alarm was found to be quicker and more effective than amitriptyline.
Effect due to factor in study?	Yes (NB there is a spontaneous 15% cure rate)
Consistency of results with other studies?	
How directly applicable to population of the guideline?	The study only included boys, the mean age was 10.4 years
Internal Validity	All the patients were boys.

Reference number 146 Study Type **Randomised Controlled Trial** RID: 13
 Fielding D;
 The response of day and night wetting children and children who wet only at night to retention control training and the enuresis alarm
 1980 18 pgs 305 317

Number of subjects 45 patients who only night time wet, and 30 patients who night and day time wet.

Inclusion/Exclusion Criteria: Patients had to wet the bed at least once a week. They had to be aged between 5 and 15 years, have no UTI, no evidence of organic cause of NE and have not been treated in the previous 12 months. Children who day time wet only were excluded.

Characteristics of subjects or environment/prognostic factor Of the night time wetters: 30 patients were male, the age ranged from 5 years and 2 months to 13 years and 10 months. The mean age of males was 9.08 ± 4.54 years and in females was 7.96 ± 5.53 years.
 Of day time and night time wetters: 24 were female. The age ranged from 5 years to 12 years and 5 months. The mean age of males was 7.96 ± 2.40 years and in females was 7.08 ± 2.83 years.

Recruitment: Patients were referred by paediatricians and psychiatrists to 2 clinics set up for the study.

Setting: Treatment administered at home, Liverpool, UK.

Interventions/Test /Factor being investigated Group A: retention control and alarm
 Group B: alarm only

Comparitors Between study groups and between night and day wetters and night time only wetters.

Length of Study/ Follow-up 12 months

Outcome measures studies Number of children achieving 14 consecutive dry nights, drop out rates and relapse rates.

Results 14 weeks treatment

The patients were treated for 4 weeks of retention control training and 14 weeks with the alarm. The results are reported in two subgroups, patients who have only night time wetting and those who have both night and day time wetting. After one month all children received the alarm only intervention.

For patients with night time only wetting:
 14 consecutive dry nights:
 In group A (retention control with alarm) 11 out of 16 children (69%) became dry for 14 nights compared to 14 out of 17 children (82%) in group B (alarm).

Drop out:
 24.4% dropped out in total (11 out of 45 children)

Relapse:
 At 6 month follow up 5 out of 14 (35.7%) had relapsed in the alarm group compared to 3 out of 11 (27.7%) in the alarm and RCT group.
 At 12 month follow up 8 out of 14 (57.1%) had relapsed in the alarm group compared to 4 out of 11 (36.4%) in the alarm and RCT group.
 These differences are not significant.

For patients with night and day time wetting:
 14 consecutive dry nights:
 In group A (retention control with alarm) 6 out of 8 children (75%) became dry for 14 nights compared to 3 out of 8 children (38%) in group B (alarm).

Drop out:
 40% dropped out in total (12 out of 30 children)

Relapse:
 At 6 month follow up 2 out of 3 children (66.7%) had relapsed in the alarm group compared to 4 out of 6 children (66.7%) in the alarm and RCT group.
 At 12 month follow up 2 out of 3 children (66.7%) had relapsed in the alarm group compared to 4 out of 6 children (66.7%) in the alarm and RCT group.
 There is no difference in the two treatment groups. However children with day and night time wetting relapsed earlier than those who just night time wet.

Funding	Not reported.
Does the study answer the question?	The study shows that for children who wet only at night time, alarms are more effective at achieving 14 consecutive dry nights. However for children who night and day time wet, retention control and alarm treatment is more effective. There was not significant differences between treatment groups in the number of relapses, but children who night and day time wet relapsed earlier than those who only night time wet.
Effect due to factor in study?	Yes.
Consistency of results with other studies?	No other similar studies.
How directly applicable to population of the guideline?	Population was correct (boys and girls aged between 5 and 15 years old).
Internal Validity	There was no blinding. Unclear concealment method. No baseline characteristics for individual groups.
Reference number 346	Study Type Randomised Controlled Trial
Fournier JP;Garfinkel BD;Bond A;Beauchesne H;Shapiro SK;	RID: 31
Pharmacological and behavioral management of enuresis	
1987 26	J Am Acad Child Adolesc Psychiatry
	pgs 849 853
Number of subjects	64 in total, 8 in each group
Inclusion/Exclusion Criteria:	Inclusion: aged between 5 and 14 years, no history of UTI or disease, no physical or neurological disorder, at least 2 wet nights a week for previous 6 months, no treatment in previous 3 months, no significant cognitive impairment or mental retardation, imformed consent to random allocation of treatment
Characteristics of subjects or environment/prognostic factor	73% were boys, the mean age was 8.5 years, 70% of children lived with their biological parent, 14% lived with a single parent, 83% were either the oldest or second eldest child in their family, 77% had had a first degree relative with enuresis and 61% had another relative with enuresis
Recruitment:	Newspaper adverts and referred from paediatricians.
Setting:	Treatment administered at home, Montreal Canada.
Interventions/Test /Factor being investigated	Group A: imipramine Group B: alarm Group C: alarm with imipramine The study also considered placebo and random waking, these have not been included as not relevant comparators.
Comparitors	Between treatment groups.
Length of Study/ Follow-up	3 months.

Outcome measures studies Change in number of wet nights, and drop outs.

Results 6 weeks treatment

In the alarm group 1 out of 8 children dropped out compared to 1 out of 8 in the imipramine group and 0 out of 8 in the alarm and imipramine group.

In the alarm group the mean number of wet nights during the last week of treatment was 2.5 compared to 1.9 in the imipramine group and 1 in the alarm and imipramine group.

Drop out:
In total 4 boys dropped out due to side-effects or non-compliance and 1 girl dropped out due to having a UTI.

Funding Not reported

Does the study answer the question? The study showed that imipramine had a faster effect than the other treatments. However at 4 weeks the most effective treatments were alarm, alarm with imipramine and imipramine alone. At the 3 month follow up the most successful treatments were alarm and imipramine.

Effect due to factor in study? Yes.

Consistency of results with other studies? No other similar studies.

How directly applicable to population of the guideline? Children were aged 5 - 14 years old.

Internal Validity This is a double blind trial.
The study had 3 more groups (alarm with placebo, random waking with placebo and imipramine and random waking) however there were no results for these 3 groups.

Reference number 121 **Study Type** **Randomised Controlled Trial** RID: 7

Geffken G;Johnson SB;Walker D;

Behavioral interventions for childhood nocturnal enuresis: the differential effect of bladder capacity on treatment progress and outcome

1986 5 pgs 261 272

Number of subjects 50 in total: 10 patients dropped out which left 10 in each of the four groups

Inclusion/Exclusion Criteria: Inclusion: aged 5-13 years, NE for at least 3 months, and wetting at least 2 times a week.

Characteristics of subjects or environment/prognostic factor 66% were boys. There was no significant difference between the groups in terms of age or sex.

Recruitment: Referral from departments of paediatrics from University of Florida and University of Virginia.

Setting: Florida and Virginia, USA, at home

Interventions/Test /Factor being investigated Group A: alarm (large maximal functional bladder capacity)
Group B: alarm (small maximal functional bladder capacity)
Group C: alarm with retention control (large maximal functional bladder capacity)
Group D: alarm with retention control (small maximal functional bladder capacity)

Comparitors Between group A and C and between group B and D.

Length of Study/ Follow-up	8 weeks or more.
Outcome measures studies	Number of children dry for 14 consecutive nights, change in number of wet nights, and relapse.
Results	<p>14 weeks treatment</p> <p>Over all 92.5% (37 out of the 40) patients were dry for 14 consecutive nights; 2 of the patients who did not become dry during treatment became dry during followup. 41% (16 out of 39) patients relapsed during an 8 week follow up (relapse was wet 3 or more nights during a 2 week period).</p> <p>The patients were divided into two groups those with a large maximal functional bladder capacity and those with a small maximal bladder capacity.</p> <p>Dry for 14 consecutive nights: For patients with large maximal bladder capacity, both treatment groups (alarm alone and alarm with retention control) 9 out of 10 patients became dry for 14 consecutive nights. For patients with small maximal bladder capacity in the group which had alarm treatment 10 out of 10 patients became dry for 14 nights compared to 9 out of 10 in the group which had alarm with retention control treatment.</p> <p>Change in number of wet nights: For patients with a large bladder capacity; the mean number of wet nights per week at end of treatment for the alarm group was 3.2 compared to 2.9 for the retention control and alarm group. At follow up the mean number of wet nights per week was 1.5 for the alarm group and 0 for the retention control and alarm group.</p> <p>For patients with a small bladder capacity; the mean number of wet nights per week at end of treatment for the alarm group was 3.4 compared to 3 for the retention control and alarm group. At follow up the mean number of wet nights per week was 1.7 for the alarm group and 1.3 for the retention control and alarm group.</p> <p>The study showed the relationship during treatment between maximal functional bladder capacity and change in number of wet nights was significant $F(1,33) = 4.90$ $p < 0.03$, this relationship was also shown to be significant during followup $F(1,36) = 4.74$ $p < 0.04$</p> <p>Relapse: For patients with large maximal bladder capacity the group having alarm therapy alone had the smallest relapse rate (33%). The group having alarm with retention control had a 40% relapse rate. For patients with small maximal bladder capacity the group with alarm only had the largest relapse rate of the study (60%) where as the group having alarm with retention control had the smallest relapse rate (33%).</p>
Funding	Not reported
Does the study answer the question?	Overall 92.5% of all patients achieved 14 consecutive dry nights The study concluded that for patients with a small maximal bladder capacity there was some advantage to treating with alarm and retention control, but for patients with large maximal bladder capacity combining alarm with retention control was not more successful than alarm treatment alone.
Effect due to factor in study?	Yes.
Consistency of results with other studies?	Similar to other studies with same comparators.
How directly applicable to population of the guideline?	Children's age range was 5-13 years.

Internal Validity It is not stated why patients dropped out, from which group, or the initial number in each treatment group.

Reference number 363 **Study Type** **Randomised Controlled Trial** RID:
Houts AC;Peterson JK;Whelan JP; 47
Prevention of relapse in full-spectrum home training for primary enuresis
1986 17 pgs 462 469

Number of subjects 56 patients in total, 15 in group A, 15 in group B and 11 in the control group.

Inclusion/Exclusion Criteria: Inclusion: primary enuresis.

Characteristics of subjects or environment/prognostic factor In the treatment groups there were 35 males and 10 females. The mean age for the males was 8.35 (2.54 SD) years and for females was 9.06 (2.72 SD) and range for both was 5-13 years old. Most were wet every night and none had been dry for 2 or more months.
In the control group the mean number of wet nights per week was 5.41 (1.63 SD). The groups (treatment and control) did not vary significantly in age, gender, socioeconomic status and family history of enuresis.

Recruitment: From paediatric referrals to the Memphis State University Enuresis Clinic and from media announcements

Setting: At home, USA.

Interventions/Test /Factor being investigated Group A: alarm with retention control training
Group B: alarm
Group C: control group - no treatment (waiting list)

Comparitors Between groups A, B and C.

Length of Study/ Follow-up 1 year.

Outcome measures studies Number of children achieving 14 dry consecutive nights, number not dry for 14 consecutive nights, drop outs and relapse.

Results Duration of treatment was 16 weeks.

14 consecutive dry nights:
9 out of 15 children in the alarm only group achieved 14 nights dry compared with 13 out of 15 in alarm with retention control group and 0 out of 11 in the control group.

Drop out:
3 out of 15 children in the alarm only group dropped out compared with 2 out of 15 children in alarm with retention control group and 0 out of 11 children in the control group.

Patients who failed to be dry for 14 nights tended to be older (mean = 9.58 years SD 3.22), drop outs tended to be younger (mean 6.88 years SD 1.5) compared with patients who achieved 14 dry nights (mean 8.58 years SD 2.57).

Relapse:
Relapse was defined as wet at least 1 night in each of 2 consecutive nights
At 6 months: 3 out of 9 children in the alarm only group relapsed compared with 5 out of 13 in alarm with retention control group.

At 1 year: 3 out of 9 children in the alarm only group relapsed compared with 6 out of 13 children in alarm with retention control group.

There was a higher relapse rate in patients who had alarm with retention control compared to those who had alarm therapy alone (62% compared to 44%). However the authors state that having retention control therapy delayed the onset of relapse

(mean - 9 days (SD 5.05) for alarm alone, 22.88 days (SD 26.13) for alarm and retention control)

Relapse patients tended to be younger than those who did not relapse (mean 7.78 years SD 2.37 compared to 9.25 years SD 2.6; $p < 0.12$).

Funding Faculty Research Grant from Memphis State University and from the Centre for Applied Psychological Research made available through the Centers of Excellence Program of the State of Tennessee.

Does the study answer the question? The study showed that patients were more likely to achieve 14 nights dry if they were treated with alarm and retention control (87% compared to 60% for alarm or alarm with retention control and over learning). The study also showed that patients were less likely to relapse if they were treated with alarm and retention control and over learning. Patients who had alarm only were less likely to relapse compared to those who had alarm and retention control

Effect due to factor in study? Yes.

Consistency of results with other studies? Similar to other studies with same comparison.

How directly applicable to population of the guideline? Yes age group was 5-13 years old.

It is not reported how they allocated patients to groups.

Internal Validity

Reference number	156	Study Type	Randomised Controlled Trial	RID:	
Jehu D;Morgan RT;Turner RK;Jones A;					14
A controlled trial of the treatment of nocturnal enuresis in residential homes for children					
1977	15		pgs 1		16

Number of subjects 39 patients in total: 19 in group A and 20 in group B.

Inclusion/Exclusion Criteria: Inclusion: aged over 4 years old, wetting at least 4 times a night, attending a normal school (not a special school), have not tried alarm treatment in the previous year, and no gross handicap.

Characteristics of subjects or environment/prognostic factor In the treatment group there were 8 boys and 11 girls, in the control group there were 17 boys and 3 girls
The mean age was 9 years and 4 months, (the range was 4 years and 9 months to 14 years and 7 months)

Recruitment: A survey of children in children's home under Birmingham City Social Services was carried out to identify children who met the criteria.

Setting: Children's home in Birmingham, UK.

Interventions/Test /Factor being investigated Group A: alarm
Group B: control - no treatment

Comparitors Between group A and B

Length of Study/ Follow-up 20 months

Outcome measures studies Number of children achieving 14 consecutive dry nights, drop outs, mean number of dry nights, and number relapsing.

Results	<p>Patients were treated with the alarm for 3-4 months, until success was achieved.</p> <p>14 consecutive dry nights: In the alarm group 95% (18 out of 19) achieved 14 dry nights compared to 0% (0 out of 20) in the control group. NB the child who failed had absconded from the children's home</p> <p>Relapse At 6 months 17% had relapsed (3 out of 18 children)</p> <p>Change in mean number of wet nights: The authors reported a significant reduction in the number of wet nights for the treatment group (F=16.5068, df = 11,187, p<0.001) The mean number of wet nights for the control group was not significant (F=0.9678, df = 11,209, p>0.05)</p> <p>Drop outs: 1 child in the alarm group absconded from the children's home and was treated a failure.</p>
Funding	Department of Health and Social Security and the City of Birmingham Social Services Committee.
Does the study answer the question?	The alarm group was treated until successful. Therefore 18 out of 19 children achieved 14 nights dry (1 child absconded from the nursing home) and there was a 17% relapse rate.
Effect due to factor in study?	Yes.
Consistency of results with other studies?	Similar results as to other studies comparing alarm to no treatment.
How directly applicable to population of the guideline?	Correct population - children were aged over 4 years old.
Internal Validity	It is not reported how they allocated patients to treatment groups. There is a higher proportion of girls in the treatment group.
Reference number	349 Study Type Randomised Controlled Trial
Kolvin I;Taunch J;Currah J;Garside RF;Nolan J;Shaw WB;	RID: 884
Enuresis: a descriptive analysis and a controlled trial	
1972 14 Dev Med Child Neurol	pgs 715 726
Number of subjects	94 in total: 35 in group A, 32 in group B and 27 in group C.
Inclusion/Exclusion Criteria:	Inclusion: aged between 8 and 10 years.
Characteristics of subjects or environment/prognostic factor	<p>The mean age was 9 years and 4 months.</p> <p>Most of the patients had poor toilet facilities, with 35 patients having out-door toilets the mean number of children per family was 3.9.</p> <p>14 children had divorced parents.</p> <p>44 patients had siblings who had had enuresis and 59 had family members who had had enuresis.</p>
Recruitment:	Through a survey of schools.
Setting:	At home

Interventions/Test /Factor being investigated	Group A: imipramine Group B: alarm (pad and buzzer) Group C: placebo
Comparitors	Between groups A, B and C
Length of Study/ Follow-up	4 months.
Outcome measures studies	Mean number of wet nights.
Results	10% of patients were lost at 4 month follow up. The number of children who had greater than 80% improvement in number of dry nights: In the imipramine group 16 out of 35 children achieved a greater than 80% improvement in the number of dry nights compared to 17 out of 32 in alarm group. Mean number of wet nights at the end of treatment: In the imipramine group the mean number of wet nights was 2.3 (sd 3.5) compared to 2.3 (sd 3.2). Mean number of wet nights at follow up: In the imipramine group the mean number of wet nights at follow up was 3.35 (sd 3) compared to 2.3 (sd 2.3) in the alarm group.
Funding	Partially funded by Geigy
Does the study answer the question?	The study showed that the alarm group was slow to improve but maintained improvement after treatment was stopped. The imipramine group had a rapid improvement initially but a large decline after treatment was stopped. The placebo group's improvement was seen to remain after treatment was stopped.
Effect due to factor in study?	Yes.
Consistency of results with other studies?	Similar to other studies with same comparison.
How directly applicable to population of the guideline?	Children were aged between 8 and 10 years.

Internal Validity

Reference number	118	Study Type	Randomised Controlled Trial	RID:	
Moffatt ME;Kato C;Pless IB;					6
Improvements in self-concept after treatment of nocturnal enuresis: randomized controlled trial					
1987	110		pgs 647		652

Number of subjects	121 in total, 66 in group A and 55 in group B
Inclusion/Exclusion Criteria:	Inclusion: primary NE, aged 8-14 years, and parents were proficient in either French or English.
Characteristics of subjects or environment/prognostic factor	Age range was 8-14 years and 7 patients had day-time urgency. The study reported there was no significant difference between the treatment group and control group in age, social class, sex, parental education, language and single parent families.

Recruitment:	Patients were referred to the enuresis clinic of the Montreal Children's Hospital.
Setting:	Montreal Children's hospital, Canada, and at home
Interventions/Test /Factor being investigated	Group A: alarm, if successful patients also had overlearning Group B: control - no treatment, waiting list
Comparitors	Between group A and B
Length of Study/ Follow-up	None.
Outcome measures studies	Number of children dry for 14 consecutive nights, adverse events, CBCL behaviour rating, and Piers-Harris Self Concept score.
Results	<p>The mean treatment time for group A was 18.4 (SD5.8) weeks and for group B was 13.2 (SD 1.9).</p> <p>Dry for 14 nights: In group A (alarm) 42 out of 61 children (69%) became dry for 14 consecutive nights compared to 1 out of 55 children (2%) in group B (control).</p> <p>Adverse events: In group A (alarm) 4 children could not cope with the alarm.</p> <p>CBCL score: In group A (alarm) the baseline score was 60.1 and after treatment the mean score was 55.2. For group B (control) the baseline mean score was 61.2 and after treatment the mean score was 59.0. There was no significant difference ($p=0.11$) between the two groups with regard to changes.</p> <p>Piers-Harris Self-Concept score: In group A (alarm) the baseline score was 58.5, and after treatment the mean score was 61.5. For group B (control) the baseline mean score was 54.6 and after treatment the mean score was 53.7. There was a significant difference ($p=0.04$) in the two changes.</p> <p>The study also considered the changes to the CBCL and Piers-Harris scores relating to the success of treatment. The results showed that if treatment was successful there was a -5.2 change to the CBCL score compared to a change of -2.3 and -2.0 for >25% improvement and <25% improvement. For the Piers-Harris score there was a 3.2 change if the treatment was successful compared to 3.7 and 0.4 if the treatment was >25% improvement and <25% improvement.</p>
Funding	W. T. Grant Foundation of New York
Does the study answer the question?	The study showed that treating children with an alarm was more effective in achieving 14 dry nights compared with no treatment. The study also showed that there was a significant difference in the change in Piers-Harris Self-Concept score, with those treated with an alarm having a greater mean improvement.
Effect due to factor in study?	Yes.
Consistency of results with other studies?	Similar to other studies comparing alarm to no treatment.
How directly applicable to population of the guideline?	Age range was 8-14 years.

Internal Validity

Reference number 603 Study Type **Randomised Controlled Trial** RID: 89
 Ozden C;Ozdal OL;Aktas BK;Ozelci A;Altinova S;Memis A;
 The efficacy of the addition of short-term desmopressin to alarm therapy in the treatment of primary nocturnal enuresis
 2008 40 pgs 583 586

Number of subjects 52 in total: 30 in group A, 22 in group B.

Inclusion/Exclusion Criteria: Inclusion: primary monosymptomatic NE, aged between 6-15 years, and wetting at least 3 times a week.
 Exclusion: diurnal enuresis, UTI, polyuric disorders such as diabetes insipidus and diabetes mellitus, known history of renal disease, hypertension, genitouriological abnormalities, mental retardation, neurological disease, use of diuretic drugs, or prior use of alarms or desmopressin therapy.

Characteristics of subjects or environment/prognostic factor 54.5% were boys, the mean age was 10.1 (2.01 SD years) and the mean number of wet nights per week was 5.8 (1.4 SD). Age range was 6-15 years.
 Group A had a mean age of 9.9 (1.8 SD) years and the mean number of wet nights per week was 5.9 (1.5 SD).
 Group B had a mean age of 10.3 (2.2 SD) years and the mean number of wet nights per week was 5.7 (1.3 SD).

Recruitment: Not reported.

Setting: Turkey, treatment administered at home.

Interventions/Test /Factor being investigated Group A: alarm for 12 weeks in with 6 weeks of additional desmopressin
 Group B: alarm

Comparitors Between group A and B

Length of Study/ Follow-up 24 weeks

Outcome measures studies Change in number of wet nights. Numbers relapsing.

Results 6 weeks treatment
 Dry or 75% improvement in dry nights at 12 weeks:
 In group A (alarm and desmopressin) 22.2% (6 children) compared to 30.4% (7 children) in group B (alarm).
 Drop out:
 In group A (alarm and desmopressin) 3 out of 30 children dropped out compared to 5 out of 22 children in group B (alarm), this was not significantly different ($p > 0.05$).
 Change in mean number of wet nights:
 Before treatment group A (alarm and desmopressin) had a mean number of 5.9 (SD 1.5) wet nights and group B (alarm) had a mean number of 5.7 (SD 1.3). This difference was not significant.
 At 3 weeks group A (alarm and desmopressin) had a mean number of 2.7 (SD 0.5) and group B (alarm) had a mean number of 3.2 (SD 0.4), this difference was significant ($p = 0.0001$).
 At 6 weeks group A (alarm and desmopressin) had a mean number of 2.2 (SD 0.5) and group B (alarm) had a mean number of 2.7 (SD 0.6), this difference was significant ($p = 0.004$).
 At 12 weeks group A (alarm and desmopressin) had a mean number of 2.0 (SD 0.8) and group B (alarm) had a mean number of 1.8 (SD 0.54). This difference was not significant.

Funding Not reported.

Does the study answer the question? There was no significant difference between patients receiving alarm and desmopressin compared to alarm alone in achieving 75% improvement in the number of dry nights or in becoming dry at 12 weeks. There was a significant difference in the mean number of wet nights at 3 weeks and 6 weeks with alarm and desmopressin therapy having significantly fewer wet nights compared to alarm therapy alone.

Effect due to factor in study? Yes.

Consistency of results with other studies? No other similar studies.

How directly applicable to population of the guideline? Age range was 6-15 years.

It was not reported how the patients were recruited.

Internal Validity

Reference number	370	Study Type	Randomised Controlled Trial	RID:
	Ronen T;Wozner Y;Rahav G;			53
	Cognitive intervention in enuresis			
1992	14		pgs 1	14

Number of subjects 77 in total: 19 in group A, 18 in group B (n=40 in the two groups which are not reported here: star charts and cognitive therapy.)

Inclusion/Exclusion Criteria: Inclusion: primary NE, and aged over 5 years
Exclusion: medical problems in urinary system, or developmental problems.

Characteristics of subjects or environment/prognostic factor Mean age was 10.05 (2.28 SD) years, 51% were boys, and bed wetting was severe.

Recruitment: 100 children applied and had been invited to take part in an initial intake session as part of the regular agency procedure.

Setting: Israel, treatment was administered at home.

Interventions/Test /Factor being investigated Group A: alarm (pad and bell)
Group B: control group - no treatment, waiting list group
The study also considered cognitive behaviour therapy and star charts with rewards which were not included as not relevant comparators

Comparitors Between groups A and B

Length of Study/ Follow-up 1 year

Outcome measures studies Number of children achieving 3 consecutive dry weeks. Also, mean number of wet nights in last 3 weeks.

Results 18 weeks treatment

Dry for 21 nights:
In group A (alarm) 12 out of 19 children (63%) became dry compared to 0 out of 18 (0%) in group B (control=no treatment).

Drop out:
In group A (alarm) 4 children (21%) dropped out compared to 2 children (11%) in group B (control).

	Mean number of wet nights per 3 weeks: In group A (alarm) the mean number of wet nights was 1.23 (sd 5.28) compared to 17.22 (SD 9) in group B (control).
Funding	Not reported
Does the study answer the question?	There was no significant difference in the number of children becoming dry for 21 nights or in the change in mean number of wet nights between the patients receiving DBT and alarm and those receiving alarm therapy alone. However there were fewer relapses in the DBT and alarm group compared to the alarm group (15% compared to 60%)
Effect due to factor in study?	Yes.
Consistency of results with other studies?	Similar to other studies comparing alarm and no treatment.
How directly applicable to population of the guideline?	Children were aged over 5 years.
Internal Validity	Inadequate concealment method.
Reference number	32
Study Type	Randomised Controlled Trial
RID:	67
	Tuygun C;Eroglu M;Bakirtas H;Gucuk A;Zengin K;Imamoglu A;
	Is second-line enuretic alarm therapy after unsuccessful pharmacotherapy superior to first-line therapy in the treatment of monosymptomatic nocturnal enuresis?
	2007 78
	pgs 260 263
Number of subjects	84 patients in total: 35 in group A and 49 in group B.
Inclusion/Exclusion Criteria:	Inclusion: monosymptomatic nocturnal enuresis, and wet at least 3 times a week during the last 3 months. Exclusion: Diurnal enuresis, polyuric disorders, genitourinary system abnormalities, neurological disorders, or recurrent UTI.
Characteristics of subjects or environment/prognostic factor	The median age was 8 years (range 6-13 years). The ratio of male/ female was 3/2. There was no significant difference between the three group's age or sex. 71.73% had at least one parent with a history of enuresis. At baseline 54.34% were wet 25-30 nights a month, 20.65% were wet 20-25 nights a month and 25% were wet 15-20 nights a month.
Recruitment:	Not reported.
Setting:	Turkey, treatment administered at home.
Interventions/Test /Factor being investigated	Group A: alarm Group B: desmopressin Group C was not included in this review as considers patients who had failed treatment.
Comparitors	Between treatment groups.
Length of Study/ Follow-up	6 months
Outcome measures studies	Number of children achieving >90% decrease in number of wet nights, 50-90% decrease in number of wet nights, relapse at 6 months, and change in number of wet nights.

Results Treatment was for 3 months

>90% decrease in number of wet nights:
 After 3 months of treatment in group A (alarm) 20 out of 35 children (57.14%) had achieved a >90% decrease in number of wet nights compared to 25 out of 49 (51.02%) in group B (desmopressin). These differences were not significant.

50-90% decrease in number of wet nights:
 After 3 months of treatment in group A (alarm) 9 out of 35 children (27.71%) had achieved a 50-90% decrease in number of wet nights compared to 15 out of 49 (30.61%) in group B (desmopressin). These differences were not significant.

Relapse at 6 months:
 At 6 months, in group A, 10 out of 35 children (28.57%) had relapsed compared to 27 out of 49 (55.10%) in group B (desmopressin). The difference between groups A and B was significant p=0.008.

Change in mean number of wet nights:
 In group A (alarm) at baseline the mean number of wet nights per month was 23.2 (SD 6.23) and at the end of treatment it was 3.41 (SD7.68). This difference was significant p<0.001. In group B (desmopressin) at baseline the mean number of wet nights per month was 23.44 (SD 6.3) and at the end of treatment it was 10.7 (SD 10.94), this difference was significant p<0.001. The difference between groups A and B was also significant.

Funding Not reported.

Does the study answer the question? The study showed that treating children with an alarm was more effective than desmopressin in reducing the number of wet nights. The study showed that few children who were treated with an alarm were significantly less likely to relapse than those treated with desmopressin. All groups had a significant reduction in the mean number of wet nights per month.

Effect due to factor in study? Yes.

Consistency of results with other studies? Similar to other studies comparing desmopressin and alarm.

How directly applicable to population of the guideline? Children were aged between 6-13 years.

Internal Validity

Reference number 338 Study Type **Randomised Controlled Trial** RID: 24
 van Londen A;van Londen-Barentsen MW;van Son MJ;Mulder GA;
 Arousal training for children suffering from nocturnal enuresis: a 2 1/2 year follow-up
 1993 31 pgs 613 615

Number of subjects 127 in total, 38 in group A, 39 in group B and 36 in group C.

Inclusion/Exclusion Criteria: Inclusion: aged between 6-12 years

Characteristics of subjects or environment/prognostic factor The mean age was 8.6 years, 70% were boys, and 87% had primary NE.

Recruitment: Not reported.

Setting:	Netherlands, treatment at home		
Interventions/Test /Factor being investigated	Group A: alarm with reward stickers for correct behaviour Group B: alarm with reward stickers for dry nights and punishment sticker for wet nights Group C: alarm		
Comparitors	Between groups A, B and C.		
Length of Study/ Follow-up	2.5 years		
Outcome measures studies	Number of children dry for 14 consecutive nights, and numbers relapsing.		
Results	<p>20 weeks treatment</p> <p>Dry at 14 nights: In group A (alarm with reward stickers for correct behaviour) 37 out of 38 children achieved 14 dry nights compared to 33 out of 39 in group B (alarm with reward sticker for dry nights and punishment sticker for wet nights) and 26 out of 36 in group C (alarm alone). These differences were significant when comparing group A to group B (binomial test $P < 0.001$) and group (binomial test $P < 0.000$).</p> <p>Relapse at 2.5 years follow up: In group A (alarm with reward stickers for correct behaviour) 10 out of 37 had relapsed at the end of 2.5 years follow up compared to 30 out of 33 in group B (alarm with reward sticker for dry nights and punishment sticker for wet nights) and 13 out of 26 in group C (alarm alone).</p>		
Funding	Not reported.		
Does the study answer the question?	The study showed that giving a child an alarm with reward stickers for correct behaviour was significantly more successful in achieving 14 dry nights compared to giving a child an alarm with reward stickers for dry nights and punishment sticker for wet nights or an alarm alone.		
Effect due to factor in study?	Yes.		
Consistency of results with other studies?	No other similar studies.		
How directly applicable to population of the guideline?	Age range is 6-12 years.		
Internal Validity	Inadequate concealment method.		
Reference number	143	Study Type	Randomised Controlled Trial
	Wagner W;Johnson SB;Walker D;Carter R;Wittner J;		RID: 12
	A controlled comparison of two treatments for nocturnal enuresis		
	1982 101	pgs	302 307
Number of subjects	49 in total, 12 in each group		

Inclusion/Exclusion Criteria:	Inclusion: aged 6-16 years, IQ greater than 70, primary NE, no physical or neurological disorders, wet at least 3 times a week, no treatment for NE in previous year, and agreed to be randomised. Exclusion: day time wetting.
Characteristics of subjects or environment/prognostic factor	The mean age was 7.9 years. The baseline % of nights wet for group A (alarm) was 75%, group B (imipramine) 77.33% and group C (waiting list) 64.33%, there was no significant difference in the baseline wetting %.
Recruitment:	From local paediatric clinics and private physicians, adverts in newspapers and on TV, and contact with local schools.
Setting:	Florida, USA, treatment administered at home.
Interventions/Test /Factor being investigated	Group A: alarm (pad and bell) Group B: imipramine Group C: control - no treatment, waiting list
Comparitors	Between groups A, B and C.
Length of Study/ Follow-up	6 months.
Outcome measures studies	Number of children achieving 14 consecutive dry nights,% of wet nights, and relapse rates.
Results	14 weeks treatment Dry for 14 consecutive nights: In group A (alarm) 10 out of 12 children, 83% achieved dryness for 14 consecutive nights compared to 4 out of 12 children, 33% in group B (imipramine) and 1 out of 12 children, 8% in group C (waiting list) % of wet nights: The study showed that by the final treatment week, group A was significantly more successful than B and C (8.25% compared to 39.25% and 60.83%). In the final week of treatment the mean number of wet nights for children with alarm treatment was 0.58 and for children with imipramine was 2.75. Relapse: Relapse was defined as 3 wet nights in a 2 week period. Of the children who achieved 14 dry nights dry in group A (alarm) 5 out of 10 children (50%) relapsed compared to 4 out of 4 children (100%) in group B (imipramine) and 100% in group C (waiting list).
Funding	None reported
Does the study answer the question?	The study showed that giving a child an alarm was more successful than imipramine and a control waiting list group in achieving 14 dry nights (83% compared to 33% and 8%). The study also showed that the patients receiving alarm therapy had only a 50% relapse rate compare to 100% in both the imipramine group and waiting list group.
Effect due to factor in study?	Yes.
Consistency of results with other studies?	Similar to other studies with same comparison.
How directly applicable to population of the guideline?	Age range 6-16 years.

Internal Validity

Reference number 354 **Study Type** **Randomised Controlled Trial** RID:
Wagner WG;Matthews R; 39
The treatment of nocturnal enuresis: a controlled comparison of two models of urine alarm
1985 6 J Dev Behav Pediatr pgs 22 26

Number of subjects 39 in total: 13 in each of the 3 groups.

Inclusion/Exclusion Criteria: Inclusion: primary NE, aged 5-16 years, IQ of greater than 70, no physical or neurological disorder, wet at least 3 times a week, not had treatment for NE in previous year, agree to randomisation
Exclusion: day time wetting

Characteristics of subjects or environment/prognostic factor The mean age was 7.9 years. 51% were male and 95% were white.
Baseline % of wet nights for group A was 80.15%, for group B 83.46%, for group C 90.15%.

Recruitment: Not reported

Setting: Mississippi, USA, treatment administered at home.

Interventions/Test /Factor being investigated Group A: alarm
Group B: control group - no treatment, waiting list
The study also considered an alarm with a 3 second delay which was not a relevant comparator and was not included in the review

Comparitors Between groups A and B.

Length of Study/ Follow-up 6 months.

Outcome measures studies Number of children achieving 14 consecutive dry nights, change in number of wet nights, and relapse.

Results 12 weeks treatment
Dry for 14 consecutive nights:
In group A (alarm) 8 out of 13 children (62%) achieved dryness for 14 consecutive nights compared to 1 out of 13 children (8%) in group B (waiting list).
There was a significant difference between the alarm group and the waiting list group (P <0.01)
% of wet nights:
The study showed that by the final treatment week, group A was significantly more successful than B (5.38% compared to 72.90%).
Relapse:
Of the children who achieved 14 dry nights in group A (alarm) 2 out of 8 relapsed compared to 1 out of 1 in group B (waiting list).
The study showed the alarms did malfunction.

Funding Research Development Grant from the University of Southern Mississippi.

Does the study answer the question? The study showed that alarms were more successful than waiting lists in achieving 14 dry nights (62% compared to 8%). The study showed there was a significant difference between the alarm group and the waiting list group.

Effect due to factor in study? Yes.

Consistency of results with other studies? Similar to other studies comparing alarm to no treatment.

How directly applicable to population of the guideline? Age range 5-16 years.

Internal Validity This trial was not randomised. The patients were systematically assigned to a treatment group depending on their order seen in the clinic. Inadequate concealment method.

Reference number 127 **Study Type** **Randomised Controlled Trial** RID: 8
Wille S;
Comparison of desmopressin and enuresis alarm for nocturnal enuresis
1986 61 pgs 30 33

Number of subjects 50 patients recruited: 25 allocated to each of the two arms.

Inclusion/Exclusion Criteria: Inclusion: older than 6 years, not dry for more than 6 months since 3 years, wet at least 3 times a week, and able to give written and informed consent.
Exclusion: treatment for NE in previous years, day time wetting, cardiovascular disease, renal disorder, neurological disorder, or chronic UTI.

Characteristics of subjects or environment/prognostic factor Group A had a mean number of wet nights at baseline line of 2.1.
Group B had a mean number of wet nights at baseline line of 1.9.

Recruitment: Patients referred to S. Wille's clinic

Setting: Sweden, treatment administered at home.

Interventions/Test /Factor being investigated Group A: intranasal desmopressin
Group B: alarm

Comparitors Between groups A and B

Length of Study/ Follow-up 3 months

Outcome measures studies Number of children dry for 14 consecutive nights, relapse rates, change in number of wet nights, and adverse events.

Results 3 months treatment

Success of being dry for 28 days with only 5 wet nights or achieving a lower wetting score (score: very wet = 3, a little wet = 2, dry = 1):

In group A (desmopressin) 17 out of 24 children became dry compared to 19 out of 22 in group B (alarm).

The study stated that at the end of treatment both groups were significantly drier than before the treatment however the alarm group was more successful (alarm $p < 0.001$; desmopressin $p < 0.02$). There was no significant difference between group A (desmopressin) and group B (alarm).

Group A (desmopressin) had significantly more dry nights than group B (alarm) during the first 3 weeks ($p < 0.001$) however during the last 9 weeks of treatment the alarm group had more dry nights, and significantly more in the 11th week ($p < 0.002$). The study stated that due to the high relapse rate in the desmopressin group, over all during the first 2 weeks of treatment and at the 3 month follow up the alarm group was significantly better than the desmopressin group ($p < 0.02$, $p < 0.001$, 2 weeks and 3 months respectively)

The mean number of wet nights per week at end of treatment for the alarm group was 1.1 (SD 1.88) compared to 2.1 (SD 1.96) for the desmopressin group.

Relapse:

1 patient in the alarm group relapsed in the 3 month follow up compared to 10 in the

desmopressin group.

Drop out:

1 child from the alarm group dropped out due to lack of improvement

Adverse events:

In the alarm group 78% had false alarms, 19% said the alarm did not work when the child was wet, 56% said the alarm did not wake the child, 56% said the alarm woke other family members instead and 1 patient was afraid of the alarm. In the desmopressin group 13% reported nasal discomfort, 3% had occasional nose bleeds and 5% experienced a bad taste in the throat.

The study included a cross over of treatments for children who were unsuccessful in their original treatment group. Of the children who changed from desmopressin to alarm 2 children improved by a 2 month follow up, 3 were better than before and 5 did not respond. Of the children who changed from alarm to desmopressin 2 children did improve but subsequently relapsed. There was no significant difference between the cross over results.

Funding

Not reported

Does the study answer the question?

The study showed that both alarm treatment and desmopressin lead to a significant reduction in the number of wet nights. The study showed that alarm treatment was more successful in achieving 28 dry nights (with less than 5 wet nights) than desmopressin, however this difference was not significant until the high relapse rate of desmopressin was taken into account. With alarms then being significantly more effective. The desmopressin group had a higher relapse rate than the alarm group. More patients receiving alarm therapy reported side effects than those receiving desmopressin.

Effect due to factor in study?

Yes (NB there is a 15% spontaneous cure rate associated with NE)

Consistency of results with other studies?

Similar to other studies comparing alarm to desmopressin

How directly applicable to population of the guideline?

Patients were aged over 6 years

Internal Validity

Grading: 2-	Case-control or cohort studies with a high risk of confounding bias, or chance and a significant risk
--------------------	--

Reference number 3906 Study Type Cohort RID:
 Baller WR;Giangreco CJ; 745

Correction of nocturnal enuresis in deaf children

1970 72 Volta Review pgs 545 549

Number of subjects 21 children

Inclusion/Exclusion Criteria: Deaf children with persistent bed wetting at Iowa School for the Deaf at Council Bluffs Iowa.

Characteristics of subjects or environment/prognostic factor 15 boys and 6 girls, with age range 7 to 16 years.

Recruitment: At school.

Setting: Iowa School for the Deaf at Council Bluffs Iowa.

Interventions/Test /Factor being investigated Light alarm.

Comparitors No comparison.

Length of Study/ Follow-up 2 1/2 years follow up

Outcome measures studies Numbers of children completely dry, and numbers relapsing.

Results Only 2 or 3 children could be given the alarm at a time, with treatment for on average 3 weeks. Therefore there was over a year between the first and last child being treated.

 The alarm was a pad and bell device with a light which had a cone shaped shade to shine the light directly at the child's face. Children were given an explanation of the treatment by a consultant.

 All children (21) gained complete dryness (10 consecutive dry nights) within 30 nights (the paper states this is the normal time for a hearing child to become dry with a bell only alarm).
 One child relapsed but after 2 more treatments with the light alarm he gained dryness.

 After 2 1/2 year follow up, it was noted that the other 19 children at the school who wet the bed had also become dry within 3 months of the children in the trial. The study also noted that there were no undesirable side effects or unfavourable behaviour of the children in the trial.

Funding The alarms were provided by the Enurtone Company, Minneapolis, the consultant also worked for this company.

Does the study answer the question? The study showed all children treated with the light alarm became dry.

Effect due to factor in study? Yes, although it should be noted that all other children at the school who wet the bed also became dry.

Consistency of results with other studies? Not other studies considering deaf children treated with an alarm.

How directly applicable to population of the guideline? Deaf children aged 7 to 16 years.

Internal Validity

Question: What is the clinical and cost effectiveness of desmopressin (nasal, tablets and melts) for children and young people under 19 years old who have nocturnal enuresis?

17

Grading: 1+	Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
--------------------	--

Reference number 325 Study Type Randomised Controlled Trial RID:
 Burke JR; Mizusawa Y; Chan A; Webb KL; 204

A comparison of amitriptyline, vasopressin and amitriptyline with vasopressin in nocturnal enuresis.

1995 9 pgs 438 440

Number of subjects 45 in total: 14 in Group A (amitriptyline), 17 in Group B (desmopressin), and 14 in Group C (desmopressin and amitriptyline)

Inclusion/Exclusion Criteria: Inclusion: 6-17 years, at least 3 wet nights a week for preceding 3 month period or not dry for more than 6 months.
 Exclusion: organic causes of NE, enuresis treatment in previous 6 months, neurogenic disorder, UTI, abnormal urinalysis haematology or blood biochemistry, or concomitant medication known to interfere with study medication.

Characteristics of subjects or environment/prognostic factor In group A the mean age was 8.6 (SD 2.4) years, the mean baseline wetting was 5.8 (SD 0.9)
 In group B the mean age was 8.9 (SD 2.5) years, the mean baseline wetting was 6.0 (SD 0.9)
 In group C the mean age was 8.9 (SD 2.4) year, the mean baseline wetting was 6.3 (SD 0.9)

Recruitment: Not reported

Setting: Australia

Interventions/Test /Factor being investigated Group A: amitriptyline hydrochloride (25 mg or 50mg)
 Group B: intranasal desmopressin (20 micro grams)
 Group C: desmopressin and amitriptyline

Comparitors Between treatment groups

Length of Study/ Follow-up 12 weeks

Outcome measures studies Number of children cured, drop outs, and the mean number of wet nights at end of treatment and follow up.

Results 16 weeks of treatment

Number of children cured:
 In Group A (amitriptyline) 3 out of 14 became dry, compared to 1 out of 17 in Group B (desmopressin) and 4 out of 14 in Group C (desmopressin and amitriptyline).

Number of drop outs:
 In Group A (amitriptyline) 0 out of 14 dropped out, in Group B (desmopressin) 3 out of 17 dropped out, and in Group C (desmopressin and amitriptyline) 3 out of 14 dropped out.

Mean number of wet nights per week at end of treatment:
 The mean number of wet nights per week for Group A (amitriptyline) was 3.3 (SD 1.9), for group B (desmopressin) mean was 4.7 (SD 1.7) and for Group C (desmopressin and amitriptyline) mean was 3.3 (SD 2.5) nights.

Mean number of wet nights per week at 12 week follow up:
 The mean number of wet nights per week for Group A (amitriptyline) was 3.9 (SD 2.9), for Group B (desmopressin) mean was 3.8 (SD 1.9) nights and for Group C (desmopressin and amitriptyline) it was 5.1 (SD 3.2) nights.

Funding Not reported

Does the study answer the question? The study showed that more children became dry when treated with amitriptyline and desmopressin. Patients treated with amitriptyline alone and with desmopressin had fewer wet nights during treatment but at follow up patients in the desmopressin only group or amitriptyline only group had the fewest number of wet nights.

Effect due to factor in study? Yes

Consistency of results with other studies? No other studies

How directly applicable to population of the guideline? Aged 6-17 years

Internal Validity The trial was stopped early due to one drug becoming unavailable. Not reported if it was intention to treat analysis.

Reference number 71 **Study Type** **Randomised Controlled Trial** RID:
 Longstaffe S;Moffatt ME;Whalen JC; 367
 Behavioral and self-concept changes after six months of enuresis treatment: a randomized, controlled trial
 2000 105 pgs 935 940

Number of subjects 182 in total, 61 in group A, 60 in group B, 61 in group C.

Inclusion/Exclusion Criteria: Inclusion: aged over 7 years, monosymptomatic NE, wetting at least 12 times in a 4 week period, normal urinalysis, no history of fecal soiling and signs of normal bladder functioning.

Characteristics of subjects or environment/prognostic factor Exclusion: neurological or developmental abnormalities, diabetes insipidus, diabetes mellitus, chronic renal disease, history of constipation, or already having desmopressin or alarm therapy.

In group A (alarm): 78.7% were male, 37.7 % were first born, 13.4% had a past history of UTI, 24.6% had a history of constipation. 94.9% had tried fluid restriction, 90% had tried lifting, 53.3% had tried behavioural techniques, 3.4% had tried bladder exercises, 20% had tried alarms, 13.3% had tried desmopressin, 14.3% had tried imipramine, 10.9% had tried oxybutnin. 36.2% had family history of NE on both sides, 41.4% had family history of NE on one side.

In group B (intranasal desmopressin): 75% were male, 41.7% were first born, 6.7% had a past history of UTI, 23.3% had a history of constipation. 90% had tried fluid restriction, 86.7% had tried lifting, 58.3% had tried behavioural techniques, 11.7% had tried bladder exercises, 18.3% had tried alarms, 21.7% had tried desmopressin, 16.7% had tried imipramine, 8.6% had tried oxybutnin. 41.7% had family history of NE on both sides, 41.7% had family history of NE on one side.

In group C (placebo): 61.7% were male, 34.5 % were first born, 13.8% had a past history of UTI, 21.4% had a history of constipation. 91.7% had tried fluid restriction, 95% had tried lifting, 67.8% had tried behavioural techniques, 19% had tried bladder exercises, 23.3% had tried alarms, 18.3% had tried desmopressin, 15.5% had tried imipramine, 8.6% had tried oxybutnin. 45.6% had family history of NE on both sides, 33.3% had family history of NE on one side.

Recruitment: Phycisian adverts, newspaper adverts, and posters and radio.

Setting: Treatment administered at home.

Interventions/Test /Factor being investigated Group A: alarm
 Group B: intranasal desmopressin
 Group C: placebo

Comparitors Between group A, B and C

Length of Study/ Follow-up	6 months
Outcome measures studies	Number of patients having 14 dry nights. Self concept.
Results	<p>14 consecutive dry nights: In group A (alarm) 35 children (57%) achieved 14 dry nights compared to 29 children (48%) in group B (desmopressin) and 23 children (38%) in group C (placebo).</p> <p>Drop out: 17 children in total dropped out 8 were from group A (alarm), 5 from group B (desmopressin) and 4 from group C (placebo)</p> <p>Behavioural changes: The behavioural changes were not related to the type of treatment or success of treatment, however there were significant positive changes in intellectual, physical appearance, anxiety, popularity (analysed through the Piers-Harris Subscales), there were also significant positive results on the Achenbach CBCL, Internalizing and Externalizing Behaviour Scores and Social, Thought and Attention Problems Subscales.</p>
Funding	National Health Research and Development Program and Fering Inc
Does the study answer the question?	There was no significant difference in the number of children achieving 14 consecutive dry nights between those receiving alarm and those receiving desmopressin. However more children became dry in the two treatment groups compared to the placebo group. The study also reported a positive change in the children's behaviour; however this was not related to treatment type or outcome success.
Effect due to factor in study?	Yes.
Consistency of results with other studies?	Similar to other studies with same comparisons.
How directly applicable to population of the guideline?	Children were aged over 7 years.
Internal Validity	There were no significant differences between the 3 treatment groups' baseline characteristics.
Reference number	369
Study Type	Randomised Controlled Trial
RID:	373
Ng CFN;Wong SN;Hong Kong Childhood Enuresis Study Group.;	
Comparing alarms, desmopressin, and combined treatment in Chinese enuretic children	
2005	20
Pediatr Nephrol	pgs 163 169
Number of subjects	105 in total, 35 in Group A, 38 in Group B, 32 in Group C.
Inclusion/Exclusion Criteria:	<p>Inclusion: Primary NE, age range 7-15 years, and wetting at least 3 times a week in baseline 2 weeks.</p> <p>Exclusion: UTI in previous 3 months, day time wetting, polyuric disorders, abnormal urinalysis, renal disease, previous diuretics, unwilling to be randomised, or previous treatment of alarms, desmopressin or tricyclics.</p>
Characteristics of subjects or environment/prognos tic factor	<p>The mean age was 9.5 (1.8 SD) years, and age range 7-12 years</p> <p>In Group A (alarm) the mean age was 9.5 (1.8 SD) years, 57% children were in the age range 7-9 years, 40% in 10-12 years and 3% in 13-15 years. 63% were boys, and the mean baseline number of wet nights a week was 5.1 (1.5 SD).</p>

In Group B (desmopressin) the mean age was 9.2 (1.8 SD) years, 69% children were in the age range 7-9 years, 26% in 10-12 years and 5% in 13-15 years. 68% were boys, and the mean baseline number of wet nights a week was 5.3 (1.4 SD).

In Group C (alarm with desmopressin) the mean age was 9.8 (1.2 SD) years, 50% children were in the age range 7-9 years, 47% in 10-12 years and 3% in 13-15 years. 66% were boys, and the mean baseline number of wet nights a week was 4.9 (1.2 SD).

Recruitment:	Patients presenting to 9 public hospitals in Hong Kong with primary NE.
Setting:	Hong Kong and treatment administered at home.
Interventions/Test /Factor being investigated	Group A: alarm Group B: oral desmopressin Group C: alarm with oral desmopressin
Comparitors	Between groups A, B and C.
Length of Study/ Follow-up	12 weeks.
Outcome measures studies	Number of children dry for 14 consecutive nights, change in number of wet nights, adverse events, drop out, and relapse.
Results	<p>Dry for 14 consecutive nights: In Group A (alarm) 8 out of 15 children achieved 14 dry nights, compared to 16 out of 38 children in Group B (desmopressin) and 20 out of 32 children in Group C (alarm and desmopressin). This difference was significant $p = 0.014$.</p> <p>Mean number of dry nights: In Group A (alarm) the mean number of dry nights was 2.8 (sd 2.2) compared to 2.7 (sd 2.4) in Group B (desmopressin) and 1.3 (sd 1.9) in Group C (alarm and desmopressin).</p> <p>Drop out: 12 children dropped out in total, 7 (20%) from Group A (alarm), 2 (5%) from Group B (desmopressin) and 3 (9%) from Group C (alarm and desmopressin).</p> <p>Relapse: In the alarm group (A) 0 out of 8 children relapsed at 3 months, compared to 9 out of 16 in the desmopressin group (B) and 7 out of 20 in the alarm with desmopressin group ©.</p>
Funding	Hong Kong Paediatric Nephrology Society with a research grant from Ferring Pharmaceuticals Limited
Does the study answer the question?	The study showed that significantly more patients achieved 14 consecutive dry nights if they were treated with alarm or desmopressin alone (71% compared to 42.9% and 52.6%.) The study also showed that there was a significant difference between groups in the % reduction of wet nights during the last 4 weeks of treatment and during the first 4 weeks of follow up, with patients being treated with alarm and desmopressin being significantly more successful than alarm or desmopressin alone.
Effect due to factor in study?	Yes
Consistency of results with other studies?	Similar to other studies with same comparison.
How directly applicable to population of the guideline?	Age range was 7-15 years.
Internal Validity	Chinese population

Reference number 176 **Study Type** **Randomised Controlled Trial** RID:
 Schulman SL;Stokes A;Salzman PM; 187
 The efficacy and safety of oral desmopressin in children with primary nocturnal enuresis
 2001 166 pgs 2427 2431

Number of subjects 193 in total

Inclusion/Exclusion Criteria: Inclusion: at least 3 wet nights a week, informed consent, no treatment in previous 30 days, and aged 6-16 years.
 Exclusion: organic causes of NE, day time wetting, organic urological disease, diabetes insipidus, UTI, known hypersensitivity to desmopressin, antibiotics, diuretics, or hyperactivity.

Characteristics of subjects or environment/prognostic factor Trial 1:
 133 out of 193 were male, mean baseline wetting in 2 weeks in group A was 11 days (range 5-14), in group B 10 days (range 4-14), in group C 10 days (range 6-14), and in group D 10 days (range 6-14).

Recruitment: Not reported.

Setting: 16 centres in USA.

Interventions/Test /Factor being investigated Trial 1:
 Group A: 0.2 mg oral desmopressin
 Group B: 0.4 mg oral desmopressin
 Group C: 0.6 mg oral desmopressin
 Group D: matching placebo

Comparitors Between treatment groups.

Length of Study/ Follow-up No follow up.

Outcome measures studies Number of children achieving 14 consecutive dry nights, mean number of wet nights, drop outs, and adverse events.

Results 2 weeks of treatment
 Trial 1:
 Mean number of wet nights during 2 week treatment:
 In group A (0.2 mg desmopressin) the mean number of wet nights was 4 (SD 1.33), in group B (0.4 mg desmopressin) mean was 3.5 (SD 1.73), and in group C (0.6 mg desmopressin) mean was 4.5 (SD 1.37).

 Number who achieved 14 consecutive dry nights:
 In group A (0.2 mg desmopressin) 2 out of 44 children achieved 14 consecutive dry nights compared to 6 out of 48 in group B (0.4 mg desmopressin), 3 out of 49 in group C (0.6 mg desmopressin) and 0 out of 49 in group D (placebo).

 Drop outs:
 6 in total: due to non compliance, consent withdrawn, and failure to keep diary.

 Adverse events (1 or more per child): 43 out of 143 on desmopressin and 13 out of 48 on placebo had headache, increased cough, and abdominal pain.
 The authors reported these were unrelated to treatment and were resolved by end of trial.

Funding Not reported.

Does the study answer the question? Study showed desmopressin was more effective than placebo.

Effect due to factor in study? Yes

Consistency of results with other studies? Similar to other studies with same comparisons.

How directly applicable to population of the guideline? Age range of 5 to 14 years.

Internal Validity

Reference number 284 **Study Type** **Randomised Controlled Trial** RID:
Skoog SJ;Stokes A;Turner KL; 199
Oral desmopressin: a randomized double-blind placebo controlled study of effectiveness in children with primary nocturnal enuresis
1997 158 pgs 1035 1040

Number of subjects 153 in total, data no available for 6 so 147 in total. Group A desmopressin 200mcg n=37, Group B desmopressin 400mcg n=35, Group C desmopressin n=37 and Group D placebo n=38.

Inclusion/Exclusion Criteria: Inclusion: primary NE, and wet at least 3 times a week for 2 weeks.
Exclusion: organic causes of NE, day time wetting, organic urological disease, diabetes insipidus, UTI all within previous 3 months, previous non-response (less than 50% decrease in wet nights) to desmopressin, hypersensitivity to desmopressin, clinically significant disease that would interfere with study, ongoing systematic antibiotic use, use of diuretics or any drug affecting urinary concentration, or medical treatment for hyperactivity.

Characteristics of subjects or environment/prognostic factor 112 out of 147 were male and the mean age was 9.1 years (range 5-17 years).

Recruitment: Not reported

Setting: 14 centres in USA

Interventions/Test /Factor being investigated Group A (37): 200 micro grams oral desmopressin
Group B (35): 400 micro grams oral desmopressin
Group C (37): 600 micro grams oral desmopressin
Group D (38): placebo

Comparitors Between treatment groups

Length of Study/ Follow-up None

Outcome measures studies Mean number of wet nights in last 2 weeks,number dry for 14 nights, adverse events, and drop out rate.

Results 6 weeks of treatment

Mean number of wet nights during last 2 weeks of trial
In Group A (200 micro grams desmopressin 33 patients) the mean was 4 (SD 1.15), in Group B (400 micro grams desmopressin 33 patients) the mean was 3.5 (SD 1.44), in Group C (600 micro grams desmopressin 33 patients) the mean was 3.5 (SD 1.15) and in Group D (placebo 36 patients) the mean was 5 (SD 1.2).

Number of children who achieved 14 consecutive dry nights:
In Group A (200 micro grams desmopressin) 1 out of 33 achieved 14 consecutive dry nights compared to 4 out of 33 in Group B (400 micro grams desmopressin), 2 out of 33 in Group C (600 micro grams desmopressin) and 0 out of 36 in Group D (placebo).

Adverse events:

	66 out of 109 children on desmopressin experienced adverse events compared to 21 out of 38 on placebo (rhinitis, headache, pharyngitis, infection, cough all mild or moderate, there were 3 serious events on desmopressin where children withdrew from trial - 2 vomiting, 1 atopic dermatitis)
	Drop outs: 12 out of 147 discontinued trial.
Funding	Not reported
Does the study answer the question?	The study shows that more children become dry with desmopressin than placebo and 400 micro grams was most effective although there was little difference between the 3 doses.
Effect due to factor in study?	Yes
Consistency of results with other studies?	Similar to other studies with same comparisons.
How directly applicable to population of the guideline?	Children were age 5-17 years.
Internal Validity	Unclear allocation concealment Double blind trial
Reference number	32
Study Type	Randomised Controlled Trial
RID:	398
	Tuygun C; Eroglu M; Bakirtas H; Gucuk A; Zengin K; Imamoglu A;
	Is second-line enuretic alarm therapy after unsuccessful pharmacotherapy superior to first-line therapy in the treatment of monosymptomatic nocturnal enuresis?
	2007 78
	pgs 260 263
Number of subjects	84 patients in total, 35 in Group A, 49 in Group B.
Inclusion/Exclusion Criteria:	Inclusion: monosymptomatic nocturnal enuresis and wet at least 3 times a week during the last 3 months. Exclusion: Diurnal enuresis, polyuric disorders, genitourinary system abnormalities, neurological disorders, or recurrent UTIs.
Characteristics of subjects or environment/prognostic factor	The median age was 8 years (range 6-13 years). The ratio of male/ female was 3/2. There was no significant difference between the three groups' age or sex. 71.73% had at least one parent with a history of enuresis. At baseline 54.34% were wet 25-30 nights a month, 20.65% were wet 20-25 nights a month and 25% were wet 15-20 nights a month.
Recruitment:	Not reported
Setting:	Turkey, treatment at home
Interventions/Test /Factor being investigated	Group A: alarm Group B: desmopressin Group C was not included as these are patients who failed first line treatment
Comparators	Between groups A and B
Length of Study/ Follow-up	6 months
Outcome measures studies	Number of children with >90% decrease in number of wet nights, 50-90% decrease in number of wet nights, relapse at 6 months, change in number of wet nights.

Results Treatment was for 3 months

>90% decrease in number of wet nights:
 After 3 months of treatment in Group A (alarm) 20 out of 35 children (57.14%) had achieved a >90% in number of wet nights compared to 25 out of 49 (51.02%) in Group B (desmopressin). These differences were not significant.

50-90% decrease in number of wet nights:
 After 3 months of treatment in Group A (alarm) 9 out of 35 children (27.71%) had achieved a 50-90% in number of wet nights compared to 15 out of 49 (30.61%) in Group B (desmopressin). These differences were not significant.

Relapse at 6 months:
 At 6 months 10 out of 35 children (28.57%) in Group A had relapsed compared to 27 out of 49 (55.10%) in Group B (desmopressin). The difference between Groups A and B was significant p=0.008.

Change in mean number of wet nights:
 In Group A (alarm) at baseline the mean number of wet nights per month was 23.2 (SD 6.23) at the end of treatment it was 3.41 (SD 7.68), this difference was significant p<0.001. In Group B (desmopressin) at baseline the mean number of wet nights per month was 23.44 (SD 6.3) and at the end of treatment it was 10.7 (SD 10.94). This difference was significant(p<0.001). The difference between Groups A and B was also significant.

Funding Not reported.

Does the study answer the question? The study showed that treating children with an alarm was more effective than desmopressin in reducing the number of wet nights. The study showed that few children who were treated with an alarm were significantly less likely to relapses than those treated with desmopressin. All groups had a significant reduction in the mean number of wet nights per month.

Effect due to factor in study? Yes

Consistency of results with other studies? Similar to other studies with same comparison.

How directly applicable to population of the guideline? Children were aged between 6-13 years.

Internal Validity

Reference number 271 **Study Type** **Randomised Controlled Trial** RID:
 Yap HK;Chao SM;Tan AY;Murugasu B;Ong EK;Low EH; 195
 Efficacy and safety of oral desmopressin in the treatment of primary nocturnal enuresis in Asian children
 1998 34 pgs 151 153

Number of subjects 37 children in crossover trial.

Inclusion/Exclusion Criteria: Inclusion: primary monosymptomatic nocturnal enuresis.
 Exclusion: no current enuresis treatment.

Characteristics of subjects or environment/prognostic factor 3 excluded because data incomplete.
 22 boys.
 Aged between 7 and 18 years.
 Minimum frequency of wetting 6 nights or more during a 2 week observation period.
 Free of diurnal incontinence, and were not on any specific treatment for enuresis prior to study entry.

Recruitment:	From three participating Paediatric Departments: National University Hospital, Singapore General Hospital and Tan Tock Seng Hospital.
Setting:	Hospital clinic, Singapore.
Interventions/Test /Factor being investigated	A: (34) desmopressin 400mg oral; B: (34) Placebo. Duration of treatment 5 weeks, 2 week washout.
Comparitors	Between treatment and placebo. Crossover trial.
Length of Study/ Follow-up	2 weeks post-treatment period.
Outcome measures studies	Average number of wet nights per week; no. of children where average number of wet nights decreased to less than 3 per week.
Results	5 weeks of treatment with a 2 week wash out period Number achieving 14 dry nights: A=23/34; B=7/34. Wet nights after trial (mean, SD): A= 2.5 (2.7), B=4.5 (2.1).
Funding	Supported by Ferring Pharmaceuticals Limited.
Does the study answer the question?	The author concludes that oral desmopressin is a safe and efficacious drug for the short-term treatment of children with primary nocturnal enuresis.
Effect due to factor in study?	No.
Consistency of results with other studies?	Similar to other studies comparing desmopressin to placebo.
How directly applicable to population of the guideline?	Yes.
Internal Validity	Follow-up data unusable as all had had both treatments. Mentions randomisation but not how this was done. Double blind trial.

Grading: 1-	<i>Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*</i>
--------------------	--

Reference number 494	Study Type	Randomised Controlled Trial	RID:
Birkasova M;Birkas O;Flynn MJ;Cort JH;			219
Desmopressin in the management of nocturnal enuresis in children: a double-blind study			
1978 62		pgs 970	974

Number of subjects	22 in total. Crossover trial.
Inclusion/Exclusion Criteria:	Inclusion: failed to respond to psychotherapy and fluid restriction regime. Exclusion: organic causes.
Characteristics of subjects or environment/prognostic factor	14 out of 22 children were boys. The mean age was 6.6 (SD 2.9) years (range 4-12 years). Mean baseline wetting in 2 weeks was 10.6 (SD 4.9) nights.
Recruitment:	Not reported.
Setting:	New York, USA.
Interventions/Test /Factor being investigated	Group A: 10 intranasal desmopressin Group B: 40 intranasal desmopressin Group C: placebo
Comparitors	Between groups A, B and C
Length of Study/ Follow-up	4-6 weeks
Outcome measures studies	Mean number of wet nights per fortnight, and number becoming totally dry.
Results	2 weeks of treatment Number of wet nights per fortnight: Groups A and B had a combined mean of 4.2 (SD 4.5) compared to group C which had a mean of 11 (SD 4.4). Number who became totally dry: 5 patients receiving a higher dosage were totally dry. 9 continued desmopressin single blind for 4 to 6 weeks then given placebo 7 remained dry without drug 1 wet once monthly and 1 returned to daily wetting 4 who had wet nightly continued on DDAVP for 3 more months by which time they were dry 1 had 1 wet night per fortnight and 1 had 1 wet night in 3 2 patients who were indifferent to wetting showed no response to desmopressin or placebo
Funding	AM 10080 grant from the National Institutes of Health, the Life Sciences Foundation, Inc and the Czechoslovak Academy of sciences.
Does the study answer the question?	The study showed that children treated with desmopressin had fewer wet nights at end of treatment compared to children treated with a placebo. (no usable data for meta-analysis)
Effect due to factor in study?	High and low dose desmopressin results grouped together.

Consistency of results with other studies? Results similar to other studies of desmopressin.

How directly applicable to population of the guideline? Children aged 4-12 years.

Internal Validity High and low dosage groups were combined in the analysis. Unclear treatment groups due to cross over of groups after treatment but during follow up.

Reference number 19 **Study Type** **Randomised Controlled Trial** RID: 61
Ferrara P;Marrone G;Emmanuele V;Nicoletti A;Mastrangelo A;Tiberi E;Ruggiero A;Fasano A;Paolini P;
Homotoxicological remedies versus desmopressin versus placebo in the treatment of enuresis: a randomised, double-blind, controlled trial.
2008 23 PGS 269 274

Number of subjects 151 patients were randomised: n=51 to desmopressin, n=50 to homotoxicological remedies and n=51 to receive placebo.

Inclusion/Exclusion Criteria: Exclusion criteria: NE associated with day-time symptoms (urgency, frequency, UI, urinary tract anomalies or infections)

Characteristics of subjects or environment/prognostic factor All patients had an ICCS definition of NE and none had received treatment for NE or homotoxicological remedies within the previous 3 months. Patients were aged 6 years to 14 years (mean 8.5 years).

Recruitment: From a Department of Paediatrics in Italy.

Setting: University Hospital.

Interventions/Test /Factor being investigated Desmopressin vs. homotoxicological remedies vs. placebo

Comparitors Between Desmopressin and homotoxicological remedies and placebo.

Length of Study/ Follow-up Up to 3 months.

Outcome measures studies Mean number of wet nights per week during the 3 months observation period and after 3 months of treatment. Number and percentage of non-responders, partial responders and full responders. Children relapsing, attaining 14 dry nights and adverse effects.

Results 151 patients were randomised. n=51 to desmopressin, n=50 to homotoxicological remedies and n=51 to receive placebo.

Each patient was asked about a family history of bladder dysfunction and the number of wet nights per week. Urine analysis, urine culture and ultrasonography of kidney and bladder was conducted. A bladder diary that was completed by the patients or the parents was also used.

The first group received desmopressin tablets 0.2mg, once in the evening, plus placebo drops, 20 drops three times a day and the third group received placebo tablets, once in the evening plus placebo drops, 20 drops three times a day. The treatment was started at different times for each patient, and each one was treated for 3 months.

Non-responders to the therapy after the first 3 months period were withdrawn from the study.

Children were classified as:

-non- responders if there was no decrease, or less than 50% decrease in the

number of wet nights compared to baseline.
 -partial responders if there was a 50% or more, but less than 90% decrease in the number of wet nights compared to baseline.
 -Full responders if there was a 90% or more decrease in the number of wet nights compared to baseline.

The mean number of wet nights per week after the 3 months observation period was at least 6 or 7 in all groups.

The desmopressin group showed a statistically significant decrease (62.9%) in the number of wet nights compared to placebo (2.4%) ($p < 0.001$). After 3 months, a full response was achieved in 26 out of 50 (52%) of the children treated with desmopressin compared with 0 out of 50 (0%) of the placebo group ($p < 0.001$).

No relapse percentages were assessed between the desmopressin and placebo groups.

A statistically significant difference was reported. 26 out of 50 children treated with desmopressin achieved 14 consecutive dry nights and 0 out of 50 children treated with placebo ($p < 0.001$).

Desmopressin group- 32 entered phase 2 (2 weeks wash out) and 18 did not re-enroll due to lack of response to the therapy.
 Placebo group- None entered phase 2.

Funding

Not reported.

Does the study answer the question?

Desmopressin is more effective than homotoxicological remedies and placebo. Homotoxicological remedies are more effective than placebo.

Effect due to factor in study?

Yes.

Consistency of results with other studies?

No other similar studies.

How directly applicable to population of the guideline?

Patients were aged 6 years to 14 years.

Internal Validity

No ITT performed

Reference number 74

Study Type

Randomised Controlled Trial

RID:

Lee T;Suh HJ;Lee HJ;Lee JE;

182

Comparison of effects of treatment of primary nocturnal enuresis with oxybutynin plus desmopressin, desmopressin alone or imipramine alone: a randomized controlled clinical trial

2005 174

pgs 1084 1087

Number of subjects

#Deleted

Inclusion/Exclusion Criteria:

#Deleted

Characteristics of subjects or environment/prognostic factor

#Deleted

Recruitment:

Not reported

Setting:

2 hospitals, between 2003 and 2004

Interventions/Test /Factor being investigated	Group A: 0.1 or 0.2 md desmopressin and 5 mg oxybutinin Group B: 0.2 mg desmopressin (increased to 0.4 mg if no response) Group C: 25 mg imipramine
Comparitors	Between treatment groups
Length of Study/ Follow-up	none
Outcome measures studies	0-1 wet nights a month, drop out, mean numebr of wet nights, continued response
Results	#Error
Funding	Not reported
Does the study answer the question?	
Effect due to factor in study?	Yes
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Age range of 5 to 15 years
Internal Validity	#Deleted

Reference number 35 **Study Type** **Randomised Controlled Trial** RID: 70
Lottmann H;Froeling F;Alloussi S;El-Radhi AS;Rittig S;Riis A;Persson BE;
A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis
2007 61 pgs 1454 1460

Number of subjects 221 in total.

Inclusion/Exclusion Criteria:	Inclusion: aged 5-15 years, and primary NE. Exclusion: daytime urgency, frequency (>7 micturitions during day time), voiding postponement, infrequency (< 3 voiding during daytime), the use of non-pharmacological treatment for NE in previous 60 days, organic urological disease, day time wetting, diabetes insipidus, UTI, clinically significant renal, hepatic, gastrointestinal, pulmonary, cardiovascular, endocrine, or neurological disease.
Characteristics of subjects or environment/prognostic factor	The mean age was 9.6 (SD 2.4) years. 71.6% were male. 34.4% were aged 5-8 years, 40.8% were aged 9-11 years and 24.8% were aged 12-15 years.
Recruitment:	Not reported.
Setting:	26 centres in Europe
Interventions/Test /Factor being investigated	120 or 240 micrograms desmopressin melt.
Comparitors	0.2 or 2X0.2 mg desmopressin tablet.
Length of Study/ Follow-up	3 weeks
Outcome measures studies	Mean number of wet nights, and side effects.
Results	<p>26 centres in France, Germany, the Netherlands, UK, Sweden, Denmark, Norway, Finland and Iceland</p> <p>3 weeks of each treatment</p> <p>Mean number of wet nights per week The mean number of wet nights for the tablet was 1.88 (SD 1.94), and the mean number of wet nights for the melt was 1.90 (SD 1.85).</p> <p>The study reported that the treatment difference was -0.05 episodes/week (95% CI -0.21 to 0.1, p=0.5).</p> <p>The study reported that the age effect was -0.13 episodes/week per year age increased (95% CI -0.23 to -0.04)</p> <p>The study reported that the dose effect was 1.03 episodes/week for the high v. low dose (95% CI 0.53 to 1.53)</p> <p>Adverse events: 6 out of 109 patients in the melt desmopressin group had headaches compared to 0 out of 109 in the tablet desmopressin group. 3 out of 109 patients in the melt desmopressin group had diarrhoea compared to 0 out of 109 in the tablet desmopressin group. 3 out of 109 patients in the melt desmopressin group had viral gastroenteritis compared to 0 out of 109 in the tablet desmopressin group.</p>
Funding	Ferring pharmaceutical
Does the study answer the question?	The study reported no significant difference between tablet or melt form of desmopressin.
Effect due to factor in study?	Yes.
Consistency of results with other studies?	No other similar studies.

How directly applicable to population of the guideline? Age range 5-15 years.

Internal Validity Cross over trial

Reference number 175 **Study Type** **Randomised Controlled Trial** RID:
Muller D;Florkowski H;Chavez-Kattau K;Carlsson G;Eggert P; 186
The effect of desmopressin on short-term memory in children with primary nocturnal enuresis
2001 166 pgs 2432 2434

Number of subjects 40 in total: 19 in group A (desmopressin), and 21 in group B (placebo).

Inclusion/Exclusion Criteria: Inclusion: at least 3 wet nights per week, and primary NE.
Exclusion: organic causes of NE, anatomical abnormalities, or abnormal serum or urine analysis.

Characteristics of subjects or environment/prognostic factor 29 out of 40 were boys. None had tried previous treatment. Mean baseline wetting per week was 5.35 (median 5.5 95% CI 4.5-6). The mean age in group A was 8.7, the median was 8.9 (Range 6-13). The mean age in group B was 8.6, median 8, and range 6.3-11.9.

Recruitment: Recruited from Children's Hospital, University of Kiel, Germany.

Setting: Germany.

Interventions/Test /Factor being investigated Group A: 20 micro grams intranasal desmopressin first
Group B: 0.9% saline (Placebo) first

Comparitors 2 weeks of each treatment, then cross over

Length of Study/ Follow-up 4 weeks

Outcome measures studies Mean number of wet nights during trial, and responders.

Results 2 weeks of each treatment

Mean number of wet nights during trial:
In group A the mean number of wet nights was 3.27, median 3, 95% CI 2 to 4.
In group B the mean number of wet nights was 4.9, median 5.25, 95% CI 4.5-6. P=0.001

Responders
27 out of 40 children responded, no results for placebo

There was no difference in reaction time between groups

More children slept more deeply on desmopressin 14 out of 18 than on placebo (4 out of 18). P=0.03

Funding Not reported

Does the study answer the question? Study showed that more children responded when given desmopressin and had fewer wet nights compared to placebo treatment.

Effect due to factor in study?

Consistency of results with other studies?

How directly applicable to population of the guideline? Age 6-13 years

Internal Validity Unclear allocation concealment. Cross over trial.

Reference number 328 **Study Type** **Randomised Controlled Trial** RID:
Rushton HG;Belman AB;Zaontz M;Skoog SJ;Sihelnik S; 205
Response to desmopressin as a function of urine osmolality in the treatment of monosymptomatic nocturnal enuresis: a double-blind prospective study
1995 154 pgs 749 753

Number of subjects 96 in total: 49 in Group A and 47 in Group B.

Inclusion/Exclusion Criteria: Inclusion: confirmed monosymptomatic NE, wet at least 6 nights during 2 week baseline period.
Exclusion: organic causes of NE, day time wetting, organic urological disease, central diabetes insipidus, UTI in previous 18 months, use of drug which could affect urine concentration, medical treatment for hyperactivity or attention deficit disorder, history of acute or perennial rhinitis, rhinorrhoea or nasal polyps, clinically significant medical disease which would interfere with study.

Characteristics of subjects or environment/prognostic factor

71 out of 91 were boys. The mean age was 9.7 years (range 7-14 years). Mean number of wet nights during 2 week baseline for group A was 11.16 (SD 2.44) and for group B was 10.96 (SD 2.53). In group A 36.7% had a positive family history of NE and in group B 29.8% did.
There was no significant difference between the baseline characteristics of the two groups

Recruitment: Not reported

Setting: USA

Interventions/Test /Factor being investigated Group A: 20 micro grams desmopressin spray (doubled if not completely dry after 14 nights)
Group B: placebo (doubled if not completely dry after 14 nights)

Comparitors Between treatment groups

Length of Study/ Follow-up 5 months

Outcome measures studies Mean number of wet nights during first and last 2 weeks. Response.

Results Group A were treated with 20 micro grams desmopressin, if children were not completely dry after 14 day the dose was doubled to 40 micro grams desmopressin

Treatment for 4 weeks

Mean number of wet nights during first 2 weeks:
In Group A (20 micro grams desmopressin) the mean number of wet nights was 7.91 (SD 4.74) and in Group B (placebo) was 9.79 (SD 3.28).

Mean number of wet nights during last 2 weeks:
In Group A (40 micro grams desmopressin) the mean number of wet nights was 7.54 (SD 5.04) and in Group B (placebo) the mean number of wet nights was 9.79 (SD 3.63).

Response rate
In Group A (desmopressin) 10 out of 49 patients had an excellent response rate compared to 1 out of 47 in Group B (placebo).

The study reported no difference between responders and non responders by demographic variables (age, sex, race and family history).

Funding Rhone-Poulenc Rorer Pharmaceuticals Inc, Collegeville Pennsylvania

Does the study answer the question? The study showed that there was a higher response rate with desmopressin than with placebo. It also showed that children treated with desmopressin had fewer wet nights than those treated with placebo.

Effect due to factor in study? Yes

Consistency of results with other studies?

How directly applicable to population of the guideline? Age range 7-14 years.

Internal Validity Double blind trial

Reference number 283 **Study Type** **Randomised Controlled Trial** RID:
Uygur MC;Ozgu IH;Ozen H;Ozen S;Toklu C;Ergen A;Tekgul S;Remzi D; 198

Long-term treatment of nocturnal enuresis with desmopressin intranasal spray

1997 36 pgs 455 459

Number of subjects 65 children in crossover trial. 11 excluded before RCT because did not respond to trial of desmopressin. Total =54 children.

Inclusion/Exclusion Criteria: Inclusion: primary nocturnal enuresis. Exclusion: organic causes of NE, urological disease, non-response to 2 week trial of desmopressin.

Characteristics of subjects or environment/prognostic factor Age 7-17 years. Baseline wetting '3 or more wet nights/week'.

Recruitment: Not reported.

Setting: Turkey

Interventions/Test /Factor being investigated Period A (54): desmopressin spray, 20mg or 40 mg if no response. Period B (54): placebo spray.

Comparators Desmopressin compared to placebo.

Length of Study/ Follow-up 6 months.

Outcome measures studies Number of wet nights in 2 weeks. Drop outs.

Results	Wet nights in 2 weeks: A=1; B=9.6 (no SDs).
	Drop out: 4 dropped out in total, 1 due to UTI 3 due to no response to desmopressin
Funding	Ferring Pharmaceutical, Sweden provided desmopressin
Does the study answer the question?	The study showed that more children were dry when treated with desmopressin 20 mg or 40 mg than with desmopressin.
Effect due to factor in study?	Yes
Consistency of results with other studies?	Similar to other studies with same comparison.
How directly applicable to population of the guideline?	Age range 7-17 years.

Internal Validity

Reference number 297 **Study Type** **Randomised Controlled Trial** RID:
 Vertucci P;Lanzi C;Capece G;Fano M;Gallai V;Margari L;Mazzotta G;Menegati E;Ottaviano S;Perini A;Perniola T;Roccella M;Tiberti A;Vecchio A;Biraghi M; 425
 Desmopressin and imipramine in the management of nocturnal enuresis: a multicentre study
 1997 51 pgs 27 31

Number of subjects	57 in total, 29 who received desmopressin then imipramine, 28 who received imipramine then desmopressin
Inclusion/Exclusion Criteria:	Inclusion: primary NE aged over 5 years, wet at least 3 nights a week, parental consent Exclusion: organic or neurological dysfunction of the urinary system
Characteristics of subjects or environment/prognostic factor	The age range was 6 to 15 years. The mean age was 10 years. 37 out of 57 were male
Recruitment:	Children at Child Neuropsychiatry clinics in Italy
Setting:	Child Neuropsychiatry Clinics Italy
Interventions/Test /Factor being investigated	Group A: Desmopressin 30 mcg intranasal then imipramine 0.9 mg/kg Group B: Imipramine 0.9 mg/kg then desmopressin 30 mcg intranasal
Comparators	Between desmopressin and imipramine
Length of Study/ Follow-up	2 weeks

Outcome measures studies	number of wet nights, 14 consecutive dry nights, drop outs, side effects		
Results	<p>Data was presented in graphs - data presented below was from cochrane review Treatment was for 3 weeks of each. Results shown are for after the first 3 weeks of treatment (patients had only received one drug)</p> <p>Mean number of wet nights during first arm of trial In group A (desmopressin) the mean number of wet nights was 1, in group B (imipramine) the mean number of wet nights was 2.8</p> <p>Number who achieved 14 consecutive dry nights: 25 out of 29 achieved 14 consecutive dry nights when treated with desmopressin compared to 19 out of 28 who were treated with imipramine</p> <p>Drop outs: 5 in total</p> <p>Side effects: Desmopressin: 1 had back pain, 1 had a an inflamed nasal mucosa Imipramine: 1 had pallor, restlessness and cold extremities</p>		
Funding	Not reported		
Does the study answer the question?	Study compared desmopressin to imipramine to show that both reduced the number of wet nights, however desmopressin was more effective than imipramine		
Effect due to factor in study?	Yes		
Consistency of results with other studies?	No other similar studies		
How directly applicable to population of the guideline?	Children were aged 6 to 15 years		
Internal Validity	cross over trial, no wash out		
Reference number	127	Study Type	Randomised Controlled Trial
Wille S;			RID:
			372
	Comparison of desmopressin and enuresis alarm for nocturnal enuresis		
1986 61		pgs 30	33
Number of subjects	50 patients recruited, 25 allocated to each arm. Only 46 patients completed the trial, 22 of which were treated with the enuresis alarm, 24 were treated with intranasal desmopressin		
Inclusion/Exclusion Criteria:	<p>Inclusion: older than 6 years, not dry for more than 6 months since 3 years, wet at least 3 times a week, and written informed consent.</p> <p>Exclusion: treatment for NE in previous years, day time wetting, cardiovascular disease, renal disorder, neurological disorder, or chronic UTI.</p>		
Characteristics of subjects or environment/prognostic factor	<p>Group A had a mean number of wet nights at baseline line of 2.1 Group B had a mean number of wet nights at baseline line of 1.9</p>		
Recruitment:	Patients referred to S. Wille's clinic.		
Setting:	Sweden, treatment at home.		

Interventions/Test /Factor being investigated	Group A: intranasal desmopressin Group B: alarm
Comparitors	Between groups A and B
Length of Study/ Follow-up	3 months
Outcome measures studies	Number of children dry for 14 consecutive nights, and relapse.
Results	<p>Success of being for 28 days with only 5 wet nights or achieving a lower wetting score (score: very wet = 3, a little wet = 2, dry = 1): In group A (desmopressin) 17 out of 24 children became dry compared to 19 out of 22 in group A (alarm). The study stated that at the end of treatment both groups were significantly drier than before the treatment however the alarm group was more successful (alarm $p < 0.001$; desmopressin $p < 0.02$). There was no significant difference between group A (desmopressin) and group B (alarm).</p> <p>Group A (desmopressin) had significantly more dry nights than group B (alarm) in the first 3 weeks ($p < 0.001$). However during the last 9 weeks of treatment the alarm group had more dry nights, and significantly more in the 11th week ($p < 0.002$). The study stated that due to the high relapse rate in the desmopressin group, over all during the first 2 weeks of treatment and at 3 month follow up the alarm group was significantly better than the desmopressin group ($p < 0.02$, $p < 0.001$, 2 weeks and 3 months respectively).</p> <p>Relapse: 1 patient in the alarm group relapsed in the 3 month follow up compared to 10 in the desmopressin group.</p> <p>Drop out: 1 child from the alarm group dropped out due to lack of improvement.</p> <p>Adverse events: In the alarm group 78% had false alarms, 19% said the alarm did not work when the child was wet, 56% said the alarm did not wake the child, 56% said the alarm woke other family members instead and 1 patient was afraid of the alarm. In the desmopressin group 13% reported nasal discomfort, 3% had occasional nose bleeds and 5% experienced a bad taste in the throat.</p> <p>The study included a cross over of treatments for children who were unsuccessful in their original treatment group. Of the children who changed from desmopressin to alarm 2 children improved by a 2 month follow up, 3 were better than before and 5 did not respond. Of the children who changed from alarm to desmopressin 2 children did improve but subsequently relapsed. There was no significant difference between the cross over results.</p>
Funding	Not reported.
Does the study answer the question?	The study showed that both alarm treatment and desmopressin lead to a significant reduction in the number of wet nights. The study showed that alarm treatment was more successful in achieving 28 dry nights (with less than 5 wet nights) than desmopressin, however this difference was not significant until the high relapse rate of desmopressin was taken into account. With alarms then being significantly more effective. The desmopressin group had a higher relapse rate than the alarm group. More patients receiving alarm therapy reported side effects than those receiving desmopressin.
Effect due to factor in study?	Yes.
Consistency of results with other studies?	Similar to other studies comparing desmopressin and alarm.

How directly applicable to population of the guideline? Patients were aged over 6 years.

Internal Validity

Grading: 2+	<i>Well-conducted case-control or cohort studies with a low risk of confounding, bias or chance and a</i>
--------------------	--

Reference number 247 Study Type Cohort RID: 947
 Del G;Del G;Cennamo M;Auriemma R;Del G;Verni M;

Desmopressin is a safe drug for the treatment of enuresis

2005 39 pgs 308 312

Number of subjects	541 patients
Inclusion/Exclusion Criteria:	Inclusion: aged over 5 years, absence of malformations and infections of the urinary tract, absence of psychological disorders or neurological alterations, number of wet nights greater than 5 to 7
Characteristics of subjects or environment/prognostic factor	Children were aged over 5 years
Recruitment:	Selected patients monitored for 2 years (no details)
Setting:	Italy
Interventions/Test /Factor being investigated	30 to 40 micrograms intranasal desmopressin
Comparitors	0.3 to 0.4 mg tablet desmopressin
Length of Study/ Follow-up	No follow up
Outcome measures studies	Side effects
Results	3 months of treatment Children treated with intranasal desmopressin 7 out of 153 patients had weight gain during the first 4 days of therapy, 1 out of 153 had vomiting and abdominal pain and 1 out of 153 had headache and abdominal pain. Children treated with tablet desmopressin 22 out of 388 patients had side effects such as headache, vomiting, stomach ache, lack of appetite, vesical tenesmus, diarrhea, epistaxis, dizziness, drowsiness and weight gain in 3 patients; 10 patients interrupted treatment due to weight gain.
Funding	Not reported
Does the study answer the question?	The study showed some children treated with intranasal desmopressin had weight gain, vomiting and abdominal pain and headache and abdominal pain The study showed some children treated with tablet desmopressin had headache, vomiting, stomach ache, lack of appetite, vesical tenesmus, diarrhea, epistaxis, dizziness, drowsiness and weight gain
Effect due to factor in study?	Yes
Consistency of results with other studies?	

How directly applicable to population of the guideline? Children were aged over 5 years

Internal Validity

Reference number 739 **Study Type** **Cohort** RID:
Hjalmas K;Hanson E;Hellstrom AL;Kruse S;Sillen U; 883
Long-term treatment with desmopressin in children with primary monosymptomatic nocturnal enuresis: an open multicentre study. Swedish Enuresis Trial (SWEET) Group
1998 82 pgs 704 709

Number of subjects 393 patients

Inclusion/Exclusion Criteria: Inclusion: Aged 6 to 12 years, monosymptomatic nocturnal enuresis
Exclusion: day incontinence, previous urological history such as UTI

Characteristics of subjects or environment/prognostic factor Children had an age range of 6 to 12 years

Recruitment: Recruited to multi centre trial (no details)

Setting: Multi centre trial, Sweden

Interventions/Test /Factor being investigated 20 to 40 micrograms intranasal desmopressin (393 short term desmopressin, 242 long term desmopressin)

Comparitors No comparison

Length of Study/ Follow-up Not reported

Outcome measures studies Side effects

Results 28 days of treatment or long term (unspecified) treatment.

The study showed 2.5% of 393 children reported mild adverse events of nasal irritation and abdominal pain on short term desmopressin and 2% of 242 children had temporary bouts of aggression when on long term desmopressin

Funding Not reported

Does the study answer the question? The study showed 2.5% of children reported mild adverse events of nasal irritation and abdominal pain on short term desmopressin and 2% had temporary bouts of aggression when on long term desmopressin

Effect due to factor in study? Yes

Consistency of results with other studies?

How directly applicable to population of the guideline? Age range 6 to 12 years

Internal Validity

Reference number 703 **Study Type** **Cohort** RID:
Tullus K;Bergstrom R;Fosdal I;Winnergard I;Hjalmas K; 948
Efficacy and safety during long-term treatment of primary monosymptomatic nocturnal enuresis with desmopressin. Swedish Enuresis Trial Group
1999 88 Acta Paediatr pgs 1274 1278

Number of subjects 245 patients

Inclusion/Exclusion Criteria: Inclusion: primary monosymptomatic Ne, aged 6 to 12 years, no evidence of organic urinary tract pathology, no history of diurnal symptoms
Exclusion: clinically significant illness affecting any of the other major organ systems

Characteristics of subjects or environment/prognostic factor Children were aged 6 to 12 years

Recruitment: Consecutive patients at 24 centres

Setting: Hospital and district paediatric clinics, Sweden

Interventions/Test /Factor being investigated Intranasal desmopressin

Comparitors No comparison

Length of Study/ Follow-up No follow up

Outcome measures studies Side effects

Results 12 months of treatment.

The study showed 16% of children had headaches, 13% had gastroenteritis, 20% had psychological disturbances which included 4% had nervousness, 4% had aggressive reactions and 2% had nightmares. 1% dropped out due to abdominal pain, 1% due to aggressive reactions, 0.5% due to nightmares and 0.25% due to loss of appetite

Funding Ferring Pharmaceuticals, Malmo, Sweden

Does the study answer the question? The study showed some children treated with intranasal desmopressin had headaches, gastroenteritis, psychological disturbances, abdominal pain, aggressive reactions, nightmares and loss of appetite

Effect due to factor in study? Yes

Consistency of results with other studies?

How directly applicable to population of the guideline? Children were aged 6 to 12 years

Internal Validity

Reference number	4089	Study Type	Cohort	RID:
Wolfish NM;Barkin J;Gorodzinsky F;Schwarz R;				952
The Canadian Enuresis Study and Evaluation--short- and long-term safety and efficacy of an oral desmopressin preparation				
2003 37			pgs 22 27	

Number of subjects 256 patients

Inclusion/Exclusion Criteria: Inclusion: good health, no organic systemic pathology, wet at least 10 out of 28 consecutive nights

Characteristics of subjects or environment/prognostic factor Mean age 9.6 years, age range of 6 to 18 years. 79.3% were male, 80% had tried previous treatment (alarm or drugs)

Recruitment: Not reported

Setting: Canada

Interventions/Test /Factor being investigated 0.2 to 0.4 mg tablet desmopressin

Comparitors No comparison

Length of Study/ Follow-up No follow up

Outcome measures studies Side effects

Results 1 month of treatment

The study showed out of 256 patients, 2 children withdrew from the trial 1 due to abdominal pain and 1 due to headache and abdominal pain

Funding Not reported

Does the study answer the question? The study showed out of 256 patients, 2 children withdrew from the trial 1 due to abdominal pain and 1 due to headache and abdominal pain

Effect due to factor in study? Yes

Consistency of results with other studies?

How directly applicable to population of the guideline? Age range of 6 to 18 years

Internal Validity

Grading: 2-	Case-control or cohort studies with a high risk of confounding bias, or chance and a significant risk
--------------------	--

Reference number	3004	Study Type	Cohort	RID:
				949
	Figuroa TE;Benaim E;Griggs ST;Hvizdala EV;			
	Enuresis in sickle cell disease			
1987	153		pgs 87	1989

Number of subjects	10 patients
Inclusion/Exclusion Criteria:	Inclusion: sickle cell disease
Characteristics of subjects or environment/prognostic factor	Age range 6 to 12 years
Recruitment:	Patients at centre
Setting:	Regional sickle cell center, USA
Interventions/Test /Factor being investigated	Intranasal desmopressin
Comparitors	No comparison
Length of Study/ Follow-up	No follow up
Outcome measures studies	Side effects
Results	6 months of treatment
	The study showed 4 children did not respond to intranasal desmopressin, one of these children stopped using intranasal desmopressin due to headaches.
Funding	Not reported
Does the study answer the question?	The study showed only 1 out of 10 children with sickle cell disease stopped using intranasal desmopressin due to headaches
Effect due to factor in study?	Yes
Consistency of results with other studies?	No other studies
How directly applicable to population of the guideline?	Children had sickle cell disease, age range 6 to 12 years

Internal Validity

Reference number	3046	Study Type	Cohort	RID:
	Robson WLM;Leung AKC;			950
	Side effects associated with DDAVP treatment of nocturnal enuresis			
1994	36	J Singapore Paediatr Soc	pgs 81	82

Number of subjects	77 patients
Inclusion/Exclusion Criteria:	Inclusion: patients seen in clinics and treated with desmopressin
Characteristics of subjects or environment/prognostic factor	Mean age 9.4 years, age range 5.3 to 15.3 years, 70% were male, 64% were responders, 60% had 10 micrograms desmopressin, 40% had 20 micrograms or higher desmopressin
Recruitment:	Patients seen from November 1989 to March 1993 and treated with desmopressin
Setting:	Pediatric nephrology clinic,Canada
Interventions/Test /Factor being investigated	10 to 40 micrograms intranasal desmopressin
Comparitors	No comparison
Length of Study/ Follow-up	Not reported
Outcome measures studies	Side effects
Results	4 weeks of treatment. The study showed 1 out of 77 children suffered from headaches and1 out of 77 children had emotional lability
Funding	Not reported
Does the study answer the question?	The study showed 1 out of 77 children suffered from headaches and1 out of 77 children had emotional lability
Effect due to factor in study?	Yes
Consistency of results with other studies?	
How directly applicable to population of the guideline?	Mean age 9.4 years

Internal Validity

08 February 2010

Page 179 of 244

Question: What is the clinical and cost effectiveness of tricyclic drugs for children and young people under 19 years old who have nocturnal enuresis?

18

Grading: 1+	Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
--------------------	--

Reference number 325 Study Type Randomised Controlled Trial RID:
 Burke JR;Mizusawa Y;Chan A;Webb KL; 400

A comparison of amitriptyline, vasopressin and amitriptyline with vasopressin in nocturnal enuresis.

1995 9 pgs 438 440

Number of subjects 45 in total, 14 in group A (amitriptyline), 17 in group B (desmopressin), 14 in group C (desmopressin and amitriptyline)

Inclusion/Exclusion Criteria: Inclusion: 6-17 years, at least 3 wet nights a week for proceeding 3 month period, not dry for more than 6 months
 Exclusion: organic causes of NE, enuresis treatment in previous 6 months, neurogenic disorder, UTI, abnormal urinalysis haematology or blood biochemistry, concomitant medication known to interfere with study medication

Characteristics of subjects or environment/prognostic factor In group A the mean age was 8.6 (SD 2.4) years, the mean baseline wetting was 5.8 (SD 0.9)
 In group B the mean age was 8.9 (SD 2.5) years, the mean baseline wetting was 6.0 (SD 0.9)
 In group C the mean age was 8.9 (SD 2.4) year, the mean baseline wetting was 6.3 (SD 0.9)

Recruitment: Not reported

Setting: Australia

Interventions/Test /Factor being investigated Group A: amitriptyline hydrochloride (25 mg or 50mg)
 Group B: intranasal desmopressin (20 micro grams)
 Group C: desmopressin and amitriptyline

Comparitors Between treatment groups

Length of Study/ Follow-up 12 weeks

Outcome measures studies Number of children cured, drop outs, mean number of wet nights at end of treatment and follow up

Results 16 weeks of treatment

Number of children cured:
 In group A (amitriptyline) 3 out of 14 became dryt, compared to in group B (desmopresin) 1 out of 17 and in group C (desmopresin and amitriptyline) 4 out of 14

Number of drop outs:
 In group A (amitriptyline) 0 out of 14 dropped out, in group B (desmopresin) 3 out of 17 dropped out, in group C (desmopresin and amitriptyline) 3 out of 14 dropped out

Mean number of wet nights per week at end of treatment:
 The mean number of wet nights per week for group A (amitriptyline) was 3.3 (SD 1.9), for group B (desmopresin) was 4.7 (SD 1.7) and for group C (desmopresin and amitriptyline) was 3.3 (SD 2.5)

Mean number of wet nights per week at 12 week follow up:
 The mean number of wet nights per week for group A (amitriptyline) was 3.9 (SD 2.9), for group B (desmopresin) was 3.8 (SD 1.9) and for group C (desmopresin and amitriptyline) was 5.1 (SD 3.2)

Funding Not reported

Does the study answer the question? The study showed that more children became dry when treated with amitriptyline and desmopressin, patients treated with amitriptyline alone and with desmopressin had fewer wet nights during treatment but at follow up desmopressin alone or amitriptyline alone had the fewest number of wet nights

Effect due to factor in study? Yes

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Aged 6-17 years

Internal Validity The trial was stopped early due to one dug becoming unavaliabile
Not reported if it was intention to treat

Reference number 584 **Study Type** **Randomised Controlled Trial** RID:
Poussaint AF;Ditman KS;Greenfield R; 340
Amitriptyline in childhood enuresis
1966 7 pgs 21 25

Number of subjects 50 in total (60 before drop outs)
Trial 1: 16 in each group
Trial 2: 9 in each group

Inclusion/Exclusion Criteria: Inclusion: wet at least 1 night a week.
Exclusion: organic causes of NE, or learning difficulties.

Characteristics of subjects or environment/prognostic factor The age range was 5 to 15 years. 80% had never been dry since birth. The remainder had had brief periods of dryness.

Recruitment: Referred by doctor.

Setting: Department of psychiatry neuropsychiatric UCLA USA

Interventions/Test /Factor being investigated Trial 1:
Group A: amitriptyline (25 mg for children aged less than 12 years, 50 mg for children aged over 12 years
Group B: placebo

Trial 2:
Group A: amitriptyline (25 mg for children aged less than 12 years, 50 mg for children aged over 12 years
Group B: placebo

Comparitors Between treatment groups.

Length of Study/ Follow-up No follow up.

Outcome measures studies Number of wet nights, and side effects.

Results Data taken from Cochrane review because graphical data only presented in paper.
There were 10 drop outs in total

Trial 1:
Treatment for 4 weeks
Mean number of wet nights in last week of treatment:

In group A (amitriptyline) the mean number of wet nights was 3.1, while in group B (placebo) the mean number of wet nights was 4.6.

Side effects: (same data as trial 2)

Amitriptyline:

7 reported being irritable, 2 were calmer, 10 nocturia, 3 drowsy, 2 headache, 1 lower appetite, 1 fatigue, 1 stomach ache, and 1 scleral injection.

Placebo:

5 reported being irritable, 5 stomach ache, 1 fatigue, and 1 lower appetite.

Trial 2:

Treatment for 8 weeks

Mean number of wet nights in last week of treatment:

In group A (amitriptyline) the mean number of wet nights was 4.1, while in group B (placebo) the mean number of wet nights was 5.5.

Side effects: (same data as trial 1)

Amitriptyline:

7 reported being irritable, 2 were calmer, 10 nocturia, 3 drowsy, 2 headache, 1 lower appetite, 1 fatigue, 1 stomach ache, and 1 scleral injection.

Placebo:

5 reported being irritable, 5 stomach ache, 1 fatigue, and 1 lower appetite.

Funding

Not reported

Does the study answer the question?

Both trials compared amitriptyline to placebo and showed amitriptyline is more effective than placebo

Effect due to factor in study?

Yes.

Consistency of results with other studies?

No other similar studies.

How directly applicable to population of the guideline?

Children were aged 5 to 15 years.

Internal Validity

Data taken from Cochrane - graphical data presented in paper

Grading: 1-	Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*
--------------------	---

Reference number 571	Study Type	Randomised Controlled Trial	RID:
Agarwala S;Heycock JB;			336
A controlled trial of imipramine ('Tofranil') in the treatment of childhood enuresis			
1968 22		pgs 296	298

Number of subjects	29 in total in this cross over trial.
Inclusion/Exclusion Criteria:	Inclusion: parents consider the enuresis to be a problem, aged over 6 years, wet 6-7 times a week. Exclusion: organic causes of NE or mental retardation.
Characteristics of subjects or environment/prognostic factor	15 out of 29 were boys and the age range was 6-12 years. Some had previously been treated with imipramine.
Recruitment:	All currently attending the Outpatient Department with enuresis as their main complaint.
Setting:	Sunderland Children's Hospital.
Interventions/Test /Factor being investigated	Group A: 25 mg imipramine for 2 weeks and dose doubled (50mg) for another 2 weeks if no response. Group B: placebo.
Comparitors	Between treatment groups.
Length of Study/ Follow-up	4 weeks.
Outcome measures studies	14 consecutive dry nights, mean number of wet nights in 2 weeks of treatment, and side effects.
Results	Treatment for 2 weeks or 4 if no response Number of children who achieved 14 consecutive dry nights: In Group A 2 out of 29 achieved 14 consecutive dry nights compared to 0 out of 29 in group B. Mean number of wet nights: Group A had a mean number of 5.5 (SD 3.3) wet nights in the 2 weeks of treatment compared to 7.8 (4) in group B Side effects: 1 patient in group A suffered dizziness when treated with 50mg imipramine.
Funding	Not stated.
Does the study answer the question?	Yes it helps answer the question regarding the clinical effectiveness of Imipramine (tricyclic drug) for nocturnal enuresis. The author concludes that Imipramine is overall superior to placebo and did not occur by chance.
Effect due to factor in study?	Yes
Consistency of results with other studies?	Similar to other studies comparing imipramine to placebo.

How directly applicable to population of the guideline? Yes

Internal Validity
No washout between treatments.
Small sample.
Short study period.

Reference number 464 **Study Type** **Randomised Controlled Trial** RID:
Attenburrow AA;Stanley TV;Holland RP; 320
Nocturnal enuresis: a study
1984 228 pgs 99 102

Number of subjects 33 in total: 9 in imipramine group, 12 in placebo

Inclusion/Exclusion Criteria: Inclusion: suitable for drug therapy, parental consent, no abnormalities in blood or urine.
Exclusion: organic causes.

Characteristics of subjects or environment/prognostic factor 11 out of 33 were boys, and the median age was 7 years (range 5 to 13 years).
The baseline mean number of dry nights per week was 2.4 for imipramine group and 1.3 for placebo group.
Most had received previous simple treatments (lifting and fluid restriction).

Recruitment: Those aged over 5 years presenting with nocturnal enuresis at the department of paediatrics.

Setting: The Royal Hospital for Sick Children, Glasgow.

Interventions/Test /Factor being investigated Group A:50mg imipramine for children aged under 10 years, 75 mg imipramine for children aged over 10 years
Group B: placebo
Study also included a group treated with viloxamine, not included for this review.

Comparators Between treatment groups.

Length of Study/ Follow-up 2 weeks

Outcome measures studies Number of dry nights.
Side effects.

Results Mean number of wet nights in the final week of treatment:
group A (imipramine) had 3.2 (SD 4.5), group B (placebo) had 5.7 (2.4)

Mean number of wet nights per week at follow up:
Group A (imipramine) = 4.2 (4.8) compared to group B (placebo)= 5.7 (2.1).

Side effects
In group A 4 had lethargy, 3 had constipation, 2 had upset stomach, 1 had vomiting, sweating and sickness, 1 had vomiting and drowsiness leading to withdrawal, 1 had dizziness and dry mouth, and 1 had anorexia.
In group B 2 had a rash and 1 had nightmares.

Funding Drop outs= 13 in total
Not reported.

Does the study answer the question? Yes it looks at the clinical effectiveness of a tricyclic drug (imipramine) for nocturnal enuresis.

Effect due to factor in study? Yes

Consistency of results with other studies? Similar to other studies comparing imipramine to placebo.

How directly applicable to population of the guideline? Children aged 5 to 13 years.

Internal Validity No intention to treat analysis

Reference number 114 **Study Type** **Randomised Controlled Trial** RID:
 Batislam E;Nuhoglu B;Peskircioglu L;Emir L;Uygur C;Germiyanoglu C;Erol D; 283
 A prostaglandin synthesis inhibitor, diclofenac sodium in the treatment of primary nocturnal enuresis
 1995 63 pgs 35 38

Number of subjects 78 in total 16 in imipramine group, 12 in placebo group

Inclusion/Exclusion Criteria: Inclusion: primary Ne, wet at least 3 nights a week
 Exclusion: organic causes, previous treatment

Characteristics of subjects or environment/prognostic factor 48 out of 78 were male, age range 6 to 18 years

Recruitment: Not stated.

Setting:

Interventions/Test /Factor being investigated Group A: imipramine
 Group B: placebo
 Study also evaluated diclofenac and imipramine with diclofenac, not included for this review

Comparitors between treatment groups

Length of Study/ Follow-up 3 months

Outcome measures studies relapse at 3 months, 50% improvement, side effects, failure to improve or relapse rate

Results 50% or greater improvement
 2 out of 16 in the imipramine group and 6 out of 12 in placebo group

Funding Adverse events
 8 had mild gastrointestinal

Not reported

Does the study answer the question? Study compared imipramine to placebo

Effect due to factor in study? Yes

Consistency of results with other studies? Similar to other studies comparing imipramine to placebo

How directly applicable to population of the guideline? Yes age range 6 to 18 years

Internal Validity unclear allocation concealment, unclear group size differences

Reference number 364 **Study Type** **Randomised Controlled Trial** RID:
Danquah SA; 385
Comparative treatment of nocturnal enuresis among Ghanaian school children
1975 11 pgs 363 373

Number of subjects 30 boys, 10 in each treatment group (Group A amitriptyline, Group B alarm and Group C shaming)

Inclusion/Exclusion Criteria: Inclusion: boys with enuresis
Exclusion: those who were undergoing traditional treatment

Characteristics of subjects or environment/prognostic factor The mean age was 10.4 years and the mean IQ was 85.4 (20.12 SD).

Recruitment: From a fishing village in Ghana.

Setting: Ghanaian fishing community, at home

Interventions/Test /Factor being investigated Group A: amitriptyline
Group B: alarm
The study also looked at shaming which is not a relevant comparison so results are not reported

Comparators Between treatment groups.

Length of Study/ Follow-up 3 months

Outcome measures studies Change in number of wet nights.

Results 7 weeks treatment

The mean number of wet nights per week at the end of treatment was 3.2 for the alarm group and 4 for the amitriptyline group.

The median number of days for initial arrest were 15.5 for alarm therapy and 20 for amitriptyline.

Follow-up was conducted after 3 months post treatment. Alarm therapy was the only

	treatment that was continuously successful. The post-treatment ranking was 3.20 and following treatment was 1.49, $t=3.98$, $p<0.001$.
Funding	None reported
Does the study answer the question?	The alarm was found to be quicker and more effective.
Effect due to factor in study?	Yes.
Consistency of results with other studies?	No other similar studies.
How directly applicable to population of the guideline?	The study only included boys and the mean age was 10.4 years.
Internal Validity	All the patients were boys.

Reference number 581 **Study Type** **Randomised Controlled Trial** RID: 339
Drew LR;
Control of enuresis by imipramine
1966 2 pgs 1225 1227

Number of subjects	22 in total
Inclusion/Exclusion Criteria:	Inclusion: wet at least 3 nights a week and age 5 to 15 years.
Characteristics of subjects or environment/prognostic factor	The age range was 5 to 15 years. The baseline mean number of wet nights was 65.8% in group A (placebo then imipramine) and 64.7% in group B (imipramine then placebo).
Recruitment:	From a childrens home in Melbourne.
Setting:	Childrens home, Melbourne
Interventions/Test /Factor being investigated	Group A: Placebo then imipramine Group B: Imipramine then placebo Patients were given 2 tablets. If they had a wet night in the first week the dose was doubled to 4 tablets
Comparitors	Between imipramine and placebo.
Length of Study/ Follow-up	None.
Outcome measures studies	Number of wet nights and adverse events.
Results	4 weeks on each treatment. After these 4 weeks continued on imipramine or placebo. Number of wet nights: Group A (placebo then imipramine) had 3.79 wet nights per week, while group B (imipramine then placebo) had 2.38 wet nights per week.

Results	1 month of treatment
	Number of children who achieved 14 consecutive dry nights: 4 out of 29 children in group A (imipramine) group were cured, compared to 6 out of 26 in group B (oxybutinin) and 14 out of 34 in group C (imipramine and oxybutinin)
	The mean number of wet nights per week during treatment: The mean number of wet nights per week during treatment was 3.5 (SD 2) for group A (imipramine), the mean for group B (oxybutinin) was 2.5 (SD 1.7) and for group C (imipramine and oxybutinin) the mean was 1.4 (SD 1.5)
Funding	Not reported
Does the study answer the question?	The study showed that the most effective treatment was imipramine combined with oxybutinin
Effect due to factor in study?	Yes
Consistency of results with other studies?	Similar with other study with same comparison
How directly applicable to population of the guideline?	Age range 6-14 years

Internal Validity

Reference number 561 **Study Type** **Randomised Controlled Trial** RID: 331
 Forsythe WI;Merrett JD;
 A controlled trial of imipramine ('Tofranil') and nortriptyline ('Allegron') in the treatment of enuresis
 1969 23 pgs 210 215

Number of subjects	298 in total, 78 in imipramine and placebo group, 88 in nortriptyline and placebo group and 87 in placebo group
Inclusion/Exclusion Criteria:	Inclusion: wet at least 6 nights a week Exclusion: UTI
Characteristics of subjects or environment/prognostic factor	Age range of up to 15 years, 6 children aged under 5 years
Recruitment:	Not reported
Setting:	Royal Belfast Hospital for Sick Children
Interventions/Test /Factor being investigated	Imipramine and nortriptyline placebo Nortriptyline and imipramine placebo
Comparitors	Matching placebo
Length of Study/ Follow-up	8 weeks follow up

Outcome measures studies	14 consecutive dry nights, number of children who had a 50% reduction in the number of wet nights
Results	8 weeks of treatment The number of children who achieved 14 consecutive dry nights: 1 out of 76 children in the imipramine and placebo group achieved 14 consecutive dry nights compared to 1 out of 86 in the nortriptyline and placebo group and 1 out of 85 in the placebo group The number of children who had a 50% reduction in the number of wet nights: 22 out of 76 children in the imipramine and placebo group achieved 14 consecutive dry nights compared to 34 out of 86 in the nortriptyline and placebo group and 21 out of 85 in the placebo group
Funding	MESSRS GEIGY Ltd. And MESSERS DISTA Ltd
Does the study answer the question?	Treatment with imipramine or nortirptyline is significantly more effective than placebo treatment
Effect due to factor in study?	Yes
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Age range of up to 15 years, 6 children aged under 5 years

Internal Validity

Reference number	346	Study Type	Randomised Controlled Trial	RID:	
Fournier JP;Garfinkel BD;Bond A;Beauchesne H;Shapiro SK;					384
Pharmacological and behavioral management of enuresis					
1987	26	J Am Acad Child Adolesc Psychiatry		pgs 849	853

Number of subjects	64 in total, 8 in each group
Inclusion/Exclusion Criteria:	Inclusion: aged between 5 and 14 years, no history of UTI or disease, no physical or neurological disorder, at least 2 wet nights a week for previous 6 months, no treatment in previous 3 months, no significant cognitive impairment or mental retardation, imformed consent to random allocation of treatment
Characteristics of subjects or environment/prognostic factor	73% were boys, the mean age was 8.5 years, 70% of children lived with their biological parent, 14% lived with a single parent, 83% were either the oldest or second eldest child in their family, 77% had had a first degree relative with enuresis and 61% had another relative with enuresis
Recruitment:	Newspaper adverts and referred from paediatricians
Setting:	at home
Interventions/Test /Factor being investigated	Group A: imipramine Group B: alarm Group C: placebo Group D: alarm with imipramine

Group E: alarm with placebo
 The study also considered random waking, placebo with random waking and imipramine with random waking which are not relevant comparators for this review and were not included

Comparitors	Between treatment groups
Length of Study/ Follow-up	3 months
Outcome measures studies	Mean number of wet nights per week at the end of treatment
Results	Treatment for 6 weeks At the end of treatment the imipramine group had a mean of 1 wet night per week; the alarm group had 2.5 wet nights per week; the placebo group had 5 wet nights per week; the imipramine with alarm group had 1 wet nights per week; there were no results for the alarm and placebo group Drop out: In total 4 boys dropped out due to side-effects or non-compliance and 1 girl dropped out due to having a UTI
Funding	Not reported
Does the study answer the question?	The study showed that imipramine had a faster effect than the other treatments, however at 4 weeks the most effective treatments were alarm, alarm with imipramine and imipramine alone. At the 3 month follow up the most successful treatments were alarm, imipramine and alarm with placebo.
Effect due to factor in study?	Yes (NB there is a 15% spontaneous cure rate)
Consistency of results with other studies?	Similar to other studies with same comparison
How directly applicable to population of the guideline?	children were aged 5 - 14 years old
Internal Validity	This is a double blind trial The study had 3 more groups (alarm with placebo, random waking with placebo and imipramine and random waking) however there were no results for these 3 groups
Reference number	1742
Study Type	Randomised Controlled Trial
RID:	355
Hagglund TB;Pakkulainen K.V.;	
Enuretic children treated with imipramine (Tofranil): a cystometric study	
1964 11	Ann Paediatr Fenn
	pgs 53-59
Number of subjects	34 in study, 15 presented in results
Inclusion/Exclusion Criteria:	Inclusion: Normal IQ and wet every night. Exclusion: UTI, other urological abnormality, abnormal EEG, and daytime wetting.
Characteristics of subjects or environment/prognos tic factor	Age range of 4 to 14 years. 27 boys and 7 girls.
Recruitment:	Not reported.
Setting:	Finland.

Interventions/Test /Factor being investigated	Imipramine
Comparitors	Placebo
Length of Study/ Follow-up	3 to 8 months
Outcome measures studies	Number of children who achieved 14 consecutive dry nights
Results	The number of children who achieved 14 consecutive dry nights: 3 out of 7 children in the imipramine group achieved 14 consecutive dry nights compared to 0 out of 8 in the placebo group.
Funding	Not reported.
Does the study answer the question?	Imipramine is more effective than placebo.
Effect due to factor in study?	Yes.
Consistency of results with other studies?	No other similar studies.
How directly applicable to population of the guideline?	Age range of 4 to 14 years.

Internal Validity

Reference number	551	Study Type	Randomised Controlled Trial	RID:
Harrison JS;Albino VJ;				329
An investigation into the effects of imipramine hydrochloride on the incidence of enuresis in institutionalized children				
1970	44	S Afr Med J	pgs 253	255

Number of subjects	62 in total, 30 in imipramine group, 32 in placebo group.
Inclusion/Exclusion Criteria:	Inclusion: aged over 6 years at one of 2 orphanages run by an Augustinian Order

Characteristics of subjects or environment/prognostic factor	14 out of 62 were boys. The age range was 6 to 18 years. In the imipramine group the baseline wetting was 62% and in the placebo group the baseline wetting was 66%. Boys were sent to another institute at the age of 12 years. Therefore the over 12 years group contained only girls.	
Recruitment:	From single sex institutes.	
Setting:	Single sex orphanages, Durban.	
Interventions/Test /Factor being investigated	Group A: imipramine (25mg for children aged under 12 years, 50 mg for children aged over 12 years) Group B: placebo	
Comparitors	Between imipramine and placebo.	
Length of Study/ Follow-up	Not reported.	
Outcome measures studies	Mean number of wet nights. Drop outs.	
Results	20 nights of treatment for each. Mean number of wet nights per week at the end of treatment: (data obtained from cochrane review as paper presented data in an unusable format - only first arm of treatment is presented). The imipramine group had a mean number of wet nights of 2.52, and the placebo group had a mean number of wet nights of 3.3. 2 dropped out of the imipramine group The paper presented data that showed group one, who had imipramine then placebo, had 62.3% wet nights during the observation period, 36% wet nights during imipramine treatment, 39% wet nights during placebo treatment and 55.6% wet nights in the final observational treatment. The group which received placebo then imipramine had 65.9% wet nights during the observational period, 47.2% wet nights during the placebo treatment, 36.1% wet nights during the imipramine treatment and 56.3% wet nights during the final observational treatment.	
Funding	Giegy pharmaceutical provided the imipramine and placebo tablets.	
Does the study answer the question?	The study shows that children treated with imipramine had fewer wet nights compared to those treated with a placebo	
Effect due to factor in study?	Yes	
Consistency of results with other studies?	Similar to other studies comparing imipramine and placebo.	
How directly applicable to population of the guideline?	Children were aged 6 to 17 years. Only girls were included in the 12 to 17 years group.	
Internal Validity	The over 12 years group only contained girls	
Reference number	1741	
Study Type	Randomised Controlled Trial	
Enuresis--a study in general practice		
		RID: 354

Number of subjects	74 in total, 36 in imipramine group, 38 in placebo group.
Inclusion/Exclusion Criteria:	Inclusion: responded to a postal questionnaire, aged 5 to 15 years. Exclusion:
Characteristics of subjects or environment/prognostic factor	The age range was 5 to 15 years. 57 out of the original 99 patients (who completed the survey - number of final group was not included)
Recruitment:	Questionnaire was sent to all parents with children aged 5 to 15 years at a GP practice in London.
Setting:	GP practice, London, UK
Interventions/Test /Factor being investigated	Group A: imipramine (25 mg if aged under 6 years, 50 mg if aged over 6 years) Group B: placebo
Comparitors	Between imipramine and placebo.
Length of Study/ Follow-up	No follow up.
Outcome measures studies	Number of children who achieved 14 consecutive dry nights and adverse events.
Results	Treatment was for 30 days, if the patient was not successful they could repeat this for 5 1/2 months until cured or until the family decided to stop. Number of children who achieved 14 consecutive dry nights: 7 out of 36 in the imipramine group achieved 14 consecutive dry nights; 6 out of 38 in the placebo group achieved 14 consecutive dry nights. Adverses events Macular rash (unclear on which treatment).
Funding	Geigy Pharmaceuticals supported the study
Does the study answer the question?	The study showed there was little difference between children treated with imipramine and those treated with placebo.
Effect due to factor in study?	Yes, although no baseline characteristics given for final study population.
Consistency of results with other studies?	Similar to other studies comparing imipramine and placebo.
How directly applicable to population of the guideline?	Children aged 5 to 15 years.
Internal Validity	No baseline characteristics of final study population given.

Reference number 1743 **Study Type** **Randomised Controlled Trial** RID:
 Khorana AB; 356
 Controlled trial of imipramine hydrochloride on enuresis
 1972 16 pgs 305 308

Number of subjects 100 in total, 42 in group A (imipramine), 34 in group B (placebo)

Inclusion/Exclusion Criteria: Inclusion: consecutive children with primary enuresis.
 Exclusion: physical or neurological disorder, severe mental retardation, or unco-operative.

Characteristics of subjects or environment/prognostic factor 74 out of the initial 100 patients were male. The mean age was 8.2 years and the age range was 5 to 15 years.

Recruitment: Psychiatric inpatients in India.

Setting: psychiatric inpatients in india

Interventions/Test /Factor being investigated Group A: imipramine hydrochloride (25 mg, if aged under 10 years. If no response dose was raised to 50mg. If aged over 10 years and no response dose was raised to 75mg)
 Group B: placebo

Comparitors Between imipramine and placebo.

Length of Study/ Follow-up None

Outcome measures studies Drop outs, number who achieved 14 consecutive dry nights, and adverse events.

Results Treatment was for 12 weeks
 Number of children who achieved 14 consecutive dry nights:
 19 out of 42 children in group A (imipramine) achieved 14 consecutive dry nights; 0 out of 34 in group B (placebo) achieved 14 consecutive dry nights.

Funding Adverse events:
 None which required treatment.
 Not reported.

Does the study answer the question? Imipramine is more effective than placebo.

Effect due to factor in study? Yes.

Consistency of results with other studies? Similar to other studies comparing imipramine to placebo.

How directly applicable to population of the guideline? Children were aged 5 to 15 years.

Internal Validity Clinicians knew which treatment the children were receiving.

Reference number 349 **Study Type** **Randomised Controlled Trial** RID:
 Kolvin I;Taunch J;Currah J;Garside RF;Nolan J;Shaw WB; 382
 Enuresis: a descriptive analysis and a controlled trial

1972 14 Dev Med Child Neurol pgs 715 726

Number of subjects 94 in total, 35 in group A, 32 in group B and 27 in group C

Inclusion/Exclusion Criteria: Inclusion: aged between 8 and 10 years

Characteristics of subjects or environment/prognostic factor The mean age was 9 years and 4 months.
 Most of the patients had poor toilet facilities, with 35 patients having out-door toilets.
 The mean number of children per family was 3.9.
 14 children had divorced parents.
 44 patients had siblings who had had enuresis and 59 had family members who had had enuresis.

Recruitment: Through a survey of schools.

Setting: At home.

Interventions/Test /Factor being investigated Group A: imipramine
 Group B: alarm (pad and buzzer)
 Group C: placebo

Comparitors Between groups A, B and C

Length of Study/ Follow-up 4 months.

Outcome measures studies Mean number of wet nights.

Results 10% of patients were lost at 4 month follow up.

 The number of children who had greater than 80% improvement in number of dry nights:
 In the imipramine group 16 out of 35 children achieved a greater than 80% improvement in the number of dry nights compared to 17 out of 32 in alarm group.

 Mean number of wet nights at the end of treatment:
 In the imipramine group the mean number of wet nights was 2.3 (sd 3.5) compared to 2.3 (sd 3.2)

 Mean number of wet nights at follow up:
 In the imipramine group the mean number of wet nights at follow up was 3.35 (sd 3) compared to 2.3 (sd 2.3) in the alarm group.

Funding Partially funded by Geigy

Does the study answer the question? The study showed that the alarm group was slow to improve but maintained improvement after treatment was stopped. The imipramine group had a rapid improvement initially but a large decline after treatment was stopped. The placebo group's improvement was seen to remain after treatment was stopped.

Effect due to factor in study? Yes.

Consistency of results with other studies? Similar to other studies with same comparison.

How directly applicable to population of the guideline? Children were aged between 8 and 10 years.

Internal Validity

Reference number 567 **Study Type** **Randomised Controlled Trial** RID:
Lake B; 334

Controlled trial of nortriptyline in childhood enuresis

1968 2 pgs 582 585

Number of subjects Crossover trial with 54 in total.

Inclusion/Exclusion Criteria: Inclusion: aged 5 to 12 years, and wet at least 2 nights out of 14 nights.

Characteristics of subjects or environment/prognostic factor Age range 5 to 12 years and 37 out of 54 were male. The mean baseline wetting for the nortriptyline group was 62% and for the placebo group was 72%. 41 were deep sleepers, 16 came from emotionally disturbed homes, 9 suffered excessive threat, 5 had previous UTI, 17 had parents who were enuretic, and 35 had enuretic siblings.

Recruitment: From nine GP practices.

Setting: GP practices

Interventions/Test /Factor being investigated Group A: nortriptyline
Group B: placebo

Comparitors Nortriptyline compared to placebo

Length of Study/ Follow-up No follow up.

Outcome measures studies Number of wet nights per week and side effects.

Results Patients were split into two groups. Each group received 2 weeks of each treatment with a 2 week washout. Each group had 2 sets of treatments. That is, 16 weeks in total

Some results obtained from Cochrane review.

Number of wet nights during treatment per week:
In the nortriptyline group the mean number of wet nights was 3.56, while in the placebo group the mean number of wet nights was 4.39.

Side effects:
Nortriptyline - one child had a headache, aching arms and sore tummy.
Placebo - 1 child had headache and vomiting, 1 had drowsiness in the car which they never had before, and 11 had dry mouth and sweating.

Funding Dista Products provided nortriptyline and placebo and a grant-in-aid.

Does the study answer the question? Study compared nortriptyline to placebo to show children treated with nortriptyline had fewer wet nights compared to those treated with placebo.

Effect due to factor in study? Yes

Consistency of results with other studies? No other similar studies.

How directly applicable to population of the guideline? Children were aged 5 to 12 years.

Internal Validity Cross over trial with 2 weeks washouts between treatments.

Reference number 74 **Study Type** **Randomised Controlled Trial** RID:
 Lee T;Suh HJ;Lee HJ;Lee JE; 424
 Comparison of effects of treatment of primary nocturnal enuresis with oxybutynin plus desmopressin, desmopressin alone or imipramine alone: a randomized controlled clinical trial
 2005 174 pgs 1084 1087

Number of subjects 145 in total, 48 in group A, 49 in group B and 48 in group C

Inclusion/Exclusion Criteria: Inclusion: at least 3 wet nights a week
 Exclusion: organic causes of NE, drug treatment in previous 14 days

Characteristics of subjects or environment/prognostic factor 100 out of 145 were male, 53% had day time wetting (77 patients). The mean age was 7.8 years (SD 2.5), the age range was 5-15 years, mean baseline wetting was 6.36 (SD 1.5) nights a week

Recruitment: Not reported

Setting: 2 hospitals, between 2003 and 2004

Interventions/Test /Factor being investigated Group A: 0.1 or 0.2 md desmopressin and 5 mg oxybutinin
 Group B: 0.2 mg desmopressin (increased to 0.4 mg if no response)
 Group C: 25 mg imipramine

Comparitors Between treatment groups

Length of Study/ Follow-up none

Outcome measures studies 0-1 wet nights a month, drop out, mean number of wet nights, continued response

Results Treatment was for 6 months, all treatments were given orally before bedtime

Drop outs for all patients:
 13 in total 3 in group A (desmopressin and oxybutylinin), 3 in group B (desmopressin) and 7 in group C (imipramine)

Patients with night time wetting only:
 Mean number of wet nights per week at end of treatment:
 In group A (desmopressin and oxybutylin) the mean number of wet nights was 0.93 (SD 1.35), in group B (desmopressin) the mean number was 0.7 (SD 0.95) and in group C (imipramine) the mean number was 2.0 (2.05)

Number of children with 0-1 wet nights per month:
 In group A (desmopressin and oxybutylin) 14 out of 22 had 0-1 wet nights per month compared to 14 out of 23 in group B (desmopressin) and 3 out of 23 in group C (imipramine).

Patients with night and day time wetting:
 Mean number of wet nights per week at end of treatment:
 In group A (desmopressin and oxybutylin) the mean number of wet nights was 1.2 (SD 1.55), in group B (desmopressin) the mean number was 1.23 (SD 0.88) and in group C (imipramine) the mean number was 2.63 (2)

Number of children with 0-1 wet nights per month:
 In group A (desmopressin and oxybutylin) 9 out of 26 had 0-1 wet nights per month compared to 9 out of 26 in group B (desmopressin) and 3 out of 25 in group C (imipramine).

The mean number of wet nights continued to be reduced
 For the imipramine group the mean baseline wetting was 13.2 (sd 2.9) wet nights per 2 weeks, at 1 month the mean number of wet nights was 17.5 (sd 10.5) per 2 weeks, at 3 months was 11.6 (sd 10) nights per 2 weeks and at 6 months was 9.3 (sd 8.3) nights per 2 weeks.
 For the desmopressin group the mean baseline wetting was 12 (sd 3.5) wet nights per 2 weeks, at 1 month the mean number of wet nights was 8.3 (sd 7.3) per 2 weeks, at 3 months was 4.7 (sd 5.5) nights per 2 weeks and at 6 months was 4 (sd 4.6) nights per 2 weeks.
 For the desmopressin combined with oxybutynin group the mean baseline wetting was 13.3 (sd 3.4) wet nights per 2 weeks, at 1 month the mean number of wet nights was 6.7 (sd 7.9) per 2 weeks, at 3 months was 5.4 (sd 6.9) nights per 2 weeks and at 6 months was 3.7 (sd 5.4) nights per 2 weeks

Funding Not reported

Does the study answer the question?

Effect due to factor in study? Yes

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Yes

Unclear allocation concealment, higher dropout rate in imipramine

Internal Validity

Reference number	1655	Study Type	Randomised Controlled Trial	RID:
Manhas RS;Sharma JD;				348
Tofranil (imipramine) in childhood enuresis: a controlled clinical trail of tofranil (imipramine) in the treatment of 72 cases of childhood enuresis in Kashmir				
1967	66	Indian Pract	pgs 663	669

Number of subjects 72 in total: 29 in imipramine group, 27 in placebo group, 8 in placebo then imipramine, 8 in imipramine then placebo.

Inclusion/Exclusion Criteria: Inclusion: regular and consistent bed wetting and aged 5 to 15 years
 Exclusion: organic causes of NE.

Characteristics of subjects or environment/prognostic factor The age range was 5 to 15 years.
 No baseline characteristics given.

Recruitment: Not reported.

Inclusion/Exclusion Criteria:	Inclusion: 3 wet nights per week for more than 6 months. Exclusion: organic causes of NE, organic heart disease, hyperthyroidism, glaucoma, diabetes, kidney or liver disease, those taking thyroid, MAO inhibitors, or anticholinergic.
Characteristics of subjects or environment/prognostic factor	42 out of 57 were boys, and the age range was 5 to 15 years. 3 were aged 4 to 6 years, 12 were aged 6 to 8 years, 18 were aged 8 to 10 years, 16 were aged 10 to 12 years, 4 were aged 12 to 14 years, 4 were aged 14 to 15 years. Baseline mean number of wet nights in 26 nights was 20.7.
Recruitment:	Not reported
Setting:	Not reported
Interventions/Test /Factor being investigated	Group A: 10 mg imipramine pamoate (suspension) Group B: 25 mg imipramine pamoate (suspension) Group C: placebo all treatments were given 1 hour before bed time.
Comparitors	Between treatment groups.
Length of Study/ Follow-up	None
Outcome measures studies	Mean number of wet nights. Number of drop outs. Number of side effects.
Results	26 days of each treatment Mean number of wet nights in 26 nights: The 10 mg imipramine group had a mean number of wet nights of 13.7 (sd 4.12), the 25 mg imipramine group had a mean number of wet nights of 10.5 (sd 6.03), and the placebo group had a mean number of wet nights of 16.8 (sd 6.49). There were no drop outs. Side effects: In the 25 mg imipramine group: 4 children had anxiety, 3 had sleep disturbances, 1 had abdominal pain In the 10 mg imipramine group: 2 children had anxiety, 1 had constipation, 5 had sleep disturbances, 1 had abdominal pain, 2 lost weight In the placebo group: 1 child had anxiety, 1 had constipation, 3 had sleep disturbances, 1 had abdominal pain, and 2 lost weight.
Funding	Geigy Pharmaceuticals, Ardsley, NY
Does the study answer the question?	The study compared 25 mg imipramine to 10 mg imipramine and placebo, to show that 25 mg was the most effective treatment. 10 mg was also more effective than placebo.
Effect due to factor in study?	Yes
Consistency of results with other studies?	Results are similar to other studies comparing imipramine to placebo.
How directly applicable to population of the guideline?	Children were aged 5 to 15 years.

Internal Validity cross over trial, no wash out

Reference number 1661 **Study Type** **Randomised Controlled Trial**

Poussaint AF;Ditman KS;

RID:
349

A controlled study of Imipramine (Tofranil) in the treatment of childhood enuresis

08 February 2010

Page 203 of 244

Number of subjects	54 children were selected for treatment. 47 were treated and 7 were excluded (5 withdrew). N=13 in group 1, n=13 in group 2, n=10 in group 3 and n=11 in group 4.
Inclusion/Exclusion Criteria:	Inclusion criteria: high-frequency enuretic children; all had normal urinalyses (except one with diabetes who had it in good control). No organic factors to account for the enuresis.
Characteristics of subjects or environment/prognostic factor	Exclusion criteria: Those who were infrequently enuretic - e.g once per week. Aged 5 to 16 years old. 11 of the patients who were selected were female and 43 male. High frequency enuretic children.
Recruitment:	10 were selected from pediatric and psychiatric clinic files. 44 were referred by private physicians.
Setting:	Not explicit but maybe outpatients at UCLA, USA.
Interventions/Test /Factor being investigated	The children were allocated to four groups who received treatment for 8 weeks: 1. Imipramine (4 weeks), then placebo (4 weeks) - 13 patients. 2. Placebo (4 weeks), then imipramine (4 weeks) - 13 patients. 3. Imipramine (4 weeks), then imipramine (4 weeks) - 10 patients. 4. Placebo (4 weeks), then placebo (4 weeks) - 11 patients. A medical and social history was given by the parents; The parents and child were shown how to chart the time of dosage of medication (1/2 to 1 hour before bedtime) and to record 'wet' and 'dry' nights on the forms provided; When prescriptions were refilled (every week or two) the parents were to return the completed forms; on these occasions there were also 10-15 minute interviews with parents to discuss the treatment results, including side effects (the children were not seen unless indicated). The hospital pharmacy dispensed imipramine (coded drug) and placebo. Dosages were fixed at 25mg of imipramine for children under 12 years and 50mg for children 12 or over.
Comparitors	Crossover study four groups: 1. Treatment followed by placebo. 2. Placebo followed by treatment. 3. Treatment followed by treatment. 4. Placebo followed by placebo.
Length of Study/ Follow-up	8 weeks. End of study treatment period.
Outcome measures studies	Number of wet nights in each 4 week period of treatment compared to the average frequency of wet nights reported for the 4 week period prior to treatment and rated on a scale. Side effects.
Results	There were 7 drop-outs (5 withdrew, 2 excluded) - some could not swallow the tablets, or feared the drugs; one developed a bladder infection while receiving the placebo and one appeared to be psychotic. Results from Cochrane as results in paper was in graph form: For the crossover trial: Imipramine was better than placebo in 69%, equal in 23% and the placebo was better than drug in 8% ($p < 0.0005$). No. of children totally dry: imipramine group=6, placebo group=1 (no relapses). Only relapses were when medication abruptly withdrawn - all had medication restored. Side effects: more irritable (8) dizziness (1), dry mouth (1), decreased appetite (1) - similar complaints were reported by children receiving placebo (for the last three side effects).

When the 8 week period was finished all of the children who were still wet received an increased dose of 75mg. Eleven children became completely dry and remained so after imipramine was gradually withdrawn following 2 months of complete dryness with the medication. The only patients who relapsed were those in whom the medication was abruptly withdrawn. Therefore in follow up 24% of children were 'cured' by imipramine.

Funding	Not stated.
Does the study answer the question?	Imipramine (a tricyclic) was shown to be more beneficial than placebo in showing a decrease in enuretic nights.
Effect due to factor in study?	No.
Consistency of results with other studies?	Similar to other studies comparing imipramine and placebo.
How directly applicable to population of the guideline?	Direct.
Internal Validity	Urinalysis was given by own physician. No washout period. Results given in graphs and no standard deviations.
Reference number	309
Study Type	Randomised Controlled Trial
Smellie JM;McGrigor VS;Meadow SR;Rose SJ;Douglas MF;	RID: 317
Nocturnal enuresis: a placebo controlled trial of two antidepressant drugs	
1996 75	pgs 62 66
Number of subjects	80 in total 25 in imipramine group, 29 in placebo group (other groups not included in this review)
Inclusion/Exclusion Criteria:	Inclusion: Exclusion: organic causes of NE
Characteristics of subjects or environment/prognostic factor	In the imipramine group 19 out of 25 were boys and in the placebo group 24 out of 29 were boys. Age range was 5 to 13 years. In the imipramine group 9 were aged 5 to 6 years, 7 were aged 7 to 9 years, 9 were aged 10 to 13 years; in the placebo group 10 were aged 5 to 6 years, 12 were aged 7 to 9 years and 7 were aged 10 to 13 years. The baseline mean number of dry nights per week was 1.6 in the imipramine group and 1 in the placebo group.
Recruitment:	Participants were referred from hospital or community child health enuretic clinics by GP, paediatricians, paediatric urologists or school doctors.
Setting:	UK
Interventions/Test /Factor being investigated	Group A: 25mg imipramine Group B: placebo Study also considered mianserin which is not included in this review
Comparitors	Comparison is between imipramine and placebo.
Length of Study/ Follow-up	4 weeks

Outcome measures studies	Mean number of dry nights.
Results	Data presented in graphs - figures obtained from cochrane review Treatment for 8 weeks Mean number of dry nights in week 6: The imipramine group had a mean number of dry nights of 5, and the mean number of dry nights for the placebo group was 2.5. Number of children who achieved 14 consecutive dry nights were 11 out of 25 in the imipramine group had 7 dry nights compared to 4 out of 29 in the placebo group. Mean number of wet nights: In the imipramine group the mean number of wet nights was 2 compared to 4.5 in the placebo group. % of patients who had improvement after 4 weeks without treatment (follow up): 74% in the imipramine had improvement after 4 weeks compared to 59% in the placebo group.
Funding	Not reported
Does the study answer the question?	Study compared imipramine to placebo and results showed that more children in the imipramine group achieved 7 dry nights and continued to show improvement after 4 weeks follow up.
Effect due to factor in study?	Yes
Consistency of results with other studies?	Similar to other studies comparing imipramine and placebo.
How directly applicable to population of the guideline?	Children were aged 5 to 13 years

Internal Validity

Reference number	201	Study Type	Randomised Controlled Trial	RID:
Tahmaz L;Kibar Y;Yildirim I;Ceylan S;Dayanc M;				402
Combination therapy of imipramine with oxybutynin in children with enuresis nocturna				
2000	65		pgs 135	139

Number of subjects	77 in total: 14 in Group A, 16 in Group B, 24 in Group C and 23 in Group D.
Inclusion/Exclusion Criteria:	Inclusion: primary monosymptomatic NE, wet at least 3 nights a week, and no current treatment Exclusion: organic causes of NE, day time wetting, or UTI.
Characteristics of subjects or environment/prognostic factor	48 out of 77 were boys. The mean age was 9.44 (SD 2.17) years (range 6-14 years).
Recruitment:	Patients at Dept Urology, Military Medical Faculty, Turkey.
Setting:	Dept Urology, Military Medical Faculty, Turkey
Interventions/Test /Factor being investigated	Group A (14) imipramine 0.9-1.5 mg/kg/day B (16): oxybutinin 5 mg 3x/day C (24): imipramine + oxybutinin D (23): placebo (not described)

Comparitors	Between treatment groups.
Length of Study/ Follow-up	6 months
Outcome measures studies	Achievement of >90% reduction in number of wet nights, relapse at 6 months, adverse events, drop outs
Results	<p>3 months of treatment.</p> <p>>90% reduction in number of wet nights: 7 out of 14 in group A (imipramine) achieved >90% reduction in wet nights compared to 6 out of 16 in group B (oxybutinin), 16 out of 24 in group C (imipramine and oxybutinin) and 5 out 23 in group D (placebo)</p> <p>Relapsed at 6 months: In group A (imipramine) 5 out of 7 had relapsed at 6 months compared to 5 out of 6 in group B (oxybutinin), 4 out of 16 in group C (imipramine and oxybutinin) and 2 out of 5 in group D (placebo).</p> <p>50% improvement 5 out of 14 in group A, 6 out of 16 in group B, 6 out of 24 in group C and 8 out of 23 in group D</p> <p>Adverse events (dry mouth or nausea): In group A (imipramine) 3 out of 14 had adverse events compared to 4 out of 16 in group B (oxybutinin), 7 out of 24 in group C (imipramine and oxybutinin) and 4 out of 23 in group D (placebo)</p> <p>If completely cured patients were slowly taken off treatment.</p>
Funding	Not reported
Does the study answer the question?	All drug treatments were more effective than placebo. Imipramine combined with oxybutinin was most effective.
Effect due to factor in study?	Yes.
Consistency of results with other studies?	Consistent with other similar studies.
How directly applicable to population of the guideline?	Age range 6-14 years.
Internal Validity	Unclear allocation concealment.
Reference number	1663
Study Type	Randomised Controlled Trial
Treffert DA;	
An evaluation of imipramine in enuresis	
1964 121 Am J Psychiatry	pgs 178 179
Number of subjects	9
Inclusion/Exclusion Criteria:	Inclusion: NE

RID:
350

Characteristics of subjects or environment/prognostic factor	All patients were boys. The mean baseline wetting was 2.9 time a week. Children were in Winebago State Hospital which is a hospital for neurotic, psychotic, brain injured boys
Recruitment:	Children in Winebago State Hospital (hospital for neurotic, psychotic, brain injured boys)
Setting:	Winebago State Hospital
Interventions/Test /Factor being investigated	Group A: imipramine (25mg for children under 12 years, 50 mg for children over 12 years) Group B: placebo
Comparitors	between imipramine and placebo
Length of Study/ Follow-up	4 weeks
Outcome measures studies	number of wet nights
Results	Treatment for 4 weeks of each, data obtained from cochrane review Number of wet nights during treatment: In group A (imipramine) the number of wet nights was 1.86, in group B (placebo) the mean number of wet nights was 2.36.
Funding	Geigy Pharmaceuticals supplied imipramine and placebo
Does the study answer the question?	The study compared imipramine to placebo to show children treated with imipramine had fewer wet nights per week compared to children treated with placebo
Effect due to factor in study?	Yes
Consistency of results with other studies?	Similar to other studies comparing imipramine and placebo
How directly applicable to population of the guideline?	Children were aged 6 to 18 years
Internal Validity	cross over trial, no washout

Reference number 297

Study Type

Randomised Controlled Trial

RID:

Vertucci P;Lanzi C;Capece G;Fano M;Gallai V;Margari L;Mazzotta G;Menegati E;Ottaviano S;Perini A;Perniola T;Roccella M;Tiberti A;Vecchio A;Biraghi M;

259

Desmopressin and imipramine in the management of nocturnal enuresis: a multicentre study

1997 51

pgs 27

31

Number of subjects	57 in total, 29 who received desmopressin then imipramine, 28 who received imipramine then desmopressin.
Inclusion/Exclusion Criteria:	Inclusion: primary NE aged over 5 years, wet at least 3 nights a week, and parental consent. Exclusion: organic or neurological dysfunction of the urinary system.
Characteristics of subjects or environment/prognostic factor	The age range was 6 to 15 years. The mean age was 10 years. 37 out of 57 were male.
Recruitment:	Children at Child Neuropsychiatry clinics in Italy
Setting:	Child Neuropsychiatry Clinics Italy
Interventions/Test /Factor being investigated	Group A: Desmopressin 30 mcg intranasal then imipramine 0.9 mg/kg Group B: Imipramine 0.9 mg/kg then desmopressin 30 mcg intranasal
Comparitors	Between desmopressin and imipramine.
Length of Study/ Follow-up	2 weeks
Outcome measures studies	Number of wet nights, 14 consecutive dry nights, drop outs, and side effects.
Results	Data was presented in graphs - data presented below was from Cochrane review Treatment was for 3 weeks of each. Mean number of wet nights during first arm of trial In Group A (desmopressin) the mean number of wet nights was 1, in Group B (imipramine) the mean number of wet nights was 2.8. Number who achieved 14 consecutive dry nights: 25 out of 29 achieved 14 consecutive dry nights when treated with desmopressin compared to 19 out of 28 who were treated with imipramine. Mean number of wet nights after both drugs had been used: In group A (desmopressin then imipramine) the mean number of wet nights was 3.5 compared to 2.8 in group B (imipramine then desmopressin). Drop outs: 5 in total Side effects: Desmopressin: 1 had back pain, 1 had an inflamed nasal mucosa Imipramine: 1 had pallor, restlessness and cold extremities
Funding	Not reported
Does the study answer the question?	Study compared desmopressin to imipramine to show that both reduced the number of wet nights. However desmopressin was more effective than imipramine.
Effect due to factor in study?	Yes
Consistency of results with other studies?	
How directly applicable to population of the guideline?	Children were aged 6 to 15 years.

Cross over trial and no wash out.

Internal Validity

Reference number 143 **Study Type** **Randomised Controlled Trial** RID:
Wagner W;Johnson SB;Walker D;Carter R;Wittner J; 381
A controlled comparison of two treatments for nocturnal enuresis

1982 101 pgs 302 307

Number of subjects 49 in total, 12 in each group

Inclusion/Exclusion Criteria: Inclusion: aged 6-16 years, IQ greater than 70, primary NE, no physical or neurological disorders, wet at least 3 times a week, no treatment for NE in previous year, and agreed to be randomised.
Exclusion: day time wetting.

Characteristics of subjects or environment/prognostic factor The mean age was 7.9 years. The baseline % of nights wet for group A (alarm) was 75%, group B (imipramine) 77.33% and group C (waiting list) 64.33%. There was no significant difference between groups in % of nights wet.

Recruitment: From local paediatric clinics and private physicians, adverts in newspapers and on TV, and contact with local schools

Setting: Florida, USA and treatment was administered at home

Interventions/Test /Factor being investigated Group A: alarm (pad and bell)
Group B: imipramine
Group C: control - no treatment, waiting list

Comparators Between groups A, B and C

Length of Study/ Follow-up 44 days.

Outcome measures studies Number of patients dry for 14 consecutive nights,% of wet nights, and relapse.

Results Treatment for 14 weeks or until dry for 14 nights

There were no results for the alarm and placebo group
Dry for 14 consecutive nights:
In group A (alarm) 10 out of 12 achieved dryness for 14 consecutive nights compared to 4 out of 12 in group B (imipramine) and 1 out of 12 in group C (waiting list)

% of wet nights:
The study showed that by the final treatment week, group A was significantly more successful than B and C (8.25% compared to 39.25% and 60.83%)

Relapse:
Relapse was defined as 3 wet nights in a 2 week period.
Of the children who achieved 14 nights dry In group A (alarm) 5 out of 10 relapsed compared to 4 out of 4 in group B (imipramine) and 1 out of 1 in group C (waiting list).

Funding None reported.

Does the study answer the question? The study showed that giving a child an alarm was more successful than imipramine and a control waiting list group in achieving 14 dry nights (83% compared to 33% and 8%). The study also showed that the patients receiving alarm therapy had only a 50% relapse rate compare to 100% in both the imipramine group and waiting list group.

Effect due to factor in study? Yes.

Consistency of results with other studies? Similar to other studies with same comparison.

How directly applicable to population of the guideline? Age range 6-16 years.

Internal Validity

Grading: 2+	<i>Well-conducted case-control or cohort studies with a low risk of confounding, bias or chance and a</i>
--------------------	--

Reference number	1799	Study Type	Cohort	RID:	
Bain DJ;					945
A criticism of the use of tricyclic antidepressant drugs in the treatment of childhood enuresis					
1973	23			pgs	222 224

Number of subjects	53 cases
Inclusion/Exclusion Criteria:	Children had imipramine poisoning
Characteristics of subjects or environment/prognostic factor	Not reported
Recruitment:	Cases of imipramine poisoning in 1968 and 1970
Setting:	UK
Interventions/Test /Factor being investigated	Imipramine
Comparitors	No comparison
Length of Study/ Follow-up	Not reported
Outcome measures studies	Side effects
Results	In 1968 17 cases of poisoning were reported, by 1970 there were 36 cases. The study reported one author collected the reason for 20 deaths in children from imipramine poisoning, only one of these was from a drug prescribed for the child who died from nocturnal enuresis
Funding	Not reported
Does the study answer the question?	In 1968 17 cases of imipramine poisoning were reported, by 1970 there were 36 cases
Effect due to factor in study?	Yes
Consistency of results with other studies?	
How directly applicable to population of the guideline?	Patients were not all being treated for NE

Internal Validity

Reference number 1773 **Study Type** **Cohort** RID:
 Goel KM;Shanks RA; 944
 Amitriptyline and imipramine poisoning in children
 1974 1 pgs 261 263

Number of subjects 60 cases reviewed

Inclusion/Exclusion Criteria: Children had amitriptyline or imipramine poisoning

Characteristics of subjects or environment/prognostic factor Not reported

Recruitment: Cases of poisoning in children between January 1966 and July 1973

Setting: UK

Interventions/Test /Factor being investigated Amitriptyline or imipramine

Comparitors No comparison

Length of Study/ Follow-up Not reported

Outcome measures studies Side effects

Results The study identified 60 cases of poisoning in total, 16 of which were from the medication prescribed for the child poisoned for the treatment of nocturnal enuresis. The study reported the cases of poisoning from amitriptyline and imipramine prescribed for the treatment of nocturnal enuresis. The study reported the cardiovascular features of poisoning (prescribed for both nocturnal enuresis and depression, the study did not separate out the results for the two groups). From amitriptyline poisoning 24 children had sinus tachycardia, 2 children had sinus arrhythmia, 2 children had ventricular premature systole, 0 children had conduction disturbances, 1 child had hypotension and 1 child had cardiorespiratory arrest. From imipramine poisoning 12 children had sinus tachycardia, 2 children had sinus arrhythmia, 1 child had ventricular premature systole, 2 children had conduction disturbances, 2 children had hypotension and 2 children had cardiorespiratory arrest. The study also reported neurological and atropinic features of poisoning, from amitriptyline 36 patients had drowsiness, 17 had agitation and / or restlessness, 16 had ataxis, 5 had mydriasis, 9 had vomiting, 8 had flushing of the face, 1 had coma, 6 had convulsions, 4 had hyperreflexia, 2 had retention of urine, 3 had hallucinations, 1 had dysarthria and 2 had nystagmus. From imipramine 12 patients had drowsiness, 7 had agitation and / or restlessness, 1 had ataxis, 8 had mydriasis, 3 had vomiting, 3 had flushing of the face, 2 had coma, 2 had convulsions, 1 had hyperreflexia, 2 had retention of urine, 0 had hallucinations, 1 had dysarthria and 0 had nystagmus. The study did not report the doses of the medication prescribed or taken

Funding Not reported

Does the study answer the question? The study reported the cases of poisoning from amitriptyline and imipramine prescribed for the treatment of nocturnal enuresis.

Effect due to factor in study? Yes

Consistency of results with other studies?

How directly applicable to population of the guideline? The study considered cases of poisoning in children treated for NE or depression, results were not separated out

Internal Validity

Reference number 978 **Study Type** **Cohort** RID: 569
 Monda JM;Husmann DA;
 Primary nocturnal enuresis: a comparison among observation, imipramine, desmopressin acetate and bed-wetting alarm systems
 1995 154 PGS 745 748

Number of subjects 44 in total

Inclusion/Exclusion Criteria: Inclusion: primary monosymptomatic nocturnal enuresis, 3 or wet nights per week
 Exclusion: diurnal urinary incontinence, voiding dysfunction

Characteristics of subjects or environment/prognostic factor The age range was 6 to 14 years, the median age was 9 years

Recruitment: Attending investigators clinic

Setting: Minnesota, USA

Interventions/Test /Factor being investigated 1 mg/kg imipramine, increased to 1.5 mg/kg if still wetting after 2 weeks. Given 30 to 45 minutes before going to bed

Comparitors Study also considered desmopressin and alarms, however already have RCT evidence of these treatments for monosymptomatic children

Length of Study/ Follow-up 12 months

Outcome measures studies Dry (only 0 to 1 wet nights per month), side effects

Results 6 months of treatment after which the child was weaned off the treatment over 4 weeks, by reducing the dose by half for 2 weeks, after which this dose was given every other night for a further 2 weeks then stopped

Patients were required to keep a diary of wet and dry nights

0 to 1 wet nights per month:
 14 out of 44 children achieved only 0 to 1 wet nights per month after 6 months of treatment
 At 12 month follow up 7 out of 44 children had 0 to 1 wet nights per month

Side effects:
 3 children reported hyperactivity

Funding	Not reported
Does the study answer the question?	The study showed children with monosymptomatic NE treated with imipramine can become dry after 6 month of treatment
Effect due to factor in study?	Yes
Consistency of results with other studies?	No other studies
How directly applicable to population of the guideline?	Median age 9 years

Internal Validity

Question: What is the clinical and cost effectiveness of anticholinergic drugs for children and young people under 19 years old who have nocturnal enuresis?

19

Grading: 1-	Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*
--------------------	---

Reference number 636 Study Type **Randomised Controlled Trial** RID: 99
 Esmaeili M;

Combined treatment with oxybutynin and imipramine in enuresis

2008 33 pgs 12 16

Number of subjects 89 in total: 29 in imipramine group, 26 in oxybutinin group and 34 in imipramine and oxybutinin group.

Inclusion/Exclusion Criteria: Inclusion: primary NE, wet at least 2 nights a week for preceding 3 months, never been dry for more than 6 months
 Exclusion: voiding dysfunction other than primary NE, urologic and neurological abnormalities, prior pharmacological treatment, UTI, or diurnal enuresis.

Characteristics of subjects or environment/prognostic factor The mean age was 8.9 (SD 1.6) years, age range 6-14 years. The mean baseline wetting was 5.1 (SD 1.1) nights per week.

Recruitment: Patients were referred to the pediatric nephrology clinic at Mashhad University of Medical Sciences between November 2003 and March 2004.

Setting: Iran

Interventions/Test /Factor being investigated Group A: 10-25 mg imipramine
 Group B: 3.75-5 mg oxybutinin
 Group C: imipramine and oxybutinin

Comparitors Between treatment groups

Length of Study/ Follow-up 1 month

Outcome measures studies Dry for 14 consecutive nights, mean number of wet nights per week during treatment

Results 1 month of treatment
 Number of children who achieved 14 consecutive dry nights:
 4 out of 29 children in group A (imipramine) group were cured, compared to 6 out of 26 in group B (oxybutinin) and 14 out of 34 in group C (imipramine and oxybutinin).
 The mean number of wet nights per week during treatment:
 The mean number of wet nights per week during treatment was 3.5 (SD 2) for group A (imipramine), the mean for group B (oxybutinin) was 2.5 (SD 1.7) and for group C (imipramine and oxybutinin) the mean was 1.4 (SD 1.5)

Funding Not reported.

Does the study answer the question? The study showed that the most effective treatment was imipramine combined with oxybutinin.

Effect due to factor in study? Yes

Consistency of results with other studies? Consistent with other similar studies.

How directly applicable to population of the guideline? Age range 6-14 years.

Internal Validity

Reference number	201	Study Type	Randomised Controlled Trial	RID:
	Tahmaz L;Kibar Y;Yildirim I;Ceylan S;Dayanc M;			285
	Combination therapy of imipramine with oxybutynin in children with enuresis nocturna			
2000	65		pgs 135	139
Number of subjects	77 in total (Group A n=14, group B n=16, Group C n=24, Group D n=23)			
Inclusion/Exclusion Criteria:	Inclusion: primary monosymptomatic NE, wet at least 3 nights a week, and no current treatment. Exclusion: organic causes of NE, day time wetting, or UTI.			
Characteristics of subjects or environment/prognostic factor	48 out of 77 were boys. The mean age was 9.44 (SD 2.17) years (range 6-14 years).			
Recruitment:	Patients at Dept Urology, Military Medical Faculty, Turkey			
Setting:	Dept Urology, Military Medical Faculty, Turkey			
Interventions/Test /Factor being investigated	Group A (14) imipramine 0.9-1.5 mg/kg/day B (16): oxybutinin 5 mg 3x/day C (24): imipramine + oxybutinin D (23): placebo (not described)			
Comparitors	Between treatments.			
Length of Study/ Follow-up	6 months			
Outcome measures studies	>90% reduction in number of wet nights, 50-90% improvement in number of dry nights, relapse at 6 months, and adverse events.			
Results	3 months of treatment. >90% reduction in number of wet nights: 7 out of 14 in group A (imipramine) achieved >90% reduction in wet nights compared to 6 out of 16 in group B (oxybutinin), 16 out of 24 in group C (imipramine and oxybutinin) and 5 out 23 in group D (placebo). 50-90% reduction in number of wet nights: 5 out of 14 in group A (imipramine) achieved 50-90% reduction in wet nights compared to 6 out of 16 in group B (oxybutinin), 6 out of 24 in group C (imipramine and oxybutinin) and 8 out 23 in group D (placebo). Relapsed at 6 months: In group A (imipramine) 5 out of 7 had relapsed at 6 months compared to 5 out of 6 in group B (oxybutinin), 4 out of 16 in group C (imipramine and oxybutinin) and 2 out of 5 in group D (placebo). Adverse events (dry mouth or nausea): In group A (imipramine) 3 out of 14 had adverse events compared to 4 out of 16 in group B (oxybutinin), 7 out of 24 in group C (imipramine and oxybutinin) and 4 out of			

	23 in group D (placebo).
	If completely cured, patients were slowly taken off treatment.
Funding	Not reported
Does the study answer the question?	All drug treatments were more effective than placebo. Imipramine combined with oxybutinin was most effective.
Effect due to factor in study?	Yes
Consistency of results with other studies?	Consistent with other similar studies.
How directly applicable to population of the guideline?	Age range 6-14 years.
Internal Validity	Unclear allocation concealment

Question: What is the clinical and cost effectiveness of information and educational interventions for children and young people under 19 years old who have nocturnal enuresis?

20

Grading: 1-	Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*
--------------------	---

Reference number 1753 Study Type **Randomised Controlled Trial** RID: 396
 Redsell SA; Collier J; Garrud P; Evans JH; Cawood C;
 Multimedia versus written information for nocturnal enuresis education: a cluster randomized controlled trial
 2003 29 pgs 121 129

Number of subjects 270 in total, 108 in Group A (the "CD" group), 87 in Group B (the "Written" group), and 75 in Group C (the "Alarm only").

Inclusion/Exclusion Criteria: Inclusion: primary or secondary NE.
 Exclusion: treatment for NE in previous 6 months.

Characteristics of subjects or environment/prognostic factor Mean age 7.98 years (sd 2.23) and age range 5 to 16 years.
 176 out of 270 were male, 90.3% had primary NE, and 20.7% had secondary NE.

Recruitment: Schools.

Setting: School nurse-led enuresis clinics Leicestershire.

Interventions/Test /Factor being investigated Group A: multimedia CD rom, "all about nocturnal enuresis" to use which had 10 minute modules on "welcome to the clinic, how your bladder works, why some children wet the bed, boss of your bladder, treatments, information for grown ups, knowledge tree", children were given a suggested order to watch the modules in Group B: written leaflets, 6 leaflets with same information as the CD rom
 Group C: control group
 All children had 4 weeks of star charts and then alarm treatment

Comparitors Between groups

Length of Study/ Follow-up 6 months

Outcome measures studies Number of children who achieved 14 consecutive dry nights, number of children who relapsed at 6 months

Results 6 months of treatment

Number of children who achieved 14 consecutive dry nights:
 In Group A (CD rom) 51 out of 108 children achieved 14 consecutive dry nights compared to 41 out of 87 in Group B (written) and 36 out of 75 in Group C (alarm alone).

Number of children who failed or relapsed at 6 months:
 In Group A (CD rom) 30 out of 51 children relapsed compared to 15 out of 41 in Group B (written) and 18 out of 36 in Group C (alarm alone)

Funding Trent region NHS executive, UK.

Does the study answer the question? The study showed there was no statistically significant difference between the two types of information. However children who had the CD rom were more likely to relapse at 6 months.

Effect due to factor in study? Yes

Consistency of results with other studies? No other studies considered educational interventions.

How directly applicable to population of the guideline? Patients had a mean age of 7.98 years.

Internal Validity Adequate allocation concealment.

Question: What is the clinical and cost effectiveness of psychological interventions for children and young people under 19 years old who have nocturnal enuresis?

22

Grading: 1-	Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*
--------------------	---

Reference number 384 Study Type **Randomised Controlled Trial** RID:
 lester A;Marchesi A;Cohen A;Iester M;Bagnasco F;Bonelli R; 920

Functional enuresis: pharmacological versus behavioral treatment

1991 7 pgs 106 108

Number of subjects 168 in total, 36 in Group A (imipramine), 36 in Group B (3 step program) and 96 in Group C (counselling, 3 step program and education).

Inclusion/Exclusion Criteria: Inclusion: functional enuresis.
 Exclusion: organic causes of NE or emotional disturbance.

Characteristics of subjects or environment/prognostic factor The age range was 6 to 11 years.

Recruitment: Patients seen between 1979 and 1988.

Setting: Genoa University, Genova, Italy.

Interventions/Test /Factor being investigated Group A: imipramine for 6 weeks 0.9-1.5mg/kg maximum dosage 50 mg
 Group B: 3 step program of reassurance to parents, bladder control training and waking with an alarm clock before micturition, parental involvement
 Group C: motivational therapy and 3 step program

Comparitors Between treatment groups.

Length of Study/ Follow-up 12 month follow up.

Outcome measures studies Number of children who achieved 14 consecutive dry nights, and relapse after 12 months.

Results Children in the three step program (Group B) had 1) reassurance to the parents and tried to encourage the child; 2) bladder retention training (drink more during the morning and afternoon, reduce the number of times voided during the day, trying to hold for at least 8 hours and interrupt voiding – stop start training) and behaviour training (drink as little as possible after 7 pm, urinate before going to bed and wake up once or twice using an alarm clock); 3) parents were involved in the treatment to help the child practice and avoid family conflicts. Children in the motivation therapy group (Group C) had the 3 step program as described and motivational therapy where children, in a group, discussed their problems with a psychiatrist.

Treatment was for 6 months.

Number of children who achieved 14 consecutive dry nights
 In Group A (imipramine) 14 out of 36 achieved 14 consecutive dry nights compared to 24 out of 36 in Group B (3 step program) and 81 out of 96 in Group C (counselling, 3 step program and education).

Relapse after 12 months
 In Group A (imipramine) 2 out of 14 relapsed compared to 2 out of 24 in Group B (3 step program) and 3 out of 81 in Group C (counselling, 3 step program and education).

Funding Not reported

Does the study answer the question? The study showed that more children treated with counselling, 3 step program and education achieved 14 consecutive dry nights compared to imipramine or the 3 step program.

Effect due to factor in study? Yes

Consistency of results with other studies? No other similar studies.

How directly applicable to population of the guideline? Children were aged 6 to 11 years.

Internal Validity

Reference number 370 **Study Type** **Randomised Controlled Trial** RID: 921
 Ronen T;Wozner Y;Rahav G;
 Cognitive intervention in enuresis
 1992 14 pgs 1 14

Number of subjects 77 in total, 20 in Group A (counselling), 19 in Group B (alarm), 20 in Group C (star chart), 18 in Group D (waiting list).

Inclusion/Exclusion Criteria: Inclusion: aged over 5 years, children attending a community mental health clinic with primary NE.
 Exclusion: organic causes of NE, or mental or developmental problems.

Characteristics of subjects or environment/prognostic factor The mean age was 10.05 (sd 2.28) years, the mean baseline wetting over 3 weeks in Group A (counselling) was 19.8 (sd 1.73), in Group B (alarm) it was 19.8 (sd 2.14), in Group C (star chart) it was 18.9 (sd 2.21) and in Group D (waiting list) it was 18 (sd 8.72)

Recruitment: Children attending a community mental health clinic with primary NE

Setting: Israel

Interventions/Test /Factor being investigated Group A: Cognitive and behavioural self-control education therapy
 Group B: Pad and bell alarm
 Group C: star chart - stars were given for a dry night
 Group D: waiting list

Comparitors Between treatment groups.

Length of Study/ Follow-up 6 months follow up

Outcome measures studies Number dry for 3 consecutive weeks, mean number of wet nights in 3 weeks at the end of treatment, failed or relapse after 6 months,and drop out rate.

Results Stars were given as a reward for a dry night; cognitive behaviour therapy comprised parents and children being taught 5 components of "modification of misconceptions and irrational beliefs; rational analysis of bedwetting; sensitization to pressure in bladder; self-control training in different situations; exercises in self-observation, charting,. Self assessment and self-reinforcement".

Treatment was for 18 weeks

Number of children who were dry for 3 consecutive weeks
 In Group A (counselling) 15 out of 20 children were dry for 3 consecutive weeks compared to 12 out of 19 in Group B (alarm), 6 out of 20 in Group C (star chart) and 0 out of 18 in Group D (waiting list).

Mean number of wet nights in 3 weeks at the end of treatment:
 The mean number of wet nights over 3 weeks at the end of treatment in group A (counselling,n= 18 children) was 1.03 (sd 2.15), in Group B (alarm, n= 15 children)

mean was 1.23 (sd 5.28), in Group C (star chart, n= 14 children) mean was 3.33 (sd 5.8) and in Group D (waiting list, n= 16 children) mean was 17.22 (sd 9).

Number of children who failed or relapsed after 6 months
 In Group A (counselling) 3 out of 18 children failed or relapsed compared to 9 out of 15 in Group B (alarm) and 8 out of 14 in Group C (star chart).

Drop out:
 In Group A (counselling) 2 out of 20 children dropped out compared to 4 out of 19 in Group B (alarm), 6 out of 20 in Group C (star chart) and 11 out of 18 in Group D (waiting list).

Funding Not reported

Does the study answer the question? The study shows children treated with counselling or alarms were more successful than the other treatment groups.

Effect due to factor in study? Yes

Consistency of results with other studies? No other similar studies.

How directly applicable to population of the guideline? Children were aged over 5 years.

Internal Validity

Reference number	355	Study Type	Randomised Controlled Trial	RID:
Werry JS;COHRSEN J;				919
Enuresis: an etiologic and therapeutic study				
1965 67	J Pediatr		pgs 423	431

Number of subjects 42 in total, 21 in group A, 21 in group B

Inclusion/Exclusion Criteria:
 Inclusion: never been dry for longer than 3 months, wet at least once a week
 Exclusion: organic cause of NE

Characteristics of subjects or environment/prognostic factor
 NE patients the mean age was 9.79 (2.34 SD) years and 62% were boys

Recruitment: From enuresis clinic in a paediatric outpatients clinic of the Montreal Children's Hospital

Setting: Montreal, Canada, treatment at home

Interventions/Test /Factor being investigated
 Group A: alarm
 Group B: psychotherapy - 6 to 8 sessions over 3 months
 The study compared to non NE siblings – not a relevant comparison so not included in the question

Comparitors Between groups A and B

Length of Study/ Follow-up 4 months

Outcome measures studies Dry for 14 consecutive nights, psychologic effects

Results	<p>Treatment was until the child became dry (at least one month) or up to 4 months when the trial ended. At the end of 4 months parents were called to report how many times the child had been wet in the preceding month.</p> <p>14 consecutive dry nights: In group A (alarm) 7 out of 22 children achieved 14 consecutive dry nights compared to 2 out of 21 in group B (psychotherapy)</p> <p>Psychological effect: There was no significant differences in the psychological changes between the treatment groups. The type of treatment did not affect the psychological improvement all children improved.</p> <p>The authors noted that alarm treatment was more economic as it required less professional input than the psychotherapy treatment.</p>
Funding	Not reported
Does the study answer the question?	The results showed that children treated with an alarm were more likely to be dry for a month when the results were recorded. The study also showed that the type of treatment did not affect the physiological improvement of the child.
Effect due to factor in study?	Yes
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	The mean age for NE patients was 9.79 years

Internal Validity

Question: What is the clinical and cost effectiveness of alternative interventions for children and young people under 19 years old who have nocturnal enuresis?

23

Grading: 1-	Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*
--------------------	---

Reference number 1258	Study Type	Randomised Controlled Trial	RID:
Banerjee S;Srivastav A;Palan BM;			418
Hypnosis and self-hypnosis in the management of nocturnal enuresis: A comparative study with imipramine therapy			
1993 36		pgs 113	119

Number of subjects 50 in total, 25 in each group

Inclusion/Exclusion Criteria: Inclusion: wet every night, mno medical or surgical cause for NE

Characteristics of subjects or environment/prognostic factor 30 were male, the age range was 5 to 16 years, children were wet every night

Recruitment: Not reported

Setting: Not reported

Interventions/Test /Factor being investigated Group A: hypnotherapy; Group B: imipramine

Comparitors Between groups

Length of Study/ Follow-up Follow up: 1, 2, 3 and 6 months

Outcome measures studies number of children who were dry or improved at 3 months, number of children who relapsed at 6 months

Results 3 months of treatment

Hypnotherapy was described as the child was first taught to relax and instructed to listen to the therapist and imagine what they were describing, they were then induced into hypnosis by techniques described by Gardner and Olness, the children were then given suggestions, again based on those described by Gardner and Olness, children were given two 30 minutes sessions in the first week, then one session in the second week, further sessions depended upon the child but were between once a week and once a fortnight; children receiving imipramine had 25 mg each night, the dose was increased each week if there was no response

Number of children who were dry or improved at 3 months:
18 out of 25 children in the hypnotherapy group were dry or improved at 3 months compared to 19 out of 25 in the imipramine group.

Number of children who relapsed:
1 out of 18 children relapsed in the hypnotherapy group compared to 13 out of 19 in the imipramine group

Funding Not reported

Does the study answer the question? The trial showed there was no statistically significant difference in the number of children who became dry or had a reduced number of wet nights between children treated with hypnotherapy and children treated with imipramine, the trial showed children treated with imipramine were more likely to relapse at 6 months compared to children treated with hypnotherapy.

Effect due to factor in study? Yes

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Children had an age range of 5 to 16 years

Internal Validity

Reference number 449 **Study Type** **Randomised Controlled Trial** RID:
Edwards SD;van d; 417

Hypnotherapy as a treatment for enuresis

1985 26 pgs 161 170

Number of subjects 48 in total

Inclusion/Exclusion Criteria: Inclusion: primary or secondary NE, no organic pathology or diurnal enuresis

Characteristics of subjects or environment/prognostic factor All children were male, the mean age was 10.5 years, the mean baseline wetting for group A was 2.7, for group B was 2, for group C was 3.8 and for group D was 2

Recruitment: Letters to boys schools

Setting: Cape Peninsula, South Africa

Interventions/Test /Factor being investigated Group A: trance with suggestions
Group B: suggestions without trance
Group C: trance alone
Group D: waiting list

Comparitors between groups

Length of Study/ Follow-up 6 months

Outcome measures studies The mean number of wet nights per week at the end of treatment and at follow up

Results Trance with suggestions was described as the child was induced into a trance in a special relaxing chair and listened to suggestions on a tape through headphones. Trance without suggestions was described as being induced into trance and then woken up, however the author stated due to moral reasons the children were given minimal suggestions before the trance. Suggestions without trance was described as the same procedure as trance with suggestions but without trance.
Mean number of dry nights at the end of treatment:
In group A the mean number of wet nights at the end of treatment was 4.5 (trance with suggestions), compared to 4.5 in group B (suggestions without trance), 4.8 in group C (trance without suggestions) and 2.1 in group D (no treatment)
Mean number of dry nights at follow up:
In group A the mean number of wet nights at follow up was 4.3 (trance with suggestions), compared to 4.6 in group B (suggestions without trance), 5.1 in group C (trance without suggestions) and 2.8 in group D (no treatment)

Funding Not reported

Does the study answer the question? The trial showed there was no difference in the mean number of wet nights per week at the end of treatment between children treated with trance with suggestions and children treated with suggestions without trance. The trial showed children treated with suggestions without trance had fewer wet nights per week at follow up compared to children treated with trance with suggestions. The trial showed children treated with trance without suggestions had fewer wet nights per week at the end of treatment and at follow up compared to children treated with trance with suggestions. The trial showed children treated with trance without suggestions had fewer wet nights per week at the end of treatment and at follow up compared to children treated with suggestions without trance. The study did not give standard deviation values and therefore the mean difference and CI are not estimable.

Effect due to factor in study? Yes

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Children had a mean age of 10.5 years

Internal Validity

Reference number	19	Study Type	Randomised Controlled Trial	RID:	
	Ferrara P;Marrone G;Emmanuele V;Nicoletti A;Mastrangelo A;Tiberi E;Ruggiero A;Fasano A;Paolini P;				922
	Homotoxicological remedies versus desmopressin versus placebo in the treatment of enuresis: a randomised, double-blind, controlled trial.				
	2008	23	pgs	269	274

Number of subjects 151 patients were randomised; n=50 to desmopressin, n=50 to homotoxicological remedies and n=51 to receive placebo.

Inclusion/Exclusion Criteria: Exclusion criteria: NE associated with day-time symptoms (urgency, frequency, UI, urinary tract anomalies or infections)

Characteristics of subjects or environment/prognostic factor All patients had ICCS definition of NE and none had received treatment for NE or homotoxicological remedies within the previous 3 months. Patients aged 6 years to 14 years (mean 8.5 years).

Recruitment: From a Department of Paediatrics in Italy

Setting: University Hospital

Interventions/Test /Factor being investigated Desmopressin vs. homotoxicological remedies vs. placebo

Comparitors Comparison is between Desmopressin (dDAVP) (minirin-Valeas) and homotoxicological remedies as well as placebo.

Length of Study/ Follow-up Up to 3 months.

Outcome measures studies Number of children who achieved 14 consecutive dry nights.

Results 151 patients were randomised. n=50 to desmopressin, n=50 to homotoxicological remedies and n=51 to receive placebo.

Each patient was asked about a family history of bladder dysfunction and the

number of wet nights per week. Urine analysis, urine culture and ultrasonography of kidney and bladder was conducted. A bladder diary that was completed by the patients or the parents was also used.

The first group received desmopressin tablets 0.2mg, once in the evening, plus placebo drops (20 drops three times a day) and the third group received placebo tablets, once in the evening plus placebo drops (20 drops three times a day). Homotoxicological remedies were described as 20 solidago drops three times a day and one biopax tablet in the evening. The treatment was started at different times for each patient, and each one was treated for 3 months. Non-responders to the therapy after the first 3 months period were withdrawn from the study.

Number of children who achieved 14 consecutive dry nights:
In the homotoxicological remedies group 10 out of 50 children achieved 14 consecutive dry nights compared to 26 out of 50 in the desmopressin group and 0 out of 51 in the placebo group.

Funding Not reported.

Does the study answer the question? Study showed desmopressin is more effective than homotoxicological remedies and placebo. Homotoxicological remedies were more effective than placebo.

Effect due to factor in study? Yes

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Children had a mean age of 8.5 years

Internal Validity No ITT performed

Reference number 386 **Study Type** **Randomised Controlled Trial** RID:
Leboeuf C;Brown P;Herman A;Leembruggen K;Walton D;Crisp TC; 415
Chiropractic care of children with nocturnal enuresis: a prospective outcome study.[see comment]
1991 14 pgs 110 115

Number of subjects 171 in total: n= 71 in no treatment and n=100 in chiropractic treatment.

Inclusion/Exclusion Criteria: Inclusion: wet at least 1 night a week.
Exclusion: daytime wetting or soiling at any time; anatomical \physiological abnormalities; recurrent urinary tract infections; infrequent wetting (less than one wet night per week; possible or definite contraindications to spinal manipulative therapy; absence of indication for spinal manipulative therapy as determined by the examining chiropractor.

Characteristics of subjects or environment/prognostic factor 120 were male, the mean age was 8.3 years. Baseline wetting in the no treatment group was 5.5 days per week and 7 per week, in the chiropractic group.

Recruitment: Press advertisement and primary schools.

Setting: Australia.

Interventions/Test /Factor being investigated Chiropractic treatment.

Comparitors	No treatment.
Length of Study/ Follow-up	2 weeks.
Outcome measures studies	Mean number of wet nights per week at the end of treatment.
Results	2 weeks of treatment, results from Cochrane review. Chiropractic treatment was described as adjustments of the aberrant spinal movement through observation and palpation each visit. The mean number of wet nights per week at the end of treatment: In the chiropractic group the mean number of wet nights was 5 per week at the end of treatment compared to 5.5 in the no treatment group.
Funding	Not reported.
Does the study answer the question?	The trial showed children who had no treatment had 0.5 fewer wet nights per week at the end of treatment compared to children treated with chiropractic treatment. The study did not give standard deviation values and therefore the mean difference and CI are not estimable.
Effect due to factor in study?	Yes
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Children had a mean age of 8.3 years.

Internal Validity

Reference number 1430 **Study Type** **Randomised Controlled Trial** RID: 419
Mao XS;
Acupuncture for primary nocturnal enuresis in children: a randomised clinical trial
1998 29 Fujian Journal of Traditional Chinese Medicine pgs 18

Number of subjects	11 in total 56 in acupuncture group, 55 in sham acupuncture group
Inclusion/Exclusion Criteria:	Inclusion: age over 5 years, primary nocturnal enuresis diagnosed by 'Chinese Disease Diagnostic and Therapeutic Standards (1994)', normal urine examination, microscopy, pelvic X-ray, EEG
Characteristics of subjects or environment/prognos tic factor	the age range was 5 to 15 years, 79 out of 111 were male
Recruitment:	Not reported
Setting:	outpatient department

Interventions/Test /Factor being investigated	Group A: acupuncture; Group B: sham acupuncture
Comparitors	Between groups
Length of Study/ Follow-up	none
Outcome measures studies	the number of children who achieved 14 consecutive dry nights and the number of children who failed to achieve 14 consecutive dry nights or relapsed after treatment
Results	<p>Treatment length depended upon response</p> <p>Acupuncture was described as a needle being buried under the skin for 3 days and then a new needle buried at the same point for 3 days; children receiving sham acupuncture had a needle placed on the skin for 30 minutes daily for 6 days</p> <p>The number of children who achieved 14 consecutive dry nights: The number of children who achieved 14 consecutive dry nights in the acupuncture group was 30 out of 56 compared to 17 out of 55 in the sham acupuncture group.</p> <p>The number of children who failed to achieve 14 consecutive dry nights or relapsed after treatment: The number of children who failed to achieve 14 consecutive dry nights or relapsed after treatment in the acupuncture group was 26 out of 56 compared to 38 out of 55 in the sham acupuncture group.</p>
Funding	Not reported
Does the study answer the question?	The trial showed children treated with acupuncture were more likely to achieve 14 consecutive dry nights compared to children treated with sham acupuncture; children treated with sham acupuncture were more likely to fail to achieve 14 consecutive dry nights or relapse after treatment compared to children treated with acupuncture.
Effect due to factor in study?	Yes
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Children had an age range of 5 to 15 years

Internal Validity

Reference number	182	Study Type	Randomised Controlled Trial	RID:
Radmayr C;Schlager A;Studen M;Bartsch G;				250
Prospective randomized trial using laser acupuncture versus desmopressin in the treatment of nocturnal enuresis				
2001 40			pgs 201 205	

Number of subjects	40 in total, 20 in each group
Inclusion/Exclusion Criteria:	Inclusion: primary monosymptomatic NE, polyuria, over 5 years old, no UTI.

Characteristics of subjects or environment/prognostic factor	31 were male, the mean age in the desmopressin group was 8.6 years, the mean age in the laser acupuncture group was 8 years. The mean baseline wetting in the desmopressin group was 5.5 wet nights per week and 6 wet nights per week in the laser acupuncture group, the over all rate was 5.5 wet nights per week.
Recruitment:	Not reported
Setting:	Austria
Interventions/Test /Factor being investigated	Group A: desmopressin: Group B: laser acupuncture
Comparitors	Between groups
Length of Study/ Follow-up	6 months after the end of treatment.
Outcome measures studies	The number of children who achieved greater than 90% improvement in the number of dry nights, the number of children who achieved 50% to 90% improvement in the number of dry nights.
Results	<p>Laser acupuncture was described as predefined acupuncture points being stimulated for 30 seconds each at each visit, children had 3 sessions a week and had between 10 and 15 sessions in total; children receiving desmopressin had 20 micrograms intranasal desmopressin, which was increased to 40 micrograms if needed.</p> <p>The number of children who achieved greater than 90% improvement in the number of dry nights: In the desmopressin group 15 out of 20 children achieved a greater than 90% improvement in the number of dry nights compared to 13 out of 20 in the laser acupuncture group.</p> <p>The number of children who achieved 50% to 90% improvement in the number of dry nights: In the desmopressin group 2 out of 20 children achieved a 50% to 90% improvement in the number of dry nights compared to 2 out of 20 in the laser acupuncture group.</p>
Funding	Not reported
Does the study answer the question?	The trial showed there was no statistically significant difference in the number of children who achieved greater than 90% improvement in the number of dry nights and there was no difference in the number of children who achieved 50% to 90% improvement in the number of dry nights between children treated with laser acupuncture and children treated with desmopressin.
Effect due to factor in study?	Yes
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Children in the desmopressin group had a mean age of 8.6 years and children in laser acupuncture group had a mean age of 8 years.

Internal Validity

Reference number	337	Study Type	Randomised Controlled Trial	RID:
	Reed WR;Beavers S;Reddy SK;Kern G;			408
	Chiropractic management of primary nocturnal enuresis.[see comment]			

Number of subjects	57 in total
Inclusion/Exclusion Criteria:	Inclusion: not daytime wetting, wet at least 1 night a week Exclusion: diurnal enuresis, recurrent UTIs physical abnormalities, urological surgery, contraindication to spinal adjustment, previous NE treatment or spinal adjustment / chiropractic treatment in previous 4 weeks
Characteristics of subjects or environment/prognostic factor	The mean age in the chiropractic group was 8.1 (sd 2.8) years and in the sham group was 8.7 (sd 2.8) years. The mean baseline wetting in the chiropractic group was 9.1 (sd 3.15) wet nights per 2 weeks and in the sham group was 11.1 (sd 3).
Recruitment:	advertisement in press
Setting:	community
Interventions/Test /Factor being investigated	Group A: chiropractic treatment Group B: sham chiropractic treatment
Comparators	Between groups
Length of Study/ Follow-up	2 weeks
Outcome measures studies	The number of children who achieved greater than 50% improvement in the number of dry nights, the mean number of wet nights per 2 weeks at follow up
Results	18 weeks of treatment Chiropractic treatment was described as patients having spinal subluxation through high velocity, short lever thrust every 10 days, children were evaluated for segmental dysfunction using observation and palpation; children receiving sham chiropractic treatment followed the same procedure but received sham adjustment. The number of children who achieved greater than 50% improvement in the number of dry nights: In the chiropractic group 8 out of 31 children had a greater than 50% improvement in the number of dry nights compared to 0 out of 15 in the sham group The mean number of wet nights per 2 weeks at follow up: In the chiropractic group the mean number of wet nights per 2 weeks at follow up was 7.6 (sd 4.3) compared to 11.2 (sd 3.5) in the sham group
Funding	Not reported
Does the study answer the question?	The trial showed there was no statistically significant difference in the number of children who achieved greater than 50% improvement in the number of dry nights between children treated with chiropractic treatment and children treated with sham chiropractic treatment. The study showed children treated with chiropractic treatment had fewer wet nights per 2 weeks at follow up compared to children treated with sham chiropractic treatment.
Effect due to factor in study?	Yes
Consistency of results with other studies?	No other similar studies
How directly applicable to population of the guideline?	Children had a mean age of 8.1 to 8.7 years

Internal Validity

Grading: 2-	Case-control or cohort studies with a high risk of confounding bias, or chance and a significant risk
--------------------	--

Reference number 634 Study Type Cohort RID:
 Bjorkstrom G;Hellstrom AL;Andersson S; 527

Electro-acupuncture in the treatment of children with monosymptomatic nocturnal enuresis

2000 34 pgs 21 26

Number of subjects 25 children

Inclusion/Exclusion Criteria: Inclusion: monosymptomatic NE,

Characteristics of subjects or environment/prognostic factor Children had an age range of 7 to 16 years, The baseline median wetting was 4.7 nights per week

Recruitment: Not reported

Setting: Sweden

Interventions/Test /Factor being investigated Electro-acupuncture

Comparitors None

Length of Study/ Follow-up 6 months

Outcome measures studies The mean number of dry nights at follow up, 90% reduction in wet nights, 50 to 90% in the mean number of wet nights.

Results Twenty 30 minute sessions of electro-acupuncture over 8 weeks of treatment
 Electro-acupuncture was described as the child was placed in a supine relaxed position, 7 disposable needles were placed at specific points. For the first 3 sessions these were manual stimulated, after this 2 pairs of needles were connected to an electro-stimulator.
 The study showed the mean number of dry nights increased to 3.5 (from 2.3) during the last 3 weeks of treatment, at 3 month follow up the mean number of dry nights was 4.3 and 6 month follow up the mean number of dry nights was 5. At the end of treatment 8% of patients achieved 6 months a 90% reduction number of wet nights, at 3 and 6 months 22% had achieved a 90% reduction number of wet nights. At 6 months 26% had achieved a 50% to 90% reduction number of wet nights. 1 child dropped out due to a fear of needles.

Funding Not reported

Does the study answer the question? The study showed children treated with electro-acupuncture can become dry

Effect due to factor in study? Yes

Consistency of results with other studies? No other similar studies

How directly applicable to population of the guideline? Children had an age range of 7 to 16 years

Internal Validity

Question: What is the clinical and cost effectiveness of dose escalation in desmopressin (nasal, tablets and melts) for children and young people under 19 years old who have nocturnal enuresis?

28

Grading: 1-	Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*
--------------------	---

Reference number 176 Study Type Randomised Controlled Trial RID:
 Schulman SL;Stokes A;Salzman PM; 926

The efficacy and safety of oral desmopressin in children with primary nocturnal enuresis

2001 166 pgs 2427 2431

Number of subjects 193 in total, 148 continued into trial 2

Inclusion/Exclusion Criteria: Inclusion: at least 3 wet nights a week, informed consent, no treatment in previous 30 days, aged 6-16 years, children who had not responded to dosemoressin in a first trial of desmopressin

Characteristics of subjects or environment/prognostic factor Exclusion: organic causes of NE, day time wetting, organic urological disease, diabetes insipidus, UTI, known hypersensitivity to desmopressin, antibiotics, diuretics, hyperactivity
 In trial one the patient characteristics were
 133 out of 193 were male, mean baseline wetting in 2 weeks in group 1, was 11 (range 5-14), in group 2, 10 (range 4-14), in group 3, 10 (range 6-14), in group 4, 10 (range 6-14), of these 148 continued to this trial

Recruitment: Not reported

Setting: 16 centres in USA

Interventions/Test /Factor being investigated Group A: 0.2 mg oral desmopressin increased every 2 weeks if no response
 Group B: matching placebo, tablets changed every 2 weeks if no response

Comparitors Between treatment groups

Length of Study/ Follow-up No follow up, 8 weeks of treatment

Outcome measures studies Number of children who required maximum increase in dose, number of children who required 0.2 mg, 0.4mg desmopressin, improvement of 50% or more from baseline wetting, mean number of wet nights in first and last 2 weeks, drop out, adverse events

Results Number of children who required maximum increase in dose by 8 weeks:
 In group E (desmopressin) 86 out of 99 needed the maximum increase and 38 out of 38 in group F (placebo)

Number of children who required 0.2mg desmopressin s:
 In group E (desmopressin) 1 out of 99 needed 0.2mg desmopressin and 0 out of 38 in group F (placebo)

Number of children who required an increase to 0.4 mg desmopressin:
 In group E (desmopressin) 12 out of 99 needed an increase to 0.4 mg desmopressin and 0 out of 38 in group F (placebo)

Improvement of 50% or more from baseline wetting:
 In group E (desmopressin) 51 out of 99 (28 on 0.2 mg, 16 on 0.4 mg, 8 on 0.6 mg) improved compared to 7 out of 35 in group F (placebo)

Mean number of wet nights in first 2 weeks (0.2mg desmopressin):
 In group E (desmopressin 109 patients) the mean number of wet nights was 4 (SD 1.57) and in group F (placebo 38 patients) the mean number of wet nights was 5 (SD 1.54)

Mean number of wet nights per week in last 2 weeks of treatment (up to 0.6 mg desmopressin):
 In group E (desmopressin 99 patients) the mean number of wet nights was 3.2 (SD

1.69) and in group F (placebo 38 patients) was 4.5 (SD 1.5)

Drop outs:

11 dropped out of group E (desmopressin), 0 dropped out of group F (placebo)
1 child on desmopressin and 1 on placebo stopped before end of trial because of nervousness

Adverse events (1 or more per child):

43 out of 143 on desmopressin and 13 out of 48 on placebo - rhinitis, pharyngitis, infection, headache and fever

Authors reported most were unrelated to treatment and were resolved by end of trial

Not reported

Funding

Does the study answer the question?

The study showed in this population where children had failed to achieve dryness in a previous study; most children required the full dose increase of desmopressin.

Effect due to factor in study?

Yes, although all children had previously failed desmopressin treatment

Consistency of results with other studies?

No other studies

How directly applicable to population of the guideline?

Children had failed to respond to desmopressin

Internal Validity

Study does not conduct intention to treat analysis for dose escalation. Some results were obtained from the Cochrane review. These were reposted as intention to treat.

Grading: 2+	<i>Well-conducted case-control or cohort studies with a low risk of confounding, bias or chance and a</i>
--------------------	--

Reference number	1052	Study Type	Cohort	RID:
Matthiesen TB;Rittig S;Djurhuus JC;Norgaard JP;				577
A dose titration, and an open 6-week efficacy and safety study of desmopressin tablets in the management of nocturnal enuresis				
1994	151	pgs	460	463

Number of subjects	33 patients
Inclusion/Exclusion Criteria:	Inclusion: 3 or more wet nights per week during a 2 week observation, normal on physical examination, normal hematocrit, serum creatine, serum sodium serum potassium and serum albumin levels, sterile urine, no evidence of any other urological disease, no treatment in previous 3 weeks
Characteristics of subjects or environment/prognostic factor	20 out of 33 were male, the mean age was 11.6 (sd 3) years, the age range was 7 to 18 years. All children except 9 had previously been treated for NE
Recruitment:	Not reported
Setting:	Denmark
Interventions/Test /Factor being investigated	Dose escalation of tablet desmopressin
Comparitors	No comparison
Length of Study/ Follow-up	2 weeks of treatment, no follow up
Outcome measures studies	Number of children who became dry, number of children who dropped out
Results	<p>The study conducted a 2 week dose titration, during this period children were asked to keep a diary and were seen every 2 weeks. The patients received 200 micrograms tablet desmopressin 1 hour before bed for 1 week. If after the patient was not dry for the whole week the dose was increased to 400 micrograms tablet desmopressin for one week.</p> <p>Number of children who became dry (no wet nights for whole week while on treatment): 5 children out of 33 became dry while treated with 200 micrograms tablet desmopressin for 1 week. 26 children then had their dosage increased to 400 micrograms tablet desmopressin for 1 week, during this time 2 children became dry.</p> <p>Number of children who dropped out: During the week where children were given 200 micrograms tablet desmopressin 2 children dropped out. During the following week where children were given 400 micrograms tablet desmopressin another 2 children dropped out.</p>
Funding	Ferring AB, Sweden provided desmopressin tablets
Does the study answer the question?	The study shows children treated with desmopressin can become dry if they have their dosage increased after not responding to the first dose
Effect due to factor in study?	Yes

Consistency of results with other studies? No other studies

How directly applicable to population of the guideline? Children had a mean age of 11.6 (sd 3) years

Internal Validity